{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "0a67be30",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Home path : /opt/bioasq/col-un-bioasq11\n",
      "Eval path : /opt/bioasq/Evaluation-Measures\n"
     ]
    }
   ],
   "source": [
    "%load_ext autoreload\n",
    "%autoreload 2\n",
    "import os\n",
    "import re\n",
    "import json\n",
    "import copy\n",
    "import sys\n",
    "from tqdm import tqdm\n",
    "from pprint import pprint\n",
    "\n",
    "import matplotlib.pyplot as plt\n",
    "import seaborn as sns\n",
    "\n",
    "import pytrec_eval\n",
    "import numpy as np\n",
    "import pandas as pd\n",
    "from elasticsearch import Elasticsearch\n",
    "from haystack.pipelines import Pipeline\n",
    "from haystack.nodes import BM25Retriever, ElasticsearchRetriever\n",
    "from haystack.document_stores import ElasticsearchDocumentStore\n",
    "from haystack.nodes import BM25Retriever, SentenceTransformersRanker\n",
    "from haystack.nodes.reader import FARMReader\n",
    "from haystack.utils import print_answers\n",
    "import warnings\n",
    "warnings.filterwarnings('ignore')\n",
    "\n",
    "sys.path.append('../../')\n",
    "import globals\n",
    "from elastic_search_utils import elastic_utils\n",
    "from haystack_utils.retrievers import BioASQ_Retriever\n",
    "import bioasq_eval\n",
    "import haystack_util\n",
    "\n",
    "working_folder = globals.PATH.home + '/data/working_folder'\n",
    "eval_home = globals.PATH.eval_home + '/'\n",
    "gs_google_docs = eval_home + '/examples/aueb_google_docs/aueb_nlp-bioasq6b-submissions/'\n",
    "index_name = globals.BIOASQ.index + 'working_folder'\n",
    "model_id = 'doc_retrieval_test'\n",
    "\n",
    "es = Elasticsearch(globals.ES.server)\n",
    "\n",
    "# set document store\n",
    "document_store = ElasticsearchDocumentStore()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "f51b37d8",
   "metadata": {},
   "outputs": [],
   "source": [
    "test_batch_doc = f'{globals.PATH.home}/data/11b_testset/BioASQ-task11bPhaseA-testset2.json'\n",
    "test_batch_json = json.load(open(test_batch_doc))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "id": "5223deeb",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "c57b1fb433954e86a631793d86d3c352",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/1 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "# set document store\n",
    "document_store = ElasticsearchDocumentStore()\n",
    "# create the retriever\n",
    "retriever = BioASQ_Retriever(document_store = document_store)\n",
    "\n",
    "# create the Sentence Transformer Ranker\n",
    "ranker = SentenceTransformersRanker(model_name_or_path=\"cross-encoder/ms-marco-MiniLM-L-12-v2\")\n",
    "\n",
    "# create the Query Pipeline\n",
    "pipeline = Pipeline()\n",
    "\n",
    "# add bm25 retriever\n",
    "pipeline.add_node(component=retriever, name=\"BM25Retriever\", inputs=[\"Query\"])\n",
    "pipeline.add_node(component=ranker, name=\"Ranker\", inputs=[\"BM25Retriever\"])\n",
    "my_model = \"deepset/roberta-base-squad2\"\n",
    "reader = FARMReader(model_name_or_path=my_model, use_gpu=True)\n",
    "pipeline.add_node(component=reader, name=\"Reader\", inputs=[\"Ranker\"])\n",
    "\n",
    "# run the pipeline\n",
    "prediction = pipeline.run(query=\"Which factors drive replisome disassembly during DNA replication termination and mitosis\", params={\"BM25Retriever\": {\"top_k\": 100}})"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "id": "cb26afa7",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'query': 'Which factors drive replisome disassembly during DNA replication termination and mitosis',\n",
       " 'no_ans_gap': 8.580459594726562,\n",
       " 'answers': [<Answer {'answer': 'Cullin ubiquitin ligases', 'type': 'extractive', 'score': 0.9014731049537659, 'context': 'Cullin ubiquitin ligases drive replisome disassembly during DNA replication termination. In worm, frog and mouse cells, CUL2LRR1 is required to ubiqui', 'offsets_in_document': [{'start': 0, 'end': 24}], 'offsets_in_context': [{'start': 0, 'end': 24}], 'document_ids': ['34195792'], 'meta': {'title': 'Reconstitution of human CMG helicase ubiquitylation by CUL2LRR1 and multiple E2 enzymes.', 'issue': '478(14)', 'pages': '2825-2842', 'abstract': 'Cullin ubiquitin ligases drive replisome disassembly during DNA replication termination. In worm, frog and mouse cells, CUL2LRR1 is required to ubiquitylate the MCM7 subunit of the CMG helicase. Here, we show that cullin ligases also drive CMG-MCM7 ubiquitylation in human cells, thereby making the helicase into a substrate for the p97 unfoldase. Using purified human proteins, including a panel of E2 ubiquitin-conjugating enzymes, we have reconstituted CMG helicase ubiquitylation, dependent upon neddylated CUL2LRR1. The reaction is highly specific to CMG-MCM7 and requires the LRR1 substrate targeting subunit, since replacement of LRR1 with the alternative CUL2 adaptor VHL switches ubiquitylation from CMG-MCM7 to HIF1. CUL2LRR1 firstly drives monoubiquitylation of CMG-MCM7 by the UBE2D class of E2 enzymes. Subsequently, CUL2LRR1 activates UBE2R1/R2 or UBE2G1/G2 to extend a single K48-linked ubiquitin chain on CMG-MCM7. Thereby, CUL2LRR1 converts CMG into a substrate for p97, which disassembles the ubiquitylated helicase during DNA replication termination.', 'journal': 'The Biochemical journal', 'authors': 'Le|Thanh Thi|TT|;Ainsworth|Johanna|J|;Polo Rivera|Cristian|C|;Macartney|Thomas|T|;Labib|Karim P M|KPM|0000-0001-8861-379X', 'pubdate': '2021', 'pmid': '34195792', 'mesh_terms': 'D000818:Animals; D002460:Cell Line; D003001:Cloning, Molecular; D044842:Cullin Proteins; D004265:DNA Helicases; D006801:Humans; D015151:Immunoblotting; D008239:Lysine; D064168:Minichromosome Maintenance Complex Component 7; D012097:Repressor Proteins; D061987:Sf9 Cells; D018411:Spodoptera; D025801:Ubiquitin; D044763:Ubiquitin-Conjugating Enzymes; D044767:Ubiquitin-Protein Ligases; D054875:Ubiquitination; D000074405:Valosin Containing Protein', 'publication_types': \"D016428:Journal Article; D013485:Research Support, Non-U.S. Gov't\", 'chemical_list': 'C105153:CUL2 protein, human; D044842:Cullin Proteins; C464446:LRR1 protein, human; D012097:Repressor Proteins; D025801:Ubiquitin; D044763:Ubiquitin-Conjugating Enzymes; D044767:Ubiquitin-Protein Ligases; D004265:DNA Helicases; D064168:Minichromosome Maintenance Complex Component 7; D000074405:Valosin Containing Protein; D008239:Lysine', 'keywords': 'CMG helicase; CUL2LRR1; DNA synthesis and repair; cullin ligase; p97; ubiquitins', 'doi': '10.1042/BCJ20210315', 'references': '', 'delete': False, 'affiliations': 'The MRC Protein Phosphorylation and Ubiquitylation Unit, School of Life Sciences, University of Dundee, Dundee DD1 5EH, U.K.;The MRC Protein Phosphorylation and Ubiquitylation Unit, School of Life Sciences, University of Dundee, Dundee DD1 5EH, U.K.;The MRC Protein Phosphorylation and Ubiquitylation Unit, School of Life Sciences, University of Dundee, Dundee DD1 5EH, U.K.;The MRC Protein Phosphorylation and Ubiquitylation Unit, School of Life Sciences, University of Dundee, Dundee DD1 5EH, U.K.;The MRC Protein Phosphorylation and Ubiquitylation Unit, School of Life Sciences, University of Dundee, Dundee DD1 5EH, U.K.', 'pmc': '', 'other_id': '', 'medline_ta': 'Biochem J', 'nlm_unique_id': '2984726R', 'issn_linking': '0264-6021', 'country': 'England'}}>,\n",
       "  <Answer {'answer': 'TRAIP ubiquitin ligase', 'type': 'extractive', 'score': 0.8452216386795044, 'context': 'tode Caenorhabditis elegans as a model system, we show that the TRAIP ubiquitin ligase drives replisome disassembly in response to incomplete DNA repl', 'offsets_in_document': [{'start': 584, 'end': 606}], 'offsets_in_context': [{'start': 64, 'end': 86}], 'document_ids': ['31545170'], 'meta': {'title': 'TRAIP drives replisome disassembly and mitotic DNA repair synthesis at sites of incomplete DNA replication.', 'issue': '8()', 'pages': '', 'abstract': 'The faithful segregation of eukaryotic chromosomes in mitosis requires that the genome be duplicated completely prior to anaphase. However, cells with large genomes sometimes fail to complete replication during interphase and instead enter mitosis with regions of incompletely replicated DNA. These regions are processed in early mitosis via a process known as mitotic DNA repair synthesis (MiDAS), but little is known about how cells switch from conventional DNA replication to MiDAS. Using the early embryo of the nematode Caenorhabditis elegans as a model system, we show that the TRAIP ubiquitin ligase drives replisome disassembly in response to incomplete DNA replication, thereby providing access to replication forks for other factors. Moreover, TRAIP is essential for MiDAS in human cells, and is important in both systems to prevent mitotic segregation errors. Our data indicate that TRAIP is a master regulator of the processing of incomplete DNA replication during mitosis in metazoa.', 'journal': 'eLife', 'authors': 'Sonneville|Remi|R|;Bhowmick|Rahul|R|;Hoffmann|Saskia|S|;Mailand|Niels|N|;Hickson|Ian D|ID|;Labib|Karim|K|0000-0001-8861-379X', 'pubdate': '2019', 'pmid': '31545170', 'mesh_terms': 'D000818:Animals; D017173:Caenorhabditis elegans; D029742:Caenorhabditis elegans Proteins; D002460:Cell Line; D004260:DNA Repair; D004261:DNA Replication; D017353:Gene Deletion; D006801:Humans; D008938:Mitosis; D044767:Ubiquitin-Protein Ligases', 'publication_types': \"D016428:Journal Article; D013485:Research Support, Non-U.S. Gov't\", 'chemical_list': 'D029742:Caenorhabditis elegans Proteins; D044767:Ubiquitin-Protein Ligases; C000656696:trul-1 protein, C elegans', 'keywords': 'C. elegans; DNA replication; TRAIP; chromosomes; fragile site; gene expression; genome stability; human; mitosis; ubiquitin ligase', 'doi': '', 'references': '28368371;9804418;21981920;21317883;26166571;28537574;30849395;25342810;28355556;30979826;26711499;22025633;27462463;28740117;26595769;20978077;22249291;4366476;30842657;25342805;27516545;28620461;11112326;28235849;19141674;26633632;27630194;12747829;27984745;26781088;17927961', 'delete': False, 'affiliations': 'MRC Protein Phosphorylation and Ubiquitylation Unit, School of Life Sciences, University of Dundee, Dundee, United Kingdom.;Department of Cellular and Molecular Medicine, Center for Chromosome Stability, University of Copenhagen, Copenhagen, Denmark.;Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.;Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.;Department of Cellular and Molecular Medicine, Center for Chromosome Stability, University of Copenhagen, Copenhagen, Denmark.;MRC Protein Phosphorylation and Ubiquitylation Unit, School of Life Sciences, University of Dundee, Dundee, United Kingdom.', 'pmc': '', 'other_id': '', 'medline_ta': 'Elife', 'nlm_unique_id': '101579614', 'issn_linking': '2050-084X', 'country': 'England'}}>,\n",
       "  <Answer {'answer': 'LRR-MCM interaction', 'type': 'extractive', 'score': 0.7120596766471863, 'context': 'site on CMG, including the MCM3 and MCM5 zinc-finger domains. The LRR-MCM interaction is essential for replisome disassembly and, crucially, is occlud', 'offsets_in_document': [{'start': 1051, 'end': 1070}], 'offsets_in_context': [{'start': 66, 'end': 85}], 'document_ids': ['34700328'], 'meta': {'title': 'A conserved mechanism for regulating replisome disassembly in eukaryotes.', 'issue': '600(7890)', 'pages': '743-747', 'abstract': 'Replisome disassembly is the final step of eukaryotic DNA replication and is triggered by ubiquitylation of the CDC45-MCM-GINS (CMG) replicative helicase1-3. Despite being driven by evolutionarily diverse E3 ubiquitin ligases in different eukaryotes (SCFDia2 in budding yeast1, CUL2LRR1 in metazoa4-7), replisome disassembly is governed by a common regulatory principle, in which ubiquitylation of CMG is suppressed before replication termination, to prevent replication fork collapse. Recent evidence suggests that this suppression is mediated by replication fork DNA8-10. However, it is unknown how SCFDia2 and CUL2LRR1 discriminate terminated from elongating replisomes, to selectively ubiquitylate CMG only after termination. Here we used cryo-electron microscopy to solve high-resolution structures of budding yeast and human replisome-E3 ligase assemblies. Our structures show that the leucine-rich repeat domains of Dia2 and LRR1 are structurally distinct, but bind to a common site on CMG, including the MCM3 and MCM5 zinc-finger domains. The LRR-MCM interaction is essential for replisome disassembly and, crucially, is occluded by the excluded DNA strand at replication forks, establishing the structural basis for the suppression of CMG ubiquitylation before termination. Our results elucidate a conserved mechanism for the regulation of replisome disassembly in eukaryotes, and reveal a previously unanticipated role for DNA in preserving replisome integrity.', 'journal': 'Nature', 'authors': 'Jenkyn-Bedford|Michael|M|http://orcid.org/0000-0003-2335-8278;Jones|Morgan L|ML|http://orcid.org/0000-0003-1948-4925;Baris|Yasemin|Y|;Labib|Karim P M|KPM|;Cannone|Giuseppe|G|;Yeeles|Joseph T P|JTP|http://orcid.org/0000-0002-2255-2119;Deegan|Tom D|TD|http://orcid.org/0000-0001-9639-7636', 'pubdate': '2021', 'pmid': '34700328', 'mesh_terms': 'D020285:Cryoelectron Microscopy; D004247:DNA; D004265:DNA Helicases; D004261:DNA Replication; D056890:Eukaryota; D006801:Humans; D044767:Ubiquitin-Protein Ligases', 'publication_types': \"D016428:Journal Article; D013485:Research Support, Non-U.S. Gov't\", 'chemical_list': 'D004247:DNA; D044767:Ubiquitin-Protein Ligases; D004265:DNA Helicases', 'keywords': '', 'doi': '10.1038/s41586-021-04145-3', 'references': '', 'delete': False, 'affiliations': 'MRC Laboratory of Molecular Biology, Cambridge, UK.;MRC Laboratory of Molecular Biology, Cambridge, UK.;MRC Laboratory of Molecular Biology, Cambridge, UK.;MRC Protein Phosphorylation and Ubiquitylation Unit, Sir James Black Centre, School of Life Sciences, University of Dundee, Dundee, UK.;MRC Laboratory of Molecular Biology, Cambridge, UK.;MRC Laboratory of Molecular Biology, Cambridge, UK. jyeeles@mrc-lmb.cam.ac.uk.;MRC Protein Phosphorylation and Ubiquitylation Unit, Sir James Black Centre, School of Life Sciences, University of Dundee, Dundee, UK. tdeegan@ed.ac.uk.', 'pmc': '', 'other_id': '', 'medline_ta': 'Nature', 'nlm_unique_id': '0410462', 'issn_linking': '0028-0836', 'country': 'England'}}>,\n",
       "  <Answer {'answer': 'polyubiquitylation of one of the replicative helicase subunits (Mcm7) by Cul2LRR1 ubiquitin ligase', 'type': 'extractive', 'score': 0.5987789034843445, 'context': 'S-phase is driven through polyubiquitylation of one of the replicative helicase subunits (Mcm7) by Cul2LRR1 ubiquitin ligase. Interestingly, upon inhi', 'offsets_in_document': [{'start': 168, 'end': 266}], 'offsets_in_context': [{'start': 26, 'end': 124}], 'document_ids': ['30979826'], 'meta': {'title': 'Mitotic replisome disassembly depends on TRAIP ubiquitin ligase activity.', 'issue': '2(2)', 'pages': '', 'abstract': 'We have shown previously that the process of replication machinery (replisome) disassembly at the termination of DNA replication forks in the S-phase is driven through polyubiquitylation of one of the replicative helicase subunits (Mcm7) by Cul2LRR1 ubiquitin ligase. Interestingly, upon inhibition of this pathway in Caenorhabditis elegans embryos, the replisomes retained on chromatin were unloaded in the subsequent mitosis. Here, we show that this mitotic replisome disassembly pathway exists in Xenopus laevis egg extract and we determine the first elements of its regulation. The mitotic disassembly pathway depends on the formation of K6- and K63-linked ubiquitin chains on Mcm7 by TRAIP ubiquitin ligase and the activity of p97/VCP protein segregase. Unlike in lower eukaryotes, however, it does not require SUMO modifications. Importantly, we also show that this process can remove all replisomes from mitotic chromatin, including stalled ones, which indicates a wide application for this pathway over being just a \"backup\" for terminated replisomes. Finally, we characterise the composition of the replisome retained on chromatin until mitosis.', 'journal': 'Life science alliance', 'authors': 'Priego Moreno|Sara|S|;Jones|Rebecca M|RM|;Poovathumkadavil|Divyasree|D|;Scaramuzza|Shaun|S|;Gambus|Agnieszka|A|0000-0002-4648-0332', 'pubdate': '2019', 'pmid': '30979826', 'mesh_terms': 'D000818:Animals; D016590:Aphidicolin; D002110:Caffeine; D002843:Chromatin; D016213:Cyclins; D003517:Cyclopentanes; D004261:DNA Replication; D005260:Female; D008297:Male; D064168:Minichromosome Maintenance Complex Component 7; D008938:Mitosis; D010063:Ovum; D011743:Pyrimidines; D025841:Small Ubiquitin-Related Modifier Proteins; D013094:Spermatozoa; D044763:Ubiquitin-Conjugating Enzymes; D044767:Ubiquitin-Protein Ligases; D054875:Ubiquitination; D000074405:Valosin Containing Protein; D029867:Xenopus Proteins; D014982:Xenopus laevis', 'publication_types': \"D016428:Journal Article; D013485:Research Support, Non-U.S. Gov't\", 'chemical_list': 'D002843:Chromatin; D016213:Cyclins; D003517:Cyclopentanes; D011743:Pyrimidines; D025841:Small Ubiquitin-Related Modifier Proteins; D029867:Xenopus Proteins; D016590:Aphidicolin; D002110:Caffeine; D044763:Ubiquitin-Conjugating Enzymes; D044767:Ubiquitin-Protein Ligases; C509836:Mcm7 protein, Xenopus; D064168:Minichromosome Maintenance Complex Component 7; D000074405:Valosin Containing Protein; C539933:pevonedistat', 'keywords': '', 'doi': '10.26508/lsa.201900390', 'references': '8799842;16531994;21282109;26711499;16798881;18042044;26322582;21068752;22694940;26595769;17544371;23446422;26781088;2564315;18514518;24795279;28368371;11585805;25342810;19151749;27323329;26093298;17825564;28355556;23410753;22298039;29467282;26369285;21925316;27462463;22521908;9104814;25335891;30842657;21048783;25342805;17178859;28208741;24553286;27516545;28620461;21799892;18775313;26633632;24440776;17927961;24813613;26820530', 'delete': False, 'affiliations': 'Institute for Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.;Institute for Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.;Institute for Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.;Institute for Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.;Institute for Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK a.gambus@bham.ac.uk.', 'pmc': '', 'other_id': '', 'medline_ta': 'Life Sci Alliance', 'nlm_unique_id': '101728869', 'issn_linking': '2575-1077', 'country': 'United States'}}>,\n",
       "  <Answer {'answer': 'CRL-dependent poly-ubiquitylation of Mcm7 and p97 segregase', 'type': 'extractive', 'score': 0.4138580560684204, 'context': 'during replication termination is mediated by CRL-dependent poly-ubiquitylation of Mcm7 and p97 segregase. The replisome also disassembles at stalled ', 'offsets_in_document': [{'start': 86, 'end': 145}], 'offsets_in_context': [{'start': 46, 'end': 105}], 'document_ids': ['30340827'], 'meta': {'title': 'Mitotic entry drives replisome disassembly at stalled replication forks.', 'issue': '506(1)', 'pages': '108-113', 'abstract': 'The disassembly of eukaryotic replisome during replication termination is mediated by CRL-dependent poly-ubiquitylation of Mcm7 and p97 segregase. The replisome also disassembles at stalled or collapsed replication forks under certain stress conditions, but the underlying mechanism is poorly understood. Here, we discovered a novel pathway driving stepwise disassembly of the replisome at stalled replication forks after forced entry into M-phase using Xenopus egg extracts. This pathway was dependent on M-CDK activity and K48- and K63-linked poly-ubiquitylation but not on CRL and p97, which is different from known pathways. Furthermore, this pathway could not disassemble converged replisomes whose Mcm7 subunit had been poly-ubiquitylated without p97. These results suggest that there is a distinctive pathway for replisome disassembly when stalled replication forks persist into M-phase.', 'journal': 'Biochemical and biophysical research communications', 'authors': 'Hashimoto|Yoshitami|Y|;Tanaka|Hirofumi|H|', 'pubdate': '2018', 'pmid': '30340827', 'mesh_terms': 'D000071450:ATP Binding Cassette Transporter, Subfamily B, Member 3; D048868:Adaptor Proteins, Signal Transducing; D000818:Animals; D018797:Cell Cycle Proteins; D000071877:Checkpoint Kinase 1; D002843:Chromatin; D004261:DNA Replication; D064168:Minichromosome Maintenance Complex Component 7; D008938:Mitosis; D011485:Protein Binding; D054875:Ubiquitination; D000074405:Valosin Containing Protein; D029867:Xenopus Proteins; D014982:Xenopus laevis; D015053:Zygote', 'publication_types': \"D016428:Journal Article; D013485:Research Support, Non-U.S. Gov't\", 'chemical_list': 'D000071450:ATP Binding Cassette Transporter, Subfamily B, Member 3; D048868:Adaptor Proteins, Signal Transducing; C416368:CLSPN protein, Xenopus; C502211:Cdc45 protein, Xenopus; D018797:Cell Cycle Proteins; D002843:Chromatin; C489515:TAP2 protein, Xenopus; D029867:Xenopus Proteins; D000071877:Checkpoint Kinase 1; C000605875:Chek1 protein, Xenopus; C509836:Mcm7 protein, Xenopus; D064168:Minichromosome Maintenance Complex Component 7; D000074405:Valosin Containing Protein', 'keywords': 'CDK; CMG complex; Replisome; Ubiquitylation; Xenopus egg extract; p97/VCP/Cdc48', 'doi': '10.1016/j.bbrc.2018.10.064', 'references': '', 'delete': False, 'affiliations': 'School of Life Sciences, Tokyo University of Pharmacy and Life Sciences, 1432-1 Horinouchi, Hachioji, Tokyo, 192-0392, Japan. Electronic address: hashimo@toyaku.ac.jp.;School of Life Sciences, Tokyo University of Pharmacy and Life Sciences, 1432-1 Horinouchi, Hachioji, Tokyo, 192-0392, Japan.', 'pmc': '', 'other_id': '', 'medline_ta': 'Biochem Biophys Res Commun', 'nlm_unique_id': '0372516', 'issn_linking': '0006-291X', 'country': 'United States'}}>,\n",
       "  <Answer {'answer': 'molecular mechanisms', 'type': 'extractive', 'score': 0.4106212258338928, 'context': ' years however, researchers have also focused on deciphering the molecular mechanisms underlying the disassembly of the replicative helicase during te', 'offsets_in_document': [{'start': 487, 'end': 507}], 'offsets_in_context': [{'start': 65, 'end': 85}], 'document_ids': ['32490508'], 'meta': {'title': 'Mechanisms of eukaryotic replisome disassembly.', 'issue': '48(3)', 'pages': '823-836', 'abstract': 'DNA replication is a complex process that needs to be executed accurately before cell division in order to maintain genome integrity. DNA replication is divided into three main stages: initiation, elongation and termination. One of the key events during initiation is the assembly of the replicative helicase at origins of replication, and this mechanism has been very well described over the last decades. In the last six years however, researchers have also focused on deciphering the molecular mechanisms underlying the disassembly of the replicative helicase during termination. Similar to replisome assembly, the mechanism of replisome disassembly is strictly regulated and well conserved throughout evolution, although its complexity increases in higher eukaryotes. While budding yeast rely on just one pathway for replisome disassembly in S phase, higher eukaryotes evolved an additional mitotic pathway over and above the default S phase specific pathway. Moreover, replisome disassembly has been recently found to be a key event prior to the repair of certain DNA lesions, such as under-replicated DNA in mitosis and inter-strand cross-links (ICLs) in S phase. Although replisome disassembly in human cells has not been characterised yet, they possess all of the factors involved in these pathways in model organisms, and de-regulation of many of them are known to contribute to tumorigenesis and other pathological conditions.', 'journal': 'Biochemical Society transactions', 'authors': 'Moreno|Sara Priego|SP|;Gambus|Agnieszka|A|', 'pubdate': '2020', 'pmid': '32490508', 'mesh_terms': 'D000818:Animals; D017173:Caenorhabditis elegans; D002453:Cell Cycle; D018797:Cell Cycle Proteins; D002470:Cell Survival; D004247:DNA; D004261:DNA Replication; D016678:Genome; D006801:Humans; D064168:Minichromosome Maintenance Complex Component 7; D008938:Mitosis; D009369:Neoplasms; D025941:Protein Interaction Mapping; D018741:Replication Origin; D016196:S Phase; D012441:Saccharomyces cerevisiae; D004718:Saccharomycetales; D025801:Ubiquitin; D044767:Ubiquitin-Protein Ligases; D054875:Ubiquitination; D014982:Xenopus laevis', 'publication_types': 'D016428:Journal Article; D016454:Review', 'chemical_list': 'D018797:Cell Cycle Proteins; D025801:Ubiquitin; D004247:DNA; D044767:Ubiquitin-Protein Ligases; C101624:MCM7 protein, human; D064168:Minichromosome Maintenance Complex Component 7', 'keywords': 'Cullin2-LRR1; TRAIP; genome integrity; p97; replisome disassembly; ubiquitylation', 'doi': '10.1042/BST20190363', 'references': '28368371;19910535;31545170;30675527;25739503;25835602;26255844;25957489;27555051;27075410;31200185;26866665;21981920;19913425;19965384;28537574;16531994;29530982;31509741;21317883;30850330;30849395;25342810;30804506;28355556;29357058;30979826;26711499;25643322;24267891;28301743;16487579;26322582;30700044;19896182;27565346;28451587;19465922;27462463;28740117;27200082;31249135;28886337;29357065;29123070;16421250;26595769;30842657;27086594;31249134;25342805;24553286;29924986;27516545;28620461;16751663;29489749;28235849;27644328;28739890;21719678;26633632;30647138;18805090;27649880;26121093;24726325', 'delete': False, 'affiliations': 'The Salk Institute for Biological Studies, 10010 N Torrey Pines Rd, La Jolla, CA 92037, U.S.A.;Institute for Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham B15 2TT, U.K.', 'pmc': '', 'other_id': '', 'medline_ta': 'Biochem Soc Trans', 'nlm_unique_id': '7506897', 'issn_linking': '0300-5127', 'country': 'England'}}>,\n",
       "  <Answer {'answer': 'cullin-RING ubiquitin ligase CUL-2LRR-1 drives ubiquitylation of the CMG helicase', 'type': 'extractive', 'score': 0.4068673253059387, 'context': 'ation termination. In metazoa, the cullin-RING ubiquitin ligase CUL-2LRR-1 drives ubiquitylation of the CMG helicase, leading to replisome disassembly', 'offsets_in_document': [{'start': 101, 'end': 182}], 'offsets_in_context': [{'start': 35, 'end': 116}], 'document_ids': ['34269473'], 'meta': {'title': 'TIMELESS-TIPIN and UBXN-3 promote replisome disassembly during DNA replication termination in Caenorhabditis elegans.', 'issue': '40(17)', 'pages': 'e108053', 'abstract': 'The eukaryotic replisome is rapidly disassembled during DNA replication termination. In metazoa, the cullin-RING ubiquitin ligase CUL-2LRR-1 drives ubiquitylation of the CMG helicase, leading to replisome disassembly by the p97/CDC-48 \"unfoldase\". Here, we combine in\\xa0vitro reconstitution with in\\xa0vivo studies in Caenorhabditis elegans embryos, to show that the replisome-associated TIMELESS-TIPIN complex is required for CUL-2LRR-1 recruitment and efficient CMG helicase ubiquitylation. Aided by TIMELESS-TIPIN, CUL-2LRR-1 directs a suite of ubiquitylation enzymes to ubiquitylate the MCM-7 subunit of CMG. Subsequently, the UBXN-3 adaptor protein directly stimulates the disassembly of ubiquitylated CMG by CDC-48_UFD-1_NPL-4. We show that UBXN-3 is important in\\xa0vivo for replisome disassembly in the absence of TIMELESS-TIPIN. Correspondingly, co-depletion of UBXN-3 and TIMELESS causes profound synthetic lethality. Since the human orthologue of UBXN-3, FAF1, is a candidate tumour suppressor, these findings suggest that manipulation of CMG disassembly might be applicable to future strategies for treating human cancer.', 'journal': 'The EMBO journal', 'authors': 'Xia|Yisui|Y|0000-0002-5576-2147;Fujisawa|Ryo|R|0000-0003-1985-1668;Deegan|Tom D|TD|0000-0001-9639-7636;Sonneville|Remi|R|0000-0002-2149-2652;Labib|Karim P M|KPM|0000-0001-8861-379X', 'pubdate': '2021', 'pmid': '34269473', 'mesh_terms': 'D000818:Animals; D017173:Caenorhabditis elegans; D029742:Caenorhabditis elegans Proteins; D002352:Carrier Proteins; D044842:Cullin Proteins; D004261:DNA Replication; D004259:DNA-Directed DNA Polymerase; D009097:Multienzyme Complexes; D000072020:Synthetic Lethal Mutations', 'publication_types': \"D016428:Journal Article; D013485:Research Support, Non-U.S. Gov't\", 'chemical_list': 'D029742:Caenorhabditis elegans Proteins; D002352:Carrier Proteins; D044842:Cullin Proteins; D009097:Multienzyme Complexes; C400537:TIM-1 protein, C elegans; C000608562:UBXN-3 protein, C elegans; C107915:DNA synthesome; D004259:DNA-Directed DNA Polymerase', 'keywords': 'CDC-48; CMG helicase; CUL-2LRR-1; DNA replication termination; TIMELESS-TIPIN; UBXN-3', 'doi': '10.15252/embj.2021108053', 'references': '21645854;21981920;31509741;28355556;32305021;25739503;27565338;20977550;28368371;25342810;28475898;30849395;26842564;33536622;31545170;34269473;32943574;30979826;31868589;28301743;28512218;32705708;17296725;27384026;32369734;26322582;27565346;27015313;10587644;19597341;10834843;28525741;33166393;31249135;32179092;32804080;30796221;33484638;28375744;12783801;20978077;16137625;25342805;8670823;29357060;31898220;26255844;27716483;30952443;22537386;31419624;32004468;33160249;28235849;10421634;32051583;33402676;19805627', 'delete': False, 'affiliations': 'The MRC Protein Phosphorylation and Ubiquitylation Unit, School of Life Sciences, University of Dundee, Dundee, UK.;The MRC Protein Phosphorylation and Ubiquitylation Unit, School of Life Sciences, University of Dundee, Dundee, UK.;The MRC Protein Phosphorylation and Ubiquitylation Unit, School of Life Sciences, University of Dundee, Dundee, UK.;The MRC Protein Phosphorylation and Ubiquitylation Unit, School of Life Sciences, University of Dundee, Dundee, UK.;The MRC Protein Phosphorylation and Ubiquitylation Unit, School of Life Sciences, University of Dundee, Dundee, UK.', 'pmc': '', 'other_id': '', 'medline_ta': 'EMBO J', 'nlm_unique_id': '8208664', 'issn_linking': '0261-4189', 'country': 'England'}}>,\n",
       "  <Answer {'answer': 'formation of K6- and K63-linked ubiquitin chains on Mcm7 by TRAIP ubiquitin ligase and the activity of p97/VCP protein segregase', 'type': 'extractive', 'score': 0.3846079111099243, 'context': 'nds on the formation of K6- and K63-linked ubiquitin chains on Mcm7 by TRAIP ubiquitin ligase and the activity of p97/VCP protein segregase. Unlike in', 'offsets_in_document': [{'start': 629, 'end': 757}], 'offsets_in_context': [{'start': 11, 'end': 139}], 'document_ids': ['30979826'], 'meta': {'title': 'Mitotic replisome disassembly depends on TRAIP ubiquitin ligase activity.', 'issue': '2(2)', 'pages': '', 'abstract': 'We have shown previously that the process of replication machinery (replisome) disassembly at the termination of DNA replication forks in the S-phase is driven through polyubiquitylation of one of the replicative helicase subunits (Mcm7) by Cul2LRR1 ubiquitin ligase. Interestingly, upon inhibition of this pathway in Caenorhabditis elegans embryos, the replisomes retained on chromatin were unloaded in the subsequent mitosis. Here, we show that this mitotic replisome disassembly pathway exists in Xenopus laevis egg extract and we determine the first elements of its regulation. The mitotic disassembly pathway depends on the formation of K6- and K63-linked ubiquitin chains on Mcm7 by TRAIP ubiquitin ligase and the activity of p97/VCP protein segregase. Unlike in lower eukaryotes, however, it does not require SUMO modifications. Importantly, we also show that this process can remove all replisomes from mitotic chromatin, including stalled ones, which indicates a wide application for this pathway over being just a \"backup\" for terminated replisomes. Finally, we characterise the composition of the replisome retained on chromatin until mitosis.', 'journal': 'Life science alliance', 'authors': 'Priego Moreno|Sara|S|;Jones|Rebecca M|RM|;Poovathumkadavil|Divyasree|D|;Scaramuzza|Shaun|S|;Gambus|Agnieszka|A|0000-0002-4648-0332', 'pubdate': '2019', 'pmid': '30979826', 'mesh_terms': 'D000818:Animals; D016590:Aphidicolin; D002110:Caffeine; D002843:Chromatin; D016213:Cyclins; D003517:Cyclopentanes; D004261:DNA Replication; D005260:Female; D008297:Male; D064168:Minichromosome Maintenance Complex Component 7; D008938:Mitosis; D010063:Ovum; D011743:Pyrimidines; D025841:Small Ubiquitin-Related Modifier Proteins; D013094:Spermatozoa; D044763:Ubiquitin-Conjugating Enzymes; D044767:Ubiquitin-Protein Ligases; D054875:Ubiquitination; D000074405:Valosin Containing Protein; D029867:Xenopus Proteins; D014982:Xenopus laevis', 'publication_types': \"D016428:Journal Article; D013485:Research Support, Non-U.S. Gov't\", 'chemical_list': 'D002843:Chromatin; D016213:Cyclins; D003517:Cyclopentanes; D011743:Pyrimidines; D025841:Small Ubiquitin-Related Modifier Proteins; D029867:Xenopus Proteins; D016590:Aphidicolin; D002110:Caffeine; D044763:Ubiquitin-Conjugating Enzymes; D044767:Ubiquitin-Protein Ligases; C509836:Mcm7 protein, Xenopus; D064168:Minichromosome Maintenance Complex Component 7; D000074405:Valosin Containing Protein; C539933:pevonedistat', 'keywords': '', 'doi': '10.26508/lsa.201900390', 'references': '8799842;16531994;21282109;26711499;16798881;18042044;26322582;21068752;22694940;26595769;17544371;23446422;26781088;2564315;18514518;24795279;28368371;11585805;25342810;19151749;27323329;26093298;17825564;28355556;23410753;22298039;29467282;26369285;21925316;27462463;22521908;9104814;25335891;30842657;21048783;25342805;17178859;28208741;24553286;27516545;28620461;21799892;18775313;26633632;24440776;17927961;24813613;26820530', 'delete': False, 'affiliations': 'Institute for Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.;Institute for Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.;Institute for Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.;Institute for Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.;Institute for Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK a.gambus@bham.ac.uk.', 'pmc': '', 'other_id': '', 'medline_ta': 'Life Sci Alliance', 'nlm_unique_id': '101728869', 'issn_linking': '2575-1077', 'country': 'United States'}}>,\n",
       "  <Answer {'answer': 'F-box protein Dia2', 'type': 'extractive', 'score': 0.31823834776878357, 'context': 'ation termination but is poorly understood. In budding yeast, the F-box protein Dia2 drives ubiquitylation of the CMG helicase at the end of replicati', 'offsets_in_document': [{'start': 230, 'end': 248}], 'offsets_in_context': [{'start': 66, 'end': 84}], 'document_ids': ['26255844'], 'meta': {'title': 'Tethering of SCF(Dia2) to the Replisome Promotes Efficient Ubiquitylation and Disassembly of the CMG Helicase.', 'issue': '25(17)', 'pages': '2254-9', 'abstract': 'Disassembly of the Cdc45-MCM-GINS (CMG) DNA helicase, which unwinds the parental DNA duplex at eukaryotic replication forks, is the key regulated step during replication termination but is poorly understood. In budding yeast, the F-box protein Dia2 drives ubiquitylation of the CMG helicase at the end of replication, leading to a disassembly pathway that requires the Cdc48 segregase. The substrate-binding domain of Dia2 comprises leucine-rich repeats, but Dia2 also has a TPR domain at its amino terminus that interacts with the Ctf4 and Mrc1 subunits of the replisome progression complex, which assembles around the CMG helicase at replication forks. Previous studies suggested two disparate roles for the TPR domain of Dia2, either mediating replisome-specific degradation of Mrc1 and Ctf4 or else tethering SCF(Dia2) (SCF [Skp1/cullin/F-box protein]) to the replisome to increase its local concentration at replication forks. Here, we show that SCF(Dia2) does not mediate replisome-specific degradation of Mrc1 and Ctf4, either during normal S phase or in response to replication stress. Instead, the tethering of SCF(Dia2) to the replisome progression complex increases the efficiency of ubiquitylation of the Mcm7 subunit of CMG, both in vitro and in vivo. Correspondingly, loss of tethering reduces the efficiency of CMG disassembly in vivo and is synthetic lethal in combination with a disassembly-defective allele of CDC48. Residual ubiquitylation of Mcm7 in dia2-ΔTPR cells is still CMG specific, highlighting the complex regulation of the final stages of chromosome replication, about which much still remains to be learned.', 'journal': 'Current biology : CB', 'authors': 'Maculins|Timurs|T|;Nkosi|Pedro Junior|PJ|;Nishikawa|Hiroko|H|;Labib|Karim|K|', 'pubdate': '2015', 'pmid': '26255844', 'mesh_terms': 'D004261:DNA Replication; D004271:DNA, Fungal; D004268:DNA-Binding Proteins; D044783:F-Box Proteins; D064168:Minichromosome Maintenance Complex Component 7; D016196:S Phase; D012441:Saccharomyces cerevisiae; D029701:Saccharomyces cerevisiae Proteins; D054875:Ubiquitination', 'publication_types': \"D016428:Journal Article; D013485:Research Support, Non-U.S. Gov't\", 'chemical_list': 'C078338:CTF4 protein, S cerevisiae; D004271:DNA, Fungal; D004268:DNA-Binding Proteins; C495983:Dia2 protein, S cerevisiae; D044783:F-Box Proteins; D029701:Saccharomyces cerevisiae Proteins; C491088:MCM7 protein, S cerevisiae; D064168:Minichromosome Maintenance Complex Component 7', 'keywords': '', 'doi': '', 'references': '20724597;20647475;25342805;25342810;25400145;12769855;11809834;25391904;4579463;4618856;16487579;16421250;16531994;16751663;19913425;19910927;25342784', 'delete': False, 'affiliations': 'Cancer Research UK Manchester Institute, University of Manchester, Wilmslow Road, Manchester M20 4BX, UK.;MRC Protein Phosphorylation and Ubiquitylation Unit, Sir James Black Centre, College of Life Sciences, University of Dundee, Dow Street, Dundee DD1 5EH, UK.;Cancer Research UK Manchester Institute, University of Manchester, Wilmslow Road, Manchester M20 4BX, UK.;MRC Protein Phosphorylation and Ubiquitylation Unit, Sir James Black Centre, College of Life Sciences, University of Dundee, Dow Street, Dundee DD1 5EH, UK. Electronic address: kpmlabib@dundee.ac.uk.', 'pmc': '', 'other_id': '', 'medline_ta': 'Curr Biol', 'nlm_unique_id': '9107782', 'issn_linking': '0960-9822', 'country': 'England'}}>,\n",
       "  <Answer {'answer': 'under-replicated DNA in mitosis and inter-strand cross-links (ICLs) in S phase', 'type': 'extractive', 'score': 0.2701443135738373, 'context': 'air of certain DNA lesions, such as under-replicated DNA in mitosis and inter-strand cross-links (ICLs) in S phase. Although replisome disassembly in ', 'offsets_in_document': [{'start': 1090, 'end': 1168}], 'offsets_in_context': [{'start': 36, 'end': 114}], 'document_ids': ['32490508'], 'meta': {'title': 'Mechanisms of eukaryotic replisome disassembly.', 'issue': '48(3)', 'pages': '823-836', 'abstract': 'DNA replication is a complex process that needs to be executed accurately before cell division in order to maintain genome integrity. DNA replication is divided into three main stages: initiation, elongation and termination. One of the key events during initiation is the assembly of the replicative helicase at origins of replication, and this mechanism has been very well described over the last decades. In the last six years however, researchers have also focused on deciphering the molecular mechanisms underlying the disassembly of the replicative helicase during termination. Similar to replisome assembly, the mechanism of replisome disassembly is strictly regulated and well conserved throughout evolution, although its complexity increases in higher eukaryotes. While budding yeast rely on just one pathway for replisome disassembly in S phase, higher eukaryotes evolved an additional mitotic pathway over and above the default S phase specific pathway. Moreover, replisome disassembly has been recently found to be a key event prior to the repair of certain DNA lesions, such as under-replicated DNA in mitosis and inter-strand cross-links (ICLs) in S phase. Although replisome disassembly in human cells has not been characterised yet, they possess all of the factors involved in these pathways in model organisms, and de-regulation of many of them are known to contribute to tumorigenesis and other pathological conditions.', 'journal': 'Biochemical Society transactions', 'authors': 'Moreno|Sara Priego|SP|;Gambus|Agnieszka|A|', 'pubdate': '2020', 'pmid': '32490508', 'mesh_terms': 'D000818:Animals; D017173:Caenorhabditis elegans; D002453:Cell Cycle; D018797:Cell Cycle Proteins; D002470:Cell Survival; D004247:DNA; D004261:DNA Replication; D016678:Genome; D006801:Humans; D064168:Minichromosome Maintenance Complex Component 7; D008938:Mitosis; D009369:Neoplasms; D025941:Protein Interaction Mapping; D018741:Replication Origin; D016196:S Phase; D012441:Saccharomyces cerevisiae; D004718:Saccharomycetales; D025801:Ubiquitin; D044767:Ubiquitin-Protein Ligases; D054875:Ubiquitination; D014982:Xenopus laevis', 'publication_types': 'D016428:Journal Article; D016454:Review', 'chemical_list': 'D018797:Cell Cycle Proteins; D025801:Ubiquitin; D004247:DNA; D044767:Ubiquitin-Protein Ligases; C101624:MCM7 protein, human; D064168:Minichromosome Maintenance Complex Component 7', 'keywords': 'Cullin2-LRR1; TRAIP; genome integrity; p97; replisome disassembly; ubiquitylation', 'doi': '10.1042/BST20190363', 'references': '28368371;19910535;31545170;30675527;25739503;25835602;26255844;25957489;27555051;27075410;31200185;26866665;21981920;19913425;19965384;28537574;16531994;29530982;31509741;21317883;30850330;30849395;25342810;30804506;28355556;29357058;30979826;26711499;25643322;24267891;28301743;16487579;26322582;30700044;19896182;27565346;28451587;19465922;27462463;28740117;27200082;31249135;28886337;29357065;29123070;16421250;26595769;30842657;27086594;31249134;25342805;24553286;29924986;27516545;28620461;16751663;29489749;28235849;27644328;28739890;21719678;26633632;30647138;18805090;27649880;26121093;24726325', 'delete': False, 'affiliations': 'The Salk Institute for Biological Studies, 10010 N Torrey Pines Rd, La Jolla, CA 92037, U.S.A.;Institute for Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham B15 2TT, U.K.', 'pmc': '', 'other_id': '', 'medline_ta': 'Biochem Soc Trans', 'nlm_unique_id': '7506897', 'issn_linking': '0300-5127', 'country': 'England'}}>],\n",
       " 'documents': [<Document: {'content': 'We have shown previously that the process of replication machinery (replisome) disassembly at the termination of DNA replication forks in the S-phase is driven through polyubiquitylation of one of the replicative helicase subunits (Mcm7) by Cul2LRR1 ubiquitin ligase. Interestingly, upon inhibition of this pathway in Caenorhabditis elegans embryos, the replisomes retained on chromatin were unloaded in the subsequent mitosis. Here, we show that this mitotic replisome disassembly pathway exists in Xenopus laevis egg extract and we determine the first elements of its regulation. The mitotic disassembly pathway depends on the formation of K6- and K63-linked ubiquitin chains on Mcm7 by TRAIP ubiquitin ligase and the activity of p97/VCP protein segregase. Unlike in lower eukaryotes, however, it does not require SUMO modifications. Importantly, we also show that this process can remove all replisomes from mitotic chromatin, including stalled ones, which indicates a wide application for this pathway over being just a \"backup\" for terminated replisomes. Finally, we characterise the composition of the replisome retained on chromatin until mitosis.', 'content_type': 'text', 'score': 0.9997420907020569, 'meta': {'title': 'Mitotic replisome disassembly depends on TRAIP ubiquitin ligase activity.', 'issue': '2(2)', 'pages': '', 'abstract': 'We have shown previously that the process of replication machinery (replisome) disassembly at the termination of DNA replication forks in the S-phase is driven through polyubiquitylation of one of the replicative helicase subunits (Mcm7) by Cul2LRR1 ubiquitin ligase. Interestingly, upon inhibition of this pathway in Caenorhabditis elegans embryos, the replisomes retained on chromatin were unloaded in the subsequent mitosis. Here, we show that this mitotic replisome disassembly pathway exists in Xenopus laevis egg extract and we determine the first elements of its regulation. The mitotic disassembly pathway depends on the formation of K6- and K63-linked ubiquitin chains on Mcm7 by TRAIP ubiquitin ligase and the activity of p97/VCP protein segregase. Unlike in lower eukaryotes, however, it does not require SUMO modifications. Importantly, we also show that this process can remove all replisomes from mitotic chromatin, including stalled ones, which indicates a wide application for this pathway over being just a \"backup\" for terminated replisomes. Finally, we characterise the composition of the replisome retained on chromatin until mitosis.', 'journal': 'Life science alliance', 'authors': 'Priego Moreno|Sara|S|;Jones|Rebecca M|RM|;Poovathumkadavil|Divyasree|D|;Scaramuzza|Shaun|S|;Gambus|Agnieszka|A|0000-0002-4648-0332', 'pubdate': '2019', 'pmid': '30979826', 'mesh_terms': 'D000818:Animals; D016590:Aphidicolin; D002110:Caffeine; D002843:Chromatin; D016213:Cyclins; D003517:Cyclopentanes; D004261:DNA Replication; D005260:Female; D008297:Male; D064168:Minichromosome Maintenance Complex Component 7; D008938:Mitosis; D010063:Ovum; D011743:Pyrimidines; D025841:Small Ubiquitin-Related Modifier Proteins; D013094:Spermatozoa; D044763:Ubiquitin-Conjugating Enzymes; D044767:Ubiquitin-Protein Ligases; D054875:Ubiquitination; D000074405:Valosin Containing Protein; D029867:Xenopus Proteins; D014982:Xenopus laevis', 'publication_types': \"D016428:Journal Article; D013485:Research Support, Non-U.S. Gov't\", 'chemical_list': 'D002843:Chromatin; D016213:Cyclins; D003517:Cyclopentanes; D011743:Pyrimidines; D025841:Small Ubiquitin-Related Modifier Proteins; D029867:Xenopus Proteins; D016590:Aphidicolin; D002110:Caffeine; D044763:Ubiquitin-Conjugating Enzymes; D044767:Ubiquitin-Protein Ligases; C509836:Mcm7 protein, Xenopus; D064168:Minichromosome Maintenance Complex Component 7; D000074405:Valosin Containing Protein; C539933:pevonedistat', 'keywords': '', 'doi': '10.26508/lsa.201900390', 'references': '8799842;16531994;21282109;26711499;16798881;18042044;26322582;21068752;22694940;26595769;17544371;23446422;26781088;2564315;18514518;24795279;28368371;11585805;25342810;19151749;27323329;26093298;17825564;28355556;23410753;22298039;29467282;26369285;21925316;27462463;22521908;9104814;25335891;30842657;21048783;25342805;17178859;28208741;24553286;27516545;28620461;21799892;18775313;26633632;24440776;17927961;24813613;26820530', 'delete': False, 'affiliations': 'Institute for Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.;Institute for Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.;Institute for Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.;Institute for Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK.;Institute for Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK a.gambus@bham.ac.uk.', 'pmc': '', 'other_id': '', 'medline_ta': 'Life Sci Alliance', 'nlm_unique_id': '101728869', 'issn_linking': '2575-1077', 'country': 'United States'}, 'id_hash_keys': ['content'], 'embedding': None, 'id': '30979826'}>,\n",
       "  <Document: {'content': 'The disassembly of eukaryotic replisome during replication termination is mediated by CRL-dependent poly-ubiquitylation of Mcm7 and p97 segregase. The replisome also disassembles at stalled or collapsed replication forks under certain stress conditions, but the underlying mechanism is poorly understood. Here, we discovered a novel pathway driving stepwise disassembly of the replisome at stalled replication forks after forced entry into M-phase using Xenopus egg extracts. This pathway was dependent on M-CDK activity and K48- and K63-linked poly-ubiquitylation but not on CRL and p97, which is different from known pathways. Furthermore, this pathway could not disassemble converged replisomes whose Mcm7 subunit had been poly-ubiquitylated without p97. These results suggest that there is a distinctive pathway for replisome disassembly when stalled replication forks persist into M-phase.', 'content_type': 'text', 'score': 0.9996931552886963, 'meta': {'title': 'Mitotic entry drives replisome disassembly at stalled replication forks.', 'issue': '506(1)', 'pages': '108-113', 'abstract': 'The disassembly of eukaryotic replisome during replication termination is mediated by CRL-dependent poly-ubiquitylation of Mcm7 and p97 segregase. The replisome also disassembles at stalled or collapsed replication forks under certain stress conditions, but the underlying mechanism is poorly understood. Here, we discovered a novel pathway driving stepwise disassembly of the replisome at stalled replication forks after forced entry into M-phase using Xenopus egg extracts. This pathway was dependent on M-CDK activity and K48- and K63-linked poly-ubiquitylation but not on CRL and p97, which is different from known pathways. Furthermore, this pathway could not disassemble converged replisomes whose Mcm7 subunit had been poly-ubiquitylated without p97. These results suggest that there is a distinctive pathway for replisome disassembly when stalled replication forks persist into M-phase.', 'journal': 'Biochemical and biophysical research communications', 'authors': 'Hashimoto|Yoshitami|Y|;Tanaka|Hirofumi|H|', 'pubdate': '2018', 'pmid': '30340827', 'mesh_terms': 'D000071450:ATP Binding Cassette Transporter, Subfamily B, Member 3; D048868:Adaptor Proteins, Signal Transducing; D000818:Animals; D018797:Cell Cycle Proteins; D000071877:Checkpoint Kinase 1; D002843:Chromatin; D004261:DNA Replication; D064168:Minichromosome Maintenance Complex Component 7; D008938:Mitosis; D011485:Protein Binding; D054875:Ubiquitination; D000074405:Valosin Containing Protein; D029867:Xenopus Proteins; D014982:Xenopus laevis; D015053:Zygote', 'publication_types': \"D016428:Journal Article; D013485:Research Support, Non-U.S. Gov't\", 'chemical_list': 'D000071450:ATP Binding Cassette Transporter, Subfamily B, Member 3; D048868:Adaptor Proteins, Signal Transducing; C416368:CLSPN protein, Xenopus; C502211:Cdc45 protein, Xenopus; D018797:Cell Cycle Proteins; D002843:Chromatin; C489515:TAP2 protein, Xenopus; D029867:Xenopus Proteins; D000071877:Checkpoint Kinase 1; C000605875:Chek1 protein, Xenopus; C509836:Mcm7 protein, Xenopus; D064168:Minichromosome Maintenance Complex Component 7; D000074405:Valosin Containing Protein', 'keywords': 'CDK; CMG complex; Replisome; Ubiquitylation; Xenopus egg extract; p97/VCP/Cdc48', 'doi': '10.1016/j.bbrc.2018.10.064', 'references': '', 'delete': False, 'affiliations': 'School of Life Sciences, Tokyo University of Pharmacy and Life Sciences, 1432-1 Horinouchi, Hachioji, Tokyo, 192-0392, Japan. Electronic address: hashimo@toyaku.ac.jp.;School of Life Sciences, Tokyo University of Pharmacy and Life Sciences, 1432-1 Horinouchi, Hachioji, Tokyo, 192-0392, Japan.', 'pmc': '', 'other_id': '', 'medline_ta': 'Biochem Biophys Res Commun', 'nlm_unique_id': '0372516', 'issn_linking': '0006-291X', 'country': 'United States'}, 'id_hash_keys': ['content'], 'embedding': None, 'id': '30340827'}>,\n",
       "  <Document: {'content': 'The eukaryotic replisome is rapidly disassembled during DNA replication termination. In metazoa, the cullin-RING ubiquitin ligase CUL-2LRR-1 drives ubiquitylation of the CMG helicase, leading to replisome disassembly by the p97/CDC-48 \"unfoldase\". Here, we combine in\\xa0vitro reconstitution with in\\xa0vivo studies in Caenorhabditis elegans embryos, to show that the replisome-associated TIMELESS-TIPIN complex is required for CUL-2LRR-1 recruitment and efficient CMG helicase ubiquitylation. Aided by TIMELESS-TIPIN, CUL-2LRR-1 directs a suite of ubiquitylation enzymes to ubiquitylate the MCM-7 subunit of CMG. Subsequently, the UBXN-3 adaptor protein directly stimulates the disassembly of ubiquitylated CMG by CDC-48_UFD-1_NPL-4. We show that UBXN-3 is important in\\xa0vivo for replisome disassembly in the absence of TIMELESS-TIPIN. Correspondingly, co-depletion of UBXN-3 and TIMELESS causes profound synthetic lethality. Since the human orthologue of UBXN-3, FAF1, is a candidate tumour suppressor, these findings suggest that manipulation of CMG disassembly might be applicable to future strategies for treating human cancer.', 'content_type': 'text', 'score': 0.9993197917938232, 'meta': {'title': 'TIMELESS-TIPIN and UBXN-3 promote replisome disassembly during DNA replication termination in Caenorhabditis elegans.', 'issue': '40(17)', 'pages': 'e108053', 'abstract': 'The eukaryotic replisome is rapidly disassembled during DNA replication termination. In metazoa, the cullin-RING ubiquitin ligase CUL-2LRR-1 drives ubiquitylation of the CMG helicase, leading to replisome disassembly by the p97/CDC-48 \"unfoldase\". Here, we combine in\\xa0vitro reconstitution with in\\xa0vivo studies in Caenorhabditis elegans embryos, to show that the replisome-associated TIMELESS-TIPIN complex is required for CUL-2LRR-1 recruitment and efficient CMG helicase ubiquitylation. Aided by TIMELESS-TIPIN, CUL-2LRR-1 directs a suite of ubiquitylation enzymes to ubiquitylate the MCM-7 subunit of CMG. Subsequently, the UBXN-3 adaptor protein directly stimulates the disassembly of ubiquitylated CMG by CDC-48_UFD-1_NPL-4. We show that UBXN-3 is important in\\xa0vivo for replisome disassembly in the absence of TIMELESS-TIPIN. Correspondingly, co-depletion of UBXN-3 and TIMELESS causes profound synthetic lethality. Since the human orthologue of UBXN-3, FAF1, is a candidate tumour suppressor, these findings suggest that manipulation of CMG disassembly might be applicable to future strategies for treating human cancer.', 'journal': 'The EMBO journal', 'authors': 'Xia|Yisui|Y|0000-0002-5576-2147;Fujisawa|Ryo|R|0000-0003-1985-1668;Deegan|Tom D|TD|0000-0001-9639-7636;Sonneville|Remi|R|0000-0002-2149-2652;Labib|Karim P M|KPM|0000-0001-8861-379X', 'pubdate': '2021', 'pmid': '34269473', 'mesh_terms': 'D000818:Animals; D017173:Caenorhabditis elegans; D029742:Caenorhabditis elegans Proteins; D002352:Carrier Proteins; D044842:Cullin Proteins; D004261:DNA Replication; D004259:DNA-Directed DNA Polymerase; D009097:Multienzyme Complexes; D000072020:Synthetic Lethal Mutations', 'publication_types': \"D016428:Journal Article; D013485:Research Support, Non-U.S. Gov't\", 'chemical_list': 'D029742:Caenorhabditis elegans Proteins; D002352:Carrier Proteins; D044842:Cullin Proteins; D009097:Multienzyme Complexes; C400537:TIM-1 protein, C elegans; C000608562:UBXN-3 protein, C elegans; C107915:DNA synthesome; D004259:DNA-Directed DNA Polymerase', 'keywords': 'CDC-48; CMG helicase; CUL-2LRR-1; DNA replication termination; TIMELESS-TIPIN; UBXN-3', 'doi': '10.15252/embj.2021108053', 'references': '21645854;21981920;31509741;28355556;32305021;25739503;27565338;20977550;28368371;25342810;28475898;30849395;26842564;33536622;31545170;34269473;32943574;30979826;31868589;28301743;28512218;32705708;17296725;27384026;32369734;26322582;27565346;27015313;10587644;19597341;10834843;28525741;33166393;31249135;32179092;32804080;30796221;33484638;28375744;12783801;20978077;16137625;25342805;8670823;29357060;31898220;26255844;27716483;30952443;22537386;31419624;32004468;33160249;28235849;10421634;32051583;33402676;19805627', 'delete': False, 'affiliations': 'The MRC Protein Phosphorylation and Ubiquitylation Unit, School of Life Sciences, University of Dundee, Dundee, UK.;The MRC Protein Phosphorylation and Ubiquitylation Unit, School of Life Sciences, University of Dundee, Dundee, UK.;The MRC Protein Phosphorylation and Ubiquitylation Unit, School of Life Sciences, University of Dundee, Dundee, UK.;The MRC Protein Phosphorylation and Ubiquitylation Unit, School of Life Sciences, University of Dundee, Dundee, UK.;The MRC Protein Phosphorylation and Ubiquitylation Unit, School of Life Sciences, University of Dundee, Dundee, UK.', 'pmc': '', 'other_id': '', 'medline_ta': 'EMBO J', 'nlm_unique_id': '8208664', 'issn_linking': '0261-4189', 'country': 'England'}, 'id_hash_keys': ['content'], 'embedding': None, 'id': '34269473'}>,\n",
       "  <Document: {'content': 'Cullin ubiquitin ligases drive replisome disassembly during DNA replication termination. In worm, frog and mouse cells, CUL2LRR1 is required to ubiquitylate the MCM7 subunit of the CMG helicase. Here, we show that cullin ligases also drive CMG-MCM7 ubiquitylation in human cells, thereby making the helicase into a substrate for the p97 unfoldase. Using purified human proteins, including a panel of E2 ubiquitin-conjugating enzymes, we have reconstituted CMG helicase ubiquitylation, dependent upon neddylated CUL2LRR1. The reaction is highly specific to CMG-MCM7 and requires the LRR1 substrate targeting subunit, since replacement of LRR1 with the alternative CUL2 adaptor VHL switches ubiquitylation from CMG-MCM7 to HIF1. CUL2LRR1 firstly drives monoubiquitylation of CMG-MCM7 by the UBE2D class of E2 enzymes. Subsequently, CUL2LRR1 activates UBE2R1/R2 or UBE2G1/G2 to extend a single K48-linked ubiquitin chain on CMG-MCM7. Thereby, CUL2LRR1 converts CMG into a substrate for p97, which disassembles the ubiquitylated helicase during DNA replication termination.', 'content_type': 'text', 'score': 0.9991849064826965, 'meta': {'title': 'Reconstitution of human CMG helicase ubiquitylation by CUL2LRR1 and multiple E2 enzymes.', 'issue': '478(14)', 'pages': '2825-2842', 'abstract': 'Cullin ubiquitin ligases drive replisome disassembly during DNA replication termination. In worm, frog and mouse cells, CUL2LRR1 is required to ubiquitylate the MCM7 subunit of the CMG helicase. Here, we show that cullin ligases also drive CMG-MCM7 ubiquitylation in human cells, thereby making the helicase into a substrate for the p97 unfoldase. Using purified human proteins, including a panel of E2 ubiquitin-conjugating enzymes, we have reconstituted CMG helicase ubiquitylation, dependent upon neddylated CUL2LRR1. The reaction is highly specific to CMG-MCM7 and requires the LRR1 substrate targeting subunit, since replacement of LRR1 with the alternative CUL2 adaptor VHL switches ubiquitylation from CMG-MCM7 to HIF1. CUL2LRR1 firstly drives monoubiquitylation of CMG-MCM7 by the UBE2D class of E2 enzymes. Subsequently, CUL2LRR1 activates UBE2R1/R2 or UBE2G1/G2 to extend a single K48-linked ubiquitin chain on CMG-MCM7. Thereby, CUL2LRR1 converts CMG into a substrate for p97, which disassembles the ubiquitylated helicase during DNA replication termination.', 'journal': 'The Biochemical journal', 'authors': 'Le|Thanh Thi|TT|;Ainsworth|Johanna|J|;Polo Rivera|Cristian|C|;Macartney|Thomas|T|;Labib|Karim P M|KPM|0000-0001-8861-379X', 'pubdate': '2021', 'pmid': '34195792', 'mesh_terms': 'D000818:Animals; D002460:Cell Line; D003001:Cloning, Molecular; D044842:Cullin Proteins; D004265:DNA Helicases; D006801:Humans; D015151:Immunoblotting; D008239:Lysine; D064168:Minichromosome Maintenance Complex Component 7; D012097:Repressor Proteins; D061987:Sf9 Cells; D018411:Spodoptera; D025801:Ubiquitin; D044763:Ubiquitin-Conjugating Enzymes; D044767:Ubiquitin-Protein Ligases; D054875:Ubiquitination; D000074405:Valosin Containing Protein', 'publication_types': \"D016428:Journal Article; D013485:Research Support, Non-U.S. Gov't\", 'chemical_list': 'C105153:CUL2 protein, human; D044842:Cullin Proteins; C464446:LRR1 protein, human; D012097:Repressor Proteins; D025801:Ubiquitin; D044763:Ubiquitin-Conjugating Enzymes; D044767:Ubiquitin-Protein Ligases; D004265:DNA Helicases; D064168:Minichromosome Maintenance Complex Component 7; D000074405:Valosin Containing Protein; D008239:Lysine', 'keywords': 'CMG helicase; CUL2LRR1; DNA synthesis and repair; cullin ligase; p97; ubiquitins', 'doi': '10.1042/BCJ20210315', 'references': '', 'delete': False, 'affiliations': 'The MRC Protein Phosphorylation and Ubiquitylation Unit, School of Life Sciences, University of Dundee, Dundee DD1 5EH, U.K.;The MRC Protein Phosphorylation and Ubiquitylation Unit, School of Life Sciences, University of Dundee, Dundee DD1 5EH, U.K.;The MRC Protein Phosphorylation and Ubiquitylation Unit, School of Life Sciences, University of Dundee, Dundee DD1 5EH, U.K.;The MRC Protein Phosphorylation and Ubiquitylation Unit, School of Life Sciences, University of Dundee, Dundee DD1 5EH, U.K.;The MRC Protein Phosphorylation and Ubiquitylation Unit, School of Life Sciences, University of Dundee, Dundee DD1 5EH, U.K.', 'pmc': '', 'other_id': '', 'medline_ta': 'Biochem J', 'nlm_unique_id': '2984726R', 'issn_linking': '0264-6021', 'country': 'England'}, 'id_hash_keys': ['content'], 'embedding': None, 'id': '34195792'}>,\n",
       "  <Document: {'content': 'Replisome disassembly is the final step of DNA replication in eukaryotes, involving the ubiquitylation and CDC48-dependent dissolution of the CMG helicase (CDC45-MCM-GINS). Using Caenorhabditis elegans early embryos and Xenopus laevis egg extracts, we show that the E3 ligase CUL-2LRR-1 associates with the replisome and drives ubiquitylation and disassembly of CMG, together with the CDC-48 cofactors UFD-1 and NPL-4. Removal of CMG from chromatin in frog egg extracts requires CUL2 neddylation, and our data identify chromatin recruitment of CUL2LRR1 as a key regulated step during DNA replication termination. Interestingly, however, CMG persists on chromatin until prophase in worms that lack CUL-2LRR-1, but is then removed by a mitotic pathway that requires the CDC-48 cofactor UBXN-3, orthologous to the human tumour suppressor FAF1. Partial inactivation of lrr-1 and ubxn-3 leads to synthetic lethality, suggesting future approaches by which a deeper understanding of CMG disassembly in metazoa could be exploited therapeutically.', 'content_type': 'text', 'score': 0.9986580610275269, 'meta': {'title': 'CUL-2LRR-1 and UBXN-3 drive replisome disassembly during DNA replication termination and\\xa0mitosis.', 'issue': '19(5)', 'pages': '468-479', 'abstract': 'Replisome disassembly is the final step of DNA replication in eukaryotes, involving the ubiquitylation and CDC48-dependent dissolution of the CMG helicase (CDC45-MCM-GINS). Using Caenorhabditis elegans early embryos and Xenopus laevis egg extracts, we show that the E3 ligase CUL-2LRR-1 associates with the replisome and drives ubiquitylation and disassembly of CMG, together with the CDC-48 cofactors UFD-1 and NPL-4. Removal of CMG from chromatin in frog egg extracts requires CUL2 neddylation, and our data identify chromatin recruitment of CUL2LRR1 as a key regulated step during DNA replication termination. Interestingly, however, CMG persists on chromatin until prophase in worms that lack CUL-2LRR-1, but is then removed by a mitotic pathway that requires the CDC-48 cofactor UBXN-3, orthologous to the human tumour suppressor FAF1. Partial inactivation of lrr-1 and ubxn-3 leads to synthetic lethality, suggesting future approaches by which a deeper understanding of CMG disassembly in metazoa could be exploited therapeutically.', 'journal': 'Nature cell biology', 'authors': 'Sonneville|Remi|R|;Moreno|Sara Priego|SP|;Knebel|Axel|A|;Johnson|Clare|C|;Hastie|C James|CJ|;Gartner|Anton|A|;Gambus|Agnieszka|A|http://orcid.org/0000-0002-4648-0332;Labib|Karim|K|http://orcid.org/0000-0001-8861-379X', 'pubdate': '2017', 'pmid': '28368371', 'mesh_terms': 'D000251:Adenosine Triphosphatases; D000818:Animals; D030801:Animals, Genetically Modified; D017173:Caenorhabditis elegans; D029742:Caenorhabditis elegans Proteins; D002352:Carrier Proteins; D018797:Cell Cycle Proteins; D002843:Chromatin; D042002:Chromatin Assembly and Disassembly; D044842:Cullin Proteins; D004247:DNA; D005838:Genotype; D008938:Mitosis; D046912:Multiprotein Complexes; D009865:Oocytes; D010641:Phenotype; D034622:RNA Interference; D016196:S Phase; D013997:Time Factors; D054875:Ubiquitination; D000074405:Valosin Containing Protein; D029867:Xenopus Proteins; D014982:Xenopus laevis', 'publication_types': 'D016428:Journal Article; D059040:Video-Audio Media', 'chemical_list': 'D029742:Caenorhabditis elegans Proteins; D002352:Carrier Proteins; D018797:Cell Cycle Proteins; D002843:Chromatin; D044842:Cullin Proteins; D046912:Multiprotein Complexes; C000608562:UBXN-3 protein, C elegans; D029867:Xenopus Proteins; C491027:cul-2 proteins, C elegans; D004247:DNA; D000251:Adenosine Triphosphatases; D000074405:Valosin Containing Protein', 'keywords': '', 'doi': '10.1038/ncb3500', 'references': '23293021;18381889;19597341;20122406;18805092;27003891;21963883;21074724;22705378;26866665;18514518;9804418;21981920;18050450;19913425;26166571;16531994;27693351;23499531;25342810;21554755;26842564;23641252;21282109;10644704;26410407;22298039;16647269;10811609;19661920;16798881;27543292;27384026;26322582;2387862;19360080;11005825;10834843;22521908;27200082;11967157;4366476;27086594;20978077;22249291;17374636;25342805;18851830;25475837;26255844;22537386;27644328;25342784', 'delete': False, 'affiliations': 'MRC Protein Phosphorylation and Ubiquitylation Unit, School of Life Sciences, University of Dundee, Dow Street, Dundee DD1 5EH, UK.;Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK.;MRC Protein Phosphorylation and Ubiquitylation Unit, School of Life Sciences, University of Dundee, Dow Street, Dundee DD1 5EH, UK.;MRC Protein Phosphorylation and Ubiquitylation Unit, School of Life Sciences, University of Dundee, Dow Street, Dundee DD1 5EH, UK.;MRC Protein Phosphorylation and Ubiquitylation Unit, School of Life Sciences, University of Dundee, Dow Street, Dundee DD1 5EH, UK.;Centre for Gene Regulation and Expression, School of Life Sciences, University of Dundee, Dow Street, Dundee DD1 5EH, UK.;Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK.;MRC Protein Phosphorylation and Ubiquitylation Unit, School of Life Sciences, University of Dundee, Dow Street, Dundee DD1 5EH, UK.', 'pmc': '', 'other_id': '', 'medline_ta': 'Nat Cell Biol', 'nlm_unique_id': '100890575', 'issn_linking': '1465-7392', 'country': 'England'}, 'id_hash_keys': ['content'], 'embedding': None, 'id': '28368371'}>,\n",
       "  <Document: {'content': 'Replisome disassembly is the final step of eukaryotic DNA replication and is triggered by ubiquitylation of the CDC45-MCM-GINS (CMG) replicative helicase1-3. Despite being driven by evolutionarily diverse E3 ubiquitin ligases in different eukaryotes (SCFDia2 in budding yeast1, CUL2LRR1 in metazoa4-7), replisome disassembly is governed by a common regulatory principle, in which ubiquitylation of CMG is suppressed before replication termination, to prevent replication fork collapse. Recent evidence suggests that this suppression is mediated by replication fork DNA8-10. However, it is unknown how SCFDia2 and CUL2LRR1 discriminate terminated from elongating replisomes, to selectively ubiquitylate CMG only after termination. Here we used cryo-electron microscopy to solve high-resolution structures of budding yeast and human replisome-E3 ligase assemblies. Our structures show that the leucine-rich repeat domains of Dia2 and LRR1 are structurally distinct, but bind to a common site on CMG, including the MCM3 and MCM5 zinc-finger domains. The LRR-MCM interaction is essential for replisome disassembly and, crucially, is occluded by the excluded DNA strand at replication forks, establishing the structural basis for the suppression of CMG ubiquitylation before termination. Our results elucidate a conserved mechanism for the regulation of replisome disassembly in eukaryotes, and reveal a previously unanticipated role for DNA in preserving replisome integrity.', 'content_type': 'text', 'score': 0.9984357953071594, 'meta': {'title': 'A conserved mechanism for regulating replisome disassembly in eukaryotes.', 'issue': '600(7890)', 'pages': '743-747', 'abstract': 'Replisome disassembly is the final step of eukaryotic DNA replication and is triggered by ubiquitylation of the CDC45-MCM-GINS (CMG) replicative helicase1-3. Despite being driven by evolutionarily diverse E3 ubiquitin ligases in different eukaryotes (SCFDia2 in budding yeast1, CUL2LRR1 in metazoa4-7), replisome disassembly is governed by a common regulatory principle, in which ubiquitylation of CMG is suppressed before replication termination, to prevent replication fork collapse. Recent evidence suggests that this suppression is mediated by replication fork DNA8-10. However, it is unknown how SCFDia2 and CUL2LRR1 discriminate terminated from elongating replisomes, to selectively ubiquitylate CMG only after termination. Here we used cryo-electron microscopy to solve high-resolution structures of budding yeast and human replisome-E3 ligase assemblies. Our structures show that the leucine-rich repeat domains of Dia2 and LRR1 are structurally distinct, but bind to a common site on CMG, including the MCM3 and MCM5 zinc-finger domains. The LRR-MCM interaction is essential for replisome disassembly and, crucially, is occluded by the excluded DNA strand at replication forks, establishing the structural basis for the suppression of CMG ubiquitylation before termination. Our results elucidate a conserved mechanism for the regulation of replisome disassembly in eukaryotes, and reveal a previously unanticipated role for DNA in preserving replisome integrity.', 'journal': 'Nature', 'authors': 'Jenkyn-Bedford|Michael|M|http://orcid.org/0000-0003-2335-8278;Jones|Morgan L|ML|http://orcid.org/0000-0003-1948-4925;Baris|Yasemin|Y|;Labib|Karim P M|KPM|;Cannone|Giuseppe|G|;Yeeles|Joseph T P|JTP|http://orcid.org/0000-0002-2255-2119;Deegan|Tom D|TD|http://orcid.org/0000-0001-9639-7636', 'pubdate': '2021', 'pmid': '34700328', 'mesh_terms': 'D020285:Cryoelectron Microscopy; D004247:DNA; D004265:DNA Helicases; D004261:DNA Replication; D056890:Eukaryota; D006801:Humans; D044767:Ubiquitin-Protein Ligases', 'publication_types': \"D016428:Journal Article; D013485:Research Support, Non-U.S. Gov't\", 'chemical_list': 'D004247:DNA; D044767:Ubiquitin-Protein Ligases; D004265:DNA Helicases', 'keywords': '', 'doi': '10.1038/s41586-021-04145-3', 'references': '', 'delete': False, 'affiliations': 'MRC Laboratory of Molecular Biology, Cambridge, UK.;MRC Laboratory of Molecular Biology, Cambridge, UK.;MRC Laboratory of Molecular Biology, Cambridge, UK.;MRC Protein Phosphorylation and Ubiquitylation Unit, Sir James Black Centre, School of Life Sciences, University of Dundee, Dundee, UK.;MRC Laboratory of Molecular Biology, Cambridge, UK.;MRC Laboratory of Molecular Biology, Cambridge, UK. jyeeles@mrc-lmb.cam.ac.uk.;MRC Protein Phosphorylation and Ubiquitylation Unit, Sir James Black Centre, School of Life Sciences, University of Dundee, Dundee, UK. tdeegan@ed.ac.uk.', 'pmc': '', 'other_id': '', 'medline_ta': 'Nature', 'nlm_unique_id': '0410462', 'issn_linking': '0028-0836', 'country': 'England'}, 'id_hash_keys': ['content'], 'embedding': None, 'id': '34700328'}>,\n",
       "  <Document: {'content': 'Complex cellular processes are driven by the regulated assembly and disassembly of large multiprotein complexes. While we are beginning to understand the molecular mechanism for assembly of the eukaryotic DNA replication machinery (replisome), we still know relatively little about the regulation of its disassembly at replication termination. Recently, the first elements of this process have emerged, revealing that the replicative helicase, at the heart of the replisome, is polyubiquitylated prior to unloading and that this unloading requires p97 segregase activity. Two different E3 ubiquitin ligases have now been shown to ubiquitylate the helicase under different conditions: Cul2Lrr1 and TRAIP. Here, using Xenopus laevis egg extract cell-free system and biochemical approaches, we have found two p97 cofactors, Ubxn7 and Faf1, which can interact with p97 during replisome disassembly during S-phase. We show only Ubxn7, however, facilitates efficient replisome disassembly. Ubxn7 delivers this role through its interaction via independent domains with both Cul2Lrr1 and p97 to allow coupling between Mcm7 ubiquitylation and its removal from chromatin. Our data therefore characterize Ubxn7 as the first substrate-specific p97 cofactor regulating replisome disassembly in vertebrates and a rationale for the efficacy of the Cul2Lrr1 replisome unloading pathway in unperturbed S-phase.', 'content_type': 'text', 'score': 0.9981709718704224, 'meta': {'title': 'The p97 segregase cofactor Ubxn7 facilitates replisome disassembly during S-phase.', 'issue': '298(8)', 'pages': '102234', 'abstract': 'Complex cellular processes are driven by the regulated assembly and disassembly of large multiprotein complexes. While we are beginning to understand the molecular mechanism for assembly of the eukaryotic DNA replication machinery (replisome), we still know relatively little about the regulation of its disassembly at replication termination. Recently, the first elements of this process have emerged, revealing that the replicative helicase, at the heart of the replisome, is polyubiquitylated prior to unloading and that this unloading requires p97 segregase activity. Two different E3 ubiquitin ligases have now been shown to ubiquitylate the helicase under different conditions: Cul2Lrr1 and TRAIP. Here, using Xenopus laevis egg extract cell-free system and biochemical approaches, we have found two p97 cofactors, Ubxn7 and Faf1, which can interact with p97 during replisome disassembly during S-phase. We show only Ubxn7, however, facilitates efficient replisome disassembly. Ubxn7 delivers this role through its interaction via independent domains with both Cul2Lrr1 and p97 to allow coupling between Mcm7 ubiquitylation and its removal from chromatin. Our data therefore characterize Ubxn7 as the first substrate-specific p97 cofactor regulating replisome disassembly in vertebrates and a rationale for the efficacy of the Cul2Lrr1 replisome unloading pathway in unperturbed S-phase.', 'journal': 'The Journal of biological chemistry', 'authors': 'Tarcan|Zeynep|Z|;Poovathumkadavil|Divyasree|D|;Skagia|Aggeliki|A|;Gambus|Agnieszka|A|', 'pubdate': '2022', 'pmid': '35798141', 'mesh_terms': 'D048868:Adaptor Proteins, Signal Transducing; D000818:Animals; D002843:Chromatin; D004265:DNA Helicases; D004261:DNA Replication; D064168:Minichromosome Maintenance Complex Component 7; D016196:S Phase; D054875:Ubiquitination; D029867:Xenopus Proteins; D014982:Xenopus laevis', 'publication_types': \"D016428:Journal Article; D013485:Research Support, Non-U.S. Gov't\", 'chemical_list': 'D048868:Adaptor Proteins, Signal Transducing; D002843:Chromatin; D029867:Xenopus Proteins; D004265:DNA Helicases; C509836:Mcm7 protein, Xenopus; D064168:Minichromosome Maintenance Complex Component 7', 'keywords': 'DNA replication; Xenopus laevis; p97 segregase; termination of DNA replication; ubiquitin', 'doi': '10.1016/j.jbc.2022.102234', 'references': '', 'delete': False, 'affiliations': 'Institute of Cancer and Genomic Sciences, Birmingham Centre for Genome Biology, College of Medical and Dental Sciences, University of Birmingham, Vincent Drive, Birmingham United Kingdom.;Institute of Cancer and Genomic Sciences, Birmingham Centre for Genome Biology, College of Medical and Dental Sciences, University of Birmingham, Vincent Drive, Birmingham United Kingdom.;Institute of Cancer and Genomic Sciences, Birmingham Centre for Genome Biology, College of Medical and Dental Sciences, University of Birmingham, Vincent Drive, Birmingham United Kingdom.;Institute of Cancer and Genomic Sciences, Birmingham Centre for Genome Biology, College of Medical and Dental Sciences, University of Birmingham, Vincent Drive, Birmingham United Kingdom. Electronic address: a.gambus@bham.ac.uk.', 'pmc': '', 'other_id': '', 'medline_ta': 'J Biol Chem', 'nlm_unique_id': '2985121R', 'issn_linking': '0021-9258', 'country': 'United States'}, 'id_hash_keys': ['content'], 'embedding': None, 'id': '35798141'}>,\n",
       "  <Document: {'content': 'The faithful segregation of eukaryotic chromosomes in mitosis requires that the genome be duplicated completely prior to anaphase. However, cells with large genomes sometimes fail to complete replication during interphase and instead enter mitosis with regions of incompletely replicated DNA. These regions are processed in early mitosis via a process known as mitotic DNA repair synthesis (MiDAS), but little is known about how cells switch from conventional DNA replication to MiDAS. Using the early embryo of the nematode Caenorhabditis elegans as a model system, we show that the TRAIP ubiquitin ligase drives replisome disassembly in response to incomplete DNA replication, thereby providing access to replication forks for other factors. Moreover, TRAIP is essential for MiDAS in human cells, and is important in both systems to prevent mitotic segregation errors. Our data indicate that TRAIP is a master regulator of the processing of incomplete DNA replication during mitosis in metazoa.', 'content_type': 'text', 'score': 0.9981058835983276, 'meta': {'title': 'TRAIP drives replisome disassembly and mitotic DNA repair synthesis at sites of incomplete DNA replication.', 'issue': '8()', 'pages': '', 'abstract': 'The faithful segregation of eukaryotic chromosomes in mitosis requires that the genome be duplicated completely prior to anaphase. However, cells with large genomes sometimes fail to complete replication during interphase and instead enter mitosis with regions of incompletely replicated DNA. These regions are processed in early mitosis via a process known as mitotic DNA repair synthesis (MiDAS), but little is known about how cells switch from conventional DNA replication to MiDAS. Using the early embryo of the nematode Caenorhabditis elegans as a model system, we show that the TRAIP ubiquitin ligase drives replisome disassembly in response to incomplete DNA replication, thereby providing access to replication forks for other factors. Moreover, TRAIP is essential for MiDAS in human cells, and is important in both systems to prevent mitotic segregation errors. Our data indicate that TRAIP is a master regulator of the processing of incomplete DNA replication during mitosis in metazoa.', 'journal': 'eLife', 'authors': 'Sonneville|Remi|R|;Bhowmick|Rahul|R|;Hoffmann|Saskia|S|;Mailand|Niels|N|;Hickson|Ian D|ID|;Labib|Karim|K|0000-0001-8861-379X', 'pubdate': '2019', 'pmid': '31545170', 'mesh_terms': 'D000818:Animals; D017173:Caenorhabditis elegans; D029742:Caenorhabditis elegans Proteins; D002460:Cell Line; D004260:DNA Repair; D004261:DNA Replication; D017353:Gene Deletion; D006801:Humans; D008938:Mitosis; D044767:Ubiquitin-Protein Ligases', 'publication_types': \"D016428:Journal Article; D013485:Research Support, Non-U.S. Gov't\", 'chemical_list': 'D029742:Caenorhabditis elegans Proteins; D044767:Ubiquitin-Protein Ligases; C000656696:trul-1 protein, C elegans', 'keywords': 'C. elegans; DNA replication; TRAIP; chromosomes; fragile site; gene expression; genome stability; human; mitosis; ubiquitin ligase', 'doi': '', 'references': '28368371;9804418;21981920;21317883;26166571;28537574;30849395;25342810;28355556;30979826;26711499;22025633;27462463;28740117;26595769;20978077;22249291;4366476;30842657;25342805;27516545;28620461;11112326;28235849;19141674;26633632;27630194;12747829;27984745;26781088;17927961', 'delete': False, 'affiliations': 'MRC Protein Phosphorylation and Ubiquitylation Unit, School of Life Sciences, University of Dundee, Dundee, United Kingdom.;Department of Cellular and Molecular Medicine, Center for Chromosome Stability, University of Copenhagen, Copenhagen, Denmark.;Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.;Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.;Department of Cellular and Molecular Medicine, Center for Chromosome Stability, University of Copenhagen, Copenhagen, Denmark.;MRC Protein Phosphorylation and Ubiquitylation Unit, School of Life Sciences, University of Dundee, Dundee, United Kingdom.', 'pmc': '', 'other_id': '', 'medline_ta': 'Elife', 'nlm_unique_id': '101579614', 'issn_linking': '2050-084X', 'country': 'England'}, 'id_hash_keys': ['content'], 'embedding': None, 'id': '31545170'}>,\n",
       "  <Document: {'content': 'Disassembly of the Cdc45-MCM-GINS (CMG) DNA helicase, which unwinds the parental DNA duplex at eukaryotic replication forks, is the key regulated step during replication termination but is poorly understood. In budding yeast, the F-box protein Dia2 drives ubiquitylation of the CMG helicase at the end of replication, leading to a disassembly pathway that requires the Cdc48 segregase. The substrate-binding domain of Dia2 comprises leucine-rich repeats, but Dia2 also has a TPR domain at its amino terminus that interacts with the Ctf4 and Mrc1 subunits of the replisome progression complex, which assembles around the CMG helicase at replication forks. Previous studies suggested two disparate roles for the TPR domain of Dia2, either mediating replisome-specific degradation of Mrc1 and Ctf4 or else tethering SCF(Dia2) (SCF [Skp1/cullin/F-box protein]) to the replisome to increase its local concentration at replication forks. Here, we show that SCF(Dia2) does not mediate replisome-specific degradation of Mrc1 and Ctf4, either during normal S phase or in response to replication stress. Instead, the tethering of SCF(Dia2) to the replisome progression complex increases the efficiency of ubiquitylation of the Mcm7 subunit of CMG, both in vitro and in vivo. Correspondingly, loss of tethering reduces the efficiency of CMG disassembly in vivo and is synthetic lethal in combination with a disassembly-defective allele of CDC48. Residual ubiquitylation of Mcm7 in dia2-ΔTPR cells is still CMG specific, highlighting the complex regulation of the final stages of chromosome replication, about which much still remains to be learned.', 'content_type': 'text', 'score': 0.9978166818618774, 'meta': {'title': 'Tethering of SCF(Dia2) to the Replisome Promotes Efficient Ubiquitylation and Disassembly of the CMG Helicase.', 'issue': '25(17)', 'pages': '2254-9', 'abstract': 'Disassembly of the Cdc45-MCM-GINS (CMG) DNA helicase, which unwinds the parental DNA duplex at eukaryotic replication forks, is the key regulated step during replication termination but is poorly understood. In budding yeast, the F-box protein Dia2 drives ubiquitylation of the CMG helicase at the end of replication, leading to a disassembly pathway that requires the Cdc48 segregase. The substrate-binding domain of Dia2 comprises leucine-rich repeats, but Dia2 also has a TPR domain at its amino terminus that interacts with the Ctf4 and Mrc1 subunits of the replisome progression complex, which assembles around the CMG helicase at replication forks. Previous studies suggested two disparate roles for the TPR domain of Dia2, either mediating replisome-specific degradation of Mrc1 and Ctf4 or else tethering SCF(Dia2) (SCF [Skp1/cullin/F-box protein]) to the replisome to increase its local concentration at replication forks. Here, we show that SCF(Dia2) does not mediate replisome-specific degradation of Mrc1 and Ctf4, either during normal S phase or in response to replication stress. Instead, the tethering of SCF(Dia2) to the replisome progression complex increases the efficiency of ubiquitylation of the Mcm7 subunit of CMG, both in vitro and in vivo. Correspondingly, loss of tethering reduces the efficiency of CMG disassembly in vivo and is synthetic lethal in combination with a disassembly-defective allele of CDC48. Residual ubiquitylation of Mcm7 in dia2-ΔTPR cells is still CMG specific, highlighting the complex regulation of the final stages of chromosome replication, about which much still remains to be learned.', 'journal': 'Current biology : CB', 'authors': 'Maculins|Timurs|T|;Nkosi|Pedro Junior|PJ|;Nishikawa|Hiroko|H|;Labib|Karim|K|', 'pubdate': '2015', 'pmid': '26255844', 'mesh_terms': 'D004261:DNA Replication; D004271:DNA, Fungal; D004268:DNA-Binding Proteins; D044783:F-Box Proteins; D064168:Minichromosome Maintenance Complex Component 7; D016196:S Phase; D012441:Saccharomyces cerevisiae; D029701:Saccharomyces cerevisiae Proteins; D054875:Ubiquitination', 'publication_types': \"D016428:Journal Article; D013485:Research Support, Non-U.S. Gov't\", 'chemical_list': 'C078338:CTF4 protein, S cerevisiae; D004271:DNA, Fungal; D004268:DNA-Binding Proteins; C495983:Dia2 protein, S cerevisiae; D044783:F-Box Proteins; D029701:Saccharomyces cerevisiae Proteins; C491088:MCM7 protein, S cerevisiae; D064168:Minichromosome Maintenance Complex Component 7', 'keywords': '', 'doi': '', 'references': '20724597;20647475;25342805;25342810;25400145;12769855;11809834;25391904;4579463;4618856;16487579;16421250;16531994;16751663;19913425;19910927;25342784', 'delete': False, 'affiliations': 'Cancer Research UK Manchester Institute, University of Manchester, Wilmslow Road, Manchester M20 4BX, UK.;MRC Protein Phosphorylation and Ubiquitylation Unit, Sir James Black Centre, College of Life Sciences, University of Dundee, Dow Street, Dundee DD1 5EH, UK.;Cancer Research UK Manchester Institute, University of Manchester, Wilmslow Road, Manchester M20 4BX, UK.;MRC Protein Phosphorylation and Ubiquitylation Unit, Sir James Black Centre, College of Life Sciences, University of Dundee, Dow Street, Dundee DD1 5EH, UK. Electronic address: kpmlabib@dundee.ac.uk.', 'pmc': '', 'other_id': '', 'medline_ta': 'Curr Biol', 'nlm_unique_id': '9107782', 'issn_linking': '0960-9822', 'country': 'England'}, 'id_hash_keys': ['content'], 'embedding': None, 'id': '26255844'}>,\n",
       "  <Document: {'content': 'DNA replication is a complex process that needs to be executed accurately before cell division in order to maintain genome integrity. DNA replication is divided into three main stages: initiation, elongation and termination. One of the key events during initiation is the assembly of the replicative helicase at origins of replication, and this mechanism has been very well described over the last decades. In the last six years however, researchers have also focused on deciphering the molecular mechanisms underlying the disassembly of the replicative helicase during termination. Similar to replisome assembly, the mechanism of replisome disassembly is strictly regulated and well conserved throughout evolution, although its complexity increases in higher eukaryotes. While budding yeast rely on just one pathway for replisome disassembly in S phase, higher eukaryotes evolved an additional mitotic pathway over and above the default S phase specific pathway. Moreover, replisome disassembly has been recently found to be a key event prior to the repair of certain DNA lesions, such as under-replicated DNA in mitosis and inter-strand cross-links (ICLs) in S phase. Although replisome disassembly in human cells has not been characterised yet, they possess all of the factors involved in these pathways in model organisms, and de-regulation of many of them are known to contribute to tumorigenesis and other pathological conditions.', 'content_type': 'text', 'score': 0.9972708821296692, 'meta': {'title': 'Mechanisms of eukaryotic replisome disassembly.', 'issue': '48(3)', 'pages': '823-836', 'abstract': 'DNA replication is a complex process that needs to be executed accurately before cell division in order to maintain genome integrity. DNA replication is divided into three main stages: initiation, elongation and termination. One of the key events during initiation is the assembly of the replicative helicase at origins of replication, and this mechanism has been very well described over the last decades. In the last six years however, researchers have also focused on deciphering the molecular mechanisms underlying the disassembly of the replicative helicase during termination. Similar to replisome assembly, the mechanism of replisome disassembly is strictly regulated and well conserved throughout evolution, although its complexity increases in higher eukaryotes. While budding yeast rely on just one pathway for replisome disassembly in S phase, higher eukaryotes evolved an additional mitotic pathway over and above the default S phase specific pathway. Moreover, replisome disassembly has been recently found to be a key event prior to the repair of certain DNA lesions, such as under-replicated DNA in mitosis and inter-strand cross-links (ICLs) in S phase. Although replisome disassembly in human cells has not been characterised yet, they possess all of the factors involved in these pathways in model organisms, and de-regulation of many of them are known to contribute to tumorigenesis and other pathological conditions.', 'journal': 'Biochemical Society transactions', 'authors': 'Moreno|Sara Priego|SP|;Gambus|Agnieszka|A|', 'pubdate': '2020', 'pmid': '32490508', 'mesh_terms': 'D000818:Animals; D017173:Caenorhabditis elegans; D002453:Cell Cycle; D018797:Cell Cycle Proteins; D002470:Cell Survival; D004247:DNA; D004261:DNA Replication; D016678:Genome; D006801:Humans; D064168:Minichromosome Maintenance Complex Component 7; D008938:Mitosis; D009369:Neoplasms; D025941:Protein Interaction Mapping; D018741:Replication Origin; D016196:S Phase; D012441:Saccharomyces cerevisiae; D004718:Saccharomycetales; D025801:Ubiquitin; D044767:Ubiquitin-Protein Ligases; D054875:Ubiquitination; D014982:Xenopus laevis', 'publication_types': 'D016428:Journal Article; D016454:Review', 'chemical_list': 'D018797:Cell Cycle Proteins; D025801:Ubiquitin; D004247:DNA; D044767:Ubiquitin-Protein Ligases; C101624:MCM7 protein, human; D064168:Minichromosome Maintenance Complex Component 7', 'keywords': 'Cullin2-LRR1; TRAIP; genome integrity; p97; replisome disassembly; ubiquitylation', 'doi': '10.1042/BST20190363', 'references': '28368371;19910535;31545170;30675527;25739503;25835602;26255844;25957489;27555051;27075410;31200185;26866665;21981920;19913425;19965384;28537574;16531994;29530982;31509741;21317883;30850330;30849395;25342810;30804506;28355556;29357058;30979826;26711499;25643322;24267891;28301743;16487579;26322582;30700044;19896182;27565346;28451587;19465922;27462463;28740117;27200082;31249135;28886337;29357065;29123070;16421250;26595769;30842657;27086594;31249134;25342805;24553286;29924986;27516545;28620461;16751663;29489749;28235849;27644328;28739890;21719678;26633632;30647138;18805090;27649880;26121093;24726325', 'delete': False, 'affiliations': 'The Salk Institute for Biological Studies, 10010 N Torrey Pines Rd, La Jolla, CA 92037, U.S.A.;Institute for Cancer and Genomic Sciences, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham B15 2TT, U.K.', 'pmc': '', 'other_id': '', 'medline_ta': 'Biochem Soc Trans', 'nlm_unique_id': '7506897', 'issn_linking': '0300-5127', 'country': 'England'}, 'id_hash_keys': ['content'], 'embedding': None, 'id': '32490508'}>],\n",
       " 'root_node': 'Query',\n",
       " 'params': {'BM25Retriever': {'top_k': 100}},\n",
       " 'node_id': 'Reader'}"
      ]
     },
     "execution_count": 5,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "prediction"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "id": "57ece303",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      "  0%|                                                                                                                    | 0/75 [00:00<?, ?it/s]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "5224822d5d174e87badad2e2ed4e8b3a",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/1 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      "  1%|█▍                                                                                                          | 1/75 [00:05<06:26,  5.23s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "a362e59b00c24202a69d1ff5d0d4ea03",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/1 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      "  3%|██▉                                                                                                         | 2/75 [00:10<06:10,  5.07s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "5af9455933714366b56b31d6197b0ecf",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      "  4%|████▎                                                                                                       | 3/75 [00:15<06:26,  5.37s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "e22b6811c59249e798009d6fb34a8a82",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      "  5%|█████▊                                                                                                      | 4/75 [00:21<06:23,  5.40s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "a494a470ec0845169d6f94ef43f67dd1",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/1 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      "  7%|███████▏                                                                                                    | 5/75 [00:25<05:51,  5.02s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "bfc6eee56450431699f61bfd78751d33",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/1 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      "  8%|████████▋                                                                                                   | 6/75 [00:30<05:44,  5.00s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "c1e171c74dd14a0f8b9d213bcbe5648f",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      "  9%|██████████                                                                                                  | 7/75 [00:36<06:04,  5.36s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "ee60c0f9b8164f5487f010e057d9a1ad",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 11%|███████████▌                                                                                                | 8/75 [00:42<06:05,  5.46s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "269b773e3afa4804b65aa9cb16c302dc",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 12%|████████████▉                                                                                               | 9/75 [00:47<05:58,  5.43s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "7ee52a0d2aee4765a5158509fa587c39",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 13%|██████████████▎                                                                                            | 10/75 [00:54<06:10,  5.69s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "9d74199571dc4e928ae00c2d329a340f",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 15%|███████████████▋                                                                                           | 11/75 [01:00<06:13,  5.83s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "3b12d7ca0b37431a95256c8f07093a72",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 16%|█████████████████                                                                                          | 12/75 [01:05<06:01,  5.73s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "986d8fc975084ea8b6d7e0db82f49210",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 17%|██████████████████▌                                                                                        | 13/75 [01:11<06:01,  5.84s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "f82cfaf975024dad9237c46d0e5bafbf",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/1 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 19%|███████████████████▉                                                                                       | 14/75 [01:16<05:39,  5.56s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "5ff93907c4f0450e9ad933058ff3d62d",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/1 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 20%|█████████████████████▍                                                                                     | 15/75 [01:22<05:28,  5.48s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "15364166fe8042b3b62634cb8c666b7a",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 21%|██████████████████████▊                                                                                    | 16/75 [01:28<05:32,  5.63s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "aa1b4ebcf9964c91902c77c94db8c555",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/1 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 23%|████████████████████████▎                                                                                  | 17/75 [01:33<05:24,  5.59s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "d028209e69f243108a1a551d1e33a872",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 24%|█████████████████████████▋                                                                                 | 18/75 [01:39<05:30,  5.80s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "92c7c874498e42ba83713403ae45f70d",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/1 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 25%|███████████████████████████                                                                                | 19/75 [01:44<05:02,  5.39s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "cd803eaa2013406194e38db4330527a6",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/1 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 27%|████████████████████████████▌                                                                              | 20/75 [01:48<04:40,  5.09s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "74a30d93bef84449a1e65f3fe886f1ea",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 28%|█████████████████████████████▉                                                                             | 21/75 [01:54<04:52,  5.41s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "4e70a8f6ace149c58befa4853cdea109",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/1 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 29%|███████████████████████████████▍                                                                           | 22/75 [01:59<04:39,  5.26s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "4b58f8b8d9524bdb8351648471963ed6",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 31%|████████████████████████████████▊                                                                          | 23/75 [02:06<04:51,  5.60s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "d1003d055714453194843ed9c8e2ee7f",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 32%|██████████████████████████████████▏                                                                        | 24/75 [02:12<04:59,  5.87s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "a30a5b76e2a84aa489c763908e228696",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 33%|███████████████████████████████████▋                                                                       | 25/75 [02:18<04:51,  5.83s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "719b2cedd69641379ef8b4655242d4e7",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/1 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 35%|█████████████████████████████████████                                                                      | 26/75 [02:23<04:32,  5.56s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "3df922a68d5e483ab0c52127ef912a7b",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 36%|██████████████████████████████████████▌                                                                    | 27/75 [02:29<04:40,  5.84s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "c70026b7db49438b8113bd3701600bac",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 37%|███████████████████████████████████████▉                                                                   | 28/75 [02:36<04:52,  6.22s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "589bfa7f217a44ef83e4fe3745799850",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 39%|█████████████████████████████████████████▎                                                                 | 29/75 [02:43<04:51,  6.33s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "e6a92ddaa27847bba7f912aa77e98147",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 40%|██████████████████████████████████████████▊                                                                | 30/75 [02:49<04:38,  6.20s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "c7a802e7329141b6bca2ce24f2af78db",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 41%|████████████████████████████████████████████▏                                                              | 31/75 [02:54<04:25,  6.03s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "3118db4ea2024d1f9829f75623e6da5f",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/1 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 43%|█████████████████████████████████████████████▋                                                             | 32/75 [02:58<03:41,  5.14s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "ebc16930059f46c082c805965385479d",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 44%|███████████████████████████████████████████████                                                            | 33/75 [03:03<03:43,  5.31s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "82a0fcdd32df452cb8009b835b5b5df5",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 45%|████████████████████████████████████████████████▌                                                          | 34/75 [03:09<03:45,  5.51s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "5a0229d8491b48278288ef1930e8bf89",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 47%|█████████████████████████████████████████████████▉                                                         | 35/75 [03:15<03:43,  5.60s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "e7af44253c4a4a6abb80fc151cab9aab",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 48%|███████████████████████████████████████████████████▎                                                       | 36/75 [03:20<03:35,  5.53s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "d590233dc0944c1c95dcb6fb227f71b4",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/1 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 49%|████████████████████████████████████████████████████▊                                                      | 37/75 [03:25<03:14,  5.11s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "2e1c8538a130464ab8229df157b048f7",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/1 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 51%|██████████████████████████████████████████████████████▏                                                    | 38/75 [03:31<03:21,  5.45s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "450110e424594f45b71900f39ece06fe",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 52%|███████████████████████████████████████████████████████▋                                                   | 39/75 [03:36<03:15,  5.42s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "108be7cdd7b7436d9d5da656c7e3190a",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 53%|█████████████████████████████████████████████████████████                                                  | 40/75 [03:42<03:11,  5.47s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "cf1f1490bdc4464eb33e79e97b7ffc40",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 55%|██████████████████████████████████████████████████████████▍                                                | 41/75 [03:47<03:06,  5.48s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "7be00efd1bc14ab1ada13d0ab49477d1",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/1 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 56%|███████████████████████████████████████████████████████████▉                                               | 42/75 [03:52<02:53,  5.27s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "5b6ab16172924b60af0f50d6d66e79cf",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/1 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 57%|█████████████████████████████████████████████████████████████▎                                             | 43/75 [03:58<02:52,  5.39s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "a1455bb4e4a6442c9ca946c8aeef2551",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 59%|██████████████████████████████████████████████████████████████▊                                            | 44/75 [04:04<02:53,  5.60s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "cbc83b9c84ba429292258d001610c348",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/1 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 60%|████████████████████████████████████████████████████████████████▏                                          | 45/75 [04:09<02:42,  5.42s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "65d6e5674f3f49518b9cf4713c4d6cd5",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 61%|█████████████████████████████████████████████████████████████████▋                                         | 46/75 [04:16<02:51,  5.92s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "784ac27e85a94d75907701757907495c",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 63%|███████████████████████████████████████████████████████████████████                                        | 47/75 [04:22<02:43,  5.85s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "1f80ea84d1764d599c761c0907068e13",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/1 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 64%|████████████████████████████████████████████████████████████████████▍                                      | 48/75 [04:25<02:16,  5.05s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "4164e29b61f0463c842d3efa13a255b4",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/1 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 65%|█████████████████████████████████████████████████████████████████████▉                                     | 49/75 [04:29<02:07,  4.92s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "cd28dd00bb5f4cde9c42d195eff145bf",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 67%|███████████████████████████████████████████████████████████████████████▎                                   | 50/75 [04:35<02:11,  5.24s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "7048fc8977bf46fd9a9b1bcd06c77914",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 68%|████████████████████████████████████████████████████████████████████████▊                                  | 51/75 [04:41<02:07,  5.32s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "d2f7d46e79e4473f91e492f1eab62302",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/1 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 69%|██████████████████████████████████████████████████████████████████████████▏                                | 52/75 [04:46<02:03,  5.36s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "20e4fbf0f05041c7aac5d888935c9493",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 71%|███████████████████████████████████████████████████████████████████████████▌                               | 53/75 [04:52<02:00,  5.46s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "7c93be7192564205aae856c554758349",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/1 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 72%|█████████████████████████████████████████████████████████████████████████████                              | 54/75 [04:58<01:56,  5.56s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "ea800c135ad94146b523f57558d95ff7",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 73%|██████████████████████████████████████████████████████████████████████████████▍                            | 55/75 [05:04<01:52,  5.65s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "1bce6ac709704b9f871c55769c781443",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 75%|███████████████████████████████████████████████████████████████████████████████▉                           | 56/75 [05:09<01:44,  5.48s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "dc71eac451064417ba84b7213ffcaf41",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/1 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 76%|█████████████████████████████████████████████████████████████████████████████████▎                         | 57/75 [05:13<01:32,  5.15s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "e7593e79cd304dec944c6d3c5a068fe4",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 77%|██████████████████████████████████████████████████████████████████████████████████▋                        | 58/75 [05:20<01:36,  5.69s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "2685c8b50c8a47f0a7e35786fb803d44",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 79%|████████████████████████████████████████████████████████████████████████████████████▏                      | 59/75 [05:25<01:29,  5.61s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "ae86aefedc994c769ade7cb3c086c97a",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 80%|█████████████████████████████████████████████████████████████████████████████████████▌                     | 60/75 [05:32<01:30,  6.04s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "21c55c80ad724874aa4e55e444ca7a49",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 81%|███████████████████████████████████████████████████████████████████████████████████████                    | 61/75 [05:39<01:25,  6.14s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "b5d41184263d4ff9b51898a1379aea89",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/1 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 83%|████████████████████████████████████████████████████████████████████████████████████████▍                  | 62/75 [05:44<01:16,  5.89s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "a598ecced1a0422a9efdabcb7d865330",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 84%|█████████████████████████████████████████████████████████████████████████████████████████▉                 | 63/75 [05:50<01:09,  5.75s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "0c795a821e384b7ab7d3026da3770f46",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/1 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 85%|███████████████████████████████████████████████████████████████████████████████████████████▎               | 64/75 [05:54<01:00,  5.47s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "6d9c0e545640459a82b3243c67e38686",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/1 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 87%|████████████████████████████████████████████████████████████████████████████████████████████▋              | 65/75 [06:00<00:54,  5.45s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "5c34d79a43b74c5790f2efc57fa03831",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/1 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 88%|██████████████████████████████████████████████████████████████████████████████████████████████▏            | 66/75 [06:05<00:47,  5.28s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "30a0e4ad27824fc9972f416bd64417f6",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 89%|███████████████████████████████████████████████████████████████████████████████████████████████▌           | 67/75 [06:11<00:45,  5.72s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "697174b80804494a8263e2f6d43782b9",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 91%|█████████████████████████████████████████████████████████████████████████████████████████████████          | 68/75 [06:17<00:39,  5.67s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "695b818f45a7409e882c513402749904",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 92%|██████████████████████████████████████████████████████████████████████████████████████████████████▍        | 69/75 [06:24<00:35,  5.99s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "262532407c204de1bd60f09a87f32c2a",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 93%|███████████████████████████████████████████████████████████████████████████████████████████████████▊       | 70/75 [06:30<00:29,  5.96s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "fe2abad6f6b74f8e97d279dd66d525be",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 95%|█████████████████████████████████████████████████████████████████████████████████████████████████████▎     | 71/75 [06:37<00:25,  6.41s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "a564515c275146f18a7fb24a6e129fef",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 96%|██████████████████████████████████████████████████████████████████████████████████████████████████████▋    | 72/75 [06:43<00:18,  6.18s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "f091d27b103c4461ba8a49d88862ebc8",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/1 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 97%|████████████████████████████████████████████████████████████████████████████████████████████████████████▏  | 73/75 [06:47<00:11,  5.55s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "4413ba9e1db24700bfb3acfb1a52abfa",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r",
      " 99%|█████████████████████████████████████████████████████████████████████████████████████████████████████████▌ | 74/75 [06:52<00:05,  5.53s/it]"
     ]
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "704ef2730d524872b0298257426bfccf",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Inferencing Samples:   0%|          | 0/2 [00:00<?, ? Batches/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "100%|███████████████████████████████████████████████████████████████████████████████████████████████████████████| 75/75 [06:58<00:00,  5.58s/it]\n"
     ]
    }
   ],
   "source": [
    "def get_snipet_from_answer(pred):\n",
    "    is_extractive = pred.type == 'extractive'\n",
    "    answer = {}\n",
    "    answer['document'] =  globals.BIOASQ.doc_relative_url + pred.document_ids[0]\n",
    "    answer['text'] = pred.context\n",
    "    answer['offsetInBeginSection'] = pred.meta['abstract'].rfind(pred.context)\n",
    "    answer['offsetInEndSection'] = answer['offsetInBeginSection'] + len(pred.context)\n",
    "    answer[\"beginSection\"] = \"abstract\",\n",
    "    answer[\"endSection\"] = \"abstract\"\n",
    "    return answer\n",
    "    \n",
    "for sample in tqdm(test_batch_json['questions'], position=0):\n",
    "    prediction = pipeline.run(query=sample['body'], params={\"BM25Retriever\": {\"top_k\": 100}, \"Ranker\": {\"top_k\": 30}, \"Reader\": {\"top_k\": 30} })\n",
    "    snippets = []\n",
    "    doc_list_by_snnipets = []\n",
    "    for ans in prediction['answers']:\n",
    "        if ans.score > 0.3:\n",
    "            snippet = get_snipet_from_answer(ans)\n",
    "            doc_list_by_snnipets.append(snippet['document'])\n",
    "            snippets.append(snippet)\n",
    "            \n",
    "    sample['snippets'] = snippets\n",
    "    doc_list = [ globals.BIOASQ.doc_relative_url + d.id for d in prediction['documents'] ]\n",
    "    #sample['documents'] = doc_list[0:10]\n",
    "    sample['documents'] = list(set(doc_list_by_snnipets))\n",
    "    \n",
    "# mindlab base ans.score > 0.3:\n",
    "# mindlab tns ans.score > 0.4 and only snnipets docs"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "id": "ac8ba411",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'questions': [{'id': '63f03006f36125a426000018',\n",
       "   'type': 'summary',\n",
       "   'body': 'What were the results of the DESTINY-Breast04 Trial?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35665782',\n",
       "     'text': \"st cancer, trastuzumab deruxtecan resulted in significantly longer progression-free and overall survival than the physician's choice of chemotherapy. \",\n",
       "     'offsetInBeginSection': 2265,\n",
       "     'offsetInEndSection': 2415,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36386213',\n",
       "     'text': 'er (ABC). DESTINY-Breast04 (NCT03734029) has demonstrated the antitumor activity of trastuzumab deruxtecan (T-DXd). However, the balance between the e',\n",
       "     'offsetInBeginSection': 162,\n",
       "     'offsetInEndSection': 312,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31022475',\n",
       "     'text': 'fter evaluating the results of these 6 studies, none of the SNPs was significantly associated with ONJ. Recently, two whole-exome sequencing (WES) ana',\n",
       "     'offsetInBeginSection': 733,\n",
       "     'offsetInEndSection': 883,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35666611',\n",
       "     'text': ' indicate that the antibody-drug conjugate trastuzumab deruxtecan (T-DXd) is effective for patients with inoperable/metastatic HER2-low breast cancer.',\n",
       "     'offsetInBeginSection': 50,\n",
       "     'offsetInEndSection': 200,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33023880',\n",
       "     'text': 'using a validated scoring criterion.\\n\\n\\nRESULTS\\nOne hundred and seven studies met the inclusion criteria. The median quality score across studies was 1',\n",
       "     'offsetInBeginSection': 1053,\n",
       "     'offsetInEndSection': 1203,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/35665782',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/31022475',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36386213',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35666611',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33023880']},\n",
       "  {'id': '641ad941690f196b5100003d',\n",
       "   'type': 'yesno',\n",
       "   'body': 'Are LOQ and LOD the same?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/8013092',\n",
       "     'text': 'of the corresponding statistical LODs. The empirical LODs and LOQs are identical for these GC-MS assays. The observations made here about the LOD/LOQ ',\n",
       "     'offsetInBeginSection': 988,\n",
       "     'offsetInEndSection': 1138,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20166602',\n",
       "     'text': ' study. The results indicated that the estimated LODs and LOQs were not equivalent and could vary by a factor of 5 to 6 for the different methods. It ',\n",
       "     'offsetInBeginSection': 480,\n",
       "     'offsetInEndSection': 630,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21603916',\n",
       "     'text': 'pathogen biomass in host tissue, yet no generic methods exist for the determination of the limit of quantification (LOQ) and the limit of detection (L',\n",
       "     'offsetInBeginSection': 74,\n",
       "     'offsetInEndSection': 224,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28911409',\n",
       "     'text': 'd. The most appropriate approaches were compared. Our conclusion is that the visual evaluation method provided much more realistic LOD and LOQ values.',\n",
       "     'offsetInBeginSection': 1031,\n",
       "     'offsetInEndSection': 1181,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34155649',\n",
       "     'text': 'with coefficients of determination ≥0.99. The LOD and LOQ were in the ranges of 0.16-0.39 and 0.52-1.28\\xa0mg/kg, respectively. The percentage recoveries',\n",
       "     'offsetInBeginSection': 551,\n",
       "     'offsetInEndSection': 701,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15936163',\n",
       "     'text': 'nt (r) of 0.9999, calculated by least square method. The LOD and LOQ were 0.08 and 0.26 microg/mL, respectively. Based on the preliminary spectrophoto',\n",
       "     'offsetInBeginSection': 632,\n",
       "     'offsetInEndSection': 782,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34155649',\n",
       "     'text': 'efficients of determination ≥0.99. The LOD and LOQ were in the ranges of 0.16-0.39 and 0.52-1.28\\xa0mg/kg, respectively. The percentage recoveries of the',\n",
       "     'offsetInBeginSection': 558,\n",
       "     'offsetInEndSection': 708,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18178357',\n",
       "     'text': 'ision, accuracy, specificity and robustness. The LOD and LOQ values were found to be 0.3 and 1.0 microg/ml, respectively. The method is linear within ',\n",
       "     'offsetInBeginSection': 515,\n",
       "     'offsetInEndSection': 665,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21313803',\n",
       "     'text': 'ity, repeatability, LOD, and LOQ. The LOD and LOQ of nine compounds were in the range of 0.09-10 and 0.3-25 microg/mL, respectively. The wavelength us',\n",
       "     'offsetInBeginSection': 329,\n",
       "     'offsetInEndSection': 479,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21662779',\n",
       "     'text': 'espectively. For ESI-MS detection, LOD and LOQ are in the ranges 10-25 and 20-50 μg/L, respectively. LOD obtained by ESI-MS for the determination of g',\n",
       "     'offsetInBeginSection': 575,\n",
       "     'offsetInEndSection': 725,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32308686',\n",
       "     'text': 'omparable with a selected HPLC reference method. Both methods displayed same precision and credibility. Reaction stoichiometry between tryptophan and ',\n",
       "     'offsetInBeginSection': 623,\n",
       "     'offsetInEndSection': 773,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31108780',\n",
       "     'text': ' LOQ was 0.05\\u202fmg/kg. Besides, LOD and LOQ of glycidyl ester were 0.024 and 0.06\\u202fmg/kg respectively. A blank spiked with MCPD esters (0.03, 0.10 and 0.',\n",
       "     'offsetInBeginSection': 635,\n",
       "     'offsetInEndSection': 785,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/1783594',\n",
       "     'text': 'V) that compares favorably to the Horwitz CV. LOD and LOQ are equivalent to 3 and 10 times, respectively, the background signal contributed by a sampl',\n",
       "     'offsetInBeginSection': 641,\n",
       "     'offsetInEndSection': 791,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35295076',\n",
       "     'text': '=0.1197). Given their superimposable outcomes, the LODneg and LODpos-LOQneg categories were combined. Two-year overall survival of LODneg/LODpos-LOQne',\n",
       "     'offsetInBeginSection': 965,\n",
       "     'offsetInEndSection': 1115,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/14647939',\n",
       "     'text': 'Immunoanalytical methods at a very low limit of detection (LOD) and a low limit of quantification (LOQ) are becoming more and more important for envir',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/21662779',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/14647939',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/21603916',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/8013092',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/21313803',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/28911409',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32308686',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/31108780',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/20166602',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/15936163',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/1783594',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35295076',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/18178357',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34155649']},\n",
       "  {'id': '642a029d57b1c7a315000011',\n",
       "   'type': 'summary',\n",
       "   'body': 'Histone acetyltransferases (HATs) transfer acetyl groups from acetyl CoA to lysine residues on histones. What is the purpose of this transfer?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32157780',\n",
       "     'text': 'ansfer acetyl groups onto histones and thereby regulate both gene expression and chromosomal structures. Previous work has shown that the activation o',\n",
       "     'offsetInBeginSection': 63,\n",
       "     'offsetInEndSection': 213,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32695779',\n",
       "     'text': 'ses of proteins, histone acetyltransferases (HATs) that add acetyl groups to lysine amino acids, bromodomain (BRD) containing proteins that are one of',\n",
       "     'offsetInBeginSection': 66,\n",
       "     'offsetInEndSection': 216,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/11112280',\n",
       "     'text': 'residues in the N-terminal tails of nucleosomal histones to promote transcriptional activation. Recent structural and enzymatic work on the GCN5/PCAF ',\n",
       "     'offsetInBeginSection': 91,\n",
       "     'offsetInEndSection': 241,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12391296',\n",
       "     'text': 'ther transcription factors, such as the p53 tumor suppressor, to promote gene activation. HAT enzymes fall into subfamilies with divergence in sequenc',\n",
       "     'offsetInBeginSection': 106,\n",
       "     'offsetInEndSection': 256,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12368900',\n",
       "     'text': ' A (CoA) to acetylate specific Lys residues within histones to regulate gene expression. The structure of an ESA1-CoA complex reveals structural simil',\n",
       "     'offsetInBeginSection': 108,\n",
       "     'offsetInEndSection': 258,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12624111',\n",
       "     'text': ') are a group of enzymes that play a significant role in the regulation of gene expression. These enzymes covalently modify the N-terminal lysine resi',\n",
       "     'offsetInBeginSection': 32,\n",
       "     'offsetInEndSection': 182,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/10790315',\n",
       "     'text': 'Histone acetyltransferases (HATs) catalyze the acetyl-group transfer from acetyl-CoA to the epsilon-amino group of specific lysine residues within cor',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21057107',\n",
       "     'text': 'tisubunit complexes in which accessory proteins regulate substrate specificity and catalytic efficiency. Rtt109 is a particularly interesting example ',\n",
       "     'offsetInBeginSection': 54,\n",
       "     'offsetInEndSection': 204,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31818759',\n",
       "     'text': 'enzyme A (Ac-CoA) to lysine residues of substrate peptide, thus generating CoA molecule. Later, CoA, which acts as an initiator, can embrace its aptam',\n",
       "     'offsetInBeginSection': 371,\n",
       "     'offsetInEndSection': 521,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19056256',\n",
       "     'text': 'ering substrate specificity, targeting to specific loci, enhancing acetyltransferase activity, restricting access of non-target proteins, and coordina',\n",
       "     'offsetInBeginSection': 567,\n",
       "     'offsetInEndSection': 717,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19577000',\n",
       "     'text': 'otes. Different subtypes of histone acetyl transferases (HATs) catalyze the acetylation of histones on specific lysine residues. A potential role of H',\n",
       "     'offsetInBeginSection': 143,\n",
       "     'offsetInEndSection': 293,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28240169',\n",
       "     'text': 'o lysines of both histone and non-histone substrates and thereby induce transcription either by chromatin remodeling or direct transcription factor ac',\n",
       "     'offsetInBeginSection': 108,\n",
       "     'offsetInEndSection': 258,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32764680',\n",
       "     'text': 'to lysine residues of histones and play a central role in transcriptional regulation in diverse biological processes. Dysregulation of HAT activity ca',\n",
       "     'offsetInBeginSection': 91,\n",
       "     'offsetInEndSection': 241,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25707943',\n",
       "     'text': 'cleosomal histone tails provides a crucial mechanism for epigenetic control of gene expression. Acetyl groups are coupled to lysine residues by histon',\n",
       "     'offsetInBeginSection': 40,\n",
       "     'offsetInEndSection': 190,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21908798',\n",
       "     'text': 'Histone acetyltransferases (HATs) catalyze the transfer of an acetyl group from an acetyl-coenzyme A donor molecule to specific lysine residues within',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/10579936',\n",
       "     'text': 'he core histone proteins is strongly correlated to the regulation of gene transcription in vivo. To directly study the effects of histone acetylation ',\n",
       "     'offsetInBeginSection': 67,\n",
       "     'offsetInEndSection': 217,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27231488',\n",
       "     'text': 'Histone acetyltransferases (HATs) are epigenetic enzymes that install acetyl groups onto lysine residues of cellular proteins such as histones, transc',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15313419',\n",
       "     'text': 'histone acetyltransferases (HATs), involved in this crucial step of gene regulation, covalently modifies the N-terminal lysine residues of histones by',\n",
       "     'offsetInBeginSection': 105,\n",
       "     'offsetInEndSection': 255,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26065557',\n",
       "     'text': 'mediate the transfer of an acetyl group from the cofactor, acetyl-CoA, to the side chain amino group of specific lysines in diverse protein substrates',\n",
       "     'offsetInBeginSection': 34,\n",
       "     'offsetInEndSection': 184,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15955204',\n",
       "     'text': 'Histone acetylation regulates gene transcription. Histone acetylation is a reversible process: histone acetyltransferases (HAT) transfer the acetyl mo',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/8514763',\n",
       "     'text': 'in vitro transfer of acetyl groups from [1-14C]acetyl-CoA to non-acetylated pea histone H4. Up to three acetyl groups can be introduced into the histone. The resulting mono-, di-, and triacetylated H4 isoforms were separated and sequenced to determine the acetylated sites. Only sites 5, 12, and 16 were used by histone acetyltransferase B, but no clear preference among them was observed. The absence of modification of other potentially acetylatable sites is another indication that acetylation of the different lysine residues in the N-terminal H4 tail serves as a specific signal in different nuclear processes',\n",
       "     'offsetInBeginSection': 240,\n",
       "     'offsetInEndSection': 854,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17325692',\n",
       "     'text': 'cting enzyme families whose enzymatic activity controls the acetylation state of protein lysine residues, notably those contained in the N-terminal ex',\n",
       "     'offsetInBeginSection': 84,\n",
       "     'offsetInEndSection': 234,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27231488',\n",
       "     'text': 'vity of inhibitors in in vitro studies and their potential use as therapeutic agents. To bridge this gap, new potent HAT inhibitors with improved prop',\n",
       "     'offsetInBeginSection': 629,\n",
       "     'offsetInEndSection': 779,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27231488',\n",
       "     'text': 'ure of HATs is that they are bi-substrate enzymes that catalyze reactions between two substrates: the cofactor acetyl coenzyme A (Ac-CoA) and a lysine',\n",
       "     'offsetInBeginSection': 1383,\n",
       "     'offsetInEndSection': 1533,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/27231488',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/21908798',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32157780',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/12368900',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/10579936',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/11112280',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/17325692',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/26065557',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/12624111',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/25707943',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32764680',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/10790315',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32695779',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/15313419',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/21057107',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/19056256',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/8514763',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/31818759',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/12391296',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/28240169',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/19577000',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/15955204']},\n",
       "  {'id': '6432fc0457b1c7a31500001f',\n",
       "   'type': 'factoid',\n",
       "   'body': 'Which gene is most frequently mutated in hereditary angioedema ?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34065094',\n",
       "     'text': 'he hands, feet, limbs, face, intestinal tract, or airway. Mutations in SERPING1, the gene that encodes C1-INH (C1 esterase inhibitor), are responsible',\n",
       "     'offsetInBeginSection': 185,\n",
       "     'offsetInEndSection': 335,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36203343',\n",
       "     'text': '), 8/79 (9%), and 3/79 (4%) of the patients respectively, revealing that SPTB is the most frequently mutated HS gene in Eastern China. Most SPTB and A',\n",
       "     'offsetInBeginSection': 539,\n",
       "     'offsetInEndSection': 689,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33780405',\n",
       "     'text': 'used by either a C1 esterase inhibitor deficiency (type 1) or mutation (type 2). This leads to overproduction of bradykinin resulting in vasodilation,',\n",
       "     'offsetInBeginSection': 80,\n",
       "     'offsetInEndSection': 230,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36417927',\n",
       "     'text': 'e of hereditary angioedema in almost all patients is a mutation in the SERPING1 gene leading to a deficiency in C1-inhibitor. Subsequently, the contac',\n",
       "     'offsetInBeginSection': 444,\n",
       "     'offsetInEndSection': 594,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33593719',\n",
       "     'text': 'childhood or adolescence. Most of these patients have mutations in the SERPING1 gene, causing either low C1 inhibitor production (hereditary angioedem',\n",
       "     'offsetInBeginSection': 353,\n",
       "     'offsetInEndSection': 503,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30146609',\n",
       "     'text': 'itor. Genetic testing revealed a heterozygous nonsense mutation of the SERPING1 gene, and a diagnosis of hereditary angioedema was made. Hereditary an',\n",
       "     'offsetInBeginSection': 514,\n",
       "     'offsetInEndSection': 664,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24760113',\n",
       "     'text': 'utosomal-dominant and life-threatening disorder caused by mutations in SERPING1 gene. It is characterized by attacks of angioedema involving the skin ',\n",
       "     'offsetInBeginSection': 76,\n",
       "     'offsetInEndSection': 226,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19477491',\n",
       "     'text': 'BACKGROUND\\nHereditary angioedema caused by mutations in the factor XII gene is a recently described disease entity that occurs mainly in women. It dif',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23282866',\n",
       "     'text': 'is and management of these patients. HAE is caused by mutations in the SERPING1 gene that result in decreased plasma levels of functional C1 inhibitor',\n",
       "     'offsetInBeginSection': 248,\n",
       "     'offsetInEndSection': 398,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27271546',\n",
       "     'text': 'therapeutic characteristics of patients with HAE linked to a mutation of FXII gene. Fifty-seven patients were identified from 24 different families. I',\n",
       "     'offsetInBeginSection': 569,\n",
       "     'offsetInEndSection': 719,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27826968',\n",
       "     'text': 'ct in the C1 esterase inhibitor (C1-INH) consequent to mutation in the SERPING1 gene, which encodes C1-INH. This disease manifests as recurrent, non-p',\n",
       "     'offsetInBeginSection': 78,\n",
       "     'offsetInEndSection': 228,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23282866',\n",
       "     'text': ' may influence HAE disease severity. HAE results from mutations in the SERPING1 gene that lead to a loss of functional C1 inhibitor. Attacks of angioe',\n",
       "     'offsetInBeginSection': 1143,\n",
       "     'offsetInEndSection': 1293,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30530986',\n",
       "     'text': ' (HAE) is a rare genetic disorder primarily caused by mutations in the SERPING1 gene encoding the C1 inhibitor (C1INH) that leads to plasma deficiency',\n",
       "     'offsetInBeginSection': 21,\n",
       "     'offsetInEndSection': 171,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20667118',\n",
       "     'text': 'the clinical symptoms. Recently, in some families mutations in the coagulation factor XII (Hageman factor) gene were detected in the affected persons.',\n",
       "     'offsetInBeginSection': 505,\n",
       "     'offsetInEndSection': 655,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19656474',\n",
       "     'text': 'riggered the clinical symptoms. In some families, mutations in the coagulation factor XII (Hageman factor) gene were detected in the affected persons.',\n",
       "     'offsetInBeginSection': 490,\n",
       "     'offsetInEndSection': 640,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34838707',\n",
       "     'text': 'and II HAE-C1INH result from inherited or spontaneous mutations in the SERPING1 gene, which encodes for C1INH. These mutations result in C1INH dysfunc',\n",
       "     'offsetInBeginSection': 411,\n",
       "     'offsetInEndSection': 561,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28601681',\n",
       "     'text': 'e genetic\\xa0disease usually caused by mutation in the C1 inhibitor or the coagulation Factor XII gene. However, in a series of patients with HAE, no cau',\n",
       "     'offsetInBeginSection': 47,\n",
       "     'offsetInEndSection': 197,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21623829',\n",
       "     'text': 'ive subjects were interviewed and investigated for mutation at the C1 inhibitor gene. Subjects reporting a history of recurrent episodes of angioedema',\n",
       "     'offsetInBeginSection': 591,\n",
       "     'offsetInEndSection': 741,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21623829',\n",
       "     'text': 'ading to elevated levels of bradykinin. More than 200 mutations in C1 inhibitor gene have been reported. The aim of this study was to analyze clinical',\n",
       "     'offsetInBeginSection': 188,\n",
       "     'offsetInEndSection': 338,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24176211',\n",
       "     'text': 'rogens, and pregnancies triggered the clinical symptoms. In some families mutations in the coagulation factor XII (Hageman factor) gene were detected.',\n",
       "     'offsetInBeginSection': 467,\n",
       "     'offsetInEndSection': 617,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16634360',\n",
       "     'text': ' protein C1 inhibitor. It is caused by heterozygous defects in the C1 inhibitor gene located on chromosome 11q, and it has an autosomal dominant inher',\n",
       "     'offsetInBeginSection': 175,\n",
       "     'offsetInEndSection': 325,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17085286',\n",
       "     'text': 'd the clinical symptoms. Recently, in some families mutations in the coagulation factor XII (Hageman factor) gene were detected in the affected women.',\n",
       "     'offsetInBeginSection': 399,\n",
       "     'offsetInEndSection': 549,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/8586465',\n",
       "     'text': 'd protein 4.1. Recent mutation analyses have revealed that the NF2 tumor suppressor gene is frequently mutated not only in vestibular schwannomas and ',\n",
       "     'offsetInBeginSection': 1248,\n",
       "     'offsetInEndSection': 1398,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27271546',\n",
       "     'text': 'l C1-INH is associated in 20% of cases with mutations in the gene for factor XII (FXII) or FXII-HAE. A recent review described 41 families, including ',\n",
       "     'offsetInBeginSection': 167,\n",
       "     'offsetInEndSection': 317,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19477491',\n",
       "     'text': 'and tranexamic acid (1 woman). No difference between mutation p.Thr309Arg and p.Thr309Lys was found.\\n\\n\\nCONCLUSIONS\\nFacial swelling is a cardinal sympt',\n",
       "     'offsetInBeginSection': 1427,\n",
       "     'offsetInEndSection': 1577,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27826968',\n",
       "     'text': 'mally low C1-INH activity (less than 25%; normal range: 70%-130%). The SERPING1 gene mutation was confirmed in this patient. She was treated with prop',\n",
       "     'offsetInBeginSection': 1064,\n",
       "     'offsetInEndSection': 1214,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33593719',\n",
       "     'text': 'y angioedema symptoms owing to mutations in FXII, PLG, ANGPT1, KNG1, and MYOF genes. Patients who exhibit none of these genetic mutations despite havi',\n",
       "     'offsetInBeginSection': 826,\n",
       "     'offsetInEndSection': 976,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28601681',\n",
       "     'text': 'ers and showed reduced binding capability to its receptor.\\n\\n\\nCONCLUSION\\nANGPT1 impairment is associated with angioedema, and ANGPT1 variants can be th',\n",
       "     'offsetInBeginSection': 1680,\n",
       "     'offsetInEndSection': 1830,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33442779',\n",
       "     'text': 'belled: normal C1 inhibitor HAE. These include genetic mutations in factor 12 gene, plasminogen gene, angiopoietin gene, kininogen 1, and myoferlin ge',\n",
       "     'offsetInBeginSection': 486,\n",
       "     'offsetInEndSection': 636,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28601681',\n",
       "     'text': 'ltiplex family with U-HAE and performed whole-exome sequencing. The angiopoietin-1 gene (ANGPT1) was investigated in all patients with familial or spo',\n",
       "     'offsetInBeginSection': 757,\n",
       "     'offsetInEndSection': 907,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/30530986',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33780405',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36417927',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/27271546',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36203343',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/8586465',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/19477491',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/24760113',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/30146609',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/20667118',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33593719',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/23282866',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/17085286',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/19656474',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/16634360',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34065094',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/28601681',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/27826968',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33442779',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34838707',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/21623829',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/24176211']},\n",
       "  {'id': '64178edb690f196b51000025',\n",
       "   'type': 'summary',\n",
       "   'body': \"What is casimersen's mechanism of action?\",\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27324312',\n",
       "     'text': 'nd the signalling pathway that couples changes in PO2 to changes in arteriolar tone (the mechanism of action) remain unclear. Many (but not all) ex vi',\n",
       "     'offsetInBeginSection': 256,\n",
       "     'offsetInEndSection': 406,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25544661',\n",
       "     'text': ' on their mechanism of action. In the present study, we posit that normative change is a plausible mechanism and provide a test of this in an eating d',\n",
       "     'offsetInBeginSection': 95,\n",
       "     'offsetInEndSection': 245,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34826604',\n",
       "     'text': 'ivation consistent with left free wall accessory pathway. With induction of tachycardia, beats with LBBB morphology have shorter cycle length than tho',\n",
       "     'offsetInBeginSection': 155,\n",
       "     'offsetInEndSection': 305,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23089283',\n",
       "     'text': 'The role of the mirror mechanism in cognition remains an intriguing and hotly debated topic in cognitive neuroscience. Since its discovery in the monk',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20735416',\n",
       "     'text': 'mechanism of action of general anaesthetics (GAs) involving membranes and protein receptors. I provide the reasons why the GABA type A receptor, the N',\n",
       "     'offsetInBeginSection': 227,\n",
       "     'offsetInEndSection': 377,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29178131',\n",
       "     'text': 'ne. However, the presumptive mechanism of action, inhibition of NMDA (N-methyl-D-aspartate) receptors, has recently been challenged. Elucidation of th',\n",
       "     'offsetInBeginSection': 187,\n",
       "     'offsetInEndSection': 337,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19719780',\n",
       "     'text': 'd the position to date and suggested a new mechanistic contender, receptor rebinding. Despite this, they still do not come to any clear conclusion. Mu',\n",
       "     'offsetInBeginSection': 185,\n",
       "     'offsetInEndSection': 335,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/20735416',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/25544661',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34826604',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/23089283',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/19719780',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/27324312',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/29178131']},\n",
       "  {'id': '6402bf2b201352f04a000007',\n",
       "   'type': 'summary',\n",
       "   'body': 'What is the mechanism of action of tiragolumab?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35576957',\n",
       "     'text': ' (16·2% [6·7-25·7]) in the placebo plus atezolizumab group had an objective response (p=0·031). Median progression-free survival was 5·4 months (95% C',\n",
       "     'offsetInBeginSection': 2161,\n",
       "     'offsetInEndSection': 2311,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32576590',\n",
       "     'text': 'tion with the PD-L1 inhibitor atezolizumab, may be effective against solid cancers. In phase I and II trials, the agent achieved statistically signifi',\n",
       "     'offsetInBeginSection': 52,\n",
       "     'offsetInEndSection': 202,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35576957',\n",
       "     'text': 'ab showed a clinically meaningful improvement in objective response rate and progression-free survival compared with placebo plus atezolizumab in pati',\n",
       "     'offsetInBeginSection': 3033,\n",
       "     'offsetInEndSection': 3183,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35576957',\n",
       "     'text': 'Targeted inhibition of the PD-L1-PD-1 pathway might be further amplified through combination of PD-1 or PD-L1 inhibitors with novel anti-TIGIT inhibitory immune checkpoint agents',\n",
       "     'offsetInBeginSection': 11,\n",
       "     'offsetInEndSection': 189,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27324312',\n",
       "     'text': 'nd the signalling pathway that couples changes in PO2 to changes in arteriolar tone (the mechanism of action) remain unclear. Many (but not all) ex vi',\n",
       "     'offsetInBeginSection': 256,\n",
       "     'offsetInEndSection': 406,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26292636',\n",
       "     'text': ' analgesic that is used worldwide for pain, but its mechanisms of action have not been fully elucidated. The majority of studies to date have focused ',\n",
       "     'offsetInBeginSection': 14,\n",
       "     'offsetInEndSection': 164,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35292828',\n",
       "     'text': 'at the association of atezolizumab and tiragolumab could restore function of CD4 and CD8 TILs in MSS-CRC and could be tested in a clinical trial in co',\n",
       "     'offsetInBeginSection': 1436,\n",
       "     'offsetInEndSection': 1586,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35292828',\n",
       "     'text': 'gest that the association of atezolizumab and tiragolumab could restore function of CD4 and CD8 TILs in MSS-CRC and could be tested in a clinical tria',\n",
       "     'offsetInBeginSection': 1429,\n",
       "     'offsetInEndSection': 1579,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35292828',\n",
       "     'text': 'f atezolizumab (anti-PD-L1) and tiragolumab (anti-TIGIT) to reactivate the immune response of tumor infiltrating lymphocytes (TILs) in MSS-CRC. We ana',\n",
       "     'offsetInBeginSection': 255,\n",
       "     'offsetInEndSection': 405,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35652612',\n",
       "     'text': 'TIGIT-targeted antibody tiragolumab missed its endpoints in two late-stage lung cancer trials, raising doubts about one of the most widely studied next-generation checkpoint targets in immuno-oncology. But numerical signs of benefit among certain patients with metastatic non-small cell lung cancer suggest that TIGIT blockade',\n",
       "     'offsetInBeginSection': 12,\n",
       "     'offsetInEndSection': 338,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/35292828',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35576957',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32576590',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/27324312',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35652612',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/26292636']},\n",
       "  {'id': '641d8fd6690f196b51000041',\n",
       "   'type': 'list',\n",
       "   'body': 'What are the serum biomarkers that have been proposed in Neuromyelitis Optica Spectrum Disorders (NMOSD) to monitor disease activity?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35887254',\n",
       "     'text': 'thophysiology of the disease, the potential use of serum and cerebrospinal fluid cytokines as disease biomarkers, the clinical utilization of ocular c',\n",
       "     'offsetInBeginSection': 656,\n",
       "     'offsetInEndSection': 806,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31471502',\n",
       "     'text': 'th a sensitivity of 73.0% and a specificity of 75.8%.\\n\\n\\nCONCLUSIONS\\nsGFAP and sNfL are likely to be good biomarkers of disease activity and disability',\n",
       "     'offsetInBeginSection': 1327,\n",
       "     'offsetInEndSection': 1477,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25468778',\n",
       "     'text': 'ients was compared by flow cytometry. The serum levels of IL-21, IL-6, IL-17, TNF-α and IL-10 were analyzed by ELISA assays. We found that in NMOSD, t',\n",
       "     'offsetInBeginSection': 427,\n",
       "     'offsetInEndSection': 577,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33019871',\n",
       "     'text': 's in serum and cerebrospinal fluid biomarkers of astrocytes, neurons, myelin sheath, and other damage after the onset of NMOSD. Besides the value of m',\n",
       "     'offsetInBeginSection': 663,\n",
       "     'offsetInEndSection': 813,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27049569',\n",
       "     'text': 'toimmune diseases. To explore the roles of the IL-12 family members IL-27 and IL-35 in the pathogenesis of neuromyelitis optica spectrum disorders (NM',\n",
       "     'offsetInBeginSection': 61,\n",
       "     'offsetInEndSection': 211,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25027264',\n",
       "     'text': 'Since the discovery of aquaporin 4-IgG, a sensitive and highly specific biomarker of neuromyelitis optica (NMO), a wide range of syndromes have been r',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36378751',\n",
       "     'text': 'ing remission may be predictive of future disease activity. Serial serum GFAP measurements are emerging as a biomarker to monitor disease activity in ',\n",
       "     'offsetInBeginSection': 1234,\n",
       "     'offsetInEndSection': 1384,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29478727',\n",
       "     'text': 'mmatory disorder of the central nervous system (CNS). Serum immunoglobulin G autoantibodies (NMO-IgG) are identified in the majority of NMOSD patients',\n",
       "     'offsetInBeginSection': 69,\n",
       "     'offsetInEndSection': 219,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32961928',\n",
       "     'text': 'd proteomic outcomes of NMOSD. We highlight short chain fatty acids, lipoproteins, amino acids, and lactate as candidate diagnostic biomarkers. Althou',\n",
       "     'offsetInBeginSection': 844,\n",
       "     'offsetInEndSection': 994,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32184342',\n",
       "     'text': 'ty and disability in MOGAD showed a distinct feature from those in NMOSD with AQP4-Ab, which implicates different pathogeneses between the 2 diseases.',\n",
       "     'offsetInBeginSection': 1480,\n",
       "     'offsetInEndSection': 1630,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27402111',\n",
       "     'text': 'ing with MRI, cerebrospinal fluid analysis along with determination of AQP4-IgG serum autoantibody status, and exclusion of other disorders. Two major',\n",
       "     'offsetInBeginSection': 841,\n",
       "     'offsetInEndSection': 991,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32547558',\n",
       "     'text': 'nflammatory demyelinating diseases of the central nervous system. Exosomal microRNAs (miRNAs) are emerging biomarkers for demyelinating diseases. In t',\n",
       "     'offsetInBeginSection': 81,\n",
       "     'offsetInEndSection': 231,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34259579',\n",
       "     'text': 'al coherence tomography angiography (OCT-A), measurement of glial fibrillary acidic protein (GFAP) serum levels, and assessment of visual acuity.\\n\\n\\nRE',\n",
       "     'offsetInBeginSection': 594,\n",
       "     'offsetInEndSection': 744,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35938660',\n",
       "     'text': 'xpands, emerging biomarkers, including serum neurofilament light chain and glial fibrillary acidic protein (GFAP), may facilitate earlier relapse dete',\n",
       "     'offsetInBeginSection': 1284,\n",
       "     'offsetInEndSection': 1434,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25468778',\n",
       "     'text': 'compared by flow cytometry. The serum levels of IL-21, IL-6, IL-17, TNF-α and IL-10 were analyzed by ELISA assays. We found that in NMOSD, the Tfh cel',\n",
       "     'offsetInBeginSection': 437,\n",
       "     'offsetInEndSection': 587,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31471502',\n",
       "     'text': 't the hypothesis that serum levels of glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL), which are an intermediate astrocyte ',\n",
       "     'offsetInBeginSection': 16,\n",
       "     'offsetInEndSection': 166,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24964112',\n",
       "     'text': 'and some brain lesions are also unique to NMOSD. Serum autoantibodies against aquaporin-4 (AQP4) are detected in most cases of NMOSD. However, some pa',\n",
       "     'offsetInBeginSection': 144,\n",
       "     'offsetInEndSection': 294,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31664710',\n",
       "     'text': 's been markedly enhanced by the discovery that serum autoantibodies that target aquaporin-4 (AQP4) are strongly associated with the disease. This spec',\n",
       "     'offsetInBeginSection': 260,\n",
       "     'offsetInEndSection': 410,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31664710',\n",
       "     'text': 'recently been evaluated. The results of these studies, involving monoclonal antibodies (mAbs) inhibiting terminal complement protein cleavage interfer',\n",
       "     'offsetInBeginSection': 808,\n",
       "     'offsetInEndSection': 958,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35401423',\n",
       "     'text': 'antibody titers, cytokine profiles, complement factors, and markers of neuronal (e.g., neurofilament light chain) or astroglial (e.g., glial fibrillary acidic protein) damage',\n",
       "     'offsetInBeginSection': 1354,\n",
       "     'offsetInEndSection': 1528,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31382910',\n",
       "     'text': 'd Expanded Disability Status Scale (EDSS) scores.\\n\\n\\nCONCLUSIONS\\nSerum IL-36β and IL-36γ levels were related to disease activity in NMOSD patients and ',\n",
       "     'offsetInBeginSection': 665,\n",
       "     'offsetInEndSection': 815,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35401423',\n",
       "     'text': 'ese include antibody titers, cytokine profiles, complement factors, and markers of neuronal (e.g., neurofilament light chain) or astroglial (e.g., gli',\n",
       "     'offsetInBeginSection': 1342,\n",
       "     'offsetInEndSection': 1492,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32559008',\n",
       "     'text': 'HODS\\nFor 236 suspected NMOSD patients referred for serum aquaporin-4 immunoglobulin G antibody (AQP4-IgG) testing between 2012 and 2014, the three set',\n",
       "     'offsetInBeginSection': 379,\n",
       "     'offsetInEndSection': 529,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32679524',\n",
       "     'text': 'ge- and sex-matched controls. We analyzed the associations between CSF YKL-40 levels and the clinical variables of NMOSD.\\n\\n\\nRESULTS\\nCompared to contro',\n",
       "     'offsetInBeginSection': 476,\n",
       "     'offsetInEndSection': 626,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32184342',\n",
       "     'text': ' those in neuromyelitis optica spectrum disorder (NMOSD) with anti-aquaporin-4 antibodies (AQP4-Abs).\\n\\n\\nMETHODS\\nUsing ultrasensitive single-molecule a',\n",
       "     'offsetInBeginSection': 202,\n",
       "     'offsetInEndSection': 352,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32679524',\n",
       "     'text': 'diseases. Our aim of this study was to investigate cerebrospinal fluid (CSF) and serum YKL-40 levels in patients with NMOSD and their association with',\n",
       "     'offsetInBeginSection': 223,\n",
       "     'offsetInEndSection': 373,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35938660',\n",
       "     'text': 'opathology, current diagnostic criteria, relapse-related risk factors, emerging biomarkers, and evolving treatment strategies pertaining to neuromyeli',\n",
       "     'offsetInBeginSection': 85,\n",
       "     'offsetInEndSection': 235,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35873620',\n",
       "     'text': 'um amyloid A. Truncated breast and ovarian cancer susceptibility protein and cystic fibrosis transmembrane conductance regulator protein were specific',\n",
       "     'offsetInBeginSection': 796,\n",
       "     'offsetInEndSection': 946,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36378751',\n",
       "     'text': 'kers for prognosis or treatment response are still lacking. Glial fibrillary acidic protein (GFAP) is mainly expressed in astrocytes and can be detect',\n",
       "     'offsetInBeginSection': 472,\n",
       "     'offsetInEndSection': 622,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34168058',\n",
       "     'text': 'is optica spectrum disorder (NMOSD) pathogenesis, we profiled the AQP4-IgG polyclonal serum repertoire and identified, quantified, and functionally ch',\n",
       "     'offsetInBeginSection': 98,\n",
       "     'offsetInEndSection': 248,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/27049569',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36378751',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34259579',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35401423',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32961928',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35873620',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/31471502',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33019871',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/25027264',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/29478727',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35887254',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32679524',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32184342',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32559008',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32547558',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35938660',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/24964112',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/25468778',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34168058',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/31664710',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/31382910',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/27402111']},\n",
       "  {'id': '6429d5c557b1c7a315000006',\n",
       "   'type': 'list',\n",
       "   'body': 'What are the major thrombotic complications in patients with COVID-19?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36289613',\n",
       "     'text': 'n has been associated with thrombotic complications, especially venous thromboembolism. Although arterial thrombotic complications are rarely seen in ',\n",
       "     'offsetInBeginSection': 17,\n",
       "     'offsetInEndSection': 167,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33569525',\n",
       "     'text': 'ne-third of COVID-19 patients show major thrombotic events, mostly pulmonary emboli. The endothelial expression of angiotensin-converting enzyme-2 rec',\n",
       "     'offsetInBeginSection': 794,\n",
       "     'offsetInEndSection': 944,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35967591',\n",
       "     'text': 'ons such as arterial and venous thromboembolism, myocardial injury or inflammation resulting in infarction, heart failure, and arrhythmias. Data sugge',\n",
       "     'offsetInBeginSection': 161,\n",
       "     'offsetInEndSection': 311,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35643053',\n",
       "     'text': 'ity and mortality. Several observational studies have described hemostatic derangements and thrombotic complications in patients with COVID-19. The ai',\n",
       "     'offsetInBeginSection': 151,\n",
       "     'offsetInEndSection': 301,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34512059',\n",
       "     'text': 'roposed, these include virus-induced endothelial cell damage, inflammation, and excess production of pro-inflammatory cytokines. As a result, most cri',\n",
       "     'offsetInBeginSection': 688,\n",
       "     'offsetInEndSection': 838,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34884354',\n",
       "     'text': 'INTRODUCTION\\nThrombosis and bleeding are recognized complications of the novel coronavirus infection (COVID-19), with a higher incidence described par',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34271813',\n",
       "     'text': 'nts. Most of these complications are associated with venous thromboembolism and pulmonary embolism; and arterial thrombosis is rare. Usually, arterial',\n",
       "     'offsetInBeginSection': 84,\n",
       "     'offsetInEndSection': 234,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34938638',\n",
       "     'text': 'ons of COVID-19. Such complications may include the pulmonary, renal, and other organs vasculature. The risk of coagulopathy is usually related to the',\n",
       "     'offsetInBeginSection': 128,\n",
       "     'offsetInEndSection': 278,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32474145',\n",
       "     'text': 'idence of thrombotic complications are in relation to deep vein thrombosis and pulmonary embolism, while the evidence about arterial thrombosis in pat',\n",
       "     'offsetInBeginSection': 162,\n",
       "     'offsetInEndSection': 312,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33296828',\n",
       "     'text': '. Common thrombotic complications include pulmonary embolism, cerebral infarction, or venous thromboembolism; less commonly seen are acute myocardial ',\n",
       "     'offsetInBeginSection': 298,\n",
       "     'offsetInEndSection': 448,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34198348',\n",
       "     'text': 'lications. These patients have a high risk for venous and arterial thrombosis of large and small vessels. Here, a 42-year-old female with celiac arter',\n",
       "     'offsetInBeginSection': 171,\n",
       "     'offsetInEndSection': 321,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34873931',\n",
       "     'text': 'infected with COVID-19. These complications are related to increased blood hypercoagulabity, which can cause both venous and arterial thrombosis. We r',\n",
       "     'offsetInBeginSection': 71,\n",
       "     'offsetInEndSection': 221,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33414129',\n",
       "     'text': 'COVID-19 has serious thrombotic complications in critically ill patients; however, thrombus is not a typical presenting symptom. This case report desc',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34884354',\n",
       "     'text': '\\n\\n\\nCONCLUSIONS\\nThis study describes a high incidence of thrombotic and bleeding complications among critically ill COVID-19 patients. The findings of ',\n",
       "     'offsetInBeginSection': 2426,\n",
       "     'offsetInEndSection': 2576,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36430724',\n",
       "     'text': 'atients are prone to thrombotic complications that may increase morbidity and mortality. These complications are thought to be driven by endothelial a',\n",
       "     'offsetInBeginSection': 35,\n",
       "     'offsetInEndSection': 185,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32944087',\n",
       "     'text': 'se cells. Besides pneumonia-induced respiratory failure, thrombotic cardiovascular complications are increasingly emerging as a major COVID-19 symptom',\n",
       "     'offsetInBeginSection': 284,\n",
       "     'offsetInEndSection': 434,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34512059',\n",
       "     'text': ', especially among critically ill patients, and are associated with poor prognosis. To date, many studies have concluded that COVID-19 increases the i',\n",
       "     'offsetInBeginSection': 327,\n",
       "     'offsetInEndSection': 477,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34066226',\n",
       "     'text': 's substantially high in patients with severe COVID-19 and that a thromboembolic event is another major complication contributing to the high morbidity',\n",
       "     'offsetInBeginSection': 373,\n",
       "     'offsetInEndSection': 523,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33074732',\n",
       "     'text': 'sease, due to the high incidence in critically ill patients and poor clinical outcomes. COVID-19 predisposes patients to a hypercoagulable state, howe',\n",
       "     'offsetInBeginSection': 94,\n",
       "     'offsetInEndSection': 244,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34104443',\n",
       "     'text': 'mended but, in addition to thrombotic complications, bleeding is a significant cause of morbidity in patients with COVID-19. Idiopathic iliopsoas hema',\n",
       "     'offsetInBeginSection': 118,\n",
       "     'offsetInEndSection': 268,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34060217',\n",
       "     'text': ' late thrombotic complications (deep vein thrombosis, pulmonary embolism, stroke, new-onset vascular access thrombosis) in maintenance hemodialysis pa',\n",
       "     'offsetInBeginSection': 269,\n",
       "     'offsetInEndSection': 419,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/32474145',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33074732',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34198348',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32944087',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35967591',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34884354',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33296828',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34873931',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33414129',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34938638',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36289613',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34066226',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34512059',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34271813',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35643053',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33569525',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34060217',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36430724',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34104443']},\n",
       "  {'id': '6433012b57b1c7a315000022',\n",
       "   'type': 'summary',\n",
       "   'body': 'What is Cinryze?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23776358',\n",
       "     'text': 'ted States: Berinert(®) for treating acute attacks and Cinryze(®) for prophylaxis in adolescent/adult patients. A recombinant C1-INH that is being con',\n",
       "     'offsetInBeginSection': 745,\n",
       "     'offsetInEndSection': 895,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20627701',\n",
       "     'text': 'utine prophylaxis include danazol given orally and the nanofiltered human C1 esterase inhibitor, CINRYZE, which is approved for intravenous administra',\n",
       "     'offsetInBeginSection': 172,\n",
       "     'offsetInEndSection': 322,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21942916',\n",
       "     'text': 'Intravenous nanofiltered human C1 inhibitor (C1-INH NF) concentrate (Cinryze®) is used as a direct replacement of deficient levels of plasma C1 inhibi',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26756974',\n",
       "     'text': 'o long-term prophylaxis consisting in an individual dose of intravenous C1-INHc (Cinryze). None of the patients had been previously treated with ecall',\n",
       "     'offsetInBeginSection': 782,\n",
       "     'offsetInEndSection': 932,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22282695',\n",
       "     'text': 'he United States was limited to androgen therapy. The human plasma-derived C1 esterase inhibitor (Cinryze™), distributed by Lev Pharmaceuticals, was a',\n",
       "     'offsetInBeginSection': 734,\n",
       "     'offsetInEndSection': 884,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29569504',\n",
       "     'text': 'a blocking the production or function of bradykinin. Cinryze® is a nanofiltered C1-INH, approved in Europe for the acute treatment, preprocedure preve',\n",
       "     'offsetInBeginSection': 406,\n",
       "     'offsetInEndSection': 556,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24805006',\n",
       "     'text': 'D METHODS\\nThe analysis included one transgenic (Ruconest) and three plasma-derived (Berinert, Cetor, Cinryze) C1-INH concentrates. C1-INH antigen conc',\n",
       "     'offsetInBeginSection': 475,\n",
       "     'offsetInEndSection': 625,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24805006',\n",
       "     'text': 'n the plasma-derived products were α1-antichymotrypsin, ceruloplasmin, Factor C3 (Cinryze/Cetor), and immunoglobulin heavy constant mu (Berinert).\\n\\n\\nC',\n",
       "     'offsetInBeginSection': 1372,\n",
       "     'offsetInEndSection': 1522,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26756974',\n",
       "     'text': 'ched to long-term prophylaxis consisting in an individual dose of intravenous C1-INHc (Cinryze). None of the patients had been previously treated with',\n",
       "     'offsetInBeginSection': 776,\n",
       "     'offsetInEndSection': 926,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31592791',\n",
       "     'text': 'ents under 18 years of age. Cinryze has FDA approval only for prophylaxis for children as young as 6 years old.\\n\\n\\nSUMMARY\\nPediatric HAE is a potential',\n",
       "     'offsetInBeginSection': 993,\n",
       "     'offsetInEndSection': 1143,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31592791',\n",
       "     'text': 'cute treatment and prophylaxis. Available agents include plasma-derived C1 esterase inhibitors (C1-INH) (Berinert, Haegarda, Cinryze), recombinant C1-',\n",
       "     'offsetInBeginSection': 351,\n",
       "     'offsetInEndSection': 501,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21895469',\n",
       "     'text': 'Cinryze is a pasteurized, nanofiltered plasma derived concentrate of C1-inhibitor (pdC1-INH) licensed for the prophylactic treatment of hereditary ang',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23282867',\n",
       "     'text': 'was approved by the U.S. Food & Drug Administration (FDA) for prophylaxis of HAE attacks in October 2008, and the second, Berinert, was approved by th',\n",
       "     'offsetInBeginSection': 822,\n",
       "     'offsetInEndSection': 972,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26106828',\n",
       "     'text': 'onest) was produced from the milk of transgenic rabbits and two plasma-derived C1-INHs (Berinert, Cinryze) underwent controlled trials to obtain marke',\n",
       "     'offsetInBeginSection': 706,\n",
       "     'offsetInEndSection': 856,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29279063',\n",
       "     'text': 'ts, and the mean age was 50.1 years. Cinryze and Berinert (both C1-esterase inhibitors) had the highest median scores (5.0) for patient confidence, fo',\n",
       "     'offsetInBeginSection': 986,\n",
       "     'offsetInEndSection': 1136,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23282867',\n",
       "     'text': 'le-blind studies. One preparation, Cinryze, was approved by the U.S. Food & Drug Administration (FDA) for prophylaxis of HAE attacks in October 2008, ',\n",
       "     'offsetInBeginSection': 778,\n",
       "     'offsetInEndSection': 928,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33485376',\n",
       "     'text': 'a-derived C1 inhibitor concentrate. She was treated with Cinryze® replacement therapy throughout the pregnancy 1000 IU i.v. 48 times. She gave birth t',\n",
       "     'offsetInBeginSection': 665,\n",
       "     'offsetInEndSection': 815,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23776358',\n",
       "     'text': ' Berinert(®) for treating acute attacks and Cinryze(®) for prophylaxis in adolescent/adult patients. A recombinant C1-INH that is being considered for',\n",
       "     'offsetInBeginSection': 756,\n",
       "     'offsetInEndSection': 906,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24805006',\n",
       "     'text': 'ic (Ruconest) and three plasma-derived (Berinert, Cetor, Cinryze) C1-INH concentrates. C1-INH antigen concentration was determined by nephelometry, to',\n",
       "     'offsetInBeginSection': 519,\n",
       "     'offsetInEndSection': 669,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27660422',\n",
       "     'text': ' for HAE treatment in the US, the European Union, or both regions: Cinryze(®), Berinert(®), and Cetor(®); however, only Cinryze is approved for long-t',\n",
       "     'offsetInBeginSection': 629,\n",
       "     'offsetInEndSection': 779,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/21942916',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/29279063',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/23282867',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/20627701',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33485376',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/27660422',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/26756974',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/24805006',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/29569504',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/31592791',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/22282695',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/21895469',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/26106828',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/23776358']},\n",
       "  {'id': '64179337690f196b51000034',\n",
       "   'type': 'yesno',\n",
       "   'body': 'Do machine learning-based methods outperform statistical methods for survival analysis?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34862545',\n",
       "     'text': ' and within neurosciences, including neurosurgery. ML methods regularly outperform classical methods and have been successfully applied to, inter alia',\n",
       "     'offsetInBeginSection': 568,\n",
       "     'offsetInEndSection': 718,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/11185421',\n",
       "     'text': 'd construct symbolic and interpretable models, their applications to survival analysis are at best rare, primarily because of the difficulty to approp',\n",
       "     'offsetInBeginSection': 274,\n",
       "     'offsetInEndSection': 424,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36227551',\n",
       "     'text': 'machine-learning-based models such as random survival forests, gradient boosted survival model, and survival support vector machine can outperform the traditional statistical methods',\n",
       "     'offsetInBeginSection': 871,\n",
       "     'offsetInEndSection': 1053,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30409119',\n",
       "     'text': 'on constraints (such as proportional hazard assumptions) and better predictive performance compared with statistical models. Upon comparing the concor',\n",
       "     'offsetInBeginSection': 1858,\n",
       "     'offsetInEndSection': 2008,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34910160',\n",
       "     'text': 'BACKGROUND\\nMachine learning-based risk prediction models may outperform traditional statistical models in large datasets with many variables, by ident',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35316964',\n",
       "     'text': 'Machine learning models may outperform traditional statistical regression algorithms for predicting clinical outcomes. Proper validation of building s',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36028137',\n",
       "     'text': '\\nCONCLUSION\\nMachine learning algorithms such as the random forest were superior to conventional Cox regression and previously reported survival scores',\n",
       "     'offsetInBeginSection': 2442,\n",
       "     'offsetInEndSection': 2592,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20153956',\n",
       "     'text': 'g the identified various risk groups.\\n\\n\\nRESULTS\\nThe machine learning models performed very effectively in predicting the survival time: the support ve',\n",
       "     'offsetInBeginSection': 1818,\n",
       "     'offsetInEndSection': 1968,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36227551',\n",
       "     'text': 'ival model, and survival support vector machine can outperform the traditional statistical methods, i.e., Cox proportional hazard model. The highest C',\n",
       "     'offsetInBeginSection': 955,\n",
       "     'offsetInEndSection': 1105,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33313792',\n",
       "     'text': \"0.68 (0.65-0.71), respectively.\\n\\n\\nCONCLUSIONS\\nThe machine learning model's predictions were more accurate than those of the treating physician or a tr\",\n",
       "     'offsetInBeginSection': 1580,\n",
       "     'offsetInEndSection': 1730,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35571512',\n",
       "     'text': 'CRP. Furthermore, RF, SVM, DT, AdaBoost, DT, and KNN outperform other machine learning algorithms in predicting the survival or death of COVID-19 pati',\n",
       "     'offsetInBeginSection': 981,\n",
       "     'offsetInEndSection': 1131,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20638252',\n",
       "     'text': \"putation methods based on machine learning algorithms outperformed imputation statistical methods in the prediction of patient outcome. Friedman's tes\",\n",
       "     'offsetInBeginSection': 1218,\n",
       "     'offsetInEndSection': 1368,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34161901',\n",
       "     'text': 'ed previously available hospitals. While machine learning algorithms outperform traditional econometric models in prediction, the gain they provide sh',\n",
       "     'offsetInBeginSection': 337,\n",
       "     'offsetInEndSection': 487,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20153956',\n",
       "     'text': 'ning method to select the predictor variables is more effective in developing the Cox survival models than the traditional methods commonly found in t',\n",
       "     'offsetInBeginSection': 2751,\n",
       "     'offsetInEndSection': 2901,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24573170',\n",
       "     'text': 's and random survival forests algorithms. Most of the rule quality measures outperform Kaplan-Meier estimate and perform at least equally well as tree',\n",
       "     'offsetInBeginSection': 1095,\n",
       "     'offsetInEndSection': 1245,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30290849',\n",
       "     'text': 'The preliminary results demonstrated that certain machine learning and radiomics analysis method could predict OS of non-small cell lung cancer accuracy',\n",
       "     'offsetInBeginSection': 1079,\n",
       "     'offsetInEndSection': 1231,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20153956',\n",
       "     'text': 'grated machine learning method to select the predictor variables is more effective in developing the Cox survival models than the traditional methods ',\n",
       "     'offsetInBeginSection': 2732,\n",
       "     'offsetInEndSection': 2882,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31896241',\n",
       "     'text': 'gh-dimensional genomic data. Furthermore, machine learning approaches have been adapted for survival analysis, to fit nonlinear and complex interactio',\n",
       "     'offsetInBeginSection': 722,\n",
       "     'offsetInEndSection': 872,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36233640',\n",
       "     'text': 'rd). The ensemble methods RF and XGB outperform other methods when data are less balanced, while SVM, LR, LASSO, and DFNN outperform other methods whe',\n",
       "     'offsetInBeginSection': 2039,\n",
       "     'offsetInEndSection': 2189,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36028137',\n",
       "     'text': 'ne learning methods, the random forest yielded the highest area under the receiver operating characteristic curve (AUC-ROC) values (1-month\\xa0=\\xa00.80; 3-',\n",
       "     'offsetInBeginSection': 1008,\n",
       "     'offsetInEndSection': 1158,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36028137',\n",
       "     'text': 'ical models. This study aimed to compare the performance of traditional statistical models with machine learning approaches for predicting survival fo',\n",
       "     'offsetInBeginSection': 367,\n",
       "     'offsetInEndSection': 517,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/30290849',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34910160',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36233640',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35316964',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33313792',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/24573170',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/20153956',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/11185421',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34862545',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/31896241',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35571512',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36227551',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36028137',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34161901',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/20638252',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/30409119']},\n",
       "  {'id': '63f03c47f36125a42600001e',\n",
       "   'type': 'factoid',\n",
       "   'body': 'ZF2001 is used for which disease?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35034583',\n",
       "     'text': 'e (ZF2001) significantly increased neutralization titers to both WT and Omicron variant. Moreover, at day 14 post the third dose, neutralizing antibod',\n",
       "     'offsetInBeginSection': 670,\n",
       "     'offsetInEndSection': 820,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35596222',\n",
       "     'text': 'conditional approval in China) to SARS-CoV-2 Delta variant-induced severe pneumonia, the lethal challenge model of K18-hACE2 transgenic mice was used ',\n",
       "     'offsetInBeginSection': 95,\n",
       "     'offsetInEndSection': 245,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34021265',\n",
       "     'text': ' CoronaVac (inactivated vaccine), ZF2001 (RBD-subunit vaccine) and natural infection. Among 86 potent NAbs identified by high-throughput single-cell V',\n",
       "     'offsetInBeginSection': 292,\n",
       "     'offsetInEndSection': 442,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36158819',\n",
       "     'text': 'iving the first dose of the ZF2001 RBD-subunit vaccine against coronavirus disease 2019 (COVID-19). Autopsy showed severe interstitial myocarditis, in',\n",
       "     'offsetInBeginSection': 109,\n",
       "     'offsetInEndSection': 259,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34877393',\n",
       "     'text': 'es (NAbs) elicited by CoronaVac (inactivated vaccine) and ZF2001 (RBD-subunit vaccine) against B.1.617 and B.1.1.7 variants. Our results showed that, ',\n",
       "     'offsetInBeginSection': 598,\n",
       "     'offsetInEndSection': 748,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36426361',\n",
       "     'text': 'Background\\nIn response to SARS-CoV-2 mutations and waning antibody levels after two-dose inactivated vaccines, we assessed whether a third dose of rec',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35311493',\n",
       "     'text': 'ement was observed in both animal models. ZF2001 has been approved for emergency use in China, Uzbekistan, Indonesia, and Columbia. The high safety, i',\n",
       "     'offsetInBeginSection': 917,\n",
       "     'offsetInEndSection': 1067,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35617368',\n",
       "     'text': 'eometric mean ratios of 2.0 (1.2 to 3.5) and 3.4 (1.8 to 6.4) compared to TIV. GMTs at 14 days after second boost of neutralizing antibodies increased',\n",
       "     'offsetInBeginSection': 2528,\n",
       "     'offsetInEndSection': 2678,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36426361',\n",
       "     'text': 'or the three groups (P=0.0005, P<0.0001, and P<0.0001).\\n\\n\\nConclusion\\nHeterologous boosting with ZF2001 was safe and immunogenic, and prime-boost inter',\n",
       "     'offsetInBeginSection': 1350,\n",
       "     'offsetInEndSection': 1500,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35634276',\n",
       "     'text': 'SARS-CoV-2 vaccines (CoronaVac, BBIBP-CorV, and ZF2001) are safe in thyroid cancer patients. The regression time of SARS-CoV-2 IgG is significantly sh',\n",
       "     'offsetInBeginSection': 1451,\n",
       "     'offsetInEndSection': 1601,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/35634276',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34021265',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35617368',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35034583',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35311493',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35596222',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34877393',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36158819',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36426361']},\n",
       "  {'id': '642c82c557b1c7a315000012',\n",
       "   'type': 'factoid',\n",
       "   'body': 'What mammal has the lowest known chromosome number?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27186334',\n",
       "     'text': 'species have 2n=36, a number considered as a pleisomorphic feature in Arecoideae since the modern species, according to floral morphology, have the lo',\n",
       "     'offsetInBeginSection': 1091,\n",
       "     'offsetInEndSection': 1241,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24500949',\n",
       "     'text': 'kelihood-inferred changes in chromosome numbers among close relatives. Typhonium, the focal genus, includes species with 2n = 65 and 2n = 8, the lowes',\n",
       "     'offsetInBeginSection': 486,\n",
       "     'offsetInEndSection': 636,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31879909',\n",
       "     'text': 'his system is based on hTERT-immortalized fibroblasts from a female Indian muntjac, a placental mammal with the lowest known chromosome number (n\\xa0=\\xa03)',\n",
       "     'offsetInBeginSection': 1306,\n",
       "     'offsetInEndSection': 1456,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29706521',\n",
       "     'text': 'nderstood. Here we used the unique cytological attributes of female Indian muntjac, the mammal with the lowest known chromosome number (2n\\xa0= 6), to ch',\n",
       "     'offsetInBeginSection': 604,\n",
       "     'offsetInEndSection': 754,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22105874',\n",
       "     'text': ' patchy distribution, poor records and low abundances. It is also the phyllotine with the lowest known diploid chromosome number (2n = 18), however it',\n",
       "     'offsetInBeginSection': 74,\n",
       "     'offsetInEndSection': 224,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25379715',\n",
       "     'text': 't chromosome number observed for the subfamily Myrmicinae and for the Hymenoptera found in the Neotropical region. Observation of a low chromosome num',\n",
       "     'offsetInBeginSection': 489,\n",
       "     'offsetInEndSection': 639,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/5444269',\n",
       "     'text': 'The Indian muntjac (Muntiacus muntjak) has a diploid chromosome number of 7 in the male and 6 in the female, the lowest number yet described in a mamm',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32843950',\n",
       "     'text': 'o-2-phenylindole) staining. The karyotype analyses show that the male B. sinicus possesses the lowest chromosome number (2n = 15) ever observed in Mec',\n",
       "     'offsetInBeginSection': 145,\n",
       "     'offsetInEndSection': 295,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/4841572',\n",
       "     'text': 'The chocolate gourami, Sphaerichthys osphromonoides, has the lowest chromosome number reported for fishes, with 2n = 16 and n = 8. Other members of th',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/9691174',\n",
       "     'text': 'osso, Central Brazil, represents the lowest chromosome number known for rodents. One female with nine chromosomes due to sex chromosome monosomy (2n =',\n",
       "     'offsetInBeginSection': 140,\n",
       "     'offsetInEndSection': 290,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30296783',\n",
       "     'text': 'e. In total, 2,758 spermatocytes and over 170,000 COs were examined. Suffolk rams exhibited the lowest mean number of COs (61.1 ± 0.15) compared to Ic',\n",
       "     'offsetInBeginSection': 533,\n",
       "     'offsetInEndSection': 683,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17189914',\n",
       "     'text': '. Among marine mammals, a C-value has been estimated only for the bottlenose dolphin (Tursiops truncatus). Thus examination of additional species of m',\n",
       "     'offsetInBeginSection': 406,\n",
       "     'offsetInEndSection': 556,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33089966',\n",
       "     'text': 'e X-chromosome scaffold, with a scaffold N50 of 115\\xa0Mb. Genome-wide heterozygosity is the lowest (0.01%) of any mammalian species analysed to date, bu',\n",
       "     'offsetInBeginSection': 713,\n",
       "     'offsetInEndSection': 863,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31879909',\n",
       "     'text': 'ul genetic tools and low chromosome number of fission yeast and Drosophila melanogaster, with the exceptional cytological features of a rat kangaroo c',\n",
       "     'offsetInBeginSection': 1150,\n",
       "     'offsetInEndSection': 1300,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/14608465',\n",
       "     'text': 'ty, with diploid numbers ranging from 2n=50 to 2n=16. We report on Callicebus lugens, which has the lowest diploid number (2n=16) yet found in the pri',\n",
       "     'offsetInBeginSection': 171,\n",
       "     'offsetInEndSection': 321,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15954092',\n",
       "     'text': 'testis development and a means of activating the X chromosome. The duckbill platypus challenges these dogmas.(1,2) Gutzner et al.(1) find no recogniza',\n",
       "     'offsetInBeginSection': 72,\n",
       "     'offsetInEndSection': 222,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24260698',\n",
       "     'text': 'The subterranean mole vole, Ellobius tancrei, with aspecific variability in autosomes (2n = 31-54) and unusual sex chromosomes (XX in males and female',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/22105874',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/15954092',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/31879909',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/29706521',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/25379715',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32843950',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/9691174',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/17189914',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/14608465',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/4841572',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/24500949',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33089966',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/30296783',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/24260698',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/5444269',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/27186334']},\n",
       "  {'id': '6429b41757b1c7a315000004',\n",
       "   'type': 'list',\n",
       "   'body': 'When modifying histones with either activating or repressing marks, such as with acetyl and methyl groups, histone acetyltransferases and histone methyltransferases normally modify which amino acids?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22122749',\n",
       "     'text': 'n structure and function by modifying the biochemical properties of key amino acids. Histone methylation events, especially on arginine- and lysine-re',\n",
       "     'offsetInBeginSection': 329,\n",
       "     'offsetInEndSection': 479,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/22122749']},\n",
       "  {'id': '643305b257b1c7a315000025',\n",
       "   'type': 'factoid',\n",
       "   'body': 'Which company produces Ruconest?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31592791',\n",
       "     'text': 'sterase inhibitors (C1-INH) (Berinert, Haegarda, Cinryze), recombinant C1-INH (Ruconest), bradykinin B2 receptor inhibitor (Icatibant), and kallikrein',\n",
       "     'offsetInBeginSection': 427,\n",
       "     'offsetInEndSection': 577,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26250409',\n",
       "     'text': 'ical studies demonstrating the efficacy and safety of Ruconest(®) (Pharming Group NV, Leiden, the Netherlands), which is now approved for use in Europ',\n",
       "     'offsetInBeginSection': 871,\n",
       "     'offsetInEndSection': 1021,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26106828',\n",
       "     'text': 'inant C1-INH concentrate (Ruconest) was produced from the milk of transgenic rabbits and two plasma-derived C1-INHs (Berinert, Cinryze) underwent cont',\n",
       "     'offsetInBeginSection': 677,\n",
       "     'offsetInEndSection': 827,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25673959',\n",
       "     'text': 'Conestat alfa (Ruconest): first recombinant C1 esterase inhibitor for the treatment of acute attacks in patients with hereditary angioedema.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 140,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26106828',\n",
       "     'text': 'atibant). At the same time, a recombinant C1-INH concentrate (Ruconest) was produced from the milk of transgenic rabbits and two plasma-derived C1-INH',\n",
       "     'offsetInBeginSection': 641,\n",
       "     'offsetInEndSection': 791,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24278067',\n",
       "     'text': 'as follows: EUR 15,226 per QALY (Ruconest(®)) and EUR 27,786 per QALY (Berinert(®) P). The probability of cost-utility (ICUR < EUR 24,279 per QALY) as',\n",
       "     'offsetInBeginSection': 1167,\n",
       "     'offsetInEndSection': 1317,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/26250409',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/25673959',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/31592791',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/24278067',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/26106828']},\n",
       "  {'id': '641635fa690f196b5100001c',\n",
       "   'type': 'factoid',\n",
       "   'body': 'What is usually the age of diagnosis in Duchenne muscular dystrophy?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25977513',\n",
       "     'text': 'nerative muscular disease affecting males. Diagnosis usually occurs in childhood and is confirmed through genetic testing and/or muscle biopsy. Accomp',\n",
       "     'offsetInBeginSection': 51,\n",
       "     'offsetInEndSection': 201,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25996334',\n",
       "     'text': 'but sporadic cases are also frequent. The average age at diagnosis is 4.83 years but an early diagnosis is possible.\\n\\n\\nCLINICAL CASE\\nAn 18-month male ',\n",
       "     'offsetInBeginSection': 248,\n",
       "     'offsetInEndSection': 398,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16638505',\n",
       "     'text': 'ctioning of 25 Dutch males with Duchenne muscular dystrophy (mean age 10.1 years) were systematically assessed. This study relied on the use of a new ',\n",
       "     'offsetInBeginSection': 237,\n",
       "     'offsetInEndSection': 387,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26022172',\n",
       "     'text': ' more severe Duchenne muscular dystrophy typically presents around ages 2 to 5 with gait disturbance, and historically has led to the loss of ambulati',\n",
       "     'offsetInBeginSection': 140,\n",
       "     'offsetInEndSection': 290,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/11929208',\n",
       "     'text': ' walking at the beginning of the second decade, and usually die by age 20 years. Until treatment of the basic genetic defect is available, medical, su',\n",
       "     'offsetInBeginSection': 178,\n",
       "     'offsetInEndSection': 328,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33012180',\n",
       "     'text': 'cluded 52 people with Duchenne muscular dystrophy with a median age of 17 years (range: 14, 40) and 183 parents/guardians. Fourteen out of 23 (61%) No',\n",
       "     'offsetInBeginSection': 763,\n",
       "     'offsetInEndSection': 913,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33012180',\n",
       "     'text': ' (a) people with a confirmed diagnosis of Duchenne muscular dystrophy (≥14 years), (b) parents and guardians and (c) neuromuscular clinicians in the U',\n",
       "     'offsetInBeginSection': 466,\n",
       "     'offsetInEndSection': 616,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/7334343',\n",
       "     'text': 'ually conclusive without using an electron microscope, from the age of one year, if serous activity of CPK reaches twenty times the normal rate. If no',\n",
       "     'offsetInBeginSection': 646,\n",
       "     'offsetInEndSection': 796,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12026234',\n",
       "     'text': 'ion caused by Duchenne muscular dystrophy are usually detected during adolescence. However, decreased physical activity can allow better tolerance of ',\n",
       "     'offsetInBeginSection': 33,\n",
       "     'offsetInEndSection': 183,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/10436681',\n",
       "     'text': 'n age of 3 years, but the accurate diagnosis was made at a mean age of 5.7 years. In only 15% of children, the disease was diagnosed in the first four',\n",
       "     'offsetInBeginSection': 402,\n",
       "     'offsetInEndSection': 552,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/2347279',\n",
       "     'text': 'ne muscular dystrophy (DMD) was reported the mother was a carrier of 30 years old with a family history of Duchenne muscular dystrophy. Her brother di',\n",
       "     'offsetInBeginSection': 80,\n",
       "     'offsetInEndSection': 230,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/2476078',\n",
       "     'text': 'A total of 33 young boys (mean age 3.4 years) with Duchenne muscular dystrophy and 21 normal controls (mean age 3.5 years) were assessed using the Gri',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16322188',\n",
       "     'text': 'ood muscular dystrophies. The disease is typically diagnosed between 3 and 7 years of age and follows a predictable clinical course marked by progress',\n",
       "     'offsetInBeginSection': 76,\n",
       "     'offsetInEndSection': 226,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19027585',\n",
       "     'text': 'lthough Duchenne muscular dystrophy can be genetically diagnosed in young patients, extensive electrocardiogram studies have not been reported. Here, ',\n",
       "     'offsetInBeginSection': 96,\n",
       "     'offsetInEndSection': 246,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33662889',\n",
       "     'text': '\\n\\nMETHODS\\nWe studied 11 boys with Duchenne muscular dystrophy aged 8.6 to 13.9 years and 11 healthy age- and sex-matched controls.\\n\\n\\nRESULTS\\nCompared ',\n",
       "     'offsetInBeginSection': 547,\n",
       "     'offsetInEndSection': 697,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/1667037',\n",
       "     'text': 'cases. In addition, CT scan showed a cortical atrophy after the age of 10 years. This finding suggests that a cerebral degenerative process is present',\n",
       "     'offsetInBeginSection': 113,\n",
       "     'offsetInEndSection': 263,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19394035',\n",
       "     'text': 'tine kinase was 4.7 years. Mean age at definitive diagnosis of DMD was 4.9 years.\\n\\n\\nCONCLUSIONS\\nThere is a delay of about 2.5 years between onset of D',\n",
       "     'offsetInBeginSection': 850,\n",
       "     'offsetInEndSection': 1000,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12206794',\n",
       "     'text': 'des three cohorts of three patients each. Patients must be at least 15 years of age. Diagnosis of Duchenne and Becker muscular dystrophy was confirmed',\n",
       "     'offsetInBeginSection': 515,\n",
       "     'offsetInEndSection': 665,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/14713321',\n",
       "     'text': 'nal peptic ulcer has not been documented up to now.\\n\\n\\nCASE PRESENTATION\\nA 26-year-old male with Duchenne muscular dystrophy with a clinical and radiog',\n",
       "     'offsetInBeginSection': 266,\n",
       "     'offsetInEndSection': 416,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12026234',\n",
       "     'text': 'tening and norepinephrine plasma level (P = .66). The majority of younger adolescents with Duchenne muscular dystrophy and abnormal ventricular functi',\n",
       "     'offsetInBeginSection': 940,\n",
       "     'offsetInEndSection': 1090,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21482750',\n",
       "     'text': 'e, 40.04 years) of 27 Duchenne muscular dystrophy patients (mean age, 11.26 years) completed the validated Children Health Questionnaire-Parent Form 5',\n",
       "     'offsetInBeginSection': 331,\n",
       "     'offsetInEndSection': 481,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19449433',\n",
       "     'text': 'pertrophy of calf muscles, and muscle weakness, which became evident at 3 years of age. In addition, she had multiple congenital anomalies including a',\n",
       "     'offsetInBeginSection': 760,\n",
       "     'offsetInEndSection': 910,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33072986',\n",
       "     'text': 'DMD/Duchenne) is a progressive X-linked disease and is the most common pediatric-onset form of muscular dystrophy, affecting approximately 1:5000 live',\n",
       "     'offsetInBeginSection': 29,\n",
       "     'offsetInEndSection': 179,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/1667037',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/2347279',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/19027585',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/12026234',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/11929208',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33072986',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/7334343',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/2476078',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/21482750',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/10436681',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/25977513',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/12206794',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/19394035',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/25996334',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/19449433',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33662889',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/26022172',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/16638505',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33012180',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/14713321',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/16322188']},\n",
       "  {'id': '6402c868201352f04a00000b',\n",
       "   'type': 'yesno',\n",
       "   'body': 'Was erythropoietin effective for optic neuritis in the TONE trial?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22465890',\n",
       "     'text': 'group developed clinically definite MS according to the Poser criteria.\\n\\n\\nCONCLUSION\\nErythropoietin may be effective, but should be used with caution.',\n",
       "     'offsetInBeginSection': 1364,\n",
       "     'offsetInEndSection': 1514,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22926853',\n",
       "     'text': 'er erythropoietin treatment.\\n\\n\\nINTERPRETATION\\nThese results give the first indications that erythropoietin might be neuroprotective in optic neuritis.',\n",
       "     'offsetInBeginSection': 1736,\n",
       "     'offsetInEndSection': 1886,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/7821473',\n",
       "     'text': 'd reaction, especially in people with high microfilarial loads. Few data are available concerning the effect of ivermectin on active optic neuritis. A',\n",
       "     'offsetInBeginSection': 454,\n",
       "     'offsetInEndSection': 604,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/9103884',\n",
       "     'text': 'ned pathology, therapy of this disease, and summarized our previous cases. Intravenous methylpredonisolone treatment is effective from our experience.',\n",
       "     'offsetInBeginSection': 167,\n",
       "     'offsetInEndSection': 317,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35501141',\n",
       "     'text': 'icosteroids accelerated visual recovery in optic neuritis (ON) without improving outcome. This finding related largely to multiple sclerosis (MS), and',\n",
       "     'offsetInBeginSection': 64,\n",
       "     'offsetInEndSection': 214,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26932144',\n",
       "     'text': 'ys or placebo (0.9% saline) administered intravenously. With an estimated power of 80%, the calculated sample size is 100 patients. The trial started ',\n",
       "     'offsetInBeginSection': 1547,\n",
       "     'offsetInEndSection': 1697,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/10340796',\n",
       "     'text': 'oup than in the control (P<.05).\\n\\n\\nCONCLUSIONS\\nPulse treatment does not appear effective for idiopathic optic neuritis even though visual function in ',\n",
       "     'offsetInBeginSection': 1064,\n",
       "     'offsetInEndSection': 1214,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22465890',\n",
       "     'text': 'OBJECTIVE\\nTo investigate the safety, tolerability, and short-term efficacy of treatment with erythropoietin in patients with optic neuritis as a first',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22926853',\n",
       "     'text': 'dels of autoimmune optic nerve inflammation, we have assessed the safety and efficacy of erythropoietin in patients presenting with a first episode of',\n",
       "     'offsetInBeginSection': 40,\n",
       "     'offsetInEndSection': 190,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15601662',\n",
       "     'text': 'cells and optic nerves revealed that neuron and axon protection was most effective when erythropoietin treatment that was started at immunization was ',\n",
       "     'offsetInBeginSection': 1206,\n",
       "     'offsetInEndSection': 1356,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27706045',\n",
       "     'text': 'ute isolated optic neuritis did not influence further evolution of MRI lesions in the brain when comparing absolute numbers. However, early conversion',\n",
       "     'offsetInBeginSection': 1161,\n",
       "     'offsetInEndSection': 1311,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/7749521',\n",
       "     'text': ' acute attack of optic neuritis reduces the rate at which multiple sclerosis develops over a 2-year period of follow-up. The findings of the trial hav',\n",
       "     'offsetInBeginSection': 261,\n",
       "     'offsetInEndSection': 411,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/7821473',\n",
       "     'text': 'days. One had received placebo, the other ivermectin. Ivermectin does not appear to precipitate or exacerbate optic neuritis at a period of 7-14 days.',\n",
       "     'offsetInBeginSection': 1473,\n",
       "     'offsetInEndSection': 1623,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35052875',\n",
       "     'text': 'L thickness of the affected eye, the neuroprotective effects of novel add-on treatments could not be demonstrated. The difference in visual outcomes w',\n",
       "     'offsetInBeginSection': 778,\n",
       "     'offsetInEndSection': 928,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/8719696',\n",
       "     'text': 'l follow up, this study showed that no single type of color defect was consistently associated with optic neuritis. Demyelinating optic neuritis does ',\n",
       "     'offsetInBeginSection': 2572,\n",
       "     'offsetInEndSection': 2722,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26367086',\n",
       "     'text': 'ng visual recovery in acute typical optic neuritis, but do not affect the final visual outcome. In optic neuritis patients, IVCS may delay progression',\n",
       "     'offsetInBeginSection': 867,\n",
       "     'offsetInEndSection': 1017,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/10577521',\n",
       "     'text': 'II4e isopters on the Goldmann perimeter. Both test procedures were conducted according to the trial protocols, and quality control assessments and cli',\n",
       "     'offsetInBeginSection': 837,\n",
       "     'offsetInEndSection': 987,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/8293145',\n",
       "     'text': 'ns of the retrochiasmal visual pathways. The role of steroids in idiopathic optic neuritis has been clarified by the Optic Neuritis Treatment Trial. T',\n",
       "     'offsetInBeginSection': 412,\n",
       "     'offsetInEndSection': 562,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26932144',\n",
       "     'text': 'T-G) in acute optic neuritis; however, the preparatory trial was not powered to show effects on visual function.\\n\\n\\nMETHODS AND ANALYSIS\\nTreatment of O',\n",
       "     'offsetInBeginSection': 450,\n",
       "     'offsetInEndSection': 600,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/10320119',\n",
       "     'text': '\\n\\n\\nCONCLUSIONS\\nIntravenous cyclophosphamide pulse therapy seems to be an effective treatment for optic neuritis refractory to corticosteroids, oral im',\n",
       "     'offsetInBeginSection': 930,\n",
       "     'offsetInEndSection': 1080,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30713249',\n",
       "     'text': 'sistant patients. However, there is no report investigating the histopathological efficacy of IVIg in optic neuritis models. In this study, we examine',\n",
       "     'offsetInBeginSection': 174,\n",
       "     'offsetInEndSection': 324,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35533337',\n",
       "     'text': 'munosuppression is preferred for the long term, but further research is necessary to establish the efficacy and cost-effectiveness of these practices.',\n",
       "     'offsetInBeginSection': 1737,\n",
       "     'offsetInEndSection': 1887,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34800417',\n",
       "     'text': ' clinical trials in patients with optic neuritis. We assessed the safety and efficacy of erythropoietin in patients with optic neuritis as a clinicall',\n",
       "     'offsetInBeginSection': 128,\n",
       "     'offsetInEndSection': 278,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/8668894',\n",
       "     'text': ' rate two years after treatment; however, this protective effect could not be demonstrated after three years. These recommendations are valid only for',\n",
       "     'offsetInBeginSection': 564,\n",
       "     'offsetInEndSection': 714,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25877841',\n",
       "     'text': 'd after any treatment related volume changes have subsided. If the treatment is successful, this form of neuroprotection should improve the recovery f',\n",
       "     'offsetInBeginSection': 1758,\n",
       "     'offsetInEndSection': 1908,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25877841',\n",
       "     'text': 'ial of lamotrigine in secondary progressive MS did not demonstrate a protective effect on brain atrophy, and indeed the opposite effect was observed d',\n",
       "     'offsetInBeginSection': 986,\n",
       "     'offsetInEndSection': 1136,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/10577521',\n",
       "     'text': 'ffected eye in optic neuritis, the central visual field shows greater abnormalities than the far peripheral visual field. When the results obtained th',\n",
       "     'offsetInBeginSection': 2266,\n",
       "     'offsetInEndSection': 2416,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26932144',\n",
       "     'text': 'lel arms. The primary objective is to determine the efficacy of erythropoietin compared to placebo given add-on to methylprednisolone as assessed by m',\n",
       "     'offsetInBeginSection': 734,\n",
       "     'offsetInEndSection': 884,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/10577521',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/8668894',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/27706045',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/15601662',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/7821473',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35533337',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/22926853',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/10340796',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/9103884',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/26932144',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/30713249',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35052875',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/8293145',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/25877841',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/7749521',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/22465890',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/8719696',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35501141',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34800417',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/26367086',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/10320119']},\n",
       "  {'id': '6424154d690f196b5100004a',\n",
       "   'type': 'summary',\n",
       "   'body': 'What is the R value with respect to hepatoxicity',\n",
       "   'snippets': [],\n",
       "   'documents': []},\n",
       "  {'id': '64299b6a57b1c7a315000001',\n",
       "   'type': 'yesno',\n",
       "   'body': 'Is COVID-19 caused by the Omicron variant less severe than infection caused by other variants?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35869843',\n",
       "     'text': 'ation, illness after infection with the SARS-CoV-2 Omicron variant is less severe compared with previous variants. Data on the disease burden of Omicr',\n",
       "     'offsetInBeginSection': 31,\n",
       "     'offsetInEndSection': 181,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36072085',\n",
       "     'text': 'nlike the previous two waves, COVID-19 due to the Omicron variant\\xa0was less severe with only 5% of hemodialysis patients\\xa0requiring admission to the int',\n",
       "     'offsetInBeginSection': 793,\n",
       "     'offsetInEndSection': 943,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36072085',\n",
       "     'text': ' during this wave. Unlike the previous two waves, COVID-19 due to the Omicron variant\\xa0was less severe with only 5% of hemodialysis patients\\xa0requiring ',\n",
       "     'offsetInBeginSection': 773,\n",
       "     'offsetInEndSection': 923,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36466505',\n",
       "     'text': 'clinical severity. Furthermore, liver damages caused by viral infection of the omicron variant were largely attenuated when compared to those by infec',\n",
       "     'offsetInBeginSection': 1273,\n",
       "     'offsetInEndSection': 1423,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35583528',\n",
       "     'text': 'ly effective in protecting against severe Covid-19 infections.Omicrons may be less severe than other variants of concern. However, its immune evasiven',\n",
       "     'offsetInBeginSection': 1314,\n",
       "     'offsetInEndSection': 1464,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36090988',\n",
       "     'text': 'ively protect COVID-19 caused by Delta and Omicron variants but was less effective against Omicron variant infection. One-dose booster immunization co',\n",
       "     'offsetInBeginSection': 1963,\n",
       "     'offsetInEndSection': 2113,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36285226',\n",
       "     'text': 'Early reports of Omicron variant confirmed patients indicated less severe disease course compared with the disease caused by previously encountered va',\n",
       "     'offsetInBeginSection': 372,\n",
       "     'offsetInEndSection': 522,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35583528',\n",
       "     'text': ' and previous infections. However, we found that infections by Omicron were significantly less severe than those caused by Delta and other previous va',\n",
       "     'offsetInBeginSection': 746,\n",
       "     'offsetInEndSection': 896,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35025038',\n",
       "     'text': 'spreads rapidly with an average doubling time of two days. The disease so far has been mild as compared with delta. Though previous infection and vacc',\n",
       "     'offsetInBeginSection': 445,\n",
       "     'offsetInEndSection': 595,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35835638',\n",
       "     'text': 'aled multiple cystic cavitations.\\n\\n\\nCONCLUSION\\nAlthough COVID-19 is not severe in most children, life-threatening conditions such as COVID-19-associat',\n",
       "     'offsetInBeginSection': 1182,\n",
       "     'offsetInEndSection': 1332,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35835638',\n",
       "     'text': 'oronavirus disease 2019 (COVID-19), including the Omicron variant, is less severe in children than in adults. To date, there has been no detailed desc',\n",
       "     'offsetInBeginSection': 18,\n",
       "     'offsetInEndSection': 168,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36466505',\n",
       "     'text': '2019 (COVID-19) pandemic, but its clinical characteristics with intrinsic severity and organ tropism remain understudied.\\n\\n\\nMethods\\nWe reported 1,001 ',\n",
       "     'offsetInBeginSection': 145,\n",
       "     'offsetInEndSection': 295,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35404391',\n",
       "     'text': 'han those <6 years old.\\n\\n\\nBACKGROUND\\nThere are limited data assessing coronavirus 2019 (COVID-19) disease severity in children/adolescents infected wi',\n",
       "     'offsetInBeginSection': 227,\n",
       "     'offsetInEndSection': 377,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36050273',\n",
       "     'text': ' previous wave.\\n\\n\\nCONCLUSION\\nThe Omicron wave group had a lower COVID-19 pneumonia prevalence than the previous wave group. Cluster-like GGOs should b',\n",
       "     'offsetInBeginSection': 1444,\n",
       "     'offsetInEndSection': 1594,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36417338',\n",
       "     'text': \"less severe clinical manifestations and decreased hospitalizations. The omicron wave swelled faster than previous waves, completely displacing the delta variant within weeks, and creating worldwide concern about final, successful pandemic control. Some authors contend that symptoms associated to omicron differ from 'traditional' symptoms and more closely resemble those of the common cold. One major COVID-19 symptom frequent with other variants-loss of taste and smell-is rarely present with omicron\",\n",
       "     'offsetInBeginSection': 104,\n",
       "     'offsetInEndSection': 606,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36296527',\n",
       "     'text': ' the treatment of the disease. However, these drugs have not shown high efficacy in reducing COVID-19 severity, and even antiviral drugs have not show',\n",
       "     'offsetInBeginSection': 212,\n",
       "     'offsetInEndSection': 362,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35411288',\n",
       "     'text': 's in its virulence\\xa0and disease severity. Most reports have shown that the Omicron variant causes mild illness. Little is known about the impact of Omi',\n",
       "     'offsetInBeginSection': 308,\n",
       "     'offsetInEndSection': 458,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35961786',\n",
       "     'text': 'SARS-CoV-2 Omicron variant seemed to cause milder disease compared to previous predominated variants.\\xa0We aimed to conduct a meta-analysis to assess th',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35123975',\n",
       "     'text': 'antly increased vaccine breakthrough rates, and were significantly less likely to be hospitalized. Omicron patients required less intense respiratory ',\n",
       "     'offsetInBeginSection': 986,\n",
       "     'offsetInEndSection': 1136,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35404391',\n",
       "     'text': 'nt infection (vs Delta) was associated with significantly lower odds of moderate or severe/critical disease (adjusted odds ratio [AOR], 0.12; 95% conf',\n",
       "     'offsetInBeginSection': 1399,\n",
       "     'offsetInEndSection': 1549,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36453218',\n",
       "     'text': 'causes COVID-19. Since its emergence in late 2021, Omicron has displaced other circulating variants and caused successive waves of infection worldwide',\n",
       "     'offsetInBeginSection': 84,\n",
       "     'offsetInEndSection': 234,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35143466',\n",
       "     'text': 'ia.§ Initial reports suggest that the Omicron variant is more transmissible and resistant to vaccine neutralization but causes less severe illness com',\n",
       "     'offsetInBeginSection': 178,\n",
       "     'offsetInEndSection': 328,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/35835638',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35025038',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36453218',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35411288',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36296527',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35123975',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35583528',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36285226',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35404391',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36072085',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36466505',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36050273',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36417338',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35869843',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36090988',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35143466',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35961786']},\n",
       "  {'id': '6432ffdf57b1c7a315000021',\n",
       "   'type': 'summary',\n",
       "   'body': 'What is hereditary angioedema?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22179171',\n",
       "     'text': 'ma of the glottis, hereditary angioedema often results in edema of the gastrointestinal tract, which can be incapacitating. Patients with hereditary a',\n",
       "     'offsetInBeginSection': 595,\n",
       "     'offsetInEndSection': 745,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33233873',\n",
       "     'text': 'ne encoding complement C1 inhibitor (hereditary angioedema with C1-inhibitor deficiency) or present with normocomplementemia and associate with elevat',\n",
       "     'offsetInBeginSection': 712,\n",
       "     'offsetInEndSection': 862,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22195758',\n",
       "     'text': 'Hereditary angioedema is a rare disorder, and patients frequently endure long duration of symptoms, frequent physician visits, and unnecessary procedu',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19849675',\n",
       "     'text': 'Hereditary angioedema is a rare genetic disorder resulting from an inherited deficiency or dysfunction of the C1-esterase inhibitor of the classic com',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31283393',\n",
       "     'text': 'Hereditary angioedema is a rare genetic disorder caused by deficiency of C1 esterase inhibitor (C1-INH) and characterized by recurrent episodes of sev',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32178893',\n",
       "     'text': 'Hereditary angioedema is an autosomal dominant disorder, presenting as sudden and recurring episodes of variable severity of subcutaneous and mucosa e',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22227095',\n",
       "     'text': 'Hereditary angioedema is a rare disease, often diagnosed with delay because of a heterogeneous clinical presentation. Before diagnosis, patients frequ',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24865240',\n",
       "     'text': 'Hereditary angioedema is a rare disease, which is caused by deficiency of compleman c1 esterase inhibitor regulatory protein in the compleman system. ',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21251443',\n",
       "     'text': 'Hereditary angioedema is a rare genetic disorder resulting from an inherited deficiency or dysfunction of the C1 inhibitor. It is characterized by rec',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/2371584',\n",
       "     'text': 'Hereditary angioedema is a rare autosomal dominant disorder due to the deficiency of functionally active C1-inhibitor. It is characterised by recurren',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34983705',\n",
       "     'text': 'Background: Hereditary angioedema is an autosomal dominant disease that presents with recurrent episodic swelling of the submucosal and/or subcutaneou',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22014012',\n",
       "     'text': 'Hereditary angioedema is a relatively rare genetic disorder affecting between one in 10,000 and one in 50,000 individuals worldwide. The most common c',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22179171',\n",
       "     'text': 'Hereditary angioedema is an autosomal dominant disease characterized by edema attacks with multiple organ involvement. It is caused by a quantitative ',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/11726426',\n",
       "     'text': 'ary angioedema is a disease associated with acute complement-mediated inflammation and swelling of the airway and other vital organs. This case descri',\n",
       "     'offsetInBeginSection': 7,\n",
       "     'offsetInEndSection': 157,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18329867',\n",
       "     'text': 'Hereditary angioedema is a rare, autosomal dominant disease inherited. The cause is a quantitative or qualitative congenital deficit in C1 inhibitor. ',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36417927',\n",
       "     'text': 'Hereditary angioedema is a rare, genetic disorder characterized by painful, debilitating and potentially life-threatening angioedema attacks in subcut',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24880254',\n",
       "     'text': 'Hereditary angioedema is a genetic disorder typically related to insufficient or dysfunctional C1-esterase inhibitor. Patients present with episodic s',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26819784',\n",
       "     'text': 'Hereditary angioedema is a rare, but potentially life-threatening genetic disorder that results from an autosomal dominant trait. It is characterized ',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23625675',\n",
       "     'text': 'Hereditary angioedema is a rare and potentially fatal autosomal dominant disorder characterised by unpredictable skin, gastrointestinal tract or respi',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/11855162',\n",
       "     'text': 'Hereditary angioedema is a rare autosomal dominant disease characterized by the edema of subcutaneous tissues, respiratory tract and bowel. It is caus',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29723342',\n",
       "     'text': 'Hereditary angioedema is an autosomal dominant disease characterized by recurrent angioedema attacks with the involvement of multiple organs. The dise',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33233873',\n",
       "     'text': 'f hereditary angioedema (OMIM#106100). Hereditary angioedema is a rare genetic disease inherited in an autosomal dominant manner and caused by a loss ',\n",
       "     'offsetInBeginSection': 94,\n",
       "     'offsetInEndSection': 244,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12572187',\n",
       "     'text': 'Hereditary angioedema is an autosomal dominant condition with a typical presentation of diffuse edematous, painless, and nonpitting swelling of the so',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/11194524',\n",
       "     'text': 'ioedema will be discussed. Hereditary angioedema (HAE) is a rare autosomal dominant disorder, which is caused by congenital deficiency of functional C',\n",
       "     'offsetInBeginSection': 257,\n",
       "     'offsetInEndSection': 407,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21137180',\n",
       "     'text': 'oedema caused by C1 esterase inhibitor deficiency is a rare autosomal dominant inherited disorder. It is characterized by recurrent episodes of potent',\n",
       "     'offsetInBeginSection': 15,\n",
       "     'offsetInEndSection': 165,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25511656',\n",
       "     'text': 'Hereditary angioedema is a rare disease, potentially life-threatening. It requires a specific treatment. Angioedema without wheals associated with abd',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19526954',\n",
       "     'text': 'BACKGROUND\\nHereditary angioedema is an autosomal dominant inherited condition that is characterized by the local development of edema of the skin, sub',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/8506211',\n",
       "     'text': 'Hereditary angioedema is an autosomal dominant disorder of the complement system in which there is a deficiency of the inhibitor of the activated firs',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18851753',\n",
       "     'text': 'INTRODUCTION\\nHereditary angioedema is the commonest inherited disorder of the complement system and has been associated with several immune glomerular',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36417927',\n",
       "     'text': 'unodeficiency disorders. Hereditary angioedema is diagnosed based on C1-inhibitor level and function. Genetic analysis is only required in rare cases ',\n",
       "     'offsetInBeginSection': 959,\n",
       "     'offsetInEndSection': 1109,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/18329867',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36417927',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/21251443',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/24880254',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/22227095',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/19849675',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/12572187',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/22179171',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/8506211',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/25511656',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/19526954',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/11194524',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/21137180',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/2371584',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/26819784',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/18851753',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33233873',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32178893',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/31283393',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/23625675',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/24865240',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/29723342',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34983705',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/11855162',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/22195758',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/11726426',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/22014012']},\n",
       "  {'id': '64178ec2690f196b51000024',\n",
       "   'type': 'summary',\n",
       "   'body': \"What is viltolarsen's mechanism of action?\",\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27324312',\n",
       "     'text': 'nd the signalling pathway that couples changes in PO2 to changes in arteriolar tone (the mechanism of action) remain unclear. Many (but not all) ex vi',\n",
       "     'offsetInBeginSection': 256,\n",
       "     'offsetInEndSection': 406,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25544661',\n",
       "     'text': ' on their mechanism of action. In the present study, we posit that normative change is a plausible mechanism and provide a test of this in an eating d',\n",
       "     'offsetInBeginSection': 95,\n",
       "     'offsetInEndSection': 245,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29178131',\n",
       "     'text': 'ne. However, the presumptive mechanism of action, inhibition of NMDA (N-methyl-D-aspartate) receptors, has recently been challenged. Elucidation of th',\n",
       "     'offsetInBeginSection': 187,\n",
       "     'offsetInEndSection': 337,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34826604',\n",
       "     'text': 'ivation consistent with left free wall accessory pathway. With induction of tachycardia, beats with LBBB morphology have shorter cycle length than tho',\n",
       "     'offsetInBeginSection': 155,\n",
       "     'offsetInEndSection': 305,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23089283',\n",
       "     'text': 'The role of the mirror mechanism in cognition remains an intriguing and hotly debated topic in cognitive neuroscience. Since its discovery in the monk',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20735416',\n",
       "     'text': 'mechanism of action of general anaesthetics (GAs) involving membranes and protein receptors. I provide the reasons why the GABA type A receptor, the N',\n",
       "     'offsetInBeginSection': 227,\n",
       "     'offsetInEndSection': 377,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/20735416',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/25544661',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34826604',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/23089283',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/27324312',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/29178131']},\n",
       "  {'id': '64040bd8201352f04a00000e',\n",
       "   'type': 'yesno',\n",
       "   'body': 'Should be used bexarotene for relapsing-remitting multiple sclerosis?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21975773',\n",
       "     'text': 'y profile of NTZ is warranted. NTZ should be used only by skilled neurologists in MS centres under surveillance programs.All the data in this review c',\n",
       "     'offsetInBeginSection': 4062,\n",
       "     'offsetInEndSection': 4212,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/21975773']},\n",
       "  {'id': '6422e7f0690f196b51000045',\n",
       "   'type': 'list',\n",
       "   'body': 'Hepcidin is a key regulator of what processes?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21136948',\n",
       "     'text': 'Hepcidin, a key regulator of iron homeostasis, is known to have three isoforms: hepcidin-20, -22, and -25. Hepcidin-25 is thought to be the major isof',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19681654',\n",
       "     'text': 'Hepcidin, a key regulator of iron metabolism, plays a crucial role in the pathogenesis of anemia of chronic disease. Although it is produced mainly in',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24293278',\n",
       "     'text': 'in, which is mainly produced by the liver, is the key regulator in iron homeostasis. Hepcidin expression is up-regulated by iron loading in vivo, but ',\n",
       "     'offsetInBeginSection': 6,\n",
       "     'offsetInEndSection': 156,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25782630',\n",
       "     'text': 'Hepcidin is the key regulator of iron absorption and recycling, and its expression is suppressed by red blood cell production. When erythropoiesis is ',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16497104',\n",
       "     'text': 'Hepcidin, a key regulator of iron metabolism, decreases intestinal absorption of iron and its release from macrophages. Iron, anemia, hypoxia, and inf',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25852110',\n",
       "     'text': 'Hepcidin is a key regulator of iron homeostasis and plays a role in the pathogenesis of anaemia of chronic disease. Its levels are increased in patien',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30530987',\n",
       "     'text': 'Hepcidin is the master regulator of iron metabolism. It plays a key role in the regulation of iron transport across the duodenal epithelium, which in ',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24123375',\n",
       "     'text': 'Hepcidin is a key regulator of iron metabolism. The expression of hepcidin is significantly induced by iron overload, inflammation, and infection of p',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33820875',\n",
       "     'text': 'ved in postmenopausal osteoporosis. Hepcidin is a key regulator of iron homeostasis. However, the exact role of hepcidin in bone metabolism and the un',\n",
       "     'offsetInBeginSection': 223,\n",
       "     'offsetInEndSection': 373,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24356737',\n",
       "     'text': 'central role in hepcidin regulation. Hepcidin is a key regulator ofiron homeostasis and has now been suggested as a central mediator ofiron metabolism',\n",
       "     'offsetInBeginSection': 70,\n",
       "     'offsetInEndSection': 220,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30798808',\n",
       "     'text': 'Hepcidin is a main regulator of iron metabolism, of which abnormal expression affects intestinal absorption and reticuloendothelial sequestration of i',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15797999',\n",
       "     'text': 'Hepcidin, a key regulator of iron metabolism, is synthesized by the liver. Hepcidin binds to the iron exporter ferroportin to regulate the release of ',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17768112',\n",
       "     'text': 'Hepcidin is the key regulator of systemic iron homeostasis. We describe the modulation of hepcidin production induced by plasma transfusions in a pati',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18936232',\n",
       "     'text': 'The discovery of hepcidin as a key regulator of iron homeostasis has advanced our current knowledge of this field. Liver-derived hepcidin peptide is s',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22160085',\n",
       "     'text': 'is synthesized by the liver, has emerged as a key regulator of systemic iron homeostasis. Hepcidin inhibits the absorption of dietary iron from the in',\n",
       "     'offsetInBeginSection': 158,\n",
       "     'offsetInEndSection': 308,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21439478',\n",
       "     'text': 'The peptide hormone hepcidin is a key homeostatic regulator of iron metabolism and involved in pathological regulation of iron in response to infectio',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16604073',\n",
       "     'text': 'Hepcidin is a key regulator of systemic iron homeostasis. Hepcidin deficiency induces iron overload, whereas hepcidin excess induces anemia. Mutations',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30374287',\n",
       "     'text': 'Hepcidin is the major regulator of systemic iron metabolism, while the role of this peptide in the brain has just recently been elucidated. Studies su',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24385536',\n",
       "     'text': 'The hepatic hormone hepcidin is a key regulator of systemic iron metabolism. Its expression is largely regulated by 2 signaling pathways: the \"iron-re',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16009323',\n",
       "     'text': 'ynthesized by hepatocytes was later proved to be a key regulator of iron metabolism at the whole body level, namely, in conditions of altered iron dem',\n",
       "     'offsetInBeginSection': 68,\n",
       "     'offsetInEndSection': 218,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16325907',\n",
       "     'text': 'ptide antibiotic produced in the liver, is a key regulator of iron balance and recycling in humans and mice. Closely related hepcidin genes and peptid',\n",
       "     'offsetInBeginSection': 53,\n",
       "     'offsetInEndSection': 203,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16755911',\n",
       "     'text': 'ines of evidence have suggested that hepcidin is a key regulator of iron metabolism at the whole body level and is relative to inflammation, infection',\n",
       "     'offsetInBeginSection': 181,\n",
       "     'offsetInEndSection': 331,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18951868',\n",
       "     'text': 'idin is a peptide hormone that functions as a key regulator of mammalian iron metabolism. Serum and urine levels are increased in inflammation and sup',\n",
       "     'offsetInBeginSection': 4,\n",
       "     'offsetInEndSection': 154,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30469435',\n",
       "     'text': 'Hepcidin is a key hormonal regulator of systemic iron homeostasis and its expression is induced by iron or inflammatory stimuli. Genetic defects in ir',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34755647',\n",
       "     'text': ' synthesized peptide hormone hepcidin is a master regulator of systemic iron metabolism. Given its role in overall health, measurement of hepcidin can',\n",
       "     'offsetInBeginSection': 198,\n",
       "     'offsetInEndSection': 348,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19338078',\n",
       "     'text': \"The small liver peptide hepcidin is a major regulator of systemic iron homeostasis in mammals, adapting iron absorption to the body's demands. Two new\",\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21136948',\n",
       "     'text': 'd cells were revealed by this method. We believe our method will facilitate quantitative investigation of the role hepcidin plays in iron homeostasis.',\n",
       "     'offsetInBeginSection': 1159,\n",
       "     'offsetInEndSection': 1309,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18333366',\n",
       "     'text': 'ly discovered peptide hormone hepcidin is the key regulator of systemic iron homeostasis. Iron metabolism is regulated in response to variations in he',\n",
       "     'offsetInBeginSection': 6,\n",
       "     'offsetInEndSection': 156,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17557118',\n",
       "     'text': 'all peptide synthesized in the liver, is a key regulator of iron absorption and homeostasis in mammals. Hepcidin production is increased by iron overl',\n",
       "     'offsetInBeginSection': 127,\n",
       "     'offsetInEndSection': 277,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16755911',\n",
       "     'text': 'he subject of this paper is to summarize the regulation of hepcidin gene expression and the understanding of functions of hepcidin. At last, giving a ',\n",
       "     'offsetInBeginSection': 1158,\n",
       "     'offsetInEndSection': 1308,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/21439478',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33820875',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/21136948',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/25852110',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34755647',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/19681654',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/18936232',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/30374287',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/30469435',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/17768112',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/24123375',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/22160085',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/24293278',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/24356737',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/15797999',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/16497104',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/19338078',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/16009323',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/18951868',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/25782630',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/16325907',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/24385536',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/17557118',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/16604073',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/16755911',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/18333366',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/30798808',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/30530987']},\n",
       "  {'id': '6429ee7457b1c7a31500000b',\n",
       "   'type': 'yesno',\n",
       "   'body': 'Can analgesics or antipyretics be taken for side effects following COVID-19 vaccination?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35738594',\n",
       "     'text': 'OVID-19 vaccination can cause specific side-effects, such as axillary lymph node swelling; therefore, breast oncologists should pay attention to such ',\n",
       "     'offsetInBeginSection': 149,\n",
       "     'offsetInEndSection': 299,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35952506',\n",
       "     'text': 'tients with BECTS reported having side effects; all effects were mild that could be relieved themselves. For Sinopharm (Beijing): BBIBP-CorV (Vero cel',\n",
       "     'offsetInBeginSection': 860,\n",
       "     'offsetInEndSection': 1010,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34940894',\n",
       "     'text': 'he second. The most common observed side effects were mild to moderate pain at the injection site (40%), followed by fatigue (24%). Grade 3 irAEs were',\n",
       "     'offsetInBeginSection': 1051,\n",
       "     'offsetInEndSection': 1201,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35775049',\n",
       "     'text': 'etween 30 and 40 years old, only after the first vaccination dose. None of the DMTs predisposed for particular side effects.\\n\\n\\nConclusions\\nAccording t',\n",
       "     'offsetInBeginSection': 1514,\n",
       "     'offsetInEndSection': 1664,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35334998',\n",
       "     'text': 'cination among Arab populations are usually non-life-threatening; flu-like symptoms and injection site pain. Certain predisposing factors have greater',\n",
       "     'offsetInBeginSection': 2211,\n",
       "     'offsetInEndSection': 2361,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34197678',\n",
       "     'text': 'effects reported following Covid-19 vaccination were mostly self-restricted local reactions that resolved quickly. Nevertheless, rare vaccine-induced ',\n",
       "     'offsetInBeginSection': 277,\n",
       "     'offsetInEndSection': 427,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34767100',\n",
       "     'text': 'cacy of the COVID-19 vaccines seems to be further reduced by immunosuppressive medications, such as glucocorticoids (GC), methotrexate (MTX), mycophen',\n",
       "     'offsetInBeginSection': 720,\n",
       "     'offsetInEndSection': 870,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35383912',\n",
       "     'text': 'd individuals with DS (median age = 19.5\\xa0years), with 50% reporting no side effects from COVID-19 vaccination. Increased seizures following COVID-19 v',\n",
       "     'offsetInBeginSection': 943,\n",
       "     'offsetInEndSection': 1093,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35244157',\n",
       "     'text': 'period of 3-13 days after COVID-19 vaccination. None was under immunosuppressive therapy. The 3 patients recovered in a few weeks and the subsequent d',\n",
       "     'offsetInBeginSection': 709,\n",
       "     'offsetInEndSection': 859,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35236842',\n",
       "     'text': ' may contribute to poor uptake. Analgesics or antipyretic medications are often used to alleviate vaccine side effects, but their effect on immunogeni',\n",
       "     'offsetInBeginSection': 105,\n",
       "     'offsetInEndSection': 255,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34199053',\n",
       "     'text': 'althy Asians who received the ChAdOx1 vaccine and determine the effect of AEs and antipyretics on early NAb production against COVID-19. Of the 182 Ko',\n",
       "     'offsetInBeginSection': 454,\n",
       "     'offsetInEndSection': 604,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34707073',\n",
       "     'text': 'ppressive effects. Because of this pharmacological property, the use of NSAIDs should be more effective in reducing the vaccine-induced systemic side ',\n",
       "     'offsetInBeginSection': 803,\n",
       "     'offsetInEndSection': 953,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34073382',\n",
       "     'text': \"ople more reassured. Most of the post-vaccination side effects are mild to moderate, which are signs that body's immune system is building protection.\",\n",
       "     'offsetInBeginSection': 2202,\n",
       "     'offsetInEndSection': 2352,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34166950',\n",
       "     'text': 'cination against COVID-19 (27 female, 20% seizure free, 96<% on antiseizure medication) and were included in the study. Two-thirds tolerated the vacci',\n",
       "     'offsetInBeginSection': 514,\n",
       "     'offsetInEndSection': 664,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35666609',\n",
       "     'text': ' people are concerned about possible cutaneous side-effects, which can delay or prevent them from being vaccinated. The objectives of this systematic ',\n",
       "     'offsetInBeginSection': 120,\n",
       "     'offsetInEndSection': 270,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/34707073',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34767100',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35738594',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34199053',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35383912',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35244157',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35666609',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34197678',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34073382',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35952506',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35334998',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34166950',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35236842',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34940894',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35775049']},\n",
       "  {'id': '6433050157b1c7a315000024',\n",
       "   'type': 'factoid',\n",
       "   'body': 'Which drug was the first recombinant human C1 inhibitor protein (C1INH) for the treatment of acute attacks of hereditary angioedema (HAE)?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24556385',\n",
       "     'text': 'BACKGROUND\\nConestat alfa (Ruconest, rhC1INH) is the first recombinant human C1 inhibitor protein (C1INH) for the treatment of acute attacks of heredit',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22171564',\n",
       "     'text': 'BACKGROUND\\nRecombinant human C1-inhibitor (rhC1INH; Ruconest®) has been developed for treatment of acute angioedema attacks in patients with hereditar',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30021471',\n",
       "     'text': ' an established treatment for both on demand and prophylaxis of HAE. Conestat alfa is a recombinant form of human C1-INH (rhC1-INH) produced in transg',\n",
       "     'offsetInBeginSection': 219,\n",
       "     'offsetInEndSection': 369,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21753889',\n",
       "     'text': 'n findings from bench to bedside trials of a new C1-INH replacement, conestat alfa. Conestat alfa is unique among the other C1-INH replacement product',\n",
       "     'offsetInBeginSection': 208,\n",
       "     'offsetInEndSection': 358,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29569504',\n",
       "     'text': 'tor (C1-INH) or via blocking the production or function of bradykinin. Cinryze® is a nanofiltered C1-INH, approved in Europe for the acute treatment, ',\n",
       "     'offsetInBeginSection': 388,\n",
       "     'offsetInEndSection': 538,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17559913',\n",
       "     'text': ' likely mediator of the swelling and pain characterizing HAE attacks. Ecallantide, a novel, recombinant protein, potently inhibits kallikrein. This is',\n",
       "     'offsetInBeginSection': 396,\n",
       "     'offsetInEndSection': 546,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17559913',\n",
       "     'text': 'dose level: 10 to ecallantide and 2 to placebo, per cohort.\\n\\n\\nRESULTS\\nEcallantide treatment ameliorated the symptoms of HAE attacks: 72.5% (29/40) of ',\n",
       "     'offsetInBeginSection': 1110,\n",
       "     'offsetInEndSection': 1260,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20441418',\n",
       "     'text': 'ccessfully used to treat HAE in selected countries, mostly in Europe. Berinert P (CSL Behring, Marburg, Germany), a human plasma-derived C1-INH, was s',\n",
       "     'offsetInBeginSection': 233,\n",
       "     'offsetInEndSection': 383,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28687108',\n",
       "     'text': 'rived C1 inhibitor concentrate, recombinant C1 inhibitor concentrate, ecallantide, and icatibant-are reviewed in this article. All have been shown to ',\n",
       "     'offsetInBeginSection': 455,\n",
       "     'offsetInEndSection': 605,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25640891',\n",
       "     'text': 'ssociated with acute C1-INH-HAE attacks, particularly with submucosal involvement. However, rhC1INH therapy was not associated with thrombotic events.',\n",
       "     'offsetInBeginSection': 1609,\n",
       "     'offsetInEndSection': 1759,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22995741',\n",
       "     'text': 'ted comparable inhibitory potency and specificity. Recently, rhC1INH (Ruconest(®)) has been approved by the European Medicines Agency for the treatmen',\n",
       "     'offsetInBeginSection': 1513,\n",
       "     'offsetInEndSection': 1663,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/22995741',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/25640891',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/20441418',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/28687108',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/30021471',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/17559913',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/29569504',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/22171564',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/24556385',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/21753889']},\n",
       "  {'id': '6417900b690f196b5100002a',\n",
       "   'type': 'factoid',\n",
       "   'body': 'What type of DMD can viltolarsen be used for?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36401022',\n",
       "     'text': 'designed to skip exon 53 of the DMD gene\\xa0for the treatment of Duchenne muscular dystrophy (DMD), one of the most common lethal genetic disorders chara',\n",
       "     'offsetInBeginSection': 79,\n",
       "     'offsetInEndSection': 229,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32519222',\n",
       "     'text': 'nter of Neurology and Psychiatry (NCNP), for the treatment of Duchenne muscular dystrophy (DMD). Viltolarsen binds to exon 53 of the dystrophin mRNA p',\n",
       "     'offsetInBeginSection': 167,\n",
       "     'offsetInEndSection': 317,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26594036',\n",
       "     'text': 'be used to monitor the efficacy of experimental therapies for Duchenne Muscular Dystrophy (DMD) in clinical trials. Identification of novel protein bi',\n",
       "     'offsetInBeginSection': 58,\n",
       "     'offsetInEndSection': 208,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33285037',\n",
       "     'text': \"n gene, and could be an effective treatment for patients with Duchenne muscular dystrophy (DMD). We investigated viltolarsen's ability to induce dystr\",\n",
       "     'offsetInBeginSection': 101,\n",
       "     'offsetInEndSection': 251,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25365558',\n",
       "     'text': 'is essential for rapidly identifying effective treatments for Duchenne muscular dystrophy (DMD), a devastating neuromuscular disorder caused by the la',\n",
       "     'offsetInBeginSection': 33,\n",
       "     'offsetInEndSection': 183,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32947786',\n",
       "     'text': 'en for DMD exon 51 skipping and golodirsen and viltolarsen for DMD exon 53 skipping, have been approved in the last 4 years. We are witnessing the sta',\n",
       "     'offsetInBeginSection': 420,\n",
       "     'offsetInEndSection': 570,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32483212',\n",
       "     'text': 'ave been recently approved by the FDA. Viltolarsen, an AON for DMD exon 53 skipping, was approved in Japan earlier this year. Although promising, the ',\n",
       "     'offsetInBeginSection': 444,\n",
       "     'offsetInEndSection': 594,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26037351',\n",
       "     'text': 'e the methods for genetic detection and prenatal diagnosis of Duchenne muscular dystrophy (DMD).\\n\\n\\nMETHODS\\nDenaturing high-performance liquid chromato',\n",
       "     'offsetInBeginSection': 20,\n",
       "     'offsetInEndSection': 170,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34569969',\n",
       "     'text': 'ies -Eteplirsen, Golodirsen, Viltolarsen, and Casimersen -for Duchenne Muscular Dystrophy (DMD). However, these treatments have only demonstrated vari',\n",
       "     'offsetInBeginSection': 102,\n",
       "     'offsetInEndSection': 252,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33610829',\n",
       "     'text': 'ntisense oligonucleotides (AONs) is a promising treatment for Duchenne muscular dystrophy (DMD). Several exon-skipping drugs, including viltolarsen (N',\n",
       "     'offsetInBeginSection': 27,\n",
       "     'offsetInEndSection': 177,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/1971151',\n",
       "     'text': 'r the gene causing the X-linked recessive muscular dystrophy (MD) type Duchenne (DMD) and Becker (BMD) has recently been cloned and made available for',\n",
       "     'offsetInBeginSection': 26,\n",
       "     'offsetInEndSection': 176,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29060790',\n",
       "     'text': 'Duchenne Muscular Dystrophy (DMD) is a genetic disorder caused by dystrophin protein deficiency. Muscle biopsy is the gold standard to determine the d',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25982038',\n",
       "     'text': ' used to distinguish the deletion or duplication genotypes of Duchenne muscular dystrophy (DMD) due to different fluorescent intensities. After PCR, t',\n",
       "     'offsetInBeginSection': 211,\n",
       "     'offsetInEndSection': 361,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32453377',\n",
       "     'text': 'An unmet need remains for safe and efficacious treatments for Duchenne muscular dystrophy (DMD). To date, there are limited agents available that addr',\n",
       "     'offsetInBeginSection': 11,\n",
       "     'offsetInEndSection': 161,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35634851',\n",
       "     'text': 's.\\n\\n\\nCONCLUSIONS\\nBased on these results at over 2 years, viltolarsen can be a new treatment option for patients with DMD amenable to exon 53 skipping.',\n",
       "     'offsetInBeginSection': 1649,\n",
       "     'offsetInEndSection': 1799,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34938127',\n",
       "     'text': 'ation-specific drug and will work for 8% of the persons with DMD who carry mutations amenable to exon 53 skipping. This review summarizes the pharmaco',\n",
       "     'offsetInBeginSection': 1011,\n",
       "     'offsetInEndSection': 1161,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35713895',\n",
       "     'text': ' 2020. The Cincinnati study reviewed data from 435 males with Duchenne muscular dystrophy, also known as DMD, who were treated at the Cincinnati Child',\n",
       "     'offsetInBeginSection': 171,\n",
       "     'offsetInEndSection': 321,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33610829',\n",
       "     'text': 'tic cell reprogramming technology and successfully developed a cellular skeletal muscle DMD model by using myogenic differentiation 1 (MYOD1)-transduc',\n",
       "     'offsetInBeginSection': 552,\n",
       "     'offsetInEndSection': 702,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33130193',\n",
       "     'text': 'd viltolarsen (VILTEPSO®) have been approved by the FDA to treat specific types of DMD. SMA is defined by the degeneration of the anterior horn cells ',\n",
       "     'offsetInBeginSection': 835,\n",
       "     'offsetInEndSection': 985,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34092651',\n",
       "     'text': 'achieving spectacular success in treating these diseases. For Duchenne muscular dystrophy (DMD), the state-of-the-art is an exon skipping therapy usin',\n",
       "     'offsetInBeginSection': 661,\n",
       "     'offsetInEndSection': 811,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23637366',\n",
       "     'text': 'A digital micromirror device (DMD) is an array of individually switchable mirrors that can be used in many advanced optical systems as a rapid spatial',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25198739',\n",
       "     'text': 'ory failure and heart failure are inevitable complications in Duchenne muscular dystrophy (DMD). Respiratory failure and heart failure undergo simulta',\n",
       "     'offsetInBeginSection': 8,\n",
       "     'offsetInEndSection': 158,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36401026',\n",
       "     'text': 'rom childhood, the earlier treatment is preferred. The canine X-linked muscular dystrophy in Japan (CXMDj), a dog model of DMD, produces no dystrophin',\n",
       "     'offsetInBeginSection': 556,\n",
       "     'offsetInEndSection': 706,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25669899',\n",
       "     'text': 'ch was first discovered 30 years ago. Despite its extensive use in DMD research, no effective treatment has yet been developed for this devastating di',\n",
       "     'offsetInBeginSection': 236,\n",
       "     'offsetInEndSection': 386,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33130193',\n",
       "     'text': ' and viltolarsen (VILTEPSO®) have been approved by the FDA to treat specific types of DMD. SMA is defined by the degeneration of the anterior horn cel',\n",
       "     'offsetInBeginSection': 832,\n",
       "     'offsetInEndSection': 982,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35634851',\n",
       "     'text': 'BACKGROUND\\nDuchenne muscular dystrophy (DMD) is a rare, genetic disease caused by mutations in the DMD gene resulting in an absence of functional dyst',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33239841',\n",
       "     'text': 'Duchenne muscular dystrophy (DMD) is a progressive muscular disorder caused by X-chromosomal DMD gene mutations. Recently, a new CRISPR/Cas9-mediated ',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34938127',\n",
       "     'text': 'Duchenne muscular dystrophy (DMD) is a fatal, X-linked recessive disorder characterized by progressive muscle loss and cardiorespiratory complications',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33239841',\n",
       "     'text': 'ed with aging, which is, to some extent, similar to what occurs in humans. Thus, cDMDR could be a valuable model for studying cardiology of human DMD.',\n",
       "     'offsetInBeginSection': 1512,\n",
       "     'offsetInEndSection': 1662,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32453377',\n",
       "     'text': 'ntrol: -65.3 m) at the week 25 visit.\\n\\n\\nConclusions and Relevance\\nSystemic treatment of participants with DMD with viltolarsen induced de novo dystrop',\n",
       "     'offsetInBeginSection': 2338,\n",
       "     'offsetInEndSection': 2488,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/25982038',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33285037',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32519222',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/29060790',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35713895',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34092651',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33610829',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32453377',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/26594036',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/26037351',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32947786',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/25365558',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/1971151',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36401026',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35634851',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/23637366',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/25669899',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/25198739',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36401022',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34569969',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33239841',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34938127',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33130193',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32483212']},\n",
       "  {'id': '63f57ea133942b094c000005',\n",
       "   'type': 'list',\n",
       "   'body': 'What is the triad of the Cat eye syndrome?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33465332',\n",
       "     'text': '0,000 live newborns. The classic triad of iris coloboma, anorectal malformations, and auricular abnormalities is present in 40% of patients. In additi',\n",
       "     'offsetInBeginSection': 106,\n",
       "     'offsetInEndSection': 256,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16145841',\n",
       "     'text': 'osome 22q11. The patients demonstrate specific abnormalities of heart, kidney, and eye. Here we attempted to produce a model for this defect by expres',\n",
       "     'offsetInBeginSection': 84,\n",
       "     'offsetInEndSection': 234,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/3109242',\n",
       "     'text': 'X-linked dominant trait. The cat eye syndrome, blepharophimosis or Kohn-Romano syndrome, Rieger syndrome, and other disorders are discussed in relatio',\n",
       "     'offsetInBeginSection': 211,\n",
       "     'offsetInEndSection': 361,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/11332976',\n",
       "     'text': 'riable pattern of multiple congenital anomalies of which coloboma of the iris and anal atresia are the best known. CES is cytogenetically characterise',\n",
       "     'offsetInBeginSection': 46,\n",
       "     'offsetInEndSection': 196,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/410302',\n",
       "     'text': 'hniques, we studied a child with typical cat-eye syndrome and ocular retraction syndrome. Although the mother was was chromosomally normal, other mate',\n",
       "     'offsetInBeginSection': 38,\n",
       "     'offsetInEndSection': 188,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35911297',\n",
       "     'text': 'hromosome 22. The classic clinical triad includes coloboma of the iris, ears, and anal malformations. This syndrome was named \"cat eye\" due to the ver',\n",
       "     'offsetInBeginSection': 87,\n",
       "     'offsetInEndSection': 237,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/2072964',\n",
       "     'text': 'In a cyanotic newborn with characteristic features of Cat-Eye-Syndrome, cytogenetic examination disclosed a supernumerary small bisatellited chromosom',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23928108',\n",
       "     'text': 'e 22, with a variable phenotype comprising anal atresia, coloboma of the iris and preauricular tags or pits. We report a girl with cat eye syndrome, p',\n",
       "     'offsetInBeginSection': 129,\n",
       "     'offsetInEndSection': 279,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/2072964',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/23928108',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33465332',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/3109242',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/16145841',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/410302',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/11332976',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35911297']},\n",
       "  {'id': '64281a47690f196b5100004f',\n",
       "   'type': 'yesno',\n",
       "   'body': 'Is OXLUMO (lumasiran) used for the treatment of primary hyperoxaluria?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31580236',\n",
       "     'text': 'order that causes overproduction and urinary excretion of oxalate. Liver transplant has been suggested as a treatment for primary hyperoxaluria type 1',\n",
       "     'offsetInBeginSection': 69,\n",
       "     'offsetInEndSection': 219,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35015123',\n",
       "     'text': '1), with doses and intervals according to body weight. Little is known as to its use in infants; the aim of this study was to describe treatment outco',\n",
       "     'offsetInBeginSection': 127,\n",
       "     'offsetInEndSection': 277,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33985991',\n",
       "     'text': 'inosis, kidney failure, and systemic oxalosis. Lumasiran, an RNA interference therapeutic, suppresses glycolate oxidase, reducing hepatic oxalate prod',\n",
       "     'offsetInBeginSection': 147,\n",
       "     'offsetInEndSection': 297,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31580236',\n",
       "     'text': 'Liver transplant can be considered a treatment for patients with primary hyperoxaluria type 1. Combined liver and kidney transplant and preemptive liver transplant could be proper options for these patients',\n",
       "     'offsetInBeginSection': 1466,\n",
       "     'offsetInEndSection': 1672,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35071135',\n",
       "     'text': 'ney failure and systemic oxalosis. Lumasiran, is a liver-directed RNA interference therapeutic agent. It has been shown to reduce hepatic oxalate prod',\n",
       "     'offsetInBeginSection': 163,\n",
       "     'offsetInEndSection': 313,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35779234',\n",
       "     'text': 'NA interference medication is now available. Lumasiran® is already available on prescription and targets the messenger RNA of glycolate oxidase, thus ',\n",
       "     'offsetInBeginSection': 781,\n",
       "     'offsetInEndSection': 931,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33985991',\n",
       "     'text': 'ad an acceptable safety profile, with no serious adverse events or study discontinuations attributed to treatment. In part A, increases in mean plasma',\n",
       "     'offsetInBeginSection': 1423,\n",
       "     'offsetInEndSection': 1573,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33985991',\n",
       "     'text': 'Lumasiran had an acceptable safety profile and reduced urinary oxalate excretion in all patients with primary hyperoxaluria type 1 to near-normal levels',\n",
       "     'offsetInBeginSection': 1931,\n",
       "     'offsetInEndSection': 2083,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35779234',\n",
       "     'text': 'n B6, RNA interference medication is now available. Lumasiran® is already available on prescription and targets the messenger RNA of glycolate oxidase',\n",
       "     'offsetInBeginSection': 774,\n",
       "     'offsetInEndSection': 924,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35731461',\n",
       "     'text': 'late oxidase and nedosiran targets lactate dehydrogenase A. Lumasiran was recently approved in the treatment of primary hyperoxaluria type 1 and nedos',\n",
       "     'offsetInBeginSection': 897,\n",
       "     'offsetInEndSection': 1047,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33789010',\n",
       "     'text': 'RNA interference (RNAi) therapeutic agent, reduces hepatic oxalate production by targeting glycolate oxidase.\\n\\n\\nMETHODS\\nIn this double-blind, phase 3 ',\n",
       "     'offsetInBeginSection': 232,\n",
       "     'offsetInEndSection': 382,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/9604807',\n",
       "     'text': 'Drug therapy receives scant attention as a treatment mode for primary hyperoxaluria (PH). Currently, pyridoxine is the only drug in the arsenal and on',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/35731461',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/31580236',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33985991',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35071135',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35015123',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35779234',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33789010',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/9604807']},\n",
       "  {'id': '6429cfb557b1c7a315000005',\n",
       "   'type': 'yesno',\n",
       "   'body': 'Should patients using inhaled glucocorticoids for asthma or COPD be advised to stop these medications to prevent COVID-19?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34476396',\n",
       "     'text': 'e an adequate supply of medication, and inhaled corticosteroids should not be withdrawnChronic obstructive pulmonary disease (COPD) is associated with',\n",
       "     'offsetInBeginSection': 410,\n",
       "     'offsetInEndSection': 560,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12877818',\n",
       "     'text': 'e highly effective in controlling airway inflammation in asthma, they are ineffective in the small group of patients with glucocorticoid-dependent and',\n",
       "     'offsetInBeginSection': 162,\n",
       "     'offsetInEndSection': 312,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35747745',\n",
       "     'text': 'ions such as inhaled corticosteroids (ICS) and biologics on COVID-19 is unclear. This systematic literature review analyzed the published evidence on ',\n",
       "     'offsetInBeginSection': 172,\n",
       "     'offsetInEndSection': 322,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33248363',\n",
       "     'text': 'a nebulizer at home, but it fundamental that all patients, regardless of whether or not suffering from COVID-19, always follow some practical advices.',\n",
       "     'offsetInBeginSection': 1239,\n",
       "     'offsetInEndSection': 1389,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34568369',\n",
       "     'text': '. 007 ± 0.38; P < 0.05) during the COVID-19 pandemic. In contrast, among COPD patients, there were no significant differences in AE frequency, clinic ',\n",
       "     'offsetInBeginSection': 1553,\n",
       "     'offsetInEndSection': 1703,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/33248363',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34568369',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34476396',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/12877818',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35747745']},\n",
       "  {'id': '6432f75757b1c7a31500001d',\n",
       "   'type': 'yesno',\n",
       "   'body': 'Is Zanubrutinib a first-generation BTK inhibitor approved by US Food and Drug Administration (FDA)?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33025948',\n",
       "     'text': 'ed. As compared to first-generation ibrutinib, zanubrutinib has higher BTK selectivity which may result in fewer off-target effects and improved poten',\n",
       "     'offsetInBeginSection': 794,\n",
       "     'offsetInEndSection': 944,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32484067',\n",
       "     'text': '-fold for 26-weeks and 39-weeks of treatment, respectively. Zanubrutinib was not genotoxic. Fertility studies showed no abnormal findings in both male',\n",
       "     'offsetInBeginSection': 832,\n",
       "     'offsetInEndSection': 982,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35993294',\n",
       "     'text': 'TKi-related adverse events, but major rates of neutropenia, and its approval is awaited. With the aim of overcoming drug resistance, noncovalent BTKi ',\n",
       "     'offsetInBeginSection': 676,\n",
       "     'offsetInEndSection': 826,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32484067',\n",
       "     'text': 'e treatment of a variety of B-cell malignancies and has received accelerated approval by the US Food and Drug Administration for treatment of adult pa',\n",
       "     'offsetInBeginSection': 103,\n",
       "     'offsetInEndSection': 253,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32731259',\n",
       "     'text': ', a first-generation BTK inhibitor, with zanubrutinib, a novel highly selective BTK inhibitor, in patients with WM. Patients with MYD88L265P disease w',\n",
       "     'offsetInBeginSection': 198,\n",
       "     'offsetInEndSection': 348,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35651781',\n",
       "     'text': 'ewer patients experience side effects and quit treatment. Zanubrutinib is currently approved for use for treatment of adult patients with MCL who have',\n",
       "     'offsetInBeginSection': 3152,\n",
       "     'offsetInEndSection': 3302,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35651781',\n",
       "     'text': 'ater selectivity was developed. In the United States, zanubrutinib, a next-generation BTK inhibitor, has been approved for treating adults with mantle',\n",
       "     'offsetInBeginSection': 511,\n",
       "     'offsetInEndSection': 661,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31420873',\n",
       "     'text': 'L) patients. Whether zanubrutinib, a second-generation selective BTK inhibitor, has similar effects as ibrutinib remains to be determined. Dynamics of',\n",
       "     'offsetInBeginSection': 190,\n",
       "     'offsetInEndSection': 340,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35680835',\n",
       "     'text': 'bitor developed in China and first approved by the U.S. Food and Drug Administration (FDA) as a novel antineoplastic drug. In recent years, with the b',\n",
       "     'offsetInBeginSection': 61,\n",
       "     'offsetInEndSection': 211,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31933167',\n",
       "     'text': ' for the treatment of B-cell malignancies. Zanubrutinib received accelerated approval in the USA on 14 November 2019 for the treatment of adult patien',\n",
       "     'offsetInBeginSection': 118,\n",
       "     'offsetInEndSection': 268,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34858810',\n",
       "     'text': 'ow incidence of atrial fibrillation. Zanubrutinib, a selective next-generation covalent BTK inhibitor, is approved by the FDA to treat adult patients ',\n",
       "     'offsetInBeginSection': 1119,\n",
       "     'offsetInEndSection': 1269,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35651781',\n",
       "     'text': 'from growing and spreading. Patients experience extended survival with ibrutinib, the first-generation BTK inhibitor approved by US Food and Drug Admi',\n",
       "     'offsetInBeginSection': 1968,\n",
       "     'offsetInEndSection': 2118,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35966045',\n",
       "     'text': 'brutinib, acalabrutinib, and zanubrutinib are Food and Drug Administration (FDA)-approved BTK inhibitors that have all demonstrated progression-free s',\n",
       "     'offsetInBeginSection': 162,\n",
       "     'offsetInEndSection': 312,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32207333',\n",
       "     'text': 'ought to contribute to its adverse events. Zanubrutinib is a next-generation BTK inhibitor with minimal off-target effects, sustained BTK occupancy in',\n",
       "     'offsetInBeginSection': 254,\n",
       "     'offsetInEndSection': 404,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29869556',\n",
       "     'text': 'n those with MYD88L265P and CXCR4WT disease. Zanubrutinib, a next-generation BTK inhibitor with potent preclinical activity in WM and minimal off-targ',\n",
       "     'offsetInBeginSection': 388,\n",
       "     'offsetInEndSection': 538,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35950210',\n",
       "     'text': 'ety profile. Zanubrutinib, one such second-generation inhibitor, was recently approved in treatment-naive and refractory/relapsed patients. Here, we r',\n",
       "     'offsetInBeginSection': 324,\n",
       "     'offsetInEndSection': 474,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35770040',\n",
       "     'text': 'se 3 ASPEN (NCT03053440) trial, the Food and Drug Administration (FDA) approved zanubrutinib for treating WM. This trial directly compared zanubrutini',\n",
       "     'offsetInBeginSection': 1196,\n",
       "     'offsetInEndSection': 1346,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32869675',\n",
       "     'text': 'alignancies.\\n\\n\\nEXPERT OPINION\\nTwo BTK inhibitors are currently Food and Drug Administration (FDA) approved for use in CLL, and multiple additional age',\n",
       "     'offsetInBeginSection': 527,\n",
       "     'offsetInEndSection': 677,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/29869556',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/31933167',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35993294',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33025948',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/31420873',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35966045',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32731259',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35950210',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35680835',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35770040',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32484067',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35651781',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34858810',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32207333',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32869675']},\n",
       "  {'id': '64178fea690f196b51000028',\n",
       "   'type': 'factoid',\n",
       "   'body': 'What types of DMD can eteplirsen be used for?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23907995',\n",
       "     'text': 'amidate morpholino oligomer, enabled dystrophin production in Duchenne muscular dystrophy (DMD) with genetic mutations amenable to skipping exon 51. T',\n",
       "     'offsetInBeginSection': 64,\n",
       "     'offsetInEndSection': 214,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30526286',\n",
       "     'text': 'rsen was approved for the treatment of eligible patients with Duchenne muscular dystrophy (DMD) in September 2016 in one of the most, if not the most,',\n",
       "     'offsetInBeginSection': 6,\n",
       "     'offsetInEndSection': 156,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34569969',\n",
       "     'text': 'ies -Eteplirsen, Golodirsen, Viltolarsen, and Casimersen -for Duchenne Muscular Dystrophy (DMD). However, these treatments have only demonstrated vari',\n",
       "     'offsetInBeginSection': 102,\n",
       "     'offsetInEndSection': 252,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29907124',\n",
       "     'text': 'ping has been considered a promising therapeutic approach for Duchenne muscular dystrophy (DMD). Eteplirsen received conditional approval in the Unite',\n",
       "     'offsetInBeginSection': 20,\n",
       "     'offsetInEndSection': 170,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27807823',\n",
       "     'text': 'ved accelerated approval from the US FDA for the treatment of Duchenne muscular dystrophy (DMD) in patients with a confirmed mutation of the DMD gene ',\n",
       "     'offsetInBeginSection': 167,\n",
       "     'offsetInEndSection': 317,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32947786',\n",
       "     'text': 'therapies, including antisense oligonucleotides eteplirsen for DMD exon 51 skipping and golodirsen and viltolarsen for DMD exon 53 skipping, have been',\n",
       "     'offsetInBeginSection': 364,\n",
       "     'offsetInEndSection': 514,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33610829',\n",
       "     'text': 'ntisense oligonucleotides (AONs) is a promising treatment for Duchenne muscular dystrophy (DMD). Several exon-skipping drugs, including viltolarsen (N',\n",
       "     'offsetInBeginSection': 27,\n",
       "     'offsetInEndSection': 177,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29035327',\n",
       "     'text': 'he first AO-based drug, eteplirsen (Exondys 51), developed for DMD exon 51 skipping. An accurate and reproducible method to quantify exon skipping eff',\n",
       "     'offsetInBeginSection': 486,\n",
       "     'offsetInEndSection': 636,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32483212',\n",
       "     'text': 'dystrophin expression. Eteplirsen and golodirsen, AONs for DMD exons 51 and 53 skipping, have been recently approved by the FDA. Viltolarsen, an AON f',\n",
       "     'offsetInBeginSection': 354,\n",
       "     'offsetInEndSection': 504,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26573217',\n",
       "     'text': 'holino oligomer designed to skip DMD exon 51 in patients with Duchenne muscular dystrophy (DMD). Three-year progression of eteplirsen-treated patients',\n",
       "     'offsetInBeginSection': 110,\n",
       "     'offsetInEndSection': 260,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29771942',\n",
       "     'text': 'erapeutic platform in recent years, especially in the case of Duchenne muscular dystrophy (DMD). Despite FDA approval of eteplirsen-the first-ever ant',\n",
       "     'offsetInBeginSection': 70,\n",
       "     'offsetInEndSection': 220,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27854228',\n",
       "     'text': 'mise for treatment of the degenerative neuromuscular disease, Duchenne musculardystrophy (DMD).\\n\\n\\nOBJECTIVE\\nToxicity studies in non-human primates (NH',\n",
       "     'offsetInBeginSection': 147,\n",
       "     'offsetInEndSection': 297,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29907124',\n",
       "     'text': 'ies involving 322 participants were included, investigating eteplirsen in one and drisapersen in four studies. There were no changes in 6MWT distance ',\n",
       "     'offsetInBeginSection': 1002,\n",
       "     'offsetInEndSection': 1152,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29067661',\n",
       "     'text': 'xon skipping and exon inclusion drugs, to treat patients with Duchenne muscular dystrophy (DMD) and spinal muscular atrophy (SMA), respectively. The e',\n",
       "     'offsetInBeginSection': 305,\n",
       "     'offsetInEndSection': 455,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35715998',\n",
       "     'text': 'is a United States-approved treatment for patients with DMD and exon 51 skip-amenable mutations. Previous analyses have shown that eteplirsen is assoc',\n",
       "     'offsetInBeginSection': 116,\n",
       "     'offsetInEndSection': 266,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29301272',\n",
       "     'text': 's in total, have been demonstrated in animal models, including dystrophic mice and dogs, using cocktail antisense oligonucleotides (AOs). Although pro',\n",
       "     'offsetInBeginSection': 559,\n",
       "     'offsetInEndSection': 709,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32691988',\n",
       "     'text': \"ies. In this year's neuromuscular Year in Review, we focus on Duchenne muscular dystrophy (DMD), reviewing studies that evaluate the respiratory effec\",\n",
       "     'offsetInBeginSection': 165,\n",
       "     'offsetInEndSection': 315,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29339778',\n",
       "     'text': 'd splicing modulation is a promising therapeutic approach for Duchenne muscular dystrophy (DMD). Recently, eteplirsen, a phosphorodiamidate morpholino',\n",
       "     'offsetInBeginSection': 23,\n",
       "     'offsetInEndSection': 173,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28280301',\n",
       "     'text': 'nts. Eteplirsen is applicable for approximately 14% of patients with DMD mutations. This article extensively reviews and discusses the available infor',\n",
       "     'offsetInBeginSection': 658,\n",
       "     'offsetInEndSection': 808,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33610829',\n",
       "     'text': 'sed AONs, including eteplirsen in differentiated MYOD1-UDCs (UDC-myotubes) and rhabdomyosarcoma cells. Exon skipping was induced more efficiently in U',\n",
       "     'offsetInBeginSection': 1011,\n",
       "     'offsetInEndSection': 1161,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27936976',\n",
       "     'text': 'Exon skipping is a therapeutic approach for Duchenne muscular dystrophy (DMD) that has been in development for close to two decades. This approach use',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23907995',\n",
       "     'text': 'of sarcoglycans and neuronal nitric oxide synthase at the sarcolemma. Ambulation-evaluable eteplirsen-treated patients experienced a 67.3 m benefit co',\n",
       "     'offsetInBeginSection': 1352,\n",
       "     'offsetInEndSection': 1502,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30171538',\n",
       "     'text': 's currently one of the most promising approaches for treating Duchenne muscular dystrophy (DMD). While we now have a number of AO drug candidates in c',\n",
       "     'offsetInBeginSection': 67,\n",
       "     'offsetInEndSection': 217,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27936976',\n",
       "     'text': 'ipping approach, outline how it needs be tailored for different DMD mutation types and describe the challenges and opportunities for each mutation typ',\n",
       "     'offsetInBeginSection': 631,\n",
       "     'offsetInEndSection': 781,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30171533',\n",
       "     'text': 'herapy for DMD in the USA, and provides a treatment option for ~14% of all DMD patients, who are amenable to exon 51 skipping. Eteplirsen is granted a',\n",
       "     'offsetInBeginSection': 719,\n",
       "     'offsetInEndSection': 869,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34797383',\n",
       "     'text': 'in gene, is considered especially promising. Applicable to approximately 14% of DMD patients, a phosphorodiamidate morpholino oligomer (PMO) antisense',\n",
       "     'offsetInBeginSection': 424,\n",
       "     'offsetInEndSection': 574,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30171554',\n",
       "     'text': ' exon-skipping AON, called eteplirsen (brand name ExonDys51), targeting exon 51 of the DMD gene, in late 2016. Using a cocktail of AONs, multiple exon',\n",
       "     'offsetInBeginSection': 385,\n",
       "     'offsetInEndSection': 535,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28661408',\n",
       "     'text': ' to treat DMD. It is the first drug to be approved to treat the underlying causes of the disease. [http://www.biospace.com/News/victory-at-last-sarept',\n",
       "     'offsetInBeginSection': 723,\n",
       "     'offsetInEndSection': 873,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29301272',\n",
       "     'text': 'd eteplirsen, which skips DMD exon 51 and is applicable to approximately 13% of DMD patients. Multiple exon skipping, which is theoretically applicabl',\n",
       "     'offsetInBeginSection': 383,\n",
       "     'offsetInEndSection': 533,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34797383',\n",
       "     'text': 'ed adverse events. The most common events observed are balance disorder, vomiting, and skin rash. Despite its safety and promise of functional benefit',\n",
       "     'offsetInBeginSection': 787,\n",
       "     'offsetInEndSection': 937,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/27936976',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/30171533',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/29771942',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/28280301',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/29035327',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/29301272',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/30171538',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33610829',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/29907124',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/30171554',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32947786',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/27854228',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/28661408',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32483212',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/27807823',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/23907995',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/26573217',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/30526286',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32691988',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35715998',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34569969',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34797383',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/29339778',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/29067661']},\n",
       "  {'id': '63eef94ff36125a426000010',\n",
       "   'type': 'yesno',\n",
       "   'body': 'Is Cinpanemab effective for Parkinson’s Disease?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35921450',\n",
       "     'text': ' The trial was stopped after the week 72 interim analysis owing to lack of efficacy. The change to week 52 in the MDS-UPDRS score was 10.8 points in t',\n",
       "     'offsetInBeginSection': 1214,\n",
       "     'offsetInEndSection': 1364,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23223310',\n",
       "     'text': 'erapy. Nevertheless, this well established therapeutic intervention loses efficacy with the progression of the disease and patients develop invalidati',\n",
       "     'offsetInBeginSection': 98,\n",
       "     'offsetInEndSection': 248,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35921450',\n",
       "     'text': \"l antibody that binds to α-synuclein, is being evaluated as a disease-modifying treatment for Parkinson's disease.\\n\\n\\nMETHODS\\nIn a 52-week, multicenter\",\n",
       "     'offsetInBeginSection': 132,\n",
       "     'offsetInEndSection': 282,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35500112',\n",
       "     'text': 'in patients with Parkinson’s disease (PD). However, its therapeutic mechanism of action is unknown. The healthy striatum exhibits rich dynamics result',\n",
       "     'offsetInBeginSection': 117,\n",
       "     'offsetInEndSection': 267,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29874003',\n",
       "     'text': 't therapeutic drugs for PD can only alleviate the patients’ symptoms, but cannot prevent or delay progression of the disease. Great efforts have been ',\n",
       "     'offsetInBeginSection': 124,\n",
       "     'offsetInEndSection': 274,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26236796',\n",
       "     'text': 'n and rehabilitation. Current treatment cannot stop the progression of the disease, although there is definite therapeutic effect. True neurorestorati',\n",
       "     'offsetInBeginSection': 286,\n",
       "     'offsetInEndSection': 436,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31731332',\n",
       "     'text': 'y a survey performed by telephone calls with good interrater reliability, patients with PD improve with LCIG treatment in many aspects of the disease.',\n",
       "     'offsetInBeginSection': 1091,\n",
       "     'offsetInEndSection': 1241,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35404466',\n",
       "     'text': ' associated with neurodegeneration  but  have  failed  to  identify  preventive  or  curative  therapies.  This  failure  mainly  originates  from  th',\n",
       "     'offsetInBeginSection': 233,\n",
       "     'offsetInEndSection': 383,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26464310',\n",
       "     'text': ' current drug treatment for PD is palliative and does not meet the clinical challenges of the disease, such as levodopa-induced dyskinesia, non-motor ',\n",
       "     'offsetInBeginSection': 150,\n",
       "     'offsetInEndSection': 300,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29714967',\n",
       "     'text': 'Parkinson’s disease(PD)diagnosis based on speech data has been proved to be an effective way in recent years.There are still some problems on preproce',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32613752',\n",
       "     'text': \"054), a monoclonal antibody targeting aggregated α-synuclein, for a phase II study in Parkinson's disease (PD). Doses and regimens were proposed based\",\n",
       "     'offsetInBeginSection': 86,\n",
       "     'offsetInEndSection': 236,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26464310',\n",
       "     'text': 'itivity in MPTP-treated mice. In summary, exercise improved dopaminergic neurotransmission and enhanced cognition in a preclinical animal model of PD.',\n",
       "     'offsetInBeginSection': 924,\n",
       "     'offsetInEndSection': 1074,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32718129',\n",
       "     'text': ' increase in hallucination among patients.\\n\\n\\nConclusion\\nLCIG is an efficient treatment modality in the management of Turkish patients with advanced Pa',\n",
       "     'offsetInBeginSection': 1859,\n",
       "     'offsetInEndSection': 2009,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32718129',\n",
       "     'text': 'gnificant increase in hallucination among patients.\\n\\n\\nConclusion\\nLCIG is an efficient treatment modality in the management of Turkish patients with ad',\n",
       "     'offsetInBeginSection': 1850,\n",
       "     'offsetInEndSection': 2000,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29708714',\n",
       "     'text': 'The effect of deep brain stimulation(DBS)surgery treatment for Parkinson’s disease is determined by the accuracy of the electrodes placement and localization.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 158,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/26236796',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35404466',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32613752',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/29708714',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/31731332',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/26464310',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/23223310',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/29714967',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35500112',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/29874003',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35921450',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32718129']},\n",
       "  {'id': '6426d131690f196b5100004e',\n",
       "   'type': 'factoid',\n",
       "   'body': 'In what organ would you find the Ashwell receptor?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20816169',\n",
       "     'text': 'The Ashwell-Morell receptor (AMR) of hepatocytes, originally termed the hepatic asialoglycoprotein receptor, was the first cellular receptor to be ide',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18488037',\n",
       "     'text': 'The Ashwell receptor, the major lectin of hepatocytes, rapidly clears from blood circulation glycoproteins bearing glycan ligands that include galacto',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27207430',\n",
       "     'text': 'n the role of post-translational modifications in platelet life-span and thrombopoietin production downstream of the hepatic Ashwell-Morrell receptor.',\n",
       "     'offsetInBeginSection': 329,\n",
       "     'offsetInEndSection': 479,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20816169',\n",
       "     'text': \"Nat. Medicine 14, pp. 648-655]. Among these components, clearance by the liver's AMR is enhanced by exposure of terminal galactose on the glycan chain\",\n",
       "     'offsetInBeginSection': 936,\n",
       "     'offsetInEndSection': 1086,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/20816169',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/27207430',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/18488037']},\n",
       "  {'id': '6429e17657b1c7a315000007',\n",
       "   'type': 'list',\n",
       "   'body': 'What histone marks are indicative of enhancers in the chromatin landscape of a given cell?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28981749',\n",
       "     'text': 's, marked by specific histone modification signatures: specifically, H3K4me1/K36me2 marks transcribed enhancers, while H3K4me1/K36me3 and H3K4me1/K79m',\n",
       "     'offsetInBeginSection': 1129,\n",
       "     'offsetInEndSection': 1279,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26957309',\n",
       "     'text': 'd 40 chromatin signatures on this unbiased enhancer set and identified H2BK20ac, a little-studied histone modification, as the most predictive mark of',\n",
       "     'offsetInBeginSection': 355,\n",
       "     'offsetInEndSection': 505,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29089515',\n",
       "     'text': 'tinct epigenomic profiles, such as expanded deposition of histone marks H3K27ac for super enhancers and H3K4me3 for broad domains, however little is k',\n",
       "     'offsetInBeginSection': 191,\n",
       "     'offsetInEndSection': 341,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21106759',\n",
       "     'text': 'stem cells and several adult tissues in the mouse. We find that histone H3K27ac distinguishes active enhancers from inactive/poised enhancer elements ',\n",
       "     'offsetInBeginSection': 667,\n",
       "     'offsetInEndSection': 817,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23526891',\n",
       "     'text': 'tion of enhancers than previous methods, but also helps identify the most informative and robust set of three chromatin marks for enhancer prediction.',\n",
       "     'offsetInBeginSection': 1099,\n",
       "     'offsetInEndSection': 1249,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28916725',\n",
       "     'text': 'ine 4 monomethylation, and histone H3 lysine 27 acetylation (H3K4me3, H3K4me1, and H3K27ac) and define, for the first time, the super enhancers and ty',\n",
       "     'offsetInBeginSection': 561,\n",
       "     'offsetInEndSection': 711,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22328731',\n",
       "     'text': ' outperforms previously published methods and that enhancers are best predicted by specific combinations of histone methylation and acetylation marks.',\n",
       "     'offsetInBeginSection': 1284,\n",
       "     'offsetInEndSection': 1434,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22491032',\n",
       "     'text': ' of specific transcription factors to enhancers and existing histone modifications. In this review, we present insights into the mechanisms of enhance',\n",
       "     'offsetInBeginSection': 716,\n",
       "     'offsetInEndSection': 866,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30755522',\n",
       "     'text': 'dbacks to control chromatin dynamics as the found motifs appear in the promoters or enhancers associated with various histone modification enzymes. Th',\n",
       "     'offsetInBeginSection': 1343,\n",
       "     'offsetInEndSection': 1493,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29754476',\n",
       "     'text': 'on of regulatory DNA and are densely occupied by transcription factors, active histone marks, and co-activators. Accumulating evidence points to the c',\n",
       "     'offsetInBeginSection': 425,\n",
       "     'offsetInEndSection': 575,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21847099',\n",
       "     'text': 'pment. The concomitant presence of the three H3K4 methylation states (H3K4me1/2/3) was found to clearly reflect the activity of bona fide T-cell gene ',\n",
       "     'offsetInBeginSection': 585,\n",
       "     'offsetInEndSection': 735,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22593555',\n",
       "     'text': 'atin landscape marked by histone H3 lysine 4 mono-methylation (H3K4me1) and histone H3 lysine 27 acetylation (H3K27ac). Nevertheless, little is known ',\n",
       "     'offsetInBeginSection': 394,\n",
       "     'offsetInEndSection': 544,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30755522',\n",
       "     'text': 'oadly mapped. We have analyzed 6 histone marks (H3K4me1, H3K4me3, H3K27ac, H3K27me3, K3H9me3, H3K36me3) across 121 human cell types and tissues from t',\n",
       "     'offsetInBeginSection': 371,\n",
       "     'offsetInEndSection': 521,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30905748',\n",
       "     'text': 'tone marks was generated to provide a deeper insight into how histone modification marks can represent enhancer regions in which histone marks indicat',\n",
       "     'offsetInBeginSection': 1174,\n",
       "     'offsetInEndSection': 1324,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24038352',\n",
       "     'text': 'eRNAs and H3K27ac to discriminate enhancer activity. We demonstrate that eRNA is more indicative of enhancer activity. Finally, we apply our fibroblas',\n",
       "     'offsetInBeginSection': 1122,\n",
       "     'offsetInEndSection': 1272,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28981749',\n",
       "     'text': ', marked by specific histone modification signatures: specifically, H3K4me1/K36me2 marks transcribed enhancers, while H3K4me1/K36me3 and H3K4me1/K79me',\n",
       "     'offsetInBeginSection': 1130,\n",
       "     'offsetInEndSection': 1280,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28916725',\n",
       "     'text': 'arks histone H3 lysine 4 trimethylation, histone H3 lysine 4 monomethylation, and histone H3 lysine 27 acetylation (H3K4me3, H3K4me1, and H3K27ac) and',\n",
       "     'offsetInBeginSection': 506,\n",
       "     'offsetInEndSection': 656,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23473601',\n",
       "     'text': ' we give an overview of enhancer-associated modifications of histones and DNA and discuss enzymatic activities involved in their dynamic deposition an',\n",
       "     'offsetInBeginSection': 672,\n",
       "     'offsetInEndSection': 822,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32912294',\n",
       "     'text': 'n overlap with those identified by chromatin accessibility and active epigenetic marking, yet a significant fraction is epigenetically repressed or di',\n",
       "     'offsetInBeginSection': 1436,\n",
       "     'offsetInEndSection': 1586,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24885402',\n",
       "     'text': 'correlated with enhancer status (poised or active), defined by surrounding histone marks. Furthermore, about fifty percent of poised and active enhanc',\n",
       "     'offsetInBeginSection': 759,\n",
       "     'offsetInEndSection': 909,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35801925',\n",
       "     'text': 'apes. Here, we analyzed genome-wide profiles of active enhancer and promoter marks in colorectal cancer cells and report DBC1 as a critical positive r',\n",
       "     'offsetInBeginSection': 401,\n",
       "     'offsetInEndSection': 551,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24038352',\n",
       "     'text': ' acetyltransferase P300 and the histone modification H3K4me1, indicate the presence of enhancers, only a fraction of enhancers are functionally active. Individual chromatin marks, such as H3K27ac and H3K27me3',\n",
       "     'offsetInBeginSection': 135,\n",
       "     'offsetInEndSection': 343,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29507293',\n",
       "     'text': 'hierarchically organized, containing both hub and non-hub enhancers. Hub enhancers share similar histone marks with non-hub enhancers, but are distinc',\n",
       "     'offsetInBeginSection': 285,\n",
       "     'offsetInEndSection': 435,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22593555',\n",
       "     'text': 'evolutionary conservation is higher for enhancers that become marked by H3K27ac at the end of gastrulation, suggesting their implication in the establ',\n",
       "     'offsetInBeginSection': 1052,\n",
       "     'offsetInEndSection': 1202,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19129543',\n",
       "     'text': 'tin conformation linked to a shift of the epigenetic signature toward repressive histone marks. Importantly, these sites are not correlated with gene ',\n",
       "     'offsetInBeginSection': 581,\n",
       "     'offsetInEndSection': 731,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25715743',\n",
       "     'text': 'with transcription factors, co-activators, histone chromatin marks, and lncRNAs. Alterations in enhancers lead to misregulation of gene expression, ca',\n",
       "     'offsetInBeginSection': 423,\n",
       "     'offsetInEndSection': 573,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33334884',\n",
       "     'text': 'dentify and define enhancers but do not consider the endogenous role of an enhancer in the context of native chromatin. We employed a combination of g',\n",
       "     'offsetInBeginSection': 204,\n",
       "     'offsetInEndSection': 354,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27089178',\n",
       "     'text': ', we find a new class of active functional enhancers that is marked by H3K122ac but lacks H3K27ac. This work suggests that, to identify enhancers, a m',\n",
       "     'offsetInBeginSection': 768,\n",
       "     'offsetInEndSection': 918,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25123274',\n",
       "     'text': 'type-specific activation after exposure to stimuli. Histone modification and promoter architecture govern the diverse responses to stimulation. Furthe',\n",
       "     'offsetInBeginSection': 926,\n",
       "     'offsetInEndSection': 1076,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30905748',\n",
       "     'text': ' epigenetic signatures. Machine learning tools, such as CSI-ANN, ChromHMM, and RFECS, were developed for predicting enhancers using various epigenetic features. However, predictions by different tools vary widely and quite a significant portion of enhancer predictions does not agree. Thus, computational methods for enhancer prediction should be further developed. In this paper, a hybrid neural network called Enhancer-CRNN, a convolutional neural network (CNN) followed by a recurrent neural network (RNN), was developed and they were used to predict enhancer regions with histone modification marks',\n",
       "     'offsetInBeginSection': 144,\n",
       "     'offsetInEndSection': 746,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/23473601',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/28981749',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/21106759',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35801925',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/29507293',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/30905748',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/27089178',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/28916725',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/22491032',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/25715743',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/26957309',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32912294',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/22593555',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/30755522',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/29089515',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33334884',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/23526891',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/22328731',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/19129543',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/21847099',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/25123274',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/29754476',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/24885402',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/24038352']},\n",
       "  {'id': '643306cc57b1c7a315000027',\n",
       "   'type': 'yesno',\n",
       "   'body': 'Can CRISPR/Cas12a be used for the detection of EGFR mutations in circulating DNA?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32486913',\n",
       "     'text': 'le lateral flow strip. These results indicate that Cas12a is able to detect both DNA and RNA targets, making it an appropriate and convenient tool to ',\n",
       "     'offsetInBeginSection': 985,\n",
       "     'offsetInEndSection': 1135,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31413315',\n",
       "     'text': 'h attomolar sensitivity but, to our knowledge, it has not been used for the detection of small molecules. Bacterial allosteric transcription factors (',\n",
       "     'offsetInBeginSection': 95,\n",
       "     'offsetInEndSection': 245,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32093010',\n",
       "     'text': 'monstrates that the CRISPR-Cas12a system could rapidly and sensitively detect circulating EGFR mutations, and thus, has potential prognostic or therap',\n",
       "     'offsetInBeginSection': 1393,\n",
       "     'offsetInEndSection': 1543,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33991961',\n",
       "     'text': 'ns-cleaves ssDNA and this feature has been widely harnessed for nucleic acid detection. Herein, we introduce a new type of Cas12a reporter, G-triplex ',\n",
       "     'offsetInBeginSection': 24,\n",
       "     'offsetInEndSection': 174,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33076176',\n",
       "     'text': ' on TEVs, PCR-based exponential amplification and CRISPR/Cas12a real-time DNA detection, we developed a novel technique, termed the aptamer-CRISPR/Cas',\n",
       "     'offsetInBeginSection': 364,\n",
       "     'offsetInEndSection': 514,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33076176',\n",
       "     'text': 'apidly and conveniently detects ultralow concentrations of CD109+ and EGFR+ TEVs directly in serum, it could be useful in NPC diagnosis and prognosis.',\n",
       "     'offsetInBeginSection': 1357,\n",
       "     'offsetInEndSection': 1507,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34074403',\n",
       "     'text': 'avage ability of CRISPR/Cas12a was established to ultra-sensitively detect gene-PIK3CAH1047R mutation. The mutated gene-PIK3CAH1047R can combine with ',\n",
       "     'offsetInBeginSection': 230,\n",
       "     'offsetInEndSection': 380,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/32486913',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33991961',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/31413315',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32093010',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33076176',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34074403']},\n",
       "  {'id': '64178ffb690f196b51000029',\n",
       "   'type': 'factoid',\n",
       "   'body': 'What type of DMD can casimersen be used for?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33861387',\n",
       "     'text': 'bclass developed by Sarepta Therapeutics for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a mutation in the DMD gene that i',\n",
       "     'offsetInBeginSection': 105,\n",
       "     'offsetInEndSection': 255,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34569969',\n",
       "     'text': 'ies -Eteplirsen, Golodirsen, Viltolarsen, and Casimersen -for Duchenne Muscular Dystrophy (DMD). However, these treatments have only demonstrated vari',\n",
       "     'offsetInBeginSection': 102,\n",
       "     'offsetInEndSection': 252,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26594036',\n",
       "     'text': 'be used to monitor the efficacy of experimental therapies for Duchenne Muscular Dystrophy (DMD) in clinical trials. Identification of novel protein bi',\n",
       "     'offsetInBeginSection': 58,\n",
       "     'offsetInEndSection': 208,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12692454',\n",
       "     'text': 'rojective technique commonly used with children) in boys with Duchenne muscular dystrophy (DMD), a fatal, progressive illness (n = 74). A reliable and',\n",
       "     'offsetInBeginSection': 37,\n",
       "     'offsetInEndSection': 187,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29791760',\n",
       "     'text': 'of dystrophin-deficient muscle. We tested the hypothesis that Duchenne muscular dystrophy (DMD) patients would have elevated levels of the macrophage-',\n",
       "     'offsetInBeginSection': 882,\n",
       "     'offsetInEndSection': 1032,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29579701',\n",
       "     'text': 'prolonged ambulation is considered important in children with Duchenne muscular dystrophy (DMD), articles describing gait deviations in DMD are scarce',\n",
       "     'offsetInBeginSection': 20,\n",
       "     'offsetInEndSection': 170,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36449321',\n",
       "     'text': 'disease progression and therapeutic response in patients with Duchenne muscular dystrophy (DMD). This study evaluates whether quantitative muscle ultr',\n",
       "     'offsetInBeginSection': 77,\n",
       "     'offsetInEndSection': 227,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25365558',\n",
       "     'text': 'is essential for rapidly identifying effective treatments for Duchenne muscular dystrophy (DMD), a devastating neuromuscular disorder caused by the la',\n",
       "     'offsetInBeginSection': 33,\n",
       "     'offsetInEndSection': 183,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34105177',\n",
       "     'text': 'Casimersen was well tolerated in participants with DMD amenable to exon 45 skipping. Most TEAEs were mild, nonserious, and unrelated to casimersen. Pl',\n",
       "     'offsetInBeginSection': 1478,\n",
       "     'offsetInEndSection': 1628,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/7599358',\n",
       "     'text': 'sed as potential treatments for inherited myopathies, such as Duchenne muscular dystrophy (DMD). The success of myoblast implantation in mouse models,',\n",
       "     'offsetInBeginSection': 63,\n",
       "     'offsetInEndSection': 213,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29791760',\n",
       "     'text': 't, we then identified a potential role for 7,8-dihydroneopterin in disease pathology. We assessed whether 7,8-dihydroneopterin could: (i) protect agai',\n",
       "     'offsetInBeginSection': 1467,\n",
       "     'offsetInEndSection': 1617,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29791760',\n",
       "     'text': '-synthesized antioxidant 7,8-dihydroneopterin was elevated in Duchenne muscular dystrophy (DMD) patients. We then examined whether 7,8-dihydroneopteri',\n",
       "     'offsetInBeginSection': 91,\n",
       "     'offsetInEndSection': 241,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/1971151',\n",
       "     'text': 'r the gene causing the X-linked recessive muscular dystrophy (MD) type Duchenne (DMD) and Becker (BMD) has recently been cloned and made available for',\n",
       "     'offsetInBeginSection': 26,\n",
       "     'offsetInEndSection': 176,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33239841',\n",
       "     'text': 'ed with aging, which is, to some extent, similar to what occurs in humans. Thus, cDMDR could be a valuable model for studying cardiology of human DMD.',\n",
       "     'offsetInBeginSection': 1512,\n",
       "     'offsetInEndSection': 1662,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16528755',\n",
       "     'text': 'ethical issues regarding screening newborns (and infants) for Duchenne muscular dystrophy (DMD). First, what are the risks and benefits of expanding n',\n",
       "     'offsetInBeginSection': 58,\n",
       "     'offsetInEndSection': 208,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26037351',\n",
       "     'text': 'e the methods for genetic detection and prenatal diagnosis of Duchenne muscular dystrophy (DMD).\\n\\n\\nMETHODS\\nDenaturing high-performance liquid chromato',\n",
       "     'offsetInBeginSection': 20,\n",
       "     'offsetInEndSection': 170,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33861387',\n",
       "     'text': ', for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon\\xa045 skipping. The approval, granted under',\n",
       "     'offsetInBeginSection': 638,\n",
       "     'offsetInEndSection': 788,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35213020',\n",
       "     'text': 'rsen, and casimersen) have been approved for the treatment of Duchenne muscular dystrophy, but many more are in development targeting an array of diff',\n",
       "     'offsetInBeginSection': 81,\n",
       "     'offsetInEndSection': 231,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34105177',\n",
       "     'text': 'INTRODUCTION/AIMS\\nDuchenne muscular dystrophy (DMD) is caused by mutations in the DMD gene resulting in the absence of dystrophin. Casimersen is a pho',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25982038',\n",
       "     'text': ' used to distinguish the deletion or duplication genotypes of Duchenne muscular dystrophy (DMD) due to different fluorescent intensities. After PCR, t',\n",
       "     'offsetInBeginSection': 211,\n",
       "     'offsetInEndSection': 361,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25669899',\n",
       "     'text': 'ch was first discovered 30 years ago. Despite its extensive use in DMD research, no effective treatment has yet been developed for this devastating di',\n",
       "     'offsetInBeginSection': 236,\n",
       "     'offsetInEndSection': 386,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23637366',\n",
       "     'text': 'fetime imaging can be realized. The DMD can also be used as a real-time optical processor for applications such as the programmable array microscope a',\n",
       "     'offsetInBeginSection': 270,\n",
       "     'offsetInEndSection': 420,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36401026',\n",
       "     'text': 'rom childhood, the earlier treatment is preferred. The canine X-linked muscular dystrophy in Japan (CXMDj), a dog model of DMD, produces no dystrophin',\n",
       "     'offsetInBeginSection': 556,\n",
       "     'offsetInEndSection': 706,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35713895',\n",
       "     'text': ' 2020. The Cincinnati study reviewed data from 435 males with Duchenne muscular dystrophy, also known as DMD, who were treated at the Cincinnati Child',\n",
       "     'offsetInBeginSection': 171,\n",
       "     'offsetInEndSection': 321,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/1459673',\n",
       "     'text': 'of the three families studied. This information can be useful for genetic counselling with particular reference to prenatal diagnosis and carrier anal',\n",
       "     'offsetInBeginSection': 298,\n",
       "     'offsetInEndSection': 448,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29173172',\n",
       "     'text': 'CRISPR strategies in vitro and in vivo.\\n\\n\\nCONCLUSIONS\\nRestoration of the wild type and shorter form of dystrophin highlights the therapeutic potential',\n",
       "     'offsetInBeginSection': 1543,\n",
       "     'offsetInEndSection': 1693,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28430230',\n",
       "     'text': 'the wavelength fit resolution. Our results show that DMDs can be used in high-resolution spectroscopy and for Fiber Bragg grating (FBG) interrogation.',\n",
       "     'offsetInBeginSection': 783,\n",
       "     'offsetInEndSection': 933,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34909800',\n",
       "     'text': 'ts exon 45 of the dystrophin gene and is expected to treat ~8% of the DMD patient population. The continued approval of this drug will be dependent on',\n",
       "     'offsetInBeginSection': 728,\n",
       "     'offsetInEndSection': 878,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29060790',\n",
       "     'text': 'Duchenne Muscular Dystrophy (DMD) is a genetic disorder caused by dystrophin protein deficiency. Muscle biopsy is the gold standard to determine the d',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/25982038',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36449321',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/29060790',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33861387',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/16528755',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34105177',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/29579701',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35213020',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/12692454',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/26594036',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/29791760',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/28430230',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/26037351',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34909800',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/25365558',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/1971151',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/1459673',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36401026',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/7599358',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/25669899',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/23637366',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34569969',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/29173172',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35713895',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33239841']},\n",
       "  {'id': '63eeefc5f36125a426000009',\n",
       "   'type': 'factoid',\n",
       "   'body': 'What is targeted by CIS43LS?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34511592',\n",
       "     'text': ' dose of the CIS43LS monoclonal antibody resulted in protection against malaria. These new findings have implications for the seasonal control of mala',\n",
       "     'offsetInBeginSection': 1100,\n",
       "     'offsetInEndSection': 1250,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/34511592']},\n",
       "  {'id': '6415b422690f196b5100000a',\n",
       "   'type': 'summary',\n",
       "   'body': 'What does Cal-light do?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28650460',\n",
       "     'text': 'ystem, Cal-Light, that translates neuronal-activity-mediated calcium signaling into gene expression in a light-dependent manner. In cultured neurons a',\n",
       "     'offsetInBeginSection': 164,\n",
       "     'offsetInEndSection': 314,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/28650460']},\n",
       "  {'id': '64172bb2690f196b5100001e',\n",
       "   'type': 'factoid',\n",
       "   'body': 'To which region of a gene does an RNA polymerase bind to initiate transcription?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31863129',\n",
       "     'text': 'rases (RNAPs) differ from other polymerases in that they can bind promoter sequences and initiate transcription de novo and this promoter recognition ',\n",
       "     'offsetInBeginSection': 141,\n",
       "     'offsetInEndSection': 291,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/6382259',\n",
       "     'text': 'Escherichia coli, which specifically initiates transcription at phage T4 late promoters, is extensively modified by ADP-ribosylation of core subunits ',\n",
       "     'offsetInBeginSection': 50,\n",
       "     'offsetInEndSection': 200,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/9603525',\n",
       "     'text': 'Initiation of transcription of a gene from a core promoter region by RNA polymerase II requires the assembly of several initiation factors to form a p',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24600005',\n",
       "     'text': 'from a reduced ability of RNA polymerase II to be recruited to the promoter-proximal regions of these genes. In contrast, depletion of hPaf1 reduces t',\n",
       "     'offsetInBeginSection': 639,\n",
       "     'offsetInEndSection': 789,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/6194892',\n",
       "     'text': 'transcription factor that binds specifically to the 5S RNA gene internal control region, is unable to initiate synthesis at the start site of the 5S R',\n",
       "     'offsetInBeginSection': 366,\n",
       "     'offsetInEndSection': 516,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/3380786',\n",
       "     'text': 'nsis subsp. kurstaki HD-1-Dipel that directs transcription from the promoter region of an insecticidal crystal protein gene. The core components of th',\n",
       "     'offsetInBeginSection': 89,\n",
       "     'offsetInEndSection': 239,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/2648001',\n",
       "     'text': ' facilitates binding of the RNA polymerase to the proper region of the promoter. The Ada protein possesses two known methyl acceptor sites, Cys69 and ',\n",
       "     'offsetInBeginSection': 1617,\n",
       "     'offsetInEndSection': 1767,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16798040',\n",
       "     'text': 'During transcription initiation by bacterial RNA polymerase, the sigma subunit recognizes the -35 and -10 promoter elements; free sigma, however, does',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/2648001',\n",
       "     'text': ' promoter by both types of Ada protein. RNA polymerase did bind to the promoter once the methylated Ada protein had bound to the upstream sequence. To',\n",
       "     'offsetInBeginSection': 940,\n",
       "     'offsetInEndSection': 1090,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27558998',\n",
       "     'text': 'tor, region 2.3 amino acids bind non-template strand DNA, trapping the promoter in a single-stranded state required for initiation of transcription. A',\n",
       "     'offsetInBeginSection': 854,\n",
       "     'offsetInEndSection': 1004,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24600005',\n",
       "     'text': ' a reduced ability of RNA polymerase II to be recruited to the promoter-proximal regions of these genes. In contrast, depletion of hPaf1 reduces the o',\n",
       "     'offsetInBeginSection': 643,\n",
       "     'offsetInEndSection': 793,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/3465670',\n",
       "     'text': \"observed that are located in the 5'-flanking region. We conclude that RNA polymerase II can initiate transcription at the cap site in isolated nuclei.\",\n",
       "     'offsetInBeginSection': 1044,\n",
       "     'offsetInEndSection': 1194,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/9526497',\n",
       "     'text': 'ally, the cyanobacterial RNA polymerase could initiate transcription at PlacUV5, but not from wild-type Plac promoters. The different behaviours of th',\n",
       "     'offsetInBeginSection': 1043,\n",
       "     'offsetInEndSection': 1193,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/3865211',\n",
       "     'text': 'iption initiation factor (TIF) and purified RNA polymerase I to the promoter region of the 39S ribosomal RNA gene from Acanthamoeba were studied by us',\n",
       "     'offsetInBeginSection': 41,\n",
       "     'offsetInEndSection': 191,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/6263495',\n",
       "     'text': \"ta beta alpha 2-sigma able selectively to initiate transcription at promoter sites. It is proposed that beta beta' alpha 2-nusA and beta beta' alpha 2\",\n",
       "     'offsetInBeginSection': 610,\n",
       "     'offsetInEndSection': 760,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20300884',\n",
       "     'text': 'The mammalian core promoter is a sophisticated and crucial component for the regulation of transcription mediated by the RNA polymerase II. It is gene',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/10593606',\n",
       "     'text': 'd action of transcription factors binding to the gene-internal and gene-external parts of its promoter. Here, we investigated which transcription fact',\n",
       "     'offsetInBeginSection': 85,\n",
       "     'offsetInEndSection': 235,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/7556074',\n",
       "     'text': 'a binding site for RNA polymerase. RNA polymerase is able to bind the -40 to -60 region of the ada and the aidB promoters in the absence of meAda, and',\n",
       "     'offsetInBeginSection': 402,\n",
       "     'offsetInEndSection': 552,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31863129',\n",
       "     'text': 'hether the prototype T7 RNAP is able to recognize and initiate at truncated promoters similar to mitochondrial promoters. Using an in vitro oligonucle',\n",
       "     'offsetInBeginSection': 648,\n",
       "     'offsetInEndSection': 798,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/9990859',\n",
       "     'text': 'ith the core RNA polymerase subunits forms a holoenzyme able to bind promoter DNA, but unable to melt DNA and initiate transcription unless acted on b',\n",
       "     'offsetInBeginSection': 60,\n",
       "     'offsetInEndSection': 210,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/3380786',\n",
       "     'text': ' however, this form of RNA polymerase does direct transcription from a promoter for the 27-kDa crystal protein of B. thuringiensis subsp. israelensis ',\n",
       "     'offsetInBeginSection': 752,\n",
       "     'offsetInEndSection': 902,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/9526497',\n",
       "     'text': 'ranscription factors. Addition of RcaA, a protein that binds to the promoter region of the phycobiliprotein cpeBA operon, restored accurate initiation',\n",
       "     'offsetInBeginSection': 502,\n",
       "     'offsetInEndSection': 652,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/6537904',\n",
       "     'text': 'f DNA surrounding the start point of transcription of the histone H3, H4, and actin 5C genes. Included in this binding region is the TATA box, the sta',\n",
       "     'offsetInBeginSection': 480,\n",
       "     'offsetInEndSection': 630,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/10593606',\n",
       "     'text': 'onstrate that TFIIIC is required for human 7SL transcription. The gene-external part of the promoter includes an authentic cAMP-responsive element pre',\n",
       "     'offsetInBeginSection': 708,\n",
       "     'offsetInEndSection': 858,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/3865211',\n",
       "     'text': 'IF and polymerase provides evidence that accurate transcription of the ribosomal gene may be achieved through protein-protein contacts as well as thro',\n",
       "     'offsetInBeginSection': 1226,\n",
       "     'offsetInEndSection': 1376,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/2497942',\n",
       "     'text': 'e RNA polymerase extends from 30 base pairs (bp) upstream (-30) to 20 bp downstream (+20) from the in vivo transcription start site. This finding indi',\n",
       "     'offsetInBeginSection': 299,\n",
       "     'offsetInEndSection': 449,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/2550316',\n",
       "     'text': 'a H has been shown to bind specifically to DNA in the intergenic region upstream of the purE gene cloned from this species. The RNAP binding site has ',\n",
       "     'offsetInBeginSection': 131,\n",
       "     'offsetInEndSection': 281,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/7226225',\n",
       "     'text': 'A transcription factor binds specifically to a region within the 5S ribosomal RNA gene that is known to be required for accurate initiation of transcr',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/27558998',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/20300884',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/24600005',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/3380786',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/9526497',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/6194892',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/6537904',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/2550316',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/9603525',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/3465670',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/6263495',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/2497942',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/6382259',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/7226225',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/7556074',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/2648001',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/31863129',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/10593606',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/3865211',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/9990859',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/16798040']},\n",
       "  {'id': '63f9ccdc33942b094c00000f',\n",
       "   'type': 'yesno',\n",
       "   'body': 'Is PRP-40 involved in microexon splicing?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34348142',\n",
       "     'text': 'ion of neuronal microexons, and our data indicate that PRP-40 is a central regulator of microexon splicing. Microexons can be relieved from PRP-40 dep',\n",
       "     'offsetInBeginSection': 527,\n",
       "     'offsetInEndSection': 677,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34348142',\n",
       "     'text': 'f neuronal microexons, and our data indicate that PRP-40 is a central regulator of microexon splicing. Microexons can be relieved from PRP-40 dependen',\n",
       "     'offsetInBeginSection': 532,\n",
       "     'offsetInEndSection': 682,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/7935475',\n",
       "     'text': 's with DEAH boxes. However, any such splicing factor containing the helicase motifs in vertebrates has not been identified. To identify human homologs',\n",
       "     'offsetInBeginSection': 267,\n",
       "     'offsetInEndSection': 417,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/34348142',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/7935475']},\n",
       "  {'id': '641790d6690f196b5100002d',\n",
       "   'type': 'factoid',\n",
       "   'body': 'At what range of ages usually occurs the loss of independent ambulation in Duchenne muscular dystrophy?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12363102',\n",
       "     'text': 'nsuing year that resulted in loss of independent ambulation at the age of 10. Both boys remained around the 50th centile for height and weight, and sh',\n",
       "     'offsetInBeginSection': 622,\n",
       "     'offsetInEndSection': 772,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35625891',\n",
       "     'text': 'wasting during early childhood, and loss of ambulation and death by early adulthood. Chronic inflammation due to myofiber instability leads to fibrosi',\n",
       "     'offsetInBeginSection': 123,\n",
       "     'offsetInEndSection': 273,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21784636',\n",
       "     'text': 'Patients with Duchenne muscular dystrophy (DMD) lose ambulation by age 12. Long-term steroids have lengthened ambulation by 2-5 years. Ischial weight-',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25643053',\n",
       "     'text': 'ents with Duchenne muscular dystrophy aged 17.1 ± 4.8 years (range: 9 - 28.1 years). The average Brooke functional score of these patients was 4.6 ± 1',\n",
       "     'offsetInBeginSection': 641,\n",
       "     'offsetInEndSection': 791,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19834452',\n",
       "     'text': '. Historically, DMD has resulted in loss of ambulation between ages 7 and 13 years and death in the teens or 20s. The average age at diagnosis is 5 ye',\n",
       "     'offsetInBeginSection': 301,\n",
       "     'offsetInEndSection': 451,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/3198893',\n",
       "     'text': 'ot orthoses at the point of loss of ambulation, between the ages of 6 and 12 years. There was an inverse relationship between the severity of the scol',\n",
       "     'offsetInBeginSection': 152,\n",
       "     'offsetInEndSection': 302,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/3632394',\n",
       "     'text': 'f Duchenne muscular dystrophy, comparing the age at which 16 treated patients and 38 controls lost the ability to ambulate. Survival curve analysis an',\n",
       "     'offsetInBeginSection': 87,\n",
       "     'offsetInEndSection': 237,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26022172',\n",
       "     'text': 'it disturbance, and historically has led to the loss of ambulation by age 12. It is important for the practicing pediatrician, however, to be aware of',\n",
       "     'offsetInBeginSection': 226,\n",
       "     'offsetInEndSection': 376,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12026233',\n",
       "     'text': 'trophies, resulting in early loss of ambulation between the ages of 7 and 13 years and death in the teens and twenties. Despite the phenomenal advance',\n",
       "     'offsetInBeginSection': 93,\n",
       "     'offsetInEndSection': 243,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16322188',\n",
       "     'text': 'ked by progressive skeletal muscle weakness with loss of ambulation by 12 years of age. Death occurs in early adulthood secondary to respiratory or ca',\n",
       "     'offsetInBeginSection': 211,\n",
       "     'offsetInEndSection': 361,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31922454',\n",
       "     'text': 'ression analyses. Results: Median ages at loss of ambulation were 15.6 and 13.5\\xa0years among deflazacort- and prednisone-initiated patients, respective',\n",
       "     'offsetInBeginSection': 308,\n",
       "     'offsetInEndSection': 458,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33215271',\n",
       "     'text': 'childhood with loss of ambulation usually occurring around the age of 9-11\\xa0years.\\n\\n\\nOBJECTIVE, MATERIAL AND METHODS\\nBased on current guidelines and cl',\n",
       "     'offsetInBeginSection': 99,\n",
       "     'offsetInEndSection': 249,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27382620',\n",
       "     'text': ' dystrophy is a progressive disease with loss of ambulation at around 9-10 years of age, followed, if untreated, by development of scoliosis, respirat',\n",
       "     'offsetInBeginSection': 17,\n",
       "     'offsetInEndSection': 167,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/11929208',\n",
       "     'text': ' walking at the beginning of the second decade, and usually die by age 20 years. Until treatment of the basic genetic defect is available, medical, su',\n",
       "     'offsetInBeginSection': 178,\n",
       "     'offsetInEndSection': 328,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29067658',\n",
       "     'text': 'tal muscle wasting, with loss of independent ambulation in the early teenage years, followed by cardio-respiratory complications and premature death. ',\n",
       "     'offsetInBeginSection': 263,\n",
       "     'offsetInEndSection': 413,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27221372',\n",
       "     'text': 'ctively, accelerating around the time of ambulation loss (mean age 11.8 ± 2.7 years). Chronic corticosteroid therapy was utilized in 69% of patients a',\n",
       "     'offsetInBeginSection': 389,\n",
       "     'offsetInEndSection': 539,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17257866',\n",
       "     'text': ' KAFOs at 10.2+/-1.6 years. Age at loss of ambulation in KAFOs was 12.3+/-1.9 years and at loss of standing 12.8+/-2.1 years. About 95/123 (77%) boys ',\n",
       "     'offsetInBeginSection': 1045,\n",
       "     'offsetInEndSection': 1195,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36397889',\n",
       "     'text': 'kness, respiratory impairment, and loss of ambulation.\\xa0A case study of a nine-year-old male diagnosed with DMD is presented. The patient had difficult',\n",
       "     'offsetInBeginSection': 200,\n",
       "     'offsetInEndSection': 350,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25635234',\n",
       "     'text': ' deflazacort prolonged ambulation longer than prednisone (median 14 years and 13 years, respectively). Further, use of Vitamin D and Coenzyme Q10, ins',\n",
       "     'offsetInBeginSection': 981,\n",
       "     'offsetInEndSection': 1131,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/3632394',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/25635234',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/12026233',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35625891',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/11929208',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/3198893',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/19834452',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36397889',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/27221372',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/31922454',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/26022172',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/27382620',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33215271',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/25643053',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/21784636',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/17257866',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/29067658',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/12363102',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/16322188']},\n",
       "  {'id': '6404199d201352f04a000019',\n",
       "   'type': 'yesno',\n",
       "   'body': 'Is ocrelizumab effective for primary progressive multiple sclerosis?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33519676',\n",
       "     'text': 'Objectives: The aim of this study was to describe the tolerability, safety, and effectiveness of ocrelizumab for primary progressive multiple sclerosi',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32777270',\n",
       "     'text': ' remitting and primary progressive multiple sclerosis with evidence of inflammatory activity. Guidelines suggest assessing vaccination status and even',\n",
       "     'offsetInBeginSection': 83,\n",
       "     'offsetInEndSection': 233,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33519676',\n",
       "     'text': 'of RMS patients who were followed for at least 1 year. Ocrelizumab was generally well-tolerated; the most common adverse events were infusion-related ',\n",
       "     'offsetInBeginSection': 1249,\n",
       "     'offsetInEndSection': 1399,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36454397',\n",
       "     'text': 'OBJECTIVES\\nOcrelizumab demonstrated significant clinical benefit for the treatment of relapsing (RMS) and primary progressive (PPMS) multiple sclerosi',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33868559',\n",
       "     'text': 'b is an anti-CD20 monoclonal antibody that has been shown to reduce disability progression in primary progressive multiple sclerosis (MS). The adverse',\n",
       "     'offsetInBeginSection': 21,\n",
       "     'offsetInEndSection': 171,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32607256',\n",
       "     'text': 'ability status after treatment start.\\n\\n\\nCONCLUSION\\nOcrelizumab can stabilize disability progression in patients with PPMS. Some patients even showed a',\n",
       "     'offsetInBeginSection': 1068,\n",
       "     'offsetInEndSection': 1218,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30160679',\n",
       "     'text': 'lizumab, are widely coming to multiple sclerosis (MS) therapy. Its clinical-MRI efficacy in MS with relapses as well in primary progressive MS (PPMS) ',\n",
       "     'offsetInBeginSection': 71,\n",
       "     'offsetInEndSection': 221,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30677733',\n",
       "     'text': 'rve (SUCRA) values.\\n\\n\\nRESULTS\\nResults suggest that ocrelizumab has superior efficacy to 10 of the 17 treatments in the 12-week confirmed disability pr',\n",
       "     'offsetInBeginSection': 1412,\n",
       "     'offsetInEndSection': 1562,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30008443',\n",
       "     'text': 'rogressive multiple sclerosis and relapsing forms of multiple sclerosis. Here, we review the evidence for the safety and effectiveness of ocrelizumab.',\n",
       "     'offsetInBeginSection': 254,\n",
       "     'offsetInEndSection': 404,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33352355',\n",
       "     'text': 'ng therapy (DMT) for primary progressive multiple sclerosis (MS). Although effective, adverse infusion-related reactions (IRR), such as erythema, prur',\n",
       "     'offsetInBeginSection': 77,\n",
       "     'offsetInEndSection': 227,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35079395',\n",
       "     'text': 'ombinant humanized antibody targeted against CD-20\\xa0molecule, which was approved for the treatment of relapsing and primary progressive multiple sclero',\n",
       "     'offsetInBeginSection': 20,\n",
       "     'offsetInEndSection': 170,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35964555',\n",
       "     'text': 'Ocrelizumab is an effective treatment for relapsing and primary-progressive multiple sclerosis (MS). However, the effect of ocrelizumab on leptomeningeal (LM) inflammation is unknown',\n",
       "     'offsetInBeginSection': 11,\n",
       "     'offsetInEndSection': 193,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35964555',\n",
       "     'text': ' in one patient at first dose.\\n\\n\\nCONCLUSIONS\\nTreatment with ocrelizumab was safe and clinically effective. Brain volume loss and accumulation of T1-LV',\n",
       "     'offsetInBeginSection': 1426,\n",
       "     'offsetInEndSection': 1576,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33450528',\n",
       "     'text': 'Ocrelizumab is a humanized monoclonal anti-CD20 antibody approved for treatment of relapsing-remitting and primary progressive multiple sclerosis (MS)',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32607256',\n",
       "     'text': 'om the ORATORIO clinical trial. Real-world data about the clinical effectiveness of ocrelizumab has yet to be gathered.\\n\\n\\nOBJECTIVE\\nThe aim of this st',\n",
       "     'offsetInBeginSection': 140,\n",
       "     'offsetInEndSection': 290,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32470856',\n",
       "     'text': 'Ocrelizumab is a humanized monoclonal anti-CD20 antibody approved for treatment of relapsing-remitting and primary progressive multiple sclerosis (MS)',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33948072',\n",
       "     'text': 'Ocrelizumab is an intravenous anti-CD20 monoclonal antibody, approved for use in primary progressive multiple sclerosis due to its selective depletion',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33356643',\n",
       "     'text': 'INTRODUCTION\\nOcrelizumab is the first approved drug for primary progressive multiple sclerosis. Following appraisal by health technology assessment (H',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36454397',\n",
       "     'text': '8.38), interferon β-1a (8.33) and glatiramer acetate (8.18). As the most effective option, with quality-adjusted life year (QALY) gains between 0.3 an',\n",
       "     'offsetInBeginSection': 1077,\n",
       "     'offsetInEndSection': 1227,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36007299',\n",
       "     'text': 'the basis of previous phase III studies. However, limited data were available on ocrelizumab efficacy in RMS according to the Lublin definition of act',\n",
       "     'offsetInBeginSection': 232,\n",
       "     'offsetInEndSection': 382,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31821962',\n",
       "     'text': 'mary progressive multiple sclerosis (PPMS). Its increasing use for MS has been due in part to its efficacy, unique indication for PPMS, and convenient',\n",
       "     'offsetInBeginSection': 135,\n",
       "     'offsetInEndSection': 285,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34497472',\n",
       "     'text': 'Ocrelizumab is a humanized CD20 monoclonal antibody which was approved for management of Relapsing Remitting Multiple Sclerosis (RRMS) and Primary Pro',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30597851',\n",
       "     'text': 'n of disease activity in multiple sclerosis (MS) patients and has recently been approved for the treatment of patients with relapsing MS (RMS) and pri',\n",
       "     'offsetInBeginSection': 96,\n",
       "     'offsetInEndSection': 246,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36007299',\n",
       "     'text': ' new safety signal was identified.\\n\\n\\nCONCLUSION\\nThese data confirm the efficacy of ocrelizumab in a pragmatic setting and its favorable benefit-risk p',\n",
       "     'offsetInBeginSection': 2454,\n",
       "     'offsetInEndSection': 2604,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35107597',\n",
       "     'text': 's between groups were found.\\n\\n\\nINTERPRETATION\\nWe provide real-world evidence of effectiveness of ocrelizumab and rituximab in pwPPMS. No differences i',\n",
       "     'offsetInBeginSection': 1503,\n",
       "     'offsetInEndSection': 1653,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35741088',\n",
       "     'text': 'respectively, p = 0.043). Response to ocrelizumab was linked to lower total and gray matter cerebellar volume loss over time. Reduced plasmablast depl',\n",
       "     'offsetInBeginSection': 1203,\n",
       "     'offsetInEndSection': 1353,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32524163',\n",
       "     'text': 'lar B\\xa0cells. Recently published phase\\xa03 studies confirmed that ocrelizumab is effective in the treatment of both relapsing multiple sclerosis (RMS) an',\n",
       "     'offsetInBeginSection': 162,\n",
       "     'offsetInEndSection': 312,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34735301',\n",
       "     'text': 'past 24 months.Conclusion: Six-monthly 600mg ocrelizumab infusions may be effective as a steroid sparing option for patients with severe, recurrent bi',\n",
       "     'offsetInBeginSection': 775,\n",
       "     'offsetInEndSection': 925,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/35107597',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33868559',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33352355',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32777270',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35741088',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32470856',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32524163',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36454397',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33948072',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33450528',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36007299',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32607256',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/30160679',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35079395',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33356643',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/30597851',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34497472',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/30677733',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35964555',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33519676',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34735301',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/31821962',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/30008443']},\n",
       "  {'id': '641b7bba690f196b5100003e',\n",
       "   'type': 'summary',\n",
       "   'body': 'How is Indocyanine green (ICG) used?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35874138',\n",
       "     'text': 's an operation burdened with severe postoperative complications. Fluorescence imaging, particularly using indocyanine green (ICG), offers the ability ',\n",
       "     'offsetInBeginSection': 112,\n",
       "     'offsetInEndSection': 262,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33965600',\n",
       "     'text': 'We describe a case using indocyanine green (ICG) fluorescence imaging for diagnosis of postoperative gastrointestinal fistula. When the fistula is ver',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28316935',\n",
       "     'text': 'Indocyanine Green (ICG) is frequently used during urologic robotic procedures and is generally considered to be safe. However, there are reported case',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/9018428',\n",
       "     'text': 'ine green (ICG) is a fluorescent dye that can be used to image both retinal and choroidal vessels. This study was performed to examined the retinal an',\n",
       "     'offsetInBeginSection': 139,\n",
       "     'offsetInEndSection': 289,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12963458',\n",
       "     'text': 'n time. We examined Indocyanine green (ICG) which is widely used in medical testing and is highly unstable. We showed that spatial localization of ICG',\n",
       "     'offsetInBeginSection': 82,\n",
       "     'offsetInEndSection': 232,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35662771',\n",
       "     'text': 'Using indocyanine green (ICG), a standard reagent used in liver function tests, bile leaks from exfoliated liver sections can be detected with higher ',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12880353',\n",
       "     'text': 'Indocyanine green (ICG) is widely used in medical imaging and testing. Its complex spectral behavior and low quantum yield limits some applications. W',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31129192',\n",
       "     'text': 'Indocyanine green (ICG) is a dye used for fluorescent-guided surgery. This review article addresses the recent surge in reported uses of ICG in variou',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15871512',\n",
       "     'text': 'ive fluorescence angiography in which indocyanine green (ICG) is used as a tracer has been introduced as a novel technique to confirm successful aneur',\n",
       "     'offsetInBeginSection': 28,\n",
       "     'offsetInEndSection': 178,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19065196',\n",
       "     'text': 'Indocyanine green (ICG) is a fluorescent probe used in clinical imaging. However, its utility remains limited by optical instability, rapid circulatio',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/11084282',\n",
       "     'text': 'taract extraction. Indocyanine green was used to better visualize the anterior capsule before capsulotomy. The anterior capsule stained green, but the',\n",
       "     'offsetInBeginSection': 503,\n",
       "     'offsetInEndSection': 653,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17964824',\n",
       "     'text': 'roduce our preliminary experience with indocyanine green (ICG) fluorescence angiography for the assessment of lower leg bypasses.\\n\\n\\nMETHODS\\n1ml of 0.5',\n",
       "     'offsetInBeginSection': 16,\n",
       "     'offsetInEndSection': 166,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/8235110',\n",
       "     'text': 'Indocyanine green (ICG)-enhanced laser therapy was evaluated for the treatment of experimental intraocular melanoma. Immediately after an intravenous ',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23727789',\n",
       "     'text': 'particles could be activated from \"OFF\" to \"ON\" of NIR fluorescence in an intracellular environment and used for NIR imaging and photothermal therapy.',\n",
       "     'offsetInBeginSection': 207,\n",
       "     'offsetInEndSection': 357,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15871512',\n",
       "     'text': 'noted. Indocyanine green videoangiography was used to identify four nonfunctioning STA-MCA bypasses, which could be revised successfully in all cases.',\n",
       "     'offsetInBeginSection': 1457,\n",
       "     'offsetInEndSection': 1607,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34188987',\n",
       "     'text': 'raphy is a real-time imaging modality that can be used to assess intraoperative tissue perfusion. ICG dye has proven to be feasible, safe, and cost-ef',\n",
       "     'offsetInBeginSection': 30,\n",
       "     'offsetInEndSection': 180,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/10946079',\n",
       "     'text': 'ICG) is a fluorescent dye that has been used for the imaging of retinal and choroidal vasculatures for more than 30 years. Its high molecular weight, ',\n",
       "     'offsetInBeginSection': 19,\n",
       "     'offsetInEndSection': 169,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25698588',\n",
       "     'text': 'Near-infrared fluorescence (NIRF) imaging with intraoperative administration of indocyanine green (ICG) is a technology with emerging applications in ',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34589458',\n",
       "     'text': 'arrative synthesis is presented. Conclusion: Indocyanine green fluorescence angiography is a safe imaging technology and its use is increasing rapidly',\n",
       "     'offsetInBeginSection': 1600,\n",
       "     'offsetInEndSection': 1750,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19790157',\n",
       "     'text': 'learance (Cl-ICG) has been used to assess liver function and hepatic blood flow mainly before and after hepatic surgery. Cl-ICG (invasive method) has ',\n",
       "     'offsetInBeginSection': 19,\n",
       "     'offsetInEndSection': 169,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28477043',\n",
       "     'text': 'n fluorescence (m-ICG) has been widely used for assessing real-time blood flow during aneurysm surgery. More recently, an endoscope-integrated indocya',\n",
       "     'offsetInBeginSection': 64,\n",
       "     'offsetInEndSection': 214,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27051499',\n",
       "     'text': 'e green (ICG) dye to facilitate combined/en bloc removal of epiretinal membranes (ERM) along with internal limiting membranes (ILM). The method utiliz',\n",
       "     'offsetInBeginSection': 41,\n",
       "     'offsetInEndSection': 191,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32021082',\n",
       "     'text': ' with fluorescein or indocyanine green (ICG) is a diagnostic procedure commonly used in ophthalmology. Adverse reactions to fluorescein and ICG are ra',\n",
       "     'offsetInBeginSection': 48,\n",
       "     'offsetInEndSection': 198,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32360873',\n",
       "     'text': 'line for the use of indocyanine green (ICG) in the localization of pulmonary nodules before surgery. How long ICG can remain in\\xa0vivo is unknown. Accor',\n",
       "     'offsetInBeginSection': 36,\n",
       "     'offsetInEndSection': 186,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34589458',\n",
       "     'text': 'ocyanine green fluorescence angiography is a safe imaging technology and its use is increasing rapidly in pediatric surgical specialties. However, the',\n",
       "     'offsetInBeginSection': 1648,\n",
       "     'offsetInEndSection': 1798,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36055879',\n",
       "     'text': ' chemical injected intraoperatively which can be used to visualize dermal blood flow in real time. There is little objective data available to help gu',\n",
       "     'offsetInBeginSection': 334,\n",
       "     'offsetInEndSection': 484,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/11351215',\n",
       "     'text': 'INTRODUCTION\\nSince early 90th, infra-red angiography using indocyanine green, is an additional examination done after fluorescein angiography (FA) ver',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24710988',\n",
       "     'text': 'e largely used as functional indicator, fluorescent imaging contrast agent and recently as enhancer during diode laser photocoagulation. In this study',\n",
       "     'offsetInBeginSection': 43,\n",
       "     'offsetInEndSection': 193,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33884231',\n",
       "     'text': 'Indocyanine green (ICG) angiography is a procedure that uses a fluorescent dye for a variety of medical diagnostics, including the real-time examinati',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36055879',\n",
       "     'text': 'traditional methods were used. Minimum follow-up of 9 months was obtained, leaving 93 patients in total for analysis. Success was defined as a healed amputation within 60 days of follow-up. Uneventful amputation healing occurred in 35.5% and 33.9% of indocyanine green and control patients, respectively. Overall, there was no significant difference in outcomes between groups (p\\xa0=\\xa0.965), or success versus failure (p\\xa0=\\xa01.0). Patient undergoing minor lower extremity amputation with the use of ICG fluorescence angiography',\n",
       "     'offsetInBeginSection': 718,\n",
       "     'offsetInEndSection': 1240,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/9018428',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34589458',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36055879',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/12880353',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33965600',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/10946079',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/19790157',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/23727789',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/27051499',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32021082',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35662771',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/28316935',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33884231',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/24710988',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/11351215',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/8235110',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/17964824',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/12963458',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35874138',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34188987',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/19065196',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/15871512',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/25698588',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/31129192',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/11084282',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32360873',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/28477043']},\n",
       "  {'id': '6428da74690f196b51000052',\n",
       "   'type': 'factoid',\n",
       "   'body': 'What is the process that generates multiple transcripts from the same gene?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29074233',\n",
       "     'text': 'Alternative splicing, which generates multiple transcripts from the same gene, is an important modulator of gene expression that can increase proteome',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22961303',\n",
       "     'text': 'Alternative splicing, which generates multiple transcripts from the same gene and potentially different protein isoforms, is a key posttranscriptional',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28402429',\n",
       "     'text': 'Alternative splicing generates multiple transcript and protein isoforms from the same gene and thus is important in gene expression regulation. To dat',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30852095',\n",
       "     'text': 'Alternative splicing (AS) generates multiple transcripts from the same gene, however, AS contribution to proteome complexity remains elusive in plants',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29368663',\n",
       "     'text': 'ranscriptional regulation of gene expression. Selection of transcript cleavage and polyadenylation sites is a dynamic process that produces multiple t',\n",
       "     'offsetInBeginSection': 82,\n",
       "     'offsetInEndSection': 232,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33793927',\n",
       "     'text': 'nt accordingly by regulating gene expression at multiple levels. Alternative splicing (AS), a widespread mechanism in eukaryotes that post-transcripti',\n",
       "     'offsetInBeginSection': 80,\n",
       "     'offsetInEndSection': 230,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34383135',\n",
       "     'text': 'Alternative splicing is a widespread phenomenon, which generates multiple isoforms of the gene product. Reproductive development is the key process fo',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28942592',\n",
       "     'text': \"Alternative polyadenylation is an important and pervasive mechanism that generates heterogeneous 3'-termini of mRNA and is considered an important reg\",\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35821097',\n",
       "     'text': 'at give rise to phenotypic diversity in multicellular organisms. Alternative splicing generates multiple transcripts from a single gene, enriching the',\n",
       "     'offsetInBeginSection': 79,\n",
       "     'offsetInEndSection': 229,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28064309',\n",
       "     'text': 'Alternative splicing of pre-mRNA is one of the main mechanisms regulating gene expression that generates multiple transcripts from one gene. The revie',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/11868989',\n",
       "     'text': 'ervening noncoding sequences, introns, from primary transcripts. Alternative splicing generates an enormous repertoire of functional diversity by prod',\n",
       "     'offsetInBeginSection': 182,\n",
       "     'offsetInEndSection': 332,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/7665564',\n",
       "     'text': 'gene, and their relative abundance is developmentally regulated. Alternative splicing of the primary Sty transcript generates mRNAs encoding full-leng',\n",
       "     'offsetInBeginSection': 339,\n",
       "     'offsetInEndSection': 489,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18817741',\n",
       "     'text': 'Alternative splicing of messenger RNA (mRNA) precursors generates multiple transcripts from a single primary transcript. Identification and verificati',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33569514',\n",
       "     'text': \"Alternative polyadenylation (APA) is a molecular process that generates diversity at the 3' end of RNA polymerase II transcripts from over 60% of huma\",\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34440445',\n",
       "     'text': 'Alternative pre-mRNA splicing plays a very important role in expanding protein diversity as it generates numerous transcripts from a single protein-co',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33434218',\n",
       "     'text': 's of tips from the same species with improbably short branch lengths. treeinform is a method that uses phylogenetic information across species to refi',\n",
       "     'offsetInBeginSection': 304,\n",
       "     'offsetInEndSection': 454,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/11274164',\n",
       "     'text': 'Differential splicing from the bcl-X gene generates several isoforms with opposite effects on the apoptotic response. To explore the mechanism control',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24130571',\n",
       "     'text': 'ent transcripts yielding mature mRNAs, in a process known as spliced leader trans-splicing (SLTS). The best described function for SLTS is to solve po',\n",
       "     'offsetInBeginSection': 220,\n",
       "     'offsetInEndSection': 370,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29368663',\n",
       "     'text': 'promotes nucleolar dissolution in oocytes. We show that the RNA-binding protein NCL-1/Brat is a posttranscriptional regulator of numerous ribosome-rel',\n",
       "     'offsetInBeginSection': 1053,\n",
       "     'offsetInEndSection': 1203,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24139801',\n",
       "     'text': 'Alternative splicing generates multiple transcripts from a single gene, and cell-type-specific splicing profiles are important for the properties and ',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/18817741',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/22961303',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/11868989',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35821097',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/30852095',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/7665564',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33569514',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/28942592',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/24130571',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/11274164',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/28402429',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/29074233',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34440445',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/28064309',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33793927',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/24139801',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34383135',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/29368663',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33434218']},\n",
       "  {'id': '63f9cdcc33942b094c000013',\n",
       "   'type': 'yesno',\n",
       "   'body': 'Does silencing of SRRM4 inhibit tumor growth across cancers?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27346347',\n",
       "     'text': 'quently occurs in cancer, but the mechanism and functional role of this silencing in oncogenesis are not fully understood. Here, we show that oncogeni',\n",
       "     'offsetInBeginSection': 92,\n",
       "     'offsetInEndSection': 242,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/27346347']},\n",
       "  {'id': '64179aac690f196b51000037',\n",
       "   'type': 'factoid',\n",
       "   'body': 'What is the life expectancy for Duchenne muscular dystrophy patients?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/6696607',\n",
       "     'text': 'eater Los Angeles area. Regardless of their ages, which ranged from 12 years to 21, the majority of the patients, as well as the majority of the paren',\n",
       "     'offsetInBeginSection': 258,\n",
       "     'offsetInEndSection': 408,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27234309',\n",
       "     'text': 'ate the quality of life in boys with Duchenne muscular dystrophy aged 8-18 years, compared with that in matched healthy controls. A total of 85 boys w',\n",
       "     'offsetInBeginSection': 29,\n",
       "     'offsetInEndSection': 179,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/10193393',\n",
       "     'text': 'tients with Duchenne muscular dystrophy (DMD). Life expectancy is less than one year once diurnal hypercapnia develops. This study examines the effect',\n",
       "     'offsetInBeginSection': 68,\n",
       "     'offsetInEndSection': 218,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33075081',\n",
       "     'text': 'lar dystrophy (DMD) is a childhood onset muscular dystrophy leading to shortened life expectancy. There are gaps in published DMD care guidelines rega',\n",
       "     'offsetInBeginSection': 27,\n",
       "     'offsetInEndSection': 177,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28099279',\n",
       "     'text': 'and clinical history of Duchenne muscular dystrophy who is currently 53 years old. Because of improvements in cardiopulmonary care, there has been a g',\n",
       "     'offsetInBeginSection': 45,\n",
       "     'offsetInEndSection': 195,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17939910',\n",
       "     'text': 'phy), heart function, and dysphagia.\\n\\n\\nRESULTS\\nThe mean (SD) age was 26 (6) years and the mean age at which mechanical ventilation had initiated in th',\n",
       "     'offsetInBeginSection': 390,\n",
       "     'offsetInEndSection': 540,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34645707',\n",
       "     'text': 'on 2,283 patients, of whom 1,049 had died. Median life expectancy was 22.0 years (95% confidence interval [CI] 21.2, 22.4). Analyses stratified by 3 t',\n",
       "     'offsetInBeginSection': 962,\n",
       "     'offsetInEndSection': 1112,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30796500',\n",
       "     'text': 'trophy-associated cardiomyopathy, a nearly consistent feature in the third decade of life. A 26-year-old patient with Duchenne muscular dystrophy expe',\n",
       "     'offsetInBeginSection': 150,\n",
       "     'offsetInEndSection': 300,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/11929208',\n",
       "     'text': ' walking at the beginning of the second decade, and usually die by age 20 years. Until treatment of the basic genetic defect is available, medical, su',\n",
       "     'offsetInBeginSection': 178,\n",
       "     'offsetInEndSection': 328,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/1450492',\n",
       "     'text': 'f the patients with progressive muscular dystrophy from 15.8 years to 20.4 years over the last 20 years. Various new drug trials for muscular dystroph',\n",
       "     'offsetInBeginSection': 77,\n",
       "     'offsetInEndSection': 227,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30275245',\n",
       "     'text': ' decade of life. Life expectancy has improved from mid-teenage years to mid-20s with the use of glucocorticoids and beyond the third decade with venti',\n",
       "     'offsetInBeginSection': 264,\n",
       "     'offsetInEndSection': 414,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21482750',\n",
       "     'text': 'e, 40.04 years) of 27 Duchenne muscular dystrophy patients (mean age, 11.26 years) completed the validated Children Health Questionnaire-Parent Form 5',\n",
       "     'offsetInBeginSection': 331,\n",
       "     'offsetInEndSection': 481,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17939910',\n",
       "     'text': 'ge at which mechanical ventilation had initiated in the patients was 21 (5) years. Sixty-two percent had undergone tracheostomy and invasive mechanica',\n",
       "     'offsetInBeginSection': 486,\n",
       "     'offsetInEndSection': 636,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/3694224',\n",
       "     'text': 'dystrophy (DMD) demonstrated that (1) hospitalized patients showed longer life spans than their non-hospitalized affected maternal uncles, (2) patient',\n",
       "     'offsetInBeginSection': 51,\n",
       "     'offsetInEndSection': 201,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/7985396',\n",
       "     'text': 'Progressive scolioses in 20 wheelchair patients with an age between 10.5-18.3 years (mean 14.6 years) were treated by CDI. The mean preoperative angle',\n",
       "     'offsetInBeginSection': 227,\n",
       "     'offsetInEndSection': 377,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23876223',\n",
       "     'text': 'SULTS\\nLife expectancy without or with ventilatory assistance was 22.16 and 36.23 years, respectively. Similarly, life expectancy of patients born from',\n",
       "     'offsetInBeginSection': 439,\n",
       "     'offsetInEndSection': 589,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25752877',\n",
       "     'text': ' one in 5000 boys and presents in early childhood with proximal muscle weakness. Untreated boys become wheelchair bound by the age of 12 years and die of cardiorespiratory complications in their late teens to early 20s',\n",
       "     'offsetInBeginSection': 70,\n",
       "     'offsetInEndSection': 288,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/34645707',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/10193393',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/1450492',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/27234309',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/30275245',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/21482750',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/28099279',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/3694224',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/6696607',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33075081',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/30796500',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/17939910',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/25752877',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/23876223',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/7985396',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/11929208']},\n",
       "  {'id': '64041e97201352f04a00001e',\n",
       "   'type': 'yesno',\n",
       "   'body': 'Is daridorexant effective for insomnia?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35306405',\n",
       "     'text': 'UND\\nThe dual orexin receptor antagonist daridorexant did not impact nighttime respiratory function as assessed by the apnea/hypopnea index (AHI) and n',\n",
       "     'offsetInBeginSection': 7,\n",
       "     'offsetInEndSection': 157,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36473030',\n",
       "     'text': 'were the most officious doses. Treatment with daridorexant has resulted in a slightly higher incidence of adverse events [risk ratio (RR)\\u2009=\\u20091.19; 95% ',\n",
       "     'offsetInBeginSection': 861,\n",
       "     'offsetInEndSection': 1011,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32341187',\n",
       "     'text': 'OBJECTIVE\\nTo assess the dose-response of daridorexant, a new dual orexin receptor antagonist, on wake after sleep onset (WASO).\\n\\n\\nMETHODS\\nElderly (≥65',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36054921',\n",
       "     'text': 'in the two placebo-controlled phase III trials that evaluated the efficacy and safety of daridorexant. The DCE design was informed by a two-phase qual',\n",
       "     'offsetInBeginSection': 279,\n",
       "     'offsetInEndSection': 429,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36098753',\n",
       "     'text': 'e events were nasopharyngitis and headache.\\n\\n\\nCONCLUSION\\nDaridorexant was efficacious and safe. Studies that evaluate the long-term safety and compare',\n",
       "     'offsetInBeginSection': 936,\n",
       "     'offsetInEndSection': 1086,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35065036',\n",
       "     'text': ' p=0·012 at month 3). Compared with the placebo group, no significant differences were observed among participants in the daridorexant 10 mg group for',\n",
       "     'offsetInBeginSection': 4108,\n",
       "     'offsetInEndSection': 4258,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35065036',\n",
       "     'text': 'th 1; -1·0 [-2·0 to 0·01], p=0·053 at month 3). In study 2, WASO was significantly reduced among participants in the daridorexant 25 mg group compared',\n",
       "     'offsetInBeginSection': 3306,\n",
       "     'offsetInEndSection': 3456,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36473030',\n",
       "     'text': ' (RR\\u2009=\\u20092.01; 95% CI, 1.21-3.36; P\\u2009=\\u20090.007). Daridorexant is superior to placebo in improving sleep quality. However, the drug resulted in a slightly h',\n",
       "     'offsetInBeginSection': 1116,\n",
       "     'offsetInEndSection': 1266,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34331678',\n",
       "     'text': ' findings in the categorical outlier analysis. Daridorexant was safe and well tolerated and its pharmacokinetics were consistent with previous data.\\n\\n',\n",
       "     'offsetInBeginSection': 1481,\n",
       "     'offsetInEndSection': 1631,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33305817',\n",
       "     'text': 'ossover study, the effect of the dual orexin receptor antagonist daridorexant was evaluated on nighttime respiratory function and sleep in 28 patients',\n",
       "     'offsetInBeginSection': 67,\n",
       "     'offsetInEndSection': 217,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35065036',\n",
       "     'text': ' Compared with placebo, participants in the daridorexant 50 mg group had significantly improved self-reported total sleep time at month 1 (LSM differe',\n",
       "     'offsetInBeginSection': 2627,\n",
       "     'offsetInEndSection': 2777,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32937014',\n",
       "     'text': 'odynamic modelling>[1] and finally led to the selection of daridorexant, currently in phase 3 clinical trials for the treatment of insomnia disorders.',\n",
       "     'offsetInBeginSection': 599,\n",
       "     'offsetInEndSection': 749,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36045942',\n",
       "     'text': 'somnia. It was shown to be effective in reducing insomnia symptoms, increasing daytime functioning, and improving the overall quality of sleep. Darido',\n",
       "     'offsetInBeginSection': 751,\n",
       "     'offsetInEndSection': 901,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36144776',\n",
       "     'text': 'logy-based pharmacodynamic and pharmacokinetic model. The use of daridorexant is considered safe, with no clinically significant side-effects includin',\n",
       "     'offsetInBeginSection': 409,\n",
       "     'offsetInEndSection': 559,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31953863',\n",
       "     'text': 'OBJECTIVE\\nTo evaluate the dose-response relationship of daridorexant, a new dual orexin receptor antagonist, on sleep variables in subjects with insom',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35843245',\n",
       "     'text': 'zepines, daridorexant, suvorexant, and trazodone) can be effective in the acute treatment of insomnia but are associated with poor tolerability, or in',\n",
       "     'offsetInBeginSection': 3935,\n",
       "     'offsetInEndSection': 4085,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33305817',\n",
       "     'text': 'that single and repeated doses of 50 mg daridorexant do not impair nighttime respiratory function and improve sleep in patients with mild and moderate',\n",
       "     'offsetInBeginSection': 1579,\n",
       "     'offsetInEndSection': 1729,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32341187',\n",
       "     'text': 'FIER\\nNCT02841709.\\n\\n\\nCLASSIFICATION OF EVIDENCE\\nThis study provides Class I evidence that, for elderly people with insomnia, daridorexant reduced WASO.',\n",
       "     'offsetInBeginSection': 1570,\n",
       "     'offsetInEndSection': 1720,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32778207',\n",
       "     'text': ' dual orexin receptor antagonist. Daridorexant successfully passed first pivotal phase 3 clinical trial in April 2020 for the treatment of insomnia di',\n",
       "     'offsetInBeginSection': 553,\n",
       "     'offsetInEndSection': 703,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32603512',\n",
       "     'text': 'Daridorexant is a dual orexin receptor antagonist in clinical development for the treatment of insomnia. Breast-cancer resistant protein (BCRP) is an ',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34121345',\n",
       "     'text': 'okinetics (PKs), safety, and tolerability of daridorexant, a dual orexin receptor antagonist intended for the treatment of insomnia. A single-center, ',\n",
       "     'offsetInBeginSection': 83,\n",
       "     'offsetInEndSection': 233,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36473030',\n",
       "     'text': 'leep quality without impairing daytime functioning. We assess the safety and efficacy of this novel drug in the treatment of insomnia. We performed a ',\n",
       "     'offsetInBeginSection': 115,\n",
       "     'offsetInEndSection': 265,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31953863',\n",
       "     'text': 'erse events.\\n\\n\\nINTERPRETATION\\nDaridorexant induced a dose-dependent reduction in wake time after sleep onset in subjects with insomnia disorder (Clini',\n",
       "     'offsetInBeginSection': 1561,\n",
       "     'offsetInEndSection': 1711,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36045942',\n",
       "     'text': 'ary\\nIn this article, we review the most recent data on insomnia treatments and summarize the safety and efficacy of daridorexant in treating insomnia.',\n",
       "     'offsetInBeginSection': 1074,\n",
       "     'offsetInEndSection': 1224,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32134851',\n",
       "     'text': 'lf-life were similar. Daridorexant dose-dependently reduced vigilance, attention, visuomotor coordination, and postural stability. Pharmacokinetic eff',\n",
       "     'offsetInBeginSection': 1219,\n",
       "     'offsetInEndSection': 1369,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36046352',\n",
       "     'text': 'Objective: To review the safety, efficacy, and tolerability of daridorexant in treating insomnia characterized by difficulties with sleep onset and/or',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34098518',\n",
       "     'text': 'y driven by the expected central nervous system effects of daridorexant. Doses up to 50\\xa0mg daridorexant can be safely co-administered with citalopram.',\n",
       "     'offsetInBeginSection': 1656,\n",
       "     'offsetInEndSection': 1806,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36046352',\n",
       "     'text': ' agents used to treat insomnia. In addition, daridorexant appears to be as safe and effective in treating insomnia in patients of all ages including t',\n",
       "     'offsetInBeginSection': 1358,\n",
       "     'offsetInEndSection': 1508,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36366844',\n",
       "     'text': 'anagement of insomnia. Beyond the effectiveness in insomnia, it has been successfully used in patients suffering from Obstructive sleep apnoea, Chroni',\n",
       "     'offsetInBeginSection': 891,\n",
       "     'offsetInEndSection': 1041,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34415378',\n",
       "     'text': 'w DORA that exhibited in phase 3 trials in insomnia not only a beneficial effect on sleep variables, measured objectively and assessed subjectively, b',\n",
       "     'offsetInBeginSection': 232,\n",
       "     'offsetInEndSection': 382,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/31953863',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36144776',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32134851',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34331678',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34098518',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33305817',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35306405',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34415378',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36046352',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34121345',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35843245',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32937014',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32603512',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35065036',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36045942',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36366844',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36054921',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36473030',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32778207',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36098753',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32341187']},\n",
       "  {'id': '6422ee03690f196b51000046',\n",
       "   'type': 'factoid',\n",
       "   'body': 'What cells produce erythroferrone?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31723763',\n",
       "     'text': '. Here the hormone erythroferrone, produced by erythroblasts, acts on hepatocytes to suppress hepcidin production, and thereby increase dietary iron a',\n",
       "     'offsetInBeginSection': 823,\n",
       "     'offsetInEndSection': 973,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30097509',\n",
       "     'text': 'ia. Erythropoietin (EPO) enhances erythroferrone (ERFE) synthesis by erythroblasts, and ERFE suppresses hepatic hepcidin production through an unknown',\n",
       "     'offsetInBeginSection': 113,\n",
       "     'offsetInEndSection': 263,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28739636',\n",
       "     'text': 'Erythroferrone (ERFE) is a glycoprotein hormone secreted by erythroblasts in response to stimulation by erythropoietin (EPO). We previously demonstrat',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35464433',\n",
       "     'text': 'throferrone is a recently identified erythroid regulator produced by erythroblasts in the mammalian bone marrow and extramedullary sites, known to be ',\n",
       "     'offsetInBeginSection': 3,\n",
       "     'offsetInEndSection': 153,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24880340',\n",
       "     'text': 'pcidin suppression during stress erythropoiesis. ERFE is produced by erythroblasts in response to erythropoietin. ERFE-deficient mice fail to suppress',\n",
       "     'offsetInBeginSection': 305,\n",
       "     'offsetInEndSection': 455,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28629515',\n",
       "     'text': 'g erythropoiesis with liver hepcidin suppression, erythroferrone, a hormone produced and secreted by erythroid precursors, appears the best candidate.',\n",
       "     'offsetInBeginSection': 1089,\n",
       "     'offsetInEndSection': 1239,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35628152',\n",
       "     'text': 'd blood cells. Erythroferrone, a factor produced and secreted by erythroid precursors in response to erythropoietin, has been identified and character',\n",
       "     'offsetInBeginSection': 879,\n",
       "     'offsetInEndSection': 1029,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31846624',\n",
       "     'text': ' blood islands where initial erythropoiesis occurs and later in circulating blood cells. ERFE knockdown does not alter the expression of etv.2, aplnr ',\n",
       "     'offsetInBeginSection': 624,\n",
       "     'offsetInEndSection': 774,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31808893',\n",
       "     'text': 'epcidin regulation by erythropoiesis is attributed in large part to a bone marrow-derived hormone erythroferrone. Erythroferrone-induced hepcidin supp',\n",
       "     'offsetInBeginSection': 508,\n",
       "     'offsetInEndSection': 658,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26494918',\n",
       "     'text': 'In this issue of Blood, Kautz et al show that the ablation of the erythroid-derived factor erythroferrone (ERFE), which has been shown to be highly ex',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34827208',\n",
       "     'text': 'Intense physical activity contributes to an increased demand for red blood cells, which transport oxygen to working muscles. The purpose of this study',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28438754',\n",
       "     'text': '6 in primary hepatocyte cultures. Epoetin alfa (EPO) robustly induced bone marrow erythroferrone (Fam132b) mRNA in control and Smad1;Smad5;Cre mice bu',\n",
       "     'offsetInBeginSection': 1194,\n",
       "     'offsetInEndSection': 1344,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31649559',\n",
       "     'text': 're the release of erythroferrone from the expanded pool of immature erythroid cells results in hepcidin suppression and secondary iron overload that i',\n",
       "     'offsetInBeginSection': 1761,\n",
       "     'offsetInEndSection': 1911,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33372284',\n",
       "     'text': ' of erythropoietin from the kidney stimulates the production of new red blood cells, it also increases the synthesis of ERFE in bone marrow erythrobla',\n",
       "     'offsetInBeginSection': 159,\n",
       "     'offsetInEndSection': 309,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30232784',\n",
       "     'text': ' erythroblasts. In CKD mice, levels of erythroferrone mRNA in BM and splenic cells were significantly decreased, and MafB protein levels in BM cells w',\n",
       "     'offsetInBeginSection': 658,\n",
       "     'offsetInEndSection': 808,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/31649559',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/30232784',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/28739636',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/24880340',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33372284',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/31723763',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/28629515',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/31808893',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/28438754',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35628152',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/26494918',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35464433',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34827208',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/30097509',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/31846624']},\n",
       "  {'id': '6429f86657b1c7a31500000d',\n",
       "   'type': 'summary',\n",
       "   'body': 'What is the role of the Mediator in gene expression?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/10611325',\n",
       "     'text': 'refore, the gene-specific function of Mediator as an integrator of transcriptional regulatory signals is evolutionarily conserved and is essential for',\n",
       "     'offsetInBeginSection': 774,\n",
       "     'offsetInEndSection': 924,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21854862',\n",
       "     'text': 'The Mediator complex serves a crucial function in gene regulation, forming a link between gene-specific transcription factors and RNA polymerase II. M',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/10611325',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/21854862']},\n",
       "  {'id': '6415c0df690f196b51000010',\n",
       "   'type': 'factoid',\n",
       "   'body': 'What does FBDD stand for?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34348623',\n",
       "     'text': 'Fragment-Based Drug Discovery (FBDD) is a strategy to develop potent lead molecules and is frequently used in drug discovery projects of the pharmaceu',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25420726',\n",
       "     'text': 'Fragment-based drug discovery (FBDD) has caused a revolution in the process of drug discovery and design, with many FBDD leads being developed into cl',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32339336',\n",
       "     'text': 'Fragment-based drug discovery (FBDD) has become an established approach for the generation of early lead candidates. However, despite its success and ',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22459076',\n",
       "     'text': 'Fragment-based drug discovery (FBDD) has become established in both industry and academia as an alternative approach to high-throughput screening for ',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32133344',\n",
       "     'text': 'Fragment-based drug (or lead) discovery (FBDD or FBLD) has developed in the last two decades to become a successful key technology in the pharmaceutic',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32850968',\n",
       "     'text': 'Fragment-based drug discovery (FBDD) is a powerful method to develop potent small-molecule compounds starting from fragments binding weakly to targets',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20190516',\n",
       "     'text': 'Fragment-Based Drug Discovery (FBDD) has been recognized as a newly emerging lead discovery methodology that involves biophysical fragment screening a',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32592867',\n",
       "     'text': 'Fragment-based drug discovery (FBDD) is an innovative approach, progressively more applied in the academic and industrial context, to enhance hit iden',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22827744',\n",
       "     'text': 'der is introduced to various computational methods that are used for in silico FBDD, the fragment library composition for this technique, special appl',\n",
       "     'offsetInBeginSection': 631,\n",
       "     'offsetInEndSection': 781,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27124799',\n",
       "     'text': 'Fragment-based drug discovery (FBDD) is well suited for discovering both drug leads and chemical probes of protein function; it can cover broad swaths',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21371601',\n",
       "     'text': 'Fragment-based drug discovery (FBDD) has become increasingly popular over the last decade as an alternate lead generation tool to HTS approaches. Seve',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18510103',\n",
       "     'text': 'Fragment-based drug discovery (FBDD) is established as an alternative approach to high-throughput screening for generating novel small molecule drug c',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28240184',\n",
       "     'text': 'Fragment-based drug discovery (FBDD) is a broadly used strategy in structure-guided ligand design, whereby low-molecular weight hits move from lead-li',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/32133344',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/25420726',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/20190516',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32850968',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/28240184',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/22459076',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32339336',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/27124799',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/22827744',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/21371601',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34348623',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/18510103',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32592867']},\n",
       "  {'id': '64041dae201352f04a00001d',\n",
       "   'type': 'yesno',\n",
       "   'body': 'Is deucravacitinib effective for psoriasis?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34239295',\n",
       "     'text': ' well as oral small molecules, such as deucravacitinib, a tyrosine kinase 2 selective inhibitor, and piclidenoson, an agonist of the Gi protein-associ',\n",
       "     'offsetInBeginSection': 1347,\n",
       "     'offsetInEndSection': 1497,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36115523',\n",
       "     'text': 'vs 8.6% and 33.9%; P < 0.0001 for both). Efficacy was maintained until Week 52 with continuous deucravacitinib. The most frequent adverse event (AE) w',\n",
       "     'offsetInBeginSection': 832,\n",
       "     'offsetInEndSection': 982,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35820547',\n",
       "     'text': ' oral psoriasis treatments are needed.\\n\\n\\nOBJECTIVE\\nTo compare the efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibit',\n",
       "     'offsetInBeginSection': 36,\n",
       "     'offsetInEndSection': 186,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35960487',\n",
       "     'text': 'so reported by patients, with greater impact on itch. Deucravacitinib was well tolerated and safe. There were no reports of serious infections, thromb',\n",
       "     'offsetInBeginSection': 1115,\n",
       "     'offsetInEndSection': 1265,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36469536',\n",
       "     'text': \"sician's Global Assessment (sPGA) 0/1. Deucravacitinib was generally well tolerated and safe compared to placebo and apremilast. Although deucravaciti\",\n",
       "     'offsetInBeginSection': 582,\n",
       "     'offsetInEndSection': 732,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35241426',\n",
       "     'text': 'OBJECTIVE\\nTo evaluate the efficacy and safety of an oral selective tyrosine kinase 2 (TYK2) inhibitor, deucravacitinib, in patients with active psoria',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34767869',\n",
       "     'text': 'of deucravacitinib versus lower doses or placebo.\\n\\n\\nCONCLUSION\\nRobust clinical efficacy with deucravacitinib treatment was associated with decreases i',\n",
       "     'offsetInBeginSection': 1563,\n",
       "     'offsetInEndSection': 1713,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35820547',\n",
       "     'text': 'SION\\nDeucravacitinib was superior to placebo and apremilast across multiple efficacy endpoints and was well tolerated in moderate to severe psoriasis.',\n",
       "     'offsetInBeginSection': 1197,\n",
       "     'offsetInEndSection': 1347,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35820547',\n",
       "     'text': 'and sPGA 0/1 (178 [53.6%] vs 12 [7.2%] vs 54 [32.1%]; P < 0.0001). Efficacy improved beyond Week 16 and was maintained through Week 52. Adverse event ',\n",
       "     'offsetInBeginSection': 902,\n",
       "     'offsetInEndSection': 1052,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34471993',\n",
       "     'text': 's the closely related Janus kinases (JAKs) 1/2/3. Deucravacitinib was efficacious in phase 2 and 3 psoriasis trials, without clinical or laboratory pa',\n",
       "     'offsetInBeginSection': 286,\n",
       "     'offsetInEndSection': 436,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36115523',\n",
       "     'text': 'SION\\nDeucravacitinib demonstrated superiority versus placebo and apremilast and was well tolerated in adults with moderate to severe plaque psoriasis.',\n",
       "     'offsetInBeginSection': 1206,\n",
       "     'offsetInEndSection': 1356,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35747941',\n",
       "     'text': ' It is unclear whether recent safety concerns (ie, elevated rates of lung cancer and lymphoma) related to similar medications (ie, other JAK inhibitors) are shared with this novel TYK2 inhibitor',\n",
       "     'offsetInBeginSection': 152,\n",
       "     'offsetInEndSection': 346,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35280877',\n",
       "     'text': 'groups.\\n\\n\\nConclusion\\nThere is increasing evidence on the use of drugs targeting the JAK/STAT pathway as a treatment for psoriasis, although they are i',\n",
       "     'offsetInBeginSection': 2920,\n",
       "     'offsetInEndSection': 3070,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36373503',\n",
       "     'text': 'rather than other members of this kinase family. Deucravacitinib has demonstrated safety and efficacy in moderate to severe plaque psoriasis in clinic',\n",
       "     'offsetInBeginSection': 637,\n",
       "     'offsetInEndSection': 787,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35280877',\n",
       "     'text': 'funding or by those related to them. Only tofacitinib and deucravacitinib have undergone phase III clinical trials, being the only ones tested with ac',\n",
       "     'offsetInBeginSection': 1847,\n",
       "     'offsetInEndSection': 1997,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36453809',\n",
       "     'text': ' deucravacitinib, a new oral drug which selectively inhibits TYK2, granting it a low risk of off-target effects. Two phase 3, 52-week trials evaluated',\n",
       "     'offsetInBeginSection': 465,\n",
       "     'offsetInEndSection': 615,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35025062',\n",
       "     'text': ' an oral, selective tyrosine kinase 2 inhibitor that demonstrated therapeutic benefit in a Phase 2 clinical trial of adults with moderate to severe pl',\n",
       "     'offsetInBeginSection': 31,\n",
       "     'offsetInEndSection': 181,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36115523',\n",
       "     'text': 'tinib, an oral, selective tyrosine kinase 2 (TYK2) inhibitor, inhibits cytokine signaling in psoriasis pathogenesis.\\n\\n\\nOBJECTIVE\\nDemonstrate deucravac',\n",
       "     'offsetInBeginSection': 21,\n",
       "     'offsetInEndSection': 171,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36401743',\n",
       "     'text': ' The Marketing Authorisation Application for deucravacitinib for the treatment of adults with moderate to severe plaque psoriasis has been validated in the EU',\n",
       "     'offsetInBeginSection': 852,\n",
       "     'offsetInEndSection': 1010,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15090021',\n",
       "     'text': 'tion was not evident at the early stages.\\n\\n\\nCONCLUSION\\nInfliximab is not only an effective agent in the treatment of psoriasis but appears to have a v',\n",
       "     'offsetInBeginSection': 906,\n",
       "     'offsetInEndSection': 1056,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36325947',\n",
       "     'text': \"h favorable PK and safety profiles. Deucravacitinib is a promising therapeutic option for immune-mediated diseases, including Crohn's disease, psorias\",\n",
       "     'offsetInBeginSection': 995,\n",
       "     'offsetInEndSection': 1145,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34224773',\n",
       "     'text': 'n receptors. Deucravacitinib, which is an oral, selective inhibitor that binds to the regulatory domain of TYK2, and brepocitinib (PF-06700841) and PF',\n",
       "     'offsetInBeginSection': 762,\n",
       "     'offsetInEndSection': 912,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35566756',\n",
       "     'text': 'aque psoriasis. However, little evidence is available on the use of this biologic in psoriasis in difficult-to-treat locations. In this retrospective ',\n",
       "     'offsetInBeginSection': 109,\n",
       "     'offsetInEndSection': 259,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35960487',\n",
       "     'text': 'nowledge on deucravacitinib, a new oral drug that selectively inhibits TYK2, granting it a low risk of off-target effects. After good efficacy and saf',\n",
       "     'offsetInBeginSection': 369,\n",
       "     'offsetInEndSection': 519,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34767869',\n",
       "     'text': 'ective tyrosine kinase 2 (TYK2) inhibitor, blocks IL-23, IL-12, and type I IFN signaling in cellular assays.\\n\\n\\nOBJECTIVE\\nWe investigated changes in IL',\n",
       "     'offsetInBeginSection': 210,\n",
       "     'offsetInEndSection': 360,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23515267',\n",
       "     'text': ' life as well as comorbidities. Newer biological agents have been shown to be more effective than traditional therapies. In this article, we assess th',\n",
       "     'offsetInBeginSection': 193,\n",
       "     'offsetInEndSection': 343,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/36453809',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35820547',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35747941',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/23515267',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34471993',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36325947',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35566756',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36401743',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36373503',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35025062',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36469536',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35280877',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34767869',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34224773',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36115523',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34239295',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35960487',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/15090021',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35241426']},\n",
       "  {'id': '6415b6eb690f196b5100000b',\n",
       "   'type': 'list',\n",
       "   'body': 'What processes do orexin/hypocretin neurons regulate?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34052808',\n",
       "     'text': 'optogenetic studies show that orexin neurons regulate self-generated and sensory-evoked movement on rapid, subsecond timescales. Orexin cell activity ',\n",
       "     'offsetInBeginSection': 282,\n",
       "     'offsetInEndSection': 432,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16054072',\n",
       "     'text': ' have emerged as instrumental in triggering arousal and regulating energy metabolism. The lack of hypocretin signaling is the cause of narcolepsy whil',\n",
       "     'offsetInBeginSection': 64,\n",
       "     'offsetInEndSection': 214,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/11532254',\n",
       "     'text': 'nal cord. This peptide is believed to be involved in regulating feeding and wakefulness. However, to fully understand what other behaviors are regulat',\n",
       "     'offsetInBeginSection': 254,\n",
       "     'offsetInEndSection': 404,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20307612',\n",
       "     'text': 'is a critical regulator of physiological processes including sleep/wakefulness and feeding. Using organotypic slice culture of rat hypothalamus, we fo',\n",
       "     'offsetInBeginSection': 48,\n",
       "     'offsetInEndSection': 198,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/10624957',\n",
       "     'text': 'Orexin (hypocretin) appears to play a role in the regulation of energy balances. Previous reports have indicated that orexin-containing neurons are fo',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12495630',\n",
       "     'text': 'Neurons that release hypocretin/orexin modulate sleep, arousal, and energy homeostasis; the absence of hypocretin results in narcolepsy. Here we prese',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22813966',\n",
       "     'text': 'hrough interactions with neuronal systems that regulate emotion, reward, and energy homeostasis. Here, we briefly summarize the progress of orexin/hyp',\n",
       "     'offsetInBeginSection': 437,\n",
       "     'offsetInEndSection': 587,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32135427',\n",
       "     'text': ' to orchestrate diverse functions including sleep, reward processing, food intake, thermogenesis, and mood. Since the hypocretins/orexins were discove',\n",
       "     'offsetInBeginSection': 97,\n",
       "     'offsetInEndSection': 247,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20861370',\n",
       "     'text': 'ons (hypocretin neurons) have a critical role in the regulation of sleep/wakefulness, especially in the maintenance of arousal. Here, we revealed that',\n",
       "     'offsetInBeginSection': 11,\n",
       "     'offsetInEndSection': 161,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28025809',\n",
       "     'text': 'ntral nervous system to control sleep and arousal, circadian rhythms, metabolism, reward pathways, and other behaviors. Dysfunction of orexin/hypocret',\n",
       "     'offsetInBeginSection': 298,\n",
       "     'offsetInEndSection': 448,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30348769',\n",
       "     'text': 'in the hypothalamus play an essential role in sleep-wake control, feeding, reward, and energy homeostasis. The likelihood of anesthesia and sleep shar',\n",
       "     'offsetInBeginSection': 42,\n",
       "     'offsetInEndSection': 192,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20467915',\n",
       "     'text': 'ulated by various factors involved in regulation of energy homeostasis and sleep/wakefulness states. Bombesin receptor subtype 3 (BRS3) is an orphan r',\n",
       "     'offsetInBeginSection': 265,\n",
       "     'offsetInEndSection': 415,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26724374',\n",
       "     'text': ' are two neuropeptides that influence many behaviours, such as feeding, sleep or arousal. Orexin A/hypocretin-1 (OXA) and orexin B/hypocretin-2 (OXB) ',\n",
       "     'offsetInBeginSection': 19,\n",
       "     'offsetInEndSection': 169,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/10191330',\n",
       "     'text': 's and has been reported to increase food intake and regulate the neuroendocrine system. In the present paper, long descending axonal projections that ',\n",
       "     'offsetInBeginSection': 72,\n",
       "     'offsetInEndSection': 222,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32804153',\n",
       "     'text': 'nance of arousal and contribute to the regulation of multiple homeostatic and behavioral processes. In this issue of the JCI, Tan and Hang et al. repo',\n",
       "     'offsetInBeginSection': 96,\n",
       "     'offsetInEndSection': 246,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/9920670',\n",
       "     'text': 'nism of action for hypocretin in the central regulation of metabolic and endocrine processes. The excitatory actions of hypocretin could increase NPY ',\n",
       "     'offsetInBeginSection': 593,\n",
       "     'offsetInEndSection': 743,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15848807',\n",
       "     'text': 'pulation of orexin neurons. These neuroanatomical findings provide important insights into the neural pathways that regulate sleep/wakefulness states.',\n",
       "     'offsetInBeginSection': 998,\n",
       "     'offsetInEndSection': 1148,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22256611',\n",
       "     'text': ' has close interactions with systems that regulate emotion, energy homeostasis, reward, and arousal. These observations suggest that orexin neurons ar',\n",
       "     'offsetInBeginSection': 543,\n",
       "     'offsetInEndSection': 693,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12946712',\n",
       "     'text': 'Hypocretin/orexin modulates sleep-wake state via actions across multiple terminal fields. Within waking, hypocretin may also participate in high-arous',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21056546',\n",
       "     'text': 'exin) neuropeptide system coordinates the regulation of various physiological processes. A reduction in Nr6a1 expression was observed in hypocretin ne',\n",
       "     'offsetInBeginSection': 32,\n",
       "     'offsetInEndSection': 182,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36457878',\n",
       "     'text': ' have demonstrated that orexins may regulate different forms of affective and cognitive processes during wakefulness. The Orbitofrontal Cortex (OFC) a',\n",
       "     'offsetInBeginSection': 42,\n",
       "     'offsetInEndSection': 192,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36457878',\n",
       "     'text': 'l hypothalamus (LH) in driving the reward pathway, sleep and awake circuits, decision making and psychotic disorders. But our knowledge towards the fu',\n",
       "     'offsetInBeginSection': 1927,\n",
       "     'offsetInEndSection': 2077,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28620314',\n",
       "     'text': ' orexinergic neurons show connections to regions involved in cognition and mood regulation, including hippocampus. Orexins enhance hippocampal neuroge',\n",
       "     'offsetInBeginSection': 1252,\n",
       "     'offsetInEndSection': 1402,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15978010',\n",
       "     'text': 'FA) innervate midbrain dopamine (DA) neurons that project to corticolimbic sites and subserve psychostimulant-induced locomotor activity. However, it ',\n",
       "     'offsetInBeginSection': 90,\n",
       "     'offsetInEndSection': 240,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/11330208',\n",
       "     'text': 'ng neurons of the lateral hypothalamus are involved in control of REM sleep phenomena, but site-specific actions in control of wakefulness have been l',\n",
       "     'offsetInBeginSection': 57,\n",
       "     'offsetInEndSection': 207,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16364191',\n",
       "     'text': 'duced wakefulness. Hypocretin/orexin neurons may thus directly translate rises and falls in body energy levels into different states of consciousness.',\n",
       "     'offsetInBeginSection': 873,\n",
       "     'offsetInEndSection': 1023,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28620314',\n",
       "     'text': 'tal body functions, including sleep/wake states, feeding behavior, energy homeostasis, reward systems, cognition and mood. Furthermore, a dysfunction ',\n",
       "     'offsetInBeginSection': 368,\n",
       "     'offsetInEndSection': 518,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26322330',\n",
       "     'text': 'Hypocretin/orexin neurons regulate many behavioral functions, including addiction. Nicotine acts through nicotinic acetylcholine receptors (nAChRs) to',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15848807',\n",
       "     'text': 's hypothalamic neuropeptide plays a crucial role in regulating sleep/wakefulness states. However, very little is known about the synaptic input of ore',\n",
       "     'offsetInBeginSection': 84,\n",
       "     'offsetInEndSection': 234,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16904760',\n",
       "     'text': 'reward processing and addiction. We propose that the current evidence indicates a dichotomy in orexin function, such that orexin neurons in the lateral hypothalamus regulate reward processing for both food and abused drugs',\n",
       "     'offsetInBeginSection': 375,\n",
       "     'offsetInEndSection': 597,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/20861370',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36457878',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/26724374',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/11532254',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/10624957',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/26322330',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/15848807',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/20307612',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/12946712',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/22813966',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/12495630',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/22256611',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32135427',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34052808',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/15978010',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/20467915',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/28620314',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/16364191',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/16054072',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32804153',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/9920670',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/11330208',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/10191330',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/16904760',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/28025809',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/30348769',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/21056546']},\n",
       "  {'id': '6428da47690f196b51000051',\n",
       "   'type': 'yesno',\n",
       "   'body': 'Can the epigenetic status of introns affect gene expression?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18319396',\n",
       "     'text': 'have been found in a wide range of eukaryotes. However, not all introns affect gene expression, and direct testing is currently the only way to identi',\n",
       "     'offsetInBeginSection': 39,\n",
       "     'offsetInEndSection': 189,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24213601',\n",
       "     'text': 'Epigenetic modifications affect gene expression and thereby govern a wide range of biological processes such as differentiation, development and tumor',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32187179',\n",
       "     'text': 'n, and their contributions to genetic diversity and evolution, remain poorly understood. In this study, we investigated the genome-wide distribution o',\n",
       "     'offsetInBeginSection': 369,\n",
       "     'offsetInEndSection': 519,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15673716',\n",
       "     'text': 'and exons of human genes is shown here to negatively correlate with among-tissues breadth of gene expression. The nucleosome formation potential is al',\n",
       "     'offsetInBeginSection': 66,\n",
       "     'offsetInEndSection': 216,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31235724',\n",
       "     'text': 'Introns can increase gene expression levels using a variety of mechanisms collectively referred to as Intron Mediated Enhancement (IME). IME has been ',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22645558',\n",
       "     'text': 'xist in the transcribed DNA and the nascent RNA, and could affect expression from either location. To determine which is more relevant to IME, hybrid ',\n",
       "     'offsetInBeginSection': 121,\n",
       "     'offsetInEndSection': 271,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24455281',\n",
       "     'text': 'Epigenetic modifications can affect the long-term gene expression without any change in nucleotide sequence of the DNA. Epigenetic processes intervene',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18287520',\n",
       "     'text': ' yeast only 283 of the 6000 genes contain introns and their impact on cell function is not clear. To assess the contribution of introns to cell functi',\n",
       "     'offsetInBeginSection': 107,\n",
       "     'offsetInEndSection': 257,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23593031',\n",
       "     'text': 'Epigenetic variation, such as heritable changes of DNA methylation, can affect gene expression and thus phenotypes, but examples of natural epimutatio',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30010918',\n",
       "     'text': 'uch the same way as intergenic TEs, they are targeted by repressive epigenetic marks for transcriptional silencing. Silenced intragenic TEs generally ',\n",
       "     'offsetInBeginSection': 217,\n",
       "     'offsetInEndSection': 367,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30792737',\n",
       "     'text': 'ractical applications such as gene therapy because they strongly activate expression but only affect the transcription unit in which they are located.',\n",
       "     'offsetInBeginSection': 1249,\n",
       "     'offsetInEndSection': 1399,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28673892',\n",
       "     'text': 'karyotes, including mammals, plants, yeast, and insects, introns can increase gene expression without functioning as a binding site for transcription ',\n",
       "     'offsetInBeginSection': 10,\n",
       "     'offsetInEndSection': 160,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32988986',\n",
       "     'text': ' show that alternative transposition events are not only able to induce genome rearrangements, but also generate CIs that can control gene expression.',\n",
       "     'offsetInBeginSection': 1735,\n",
       "     'offsetInEndSection': 1885,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12702819',\n",
       "     'text': 'ver, the extent to which each of these steps contributes to the overall effect of any one intron on gene expression has not been rigorously tested. He',\n",
       "     'offsetInBeginSection': 371,\n",
       "     'offsetInEndSection': 521,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/24455281',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/18287520',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32187179',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/30010918',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/28673892',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/31235724',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32988986',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/23593031',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/12702819',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/22645558',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/15673716',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/18319396',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/30792737',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/24213601']},\n",
       "  {'id': '6415c5d4690f196b51000014',\n",
       "   'type': 'list',\n",
       "   'body': 'What was Keytruda originally approved for by the FDA?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29209918',\n",
       "     'text': 'ons in the body. FDA previously approved Keytruda for treatment of several types of malignancies, such as metastatic melanoma, metastatic non-small-ce',\n",
       "     'offsetInBeginSection': 318,\n",
       "     'offsetInEndSection': 468,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34647523',\n",
       "     'text': \" Drug Administration (FDA) for use in pediatric patients with relapsed or refractory classical Hodgkin's lymphoma. However, there is currently no publ\",\n",
       "     'offsetInBeginSection': 218,\n",
       "     'offsetInEndSection': 368,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28835513',\n",
       "     'text': 'rug Administration approval of a checkpoint inhibitor for first-line treatment of lung cancer. This approval expands the pembrolizumab indication in s',\n",
       "     'offsetInBeginSection': 1937,\n",
       "     'offsetInEndSection': 2087,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34156377',\n",
       "     'text': 'Keytruda) has been approved to treat metastatic or locally advanced esophageal or gastroesophageal junction cancer. It is used in combination with pla',\n",
       "     'offsetInBeginSection': 15,\n",
       "     'offsetInEndSection': 165,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17280539',\n",
       "     'text': ' permitted the FDA to approve devices for bridging patients in end-stage cardiac failure awaiting transplant and eventually a device for destination t',\n",
       "     'offsetInBeginSection': 896,\n",
       "     'offsetInEndSection': 1046,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32645193',\n",
       "     'text': 'eytruda) for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with ca',\n",
       "     'offsetInBeginSection': 33,\n",
       "     'offsetInEndSection': 183,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12179363',\n",
       "     'text': 'd expand contraceptive options.  The fact that this IUD is approved for 6 years makes it an even more attractive option for women choosing a contracep',\n",
       "     'offsetInBeginSection': 1071,\n",
       "     'offsetInEndSection': 1221,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28235882',\n",
       "     'text': 'ery 3 weeks by intravenous infusion for the treatment of patients with unresectable or metastatic melanoma who have progressed following treatment wit',\n",
       "     'offsetInBeginSection': 128,\n",
       "     'offsetInEndSection': 278,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/34647523',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/29209918',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/12179363',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32645193',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/17280539',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/28835513',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34156377',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/28235882']},\n",
       "  {'id': '63f5713733942b094c000003',\n",
       "   'type': 'summary',\n",
       "   'body': 'What are clinical features of the Achard-Thiers syndrome?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/1201353',\n",
       "     'text': 'e is a well-defined clinical entity consisting of widespread dysostoses and increased ligament laxity. The bony involvement appears most consistently ',\n",
       "     'offsetInBeginSection': 18,\n",
       "     'offsetInEndSection': 168,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/518037',\n",
       "     'text': 'The clinical and neuroradiological features in 4 patients with the syndrome of aberrant regeneration of the third nerve are presented. In contrast to ',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/10560599',\n",
       "     'text': 'ile other manifestations, including clinical features, CSF pressures, and imaging abnormalities, are variables dependent on the CSF volume. The term C',\n",
       "     'offsetInBeginSection': 1260,\n",
       "     'offsetInEndSection': 1410,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/10560599',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/518037',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/1201353']},\n",
       "  {'id': '642d4c9b57b1c7a315000013',\n",
       "   'type': 'yesno',\n",
       "   'body': 'Are Luminopsins a fusion proteins of luminol and Rhodopsin ?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26733686',\n",
       "     'text': 'Luminopsins are fusion proteins of luciferase and opsin that allow interrogation of neuronal circuits at different temporal and spatial resolutions by',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/26733686']},\n",
       "  {'id': '6429fe4e57b1c7a31500000f',\n",
       "   'type': 'summary',\n",
       "   'body': 'What are coactivators?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/9806345',\n",
       "     'text': 'ent and indicates a dual role for coactivators as bridging factors and chromatin remodeling proteins. The opposites of coactivators are corepressors, ',\n",
       "     'offsetInBeginSection': 879,\n",
       "     'offsetInEndSection': 1029,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19843848',\n",
       "     'text': 'Coregulators (coactivators and corepressors) occupy the driving seat for actions of all nuclear receptors, and consequently, selective receptor modula',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/11893487',\n",
       "     'text': 'Coactivators are diverse and multifunctional proteins that act downstream of DNA-binding activators to stimulate transcription. Recent studies elucida',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17476305',\n",
       "     'text': 'development and physiology. These coactivators are nuclear proteins and transcription co-regulators that function to facilitate the transcription init',\n",
       "     'offsetInBeginSection': 70,\n",
       "     'offsetInEndSection': 220,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26201947',\n",
       "     'text': 'ogen-sensitive and -insensitive prostate cancer cells. Coactivators p300 and SRC-1 are required for AR activation by interleukin-6 (IL-6), a cytokine ',\n",
       "     'offsetInBeginSection': 1188,\n",
       "     'offsetInEndSection': 1338,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/14690606',\n",
       "     'text': '160, p300, and CARM1 coactivators. We identified a coactivator, coiled-coil coactivator (CoCoA), which binds to this domain and thereby enhances trans',\n",
       "     'offsetInBeginSection': 413,\n",
       "     'offsetInEndSection': 563,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12376547',\n",
       "     'text': 'Coactivators such as TIF2 and SRC-1 modulate the positioning of the dose-response curve for agonist-bound glucocorticoid receptors (GRs) and the parti',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17244199',\n",
       "     'text': 'relevant brain regions coexpress nuclear receptor coactivators and steroid receptors. Confocal analysis revealed that in oestrogen-primed rats, most o',\n",
       "     'offsetInBeginSection': 1159,\n",
       "     'offsetInEndSection': 1309,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16604175',\n",
       "     'text': 'ucible transcription factors requiring coactivators such as members of the SRC/p160 family to modulate the transcription of their target genes. This p',\n",
       "     'offsetInBeginSection': 34,\n",
       "     'offsetInEndSection': 184,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/14690606',\n",
       "     'text': 'ARM1 coactivators. We identified a coactivator, coiled-coil coactivator (CoCoA), which binds to this domain and thereby enhances transcriptional activ',\n",
       "     'offsetInBeginSection': 429,\n",
       "     'offsetInEndSection': 579,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/11108858',\n",
       "     'text': 'ivation. Coactivators are a diverse group of molecules that bring multiple structural and enzymatic functions to the promoter. The existence of coacti',\n",
       "     'offsetInBeginSection': 278,\n",
       "     'offsetInEndSection': 428,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28607951',\n",
       "     'text': 'As coordinators of energy demands and nutritional supplies, the PGC-1 family of transcriptional coactivators regulates mitochondrial biogenesis to con',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26201947',\n",
       "     'text': ' treatment. AR coactivators are proteins which interact with one or more regions of the AR thus enhancing its function. Although several functions of ',\n",
       "     'offsetInBeginSection': 447,\n",
       "     'offsetInEndSection': 597,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21664237',\n",
       "     'text': 'Coactivators are a diverse group of non-DNA binding proteins that induce structural changes in agonist-bound nuclear receptors (NRs) that are essentia',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25024406',\n",
       "     'text': 'Transcriptional coactivators have evolved as an important new class of functional proteins that participate with virtually all transcription factors a',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19019695',\n",
       "     'text': 'Nuclear receptor (NR) coactivators are recruited to DNA by NRs, potentiating NR-dependent gene transcription. To obtain the complexity of NR-mediated ',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29786798',\n",
       "     'text': 'vators is frequently reported in prostate cancer. Coactivators such as p300/CBP are involved in modulation of androgen receptor activity by increasing',\n",
       "     'offsetInBeginSection': 51,\n",
       "     'offsetInEndSection': 201,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27654711',\n",
       "     'text': 'tors represent a large class of proteins that partner with nuclear receptors and other transcription factors to regulate gene expression. Given their ',\n",
       "     'offsetInBeginSection': 8,\n",
       "     'offsetInEndSection': 158,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16189181',\n",
       "     'text': ' and epididymis.\\n\\n\\nMETHODS\\nWe determined the localization of these three p160 coactivators in immature and mature rat testis, and epididymis by immuno',\n",
       "     'offsetInBeginSection': 506,\n",
       "     'offsetInEndSection': 656,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/14766010',\n",
       "     'text': 'The p160 coactivators, steroid receptor coactivator-1 (SRC-1), transcriptional intermediary factor-2 (TIF2) and receptor-associated coactivator-3 (RAC',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17046230',\n",
       "     'text': 'Transcriptional coactivators enhance gene expression by associating with sequence-specific transcription factors and serve as the primary targets of d',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/8571454',\n",
       "     'text': 'Coactivators are a novel class of transcriptional activator required at many eukaryotic promoters. Several coactivators have now been isolated, their ',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26201947',\n",
       "     'text': ' redundant, specific functions have been identified and analyzed. The p160 group of coactivators, SRC-1, -2, and -3 not only potentiate the activation',\n",
       "     'offsetInBeginSection': 619,\n",
       "     'offsetInEndSection': 769,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17244199',\n",
       "     'text': 'two of these nuclear receptor coactivators, steroid receptor coactivator-1 (SRC-1) and CREB-binding protein (CBP), are important in ER-mediated induct',\n",
       "     'offsetInBeginSection': 642,\n",
       "     'offsetInEndSection': 792,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/10454563',\n",
       "     'text': 'al end of p160 coactivators. C-terminal coactivator fragments lacking AD1 but containing AD2 and the AR AF-1 binding site served as efficient coactiva',\n",
       "     'offsetInBeginSection': 1188,\n",
       "     'offsetInEndSection': 1338,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12039076',\n",
       "     'text': 'and CREB-binding protein (CBP). Since coactivators function as transcription amplifiers, subtle changes in expression levels of coactivators in certai',\n",
       "     'offsetInBeginSection': 341,\n",
       "     'offsetInEndSection': 491,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15814849',\n",
       "     'text': 'e coactivators are differentially used by transcription factors, including NRs, in a cell/tissue type- and promoter-specific manner. However, the mole',\n",
       "     'offsetInBeginSection': 298,\n",
       "     'offsetInEndSection': 448,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17018837',\n",
       "     'text': ' transcriptional coactivators coordinate the overall regulation of the biological programs. One of the best-studied examples of coactivator control of metabolic pathways is the peroxisome proliferator-activated receptor coactivator 1 (PGC-1) family. These proteins are strong activators of mitochondrial function',\n",
       "     'offsetInBeginSection': 202,\n",
       "     'offsetInEndSection': 514,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15016838',\n",
       "     'text': 'es and whether the association of corepressors and coactivators with GR complexes involves competitive equilibrium reactions. In mammalian two-hybrid ',\n",
       "     'offsetInBeginSection': 584,\n",
       "     'offsetInEndSection': 734,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15016838',\n",
       "     'text': 'Corepressors and coactivators can modulate the dose-response curve and partial agonist activity of glucocorticoid receptors (GRs) complexed with agoni',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/15814849',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/14766010',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/28607951',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/17244199',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/26201947',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/17476305',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/11108858',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/15016838',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/12376547',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/17046230',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/21664237',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/14690606',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/29786798',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/16189181',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/11893487',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/16604175',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/8571454',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/10454563',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/9806345',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/19019695',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/17018837',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/19843848',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/25024406',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/27654711',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/12039076']},\n",
       "  {'id': '6412331b201352f04a000038',\n",
       "   'type': 'factoid',\n",
       "   'body': 'What are PROTACs?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35916511',\n",
       "     'text': 'Proteolysis targeting chimeras (PROTACs) technology is a novel and promising therapeutic strategy using small molecules to induce ubiquitin-dependent ',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35533582',\n",
       "     'text': 'Proteolysis-targeting chimeras (PROTACs), bifunctional molecules consisting of a ligand of protein of interest (POI), an E3 ligase ligand and a linker',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35001407',\n",
       "     'text': 'Proteolysis targeting chimaeras (PROTACs) is a cutting edge and rapidly growing technique for new drug discovery and development. Currently, the large',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34034148',\n",
       "     'text': 's a rapidly developing field in drug discovery, but PROTACs are bifunctional molecules that generally show poor bioavailability due to their relativel',\n",
       "     'offsetInBeginSection': 90,\n",
       "     'offsetInEndSection': 240,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31538491',\n",
       "     'text': 'h the potential to revolutionize drug discovery. PROTACs are heterobifunctional molecules comprising of a ligand targeting a protein of interest, a li',\n",
       "     'offsetInBeginSection': 91,\n",
       "     'offsetInEndSection': 241,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35589670',\n",
       "     'text': 'ive technology for targeted protein degradation. PROTACs are heterobifunctional molecules that can trigger the polyubiquitination of proteins of inter',\n",
       "     'offsetInBeginSection': 74,\n",
       "     'offsetInEndSection': 224,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35702041',\n",
       "     'text': 'Proteolysis-targeting chimaeras (PROTACs) have been developed to be an emerging technology for targeted protein degradation and attracted the favour o',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36120561',\n",
       "     'text': ' their potential as possible cancer therapies. PROTACs are small molecule, protein degraders that function by hijacking the built-in Ubiquitin-Proteas',\n",
       "     'offsetInBeginSection': 207,\n",
       "     'offsetInEndSection': 357,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33970635',\n",
       "     'text': 'PROTACs (proteolysis targeting chimeras) are an emerging class of promising therapeutic modalities that degrade intracellular protein targets by hijac',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30706727',\n",
       "     'text': 'y reducing or eliminating disease-causing proteins. PROTACs are bifunctional molecules that consist of a target protein ligand, a linker and an E3 lig',\n",
       "     'offsetInBeginSection': 92,\n",
       "     'offsetInEndSection': 242,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33959589',\n",
       "     'text': 'Proteolysis Targeting Chimeras (PROTACs) are heterobifunctional degraders that specifically eliminate targeted proteins by hijacking the ubiquitin-pro',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33970635',\n",
       "     'text': ' in cancer cells versus noncancerous normal cells. We show that our folate-PROTACs, including BRD PROTAC (folate-ARV-771), MEK PROTAC (folate-MS432), ',\n",
       "     'offsetInBeginSection': 693,\n",
       "     'offsetInEndSection': 843,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35471699',\n",
       "     'text': 'w smart activatable PROTACs, which exert protein degradation action only in response to internal or external stimuli. We categorize these activatable ',\n",
       "     'offsetInBeginSection': 624,\n",
       "     'offsetInEndSection': 774,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33369705',\n",
       "     'text': 'isease settings. Since its development in 2001, the field of targeted protein degradation, in which PROTACs are used, has expanded rapidly. However, e',\n",
       "     'offsetInBeginSection': 632,\n",
       "     'offsetInEndSection': 782,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35763424',\n",
       "     'text': 'Proteolysis-targeting chimeras (PROTACs) is a fast-growing technology providing many strengths over inhibition of protein activity directly and is att',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33369705',\n",
       "     'text': 'Chimeras (PROTACs) are a family of heterobifunctional small molecules that specifically target cellular proteins for degradation. Given that their mod',\n",
       "     'offsetInBeginSection': 22,\n",
       "     'offsetInEndSection': 172,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32270707',\n",
       "     'text': 'uitin-proteasome system. PROTAC molecules (PROTACs) are a class of heterobifunctional molecules, which contain a ligand targeting the protein of inter',\n",
       "     'offsetInBeginSection': 106,\n",
       "     'offsetInEndSection': 256,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32718354',\n",
       "     'text': 'Proteolysis targeting chimeras (PROTACs) are heterobifunctional small molecules that utilize the ubiquitin proteasome system (UPS) to degrade proteins',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35410300',\n",
       "     'text': 'Proteolysis-targeting chimeras (PROTACs) are engineered techniques for targeted protein degradation. A bifunctional PROTAC molecule with two covalentl',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35471699',\n",
       "     'text': 'Proteolysis-targeting chimeras (PROTACs) are heterobifunctional chemicals that degrade proteins at the post-translational level, which represent an em',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29473971',\n",
       "     'text': 'Proteolysis-targeting chimeric molecules (PROTACs) represent an emerging technique that is receiving much attention for therapeutic intervention. The ',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33081540',\n",
       "     'text': 'INTRODUCTION\\nPROTACs represent a novel class of heterobifunctional molecules that simultaneously bind to a target protein and to an E3 ligase complex,',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30631068',\n",
       "     'text': 'PROteolysis-TArgeting Chimeras (PROTACs) are hetero-bifunctional molecules that recruit an E3 ubiquitin ligase to a given substrate protein resulting ',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32866456',\n",
       "     'text': 'Proteolysis-targeting chimeras (PROTACs), the hetero-bifunctional compounds containing a specific ligand to bind the target protein, a suitable linker',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31047748',\n",
       "     'text': \"Proteolysis targeting chimeras (PROTACs) are heterobifunctional compounds with molecular weights and other properties that lie outside the classic 'ru\",\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36041010',\n",
       "     'text': 'Proteolysis-targeting chimeras (PROTACs) are a promising new class of drugs that selectively degrade cellular proteins of interest. PROTACs that targe',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31538491',\n",
       "     'text': ' of selectivity are discussed. Specific types such as homoPROTACs, PROTACs targeting Tau protein and the first PROTACs recently entering clinical tria',\n",
       "     'offsetInBeginSection': 592,\n",
       "     'offsetInEndSection': 742,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36232374',\n",
       "     'text': 'Proteolysis-targeting chimeras (PROTACs) are molecules that selectively degrade a protein of interest (POI). The incorporation of ligands that recruit',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32698111',\n",
       "     'text': ' to treat cancer. PROTACs are made up of ligands of target proteins, E3 ligase recruiting elements and linkers. PROTACs can hijack the intracellular i',\n",
       "     'offsetInBeginSection': 115,\n",
       "     'offsetInEndSection': 265,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31064868',\n",
       "     'text': 'Proteolysis-targeting chimeras (PROTAC) are bifunctional molecules that hijack endogenous E3 ubiquitin ligases to induce ubiquitination and subsequent',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/30706727',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/30631068',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/31538491',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33959589',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33970635',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35589670',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35916511',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35471699',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35533582',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36232374',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35410300',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/31064868',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36041010',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32270707',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34034148',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32698111',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35763424',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35702041',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33081540',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/29473971',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36120561',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32866456',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/31047748',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32718354',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33369705',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35001407']},\n",
       "  {'id': '62008022c9dfcb9c0900001b',\n",
       "   'type': 'list',\n",
       "   'body': 'Which variables are included in the ALBI grade?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33788758',\n",
       "     'text': 'grade 2/3 was significantly associated with older age, male sex, advanced pT status, and histological type. Even after propensity-score matching, ALBI',\n",
       "     'offsetInBeginSection': 569,\n",
       "     'offsetInEndSection': 719,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33392490',\n",
       "     'text': 'roach to assess liver function using 2 laboratory parameters, serum albumin and bilirubin (ALBI), both before and during treatment with ramucirumab in',\n",
       "     'offsetInBeginSection': 2169,\n",
       "     'offsetInEndSection': 2319,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31191834',\n",
       "     'text': ' age, gender, cause of cirrhosis, ALBI Grade along with the site, size and number of tumors were recorded. Radiological response to TACE was assessed ',\n",
       "     'offsetInBeginSection': 506,\n",
       "     'offsetInEndSection': 656,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28688815',\n",
       "     'text': 'nt; or Model for End-Stage Liver Disease score > 15. Serum albumin, bilirubin, and platelet values were used to determine ALBI and PALBI grades. Overa',\n",
       "     'offsetInBeginSection': 681,\n",
       "     'offsetInEndSection': 831,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33392490',\n",
       "     'text': 'rived from a validated nomogram to objectively assess prognosis and liver function in patients with hepatocellular carcinoma (HCC). In this post hoc a',\n",
       "     'offsetInBeginSection': 64,\n",
       "     'offsetInEndSection': 214,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32411593',\n",
       "     'text': 'variate analysis suggested that the ALBI grade, AAPR, CA19-9, tumor number, and microvascular invasion were independent prognostic predictors for OS. ',\n",
       "     'offsetInBeginSection': 1053,\n",
       "     'offsetInEndSection': 1203,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36411535',\n",
       "     'text': 'n (ALBI) grade is an index of liver function based on total bilirubin (T-BIL) and albumin levels, and its usefulness has been widely reported. This st',\n",
       "     'offsetInBeginSection': 27,\n",
       "     'offsetInEndSection': 177,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27038686',\n",
       "     'text': 'BI grade provided distinct survival curves for C-P B (P = .02), BCLC B (P = .001), and BCLC C (P = .02). When substratified by BCLC stage, ALBI grade ',\n",
       "     'offsetInBeginSection': 1241,\n",
       "     'offsetInEndSection': 1391,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28295594',\n",
       "     'text': 'his study aimed to elucidate the application of ALBI grade in baseline and sorafenib-end in advanced HCC patients who received sorafenib.\\n\\n\\nMETHODS\\nA ',\n",
       "     'offsetInBeginSection': 170,\n",
       "     'offsetInEndSection': 320,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33442542',\n",
       "     'text': 'score, the ALBI score uses only objective parameters, albumin (Alb) and total bilirubin (T.Bil), enabling a better evaluation. However, the complex ca',\n",
       "     'offsetInBeginSection': 173,\n",
       "     'offsetInEndSection': 323,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32411593',\n",
       "     'text': 's unclear whether the albumin-bilirubin (ALBI) grade and albumin-to-alkaline phosphatase ratio (AAPR) can predict long-term outcomes of surgically tre',\n",
       "     'offsetInBeginSection': 100,\n",
       "     'offsetInEndSection': 250,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33392490',\n",
       "     'text': 'ected by baseline ALBI grade, macrovascular invasion, tumour response, geographical region, or prior locoregional therapy. Baseline ALBI grades 2 and ',\n",
       "     'offsetInBeginSection': 1366,\n",
       "     'offsetInEndSection': 1516,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27038686',\n",
       "     'text': 'ation for hepatocellular carcinoma.\\n\\n\\nMATERIALS AND METHODS\\nBaseline albumin and bilirubin values of 765 consecutive patients treated with conventiona',\n",
       "     'offsetInBeginSection': 132,\n",
       "     'offsetInEndSection': 282,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33346079',\n",
       "     'text': 'cantly associated with mortality (ALBI grade 2: odds ratio [OR] 5.24; p < 0.001; ALBI grade 3: OR 25.6; p < 0.001) and morbidity (ALBI grade 2: OR 2.1',\n",
       "     'offsetInBeginSection': 1289,\n",
       "     'offsetInEndSection': 1439,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30842180',\n",
       "     'text': 'ivariate analysis revealed that the ALBI grade combined with the CA19-9 concentration, served as an independent prognostic indicator.\\n\\n\\nCONCLUSION\\nThe',\n",
       "     'offsetInBeginSection': 1204,\n",
       "     'offsetInEndSection': 1354,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32411593',\n",
       "     'text': ' analysis suggested that the ALBI grade, AAPR, CA19-9, tumor number, and microvascular invasion were independent prognostic predictors for OS. ALBI gr',\n",
       "     'offsetInBeginSection': 1060,\n",
       "     'offsetInEndSection': 1210,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35211856',\n",
       "     'text': 'C). Furthermore, the association between the ALBI grade and skeletal muscle-related indices is unclear.\\n\\n\\nMETHODS\\nThis study enrolled 1015 patients wh',\n",
       "     'offsetInBeginSection': 205,\n",
       "     'offsetInEndSection': 355,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27214151',\n",
       "     'text': 'atocellular Carcinoma (HCC). ALBI grade 1 vs 2 were proposed as stratification factors within the Child Pugh (CP) A class. However, the original publi',\n",
       "     'offsetInBeginSection': 135,\n",
       "     'offsetInEndSection': 285,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33627573',\n",
       "     'text': ' platelet-albumin-bilirubin grade. These results suggested incorporating CSPH into the ALBI grade could strengthen its prognostic power. The ALBI-P sc',\n",
       "     'offsetInBeginSection': 1387,\n",
       "     'offsetInEndSection': 1537,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36291867',\n",
       "     'text': 'requency ablation and surgical resection), the mALBI grade (grade 2 vs. 1 and grade 3 vs. 2) was an independent predictor of OS. Original ALBI grade 2',\n",
       "     'offsetInBeginSection': 1064,\n",
       "     'offsetInEndSection': 1214,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30842180',\n",
       "     'text': 'cance of the combination of the ALBI grade with serum carbohydrate antigen 19-9 (CA 19-9) concentration, the most frequently used tumor marker in panc',\n",
       "     'offsetInBeginSection': 177,\n",
       "     'offsetInEndSection': 327,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26647219',\n",
       "     'text': 'ng hepatocellular carcinoma (HCC) patients based on hepatic function and predicting their prognosis.\\n\\n\\nMETHOD\\nFrom 2000 to 2014, 2584 naïve HCC [69.0\\u2009',\n",
       "     'offsetInBeginSection': 322,\n",
       "     'offsetInEndSection': 472,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31025380',\n",
       "     'text': 'dentified using an international multi-institutional database. Clinicopathologic factors including ALBI score were assessed using bivariate and multiv',\n",
       "     'offsetInBeginSection': 285,\n",
       "     'offsetInEndSection': 435,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29976502',\n",
       "     'text': ' ALBI score was included as a binary variable, the ALBI grade, tumor thrombus, and trial were significant predictors of OS. When the ALBI score was co',\n",
       "     'offsetInBeginSection': 1642,\n",
       "     'offsetInEndSection': 1792,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31191834',\n",
       "     'text': \"2017 were included. Patient's age, gender, cause of cirrhosis, ALBI Grade along with the site, size and number of tumors were recorded. Radiological r\",\n",
       "     'offsetInBeginSection': 477,\n",
       "     'offsetInEndSection': 627,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27214151',\n",
       "     'text': '(HR) = 1.60 (95%CI: 1.35-1.89, P < 0.001) for A6 vs A5. Median OS was 10.9, 6.6 and 3.0 months for ALBI grade 1, 2 and 3, respectively (P < 0.001), HR',\n",
       "     'offsetInBeginSection': 1081,\n",
       "     'offsetInEndSection': 1231,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/33788758',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33346079',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/30842180',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/31025380',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33392490',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33627573',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/27038686',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35211856',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32411593',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/27214151',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/26647219',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33442542',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/28688815',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36411535',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/31191834',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/29976502',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/28295594',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36291867']},\n",
       "  {'id': '64240f33690f196b51000049',\n",
       "   'type': 'list',\n",
       "   'body': 'What drugs are used to treat FIP, Feline Infectious Peritonitis in cats?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19482534',\n",
       "     'text': 'fatal disease. Three cats with dry form FIP were treated with Polyprenyl Immunostimulant. Two of the three cats are still on treatment and are alive a',\n",
       "     'offsetInBeginSection': 52,\n",
       "     'offsetInEndSection': 202,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33799985',\n",
       "     'text': 'ed, and most of the affected cats die or are euthanized. Anecdotally, doxycycline has been used to treat FIP-affected cats, but there are currently no',\n",
       "     'offsetInBeginSection': 191,\n",
       "     'offsetInEndSection': 341,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36387398',\n",
       "     'text': 'ive and no relapse was observed.\\n\\n\\nConclusions and relevance\\nGS-441524 combined with GC376 can be safely and effectively used to treat FIP and reduces',\n",
       "     'offsetInBeginSection': 1427,\n",
       "     'offsetInEndSection': 1577,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15123155',\n",
       "     'text': 'ritonitis (FIP) were treated with a combination of recombinant feline interferon and glucocorticoid. A complete remission (over 2 years) and a partial',\n",
       "     'offsetInBeginSection': 78,\n",
       "     'offsetInEndSection': 228,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18196725',\n",
       "     'text': 'a or a placebo. All cats received adjunctive treatment with glucocorticoids and antibiotics and passive immunization with Feliserin.\\n\\n\\nRESULTS\\nThere w',\n",
       "     'offsetInBeginSection': 604,\n",
       "     'offsetInEndSection': 754,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24458025',\n",
       "     'text': 's slightly better in specific pathogen-free cats treated with NP7 and NP8 with fCpG-ODNs. However, immune tolerance was suggested to be induced by the',\n",
       "     'offsetInBeginSection': 621,\n",
       "     'offsetInEndSection': 771,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/8588340',\n",
       "     'text': 'tious peritonitis (FIP) virus antigen was demonstrated after methanol, ethanol or formalin fixation in paraffin-embedded tissues by means of monoclona',\n",
       "     'offsetInBeginSection': 12,\n",
       "     'offsetInEndSection': 162,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33644160',\n",
       "     'text': 'avirus (FIP virus: FIPV). For the treatment of FIP, several effective antivirals were recently reported, but many of these are not available for pract',\n",
       "     'offsetInBeginSection': 116,\n",
       "     'offsetInEndSection': 266,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36297266',\n",
       "     'text': 'twice daily. This study provides a proof of principle for the use of molnupiravir in cats and supports the need for future studies to further evaluate',\n",
       "     'offsetInBeginSection': 1076,\n",
       "     'offsetInEndSection': 1226,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36015002',\n",
       "     'text': ' cats that presented with these laboratory changes. This study shows that PI is beneficial in the treatment of FIP, and more studies are needed to est',\n",
       "     'offsetInBeginSection': 1229,\n",
       "     'offsetInEndSection': 1379,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33799985',\n",
       "     'text': 'ration 50% (IC50) 4.1 µg/mL and IC90 5.4 µg/mL. Our data suggest that doxycycline has some inhibitory effect on FIPV replication in vitro, which suppo',\n",
       "     'offsetInBeginSection': 1099,\n",
       "     'offsetInEndSection': 1249,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32441826',\n",
       "     'text': 'spite a variety of historically used treatments. Recently developed antiviral drugs have shown promise in treatment of nonneurological FIP, but data f',\n",
       "     'offsetInBeginSection': 317,\n",
       "     'offsetInEndSection': 467,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36387398',\n",
       "     'text': 'ate the efficacy of the nucleotide analog GS-441524 in combination with the 3C-like protease inhibitor GC376 for the treatment of naturally aquired fe',\n",
       "     'offsetInBeginSection': 61,\n",
       "     'offsetInEndSection': 211,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32456286',\n",
       "     'text': 'al activity against type I FIPV infection. Our study suggested that HCQ and rfIFN-ω are applicable for treatment of FIP. Further clinical studies are ',\n",
       "     'offsetInBeginSection': 839,\n",
       "     'offsetInEndSection': 989,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22092616',\n",
       "     'text': 'All cats received additional treatment with glucocorticoids, antibiotics, and low molecular weight heparin according to methods.\\n\\n\\nRESULTS\\nThere was n',\n",
       "     'offsetInBeginSection': 569,\n",
       "     'offsetInEndSection': 719,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36015002',\n",
       "     'text': 'ophysiology; hence treatment with an immune stimulant such as Polyprenyl Immunostimulant™ (PI), which enhances cell-mediated immunity by upregulating ',\n",
       "     'offsetInBeginSection': 175,\n",
       "     'offsetInEndSection': 325,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32441826',\n",
       "     'text': 'cranial and caudal segment disease with ocular imaging. Treatment with GS-441524 shows clinical efficacy and may result in clearance and long-term res',\n",
       "     'offsetInBeginSection': 1459,\n",
       "     'offsetInEndSection': 1609,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36297266',\n",
       "     'text': ' complex and historically fatal disease, though recent advances in antiviral therapy have uncovered potential treatments. A newer therapeutic option, ',\n",
       "     'offsetInBeginSection': 40,\n",
       "     'offsetInEndSection': 190,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26850532',\n",
       "     'text': ' cats. Progression to FIP was prevented in 2 out of 3 cats treated with mAb 2-4, whereas all 3 cats developed FIP in the placebo control group. Plasma',\n",
       "     'offsetInBeginSection': 595,\n",
       "     'offsetInEndSection': 745,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18395801',\n",
       "     'text': 'glucocorticoids as a therapy for FIP. Some veterinarians prescribe immune modulators to treat cats with FIP with no documented controlled evidence of ',\n",
       "     'offsetInBeginSection': 586,\n",
       "     'offsetInEndSection': 736,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26656689',\n",
       "     'text': ' most important fatal infectious diseases of cats worldwide. No specific vaccines or drugs have been approved to treat FIP. CoV main proteases (M(pro)',\n",
       "     'offsetInBeginSection': 289,\n",
       "     'offsetInEndSection': 439,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/9637307',\n",
       "     'text': 'is (FIP). We tried to evaluate the effect of thromboxane (Tx) synthetase inhibitor, ozagrel hydrochloride, on the progression of symptoms and clinicop',\n",
       "     'offsetInBeginSection': 91,\n",
       "     'offsetInEndSection': 241,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26592814',\n",
       "     'text': 'f cats in multi-cat households per year. In an effort to develop small molecule drugs targeting FIP for the treatment of cats, we screened a small set',\n",
       "     'offsetInBeginSection': 326,\n",
       "     'offsetInEndSection': 476,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26850532',\n",
       "     'text': 'uced conditions in vitro. In the present study, we investigated whether mAb 2-4 improved the FIP symptoms and survival rate of experimentally FIPV-ino',\n",
       "     'offsetInBeginSection': 434,\n",
       "     'offsetInEndSection': 584,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30658691',\n",
       "     'text': 'Feline coronaviruses (FCoVs) are the causative agents of severe systemic disease (feline infectious peritonitis: FIP) in domestic and wild cats. FCoVs',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33138721',\n",
       "     'text': \" immunomodulators to stimulate the patient's immune system non-specifically to reduce the clinical effects of the virus through a robust immune response, (2) immunosuppressive agents to dampen clinical signs temporarily, and (3) re-purposed human antiviral drugs\",\n",
       "     'offsetInBeginSection': 294,\n",
       "     'offsetInEndSection': 556,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27264736',\n",
       "     'text': 'rmed to have fTNF-alpha neutralization activity. Purified mouse mAb 2-4 and chimeric mAb 2-4 were repeatedly administered to cats, and the changes in ',\n",
       "     'offsetInBeginSection': 703,\n",
       "     'offsetInEndSection': 853,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/1319173',\n",
       "     'text': 'Anti-idiotypic antibodies (Ab2s) generated against neutralizing antibodies (Ab1s) specific for feline infectious peritonitis virus (FIPV) were shown t',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24095161',\n",
       "     'text': 'o the progression of FIP. Thus, the administration of a feline TNF-alpha-neutralizing antibody to cats with FIP may reduce the disease progression. In',\n",
       "     'offsetInBeginSection': 154,\n",
       "     'offsetInEndSection': 304,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/36387398',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/27264736',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33138721',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32456286',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/26850532',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/9637307',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/24095161',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/1319173',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/22092616',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/18395801',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/24458025',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/19482534',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36015002',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33799985',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/30658691',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/26656689',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/18196725',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/8588340',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32441826',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36297266',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/15123155',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/26592814',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33644160']},\n",
       "  {'id': '6428da98690f196b51000053',\n",
       "   'type': 'yesno',\n",
       "   'body': 'Is there a way to distinguish COVID-19 clinically from other respiratory illnesses, such as influenza?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33947345',\n",
       "     'text': 'million cases have occurred worldwide as of June 16, 2020. However, it is important to distinguish COVID-19 from other respiratory infectious diseases',\n",
       "     'offsetInBeginSection': 88,\n",
       "     'offsetInEndSection': 238,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33821230',\n",
       "     'text': ' hospitalized patients with other viral pneumonias such as influenza is unknown.\\n\\n\\nObjectives\\nTo assess the incidence of venous and arterial thromboti',\n",
       "     'offsetInBeginSection': 327,\n",
       "     'offsetInEndSection': 477,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33907612',\n",
       "     'text': 'n most\\xa0other contagious respiratory illnesses. The\\xa0mechanisms underlying this difference remain unclear.\\n\\n\\nMETHODS\\nWe compared the immunological lands',\n",
       "     'offsetInBeginSection': 79,\n",
       "     'offsetInEndSection': 229,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32832306',\n",
       "     'text': 'COVID-19) are both contagious respiratory illnesses, but they are caused by different viruses. COVID-19 pandemic is caused by a novel virus - severe a',\n",
       "     'offsetInBeginSection': 40,\n",
       "     'offsetInEndSection': 190,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34111501',\n",
       "     'text': 'pared to other respiratory viral illnesses, few formal comparisons of these viruses on kidney health exist. In this retrospective cohort study, we com',\n",
       "     'offsetInBeginSection': 199,\n",
       "     'offsetInEndSection': 349,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33090987',\n",
       "     'text': ' Data that examine all in-hospital complications of COVID-19 and that compare these complications with those associated with other viral respiratory pathogens, such as influenza, are lacking',\n",
       "     'offsetInBeginSection': 213,\n",
       "     'offsetInEndSection': 403,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36410319',\n",
       "     'text': 'ose with dengue or influenza, adjusting for age, subregion, and days from illness onset to presentation for clinical care. Among 13,431 participants, ',\n",
       "     'offsetInBeginSection': 697,\n",
       "     'offsetInEndSection': 847,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34728719',\n",
       "     'text': 'other respiratory viral infections, such as Influenza, has not hitherto been extensively studied. We aimed to compare the prognostic value of NLR in C',\n",
       "     'offsetInBeginSection': 163,\n",
       "     'offsetInEndSection': 313,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33615750',\n",
       "     'text': ' it is important to accurately differentiate these two different respiratory tract infections on the basis of their respective early-stage characteristics',\n",
       "     'offsetInBeginSection': 328,\n",
       "     'offsetInEndSection': 482,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32511543',\n",
       "     'text': 'evere respiratory distress, such as influenza virus infection, are not fully understood. Here we addressed this by developing a prospective observatio',\n",
       "     'offsetInBeginSection': 190,\n",
       "     'offsetInEndSection': 340,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33869239',\n",
       "     'text': ' be the cough sound, which comes in different types and forms. A reliable lab-free tool for early and accurate diagnosis, which can differentiate betw',\n",
       "     'offsetInBeginSection': 733,\n",
       "     'offsetInEndSection': 883,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32881022',\n",
       "     'text': 'tay. With our findings, we emphasize that epidemiological risk factors and clinical symptoms are more useful than laboratory and radiological abnormal',\n",
       "     'offsetInBeginSection': 1168,\n",
       "     'offsetInEndSection': 1318,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33090987',\n",
       "     'text': 'th influenza and might aid clinicians and researchers in recognizing, monitoring, and managing the spectrum of COVID-19 manifestations. The higher ris',\n",
       "     'offsetInBeginSection': 2599,\n",
       "     'offsetInEndSection': 2749,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33901185',\n",
       "     'text': 'er dengue attack rates. At clinical presentation, nine basic clinical and epidemiological indicators may help to distinguish COVID-19 or dengue from e',\n",
       "     'offsetInBeginSection': 2003,\n",
       "     'offsetInEndSection': 2153,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34590732',\n",
       "     'text': 'vulnerable. The success and efficacy of vaccination campaigns for other respiratory illnesses, such as influenza, may help inform messaging around COV',\n",
       "     'offsetInBeginSection': 129,\n",
       "     'offsetInEndSection': 279,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33995342',\n",
       "     'text': 'he factors distinguishing SARS-CoV-2 from other respiratory viruses are unknown. Here, we compared the clinical, histopathological, and immunological ',\n",
       "     'offsetInBeginSection': 290,\n",
       "     'offsetInEndSection': 440,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32497283',\n",
       "     'text': 'some other respiratory pathogens. However, the information of COVID-19 and influenza coinfection is limited. In this study, we reported our coinfected',\n",
       "     'offsetInBeginSection': 265,\n",
       "     'offsetInEndSection': 415,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33135801',\n",
       "     'text': 'It is difficult to distinguish coronavirus disease-2019 (COVID-19) from other viral respiratory tract infections owing to the similarities in clinical and radiological findings',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 176,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33907612',\n",
       "     'text': 'munity-L, respectively. These data indicate that most COVID-19 patients have weaker immune signatures than influenza and RSV patients, as evidenced by',\n",
       "     'offsetInBeginSection': 812,\n",
       "     'offsetInEndSection': 962,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33970449',\n",
       "     'text': 'ns in children populations worldwide. This study is aimed to compare the clinical and laboratory characteristics of COVID-19 and H1N1 influenza infect',\n",
       "     'offsetInBeginSection': 281,\n",
       "     'offsetInEndSection': 431,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33901185',\n",
       "     'text': 'sociated with COVID-19 or with dengue were sought using multinomial logistic regression models, taking other febrile illnesses (OFIs) as controls. Adj',\n",
       "     'offsetInBeginSection': 875,\n",
       "     'offsetInEndSection': 1025,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33090987',\n",
       "     'text': 'tes,* were analyzed. Using International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) codes, complications in patient',\n",
       "     'offsetInBeginSection': 756,\n",
       "     'offsetInEndSection': 906,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32905055',\n",
       "     'text': 'irculate in the following seasons, it is essential to understand how COVID-19 influences other respiratory diseases, especially influenza. In this stu',\n",
       "     'offsetInBeginSection': 49,\n",
       "     'offsetInEndSection': 199,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34111501',\n",
       "     'text': 'ed with COVID-19 compared to influenza, a finding that may be driven largely by illness severity. Hence, the combined impact of these two illnesses on',\n",
       "     'offsetInBeginSection': 1394,\n",
       "     'offsetInEndSection': 1544,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33137167',\n",
       "     'text': 'er, MDW ≥ 20 and NLR > 5 effectively identified influenza infection (AUC: 0.7055). Thus, MDW and NLR can distinguish COVID-19 from influenza and URIs.',\n",
       "     'offsetInBeginSection': 880,\n",
       "     'offsetInEndSection': 1030,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33907612',\n",
       "     'text': ' Gene ontology analysis showed that the innate and adaptive immune responses were significantly downregulated in COVID-19 versus healthy individuals.\\n\\n\\nCONCLUSIONS\\nCompared to influenza and RSV, COVID-19 displayed significantly different immunological\\xa0profiles',\n",
       "     'offsetInBeginSection': 1447,\n",
       "     'offsetInEndSection': 1707,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36362465',\n",
       "     'text': 'ng debate whether lung physiology of COVID-19-associated acute respiratory distress syndrome (ARDS) differs from ARDS of other origin. Objective: The ',\n",
       "     'offsetInBeginSection': 26,\n",
       "     'offsetInEndSection': 176,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32903584',\n",
       "     'text': 'the order of symptom occurrence could help patients and medical professionals more quickly distinguish COVID-19 from other respiratory diseases, yet such essential information is largely unavailable',\n",
       "     'offsetInBeginSection': 375,\n",
       "     'offsetInEndSection': 573,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32511543',\n",
       "     'text': 'VID-19 patients could be distinguished statistically based on cytokine module expression, particularly after controlling for the significant effects o',\n",
       "     'offsetInBeginSection': 1754,\n",
       "     'offsetInEndSection': 1904,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34981695',\n",
       "     'text': 'ID-19 over other viral infections. However, the differences between the groups were not substantial enough and would probably not suffice to distingui',\n",
       "     'offsetInBeginSection': 1155,\n",
       "     'offsetInEndSection': 1305,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/33901185',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33907612',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33947345',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33090987',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32511543',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32881022',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32905055',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33995342',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33821230',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34728719',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34111501',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33135801',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32497283',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32832306',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33869239',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32903584',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36410319',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33137167',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36362465',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34981695',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33615750',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33970449',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34590732']},\n",
       "  {'id': '6415c8f1690f196b51000017',\n",
       "   'type': 'factoid',\n",
       "   'body': 'Which form of cancer have paclitaxel, docetaxel, doxorubicin, and epirubicin been approved for?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26918039',\n",
       "     'text': 'used in the treatment of a variety of cancers, including those of squamous histology. In their formulation, both agents require solvents, which have b',\n",
       "     'offsetInBeginSection': 92,\n",
       "     'offsetInEndSection': 242,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/8629032',\n",
       "     'text': 'rubicin (Farmitalia Carlo Erba, Milan, Italy) in patients with metastatic breast cancer. In addition to standard eligibility criteria, patients with c',\n",
       "     'offsetInBeginSection': 169,\n",
       "     'offsetInEndSection': 319,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/9865708',\n",
       "     'text': 'her doxorubicin or epirubicin has significant activity against metastatic breast cancer. However, the optimal schedule in terms of activity and toxici',\n",
       "     'offsetInBeginSection': 90,\n",
       "     'offsetInEndSection': 240,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/11552225',\n",
       "     'text': 'y be effectively combined with doxorubicin in the treatment of metastatic breast cancer, the drug-drug interaction between paclitaxel and doxorubicin ',\n",
       "     'offsetInBeginSection': 1362,\n",
       "     'offsetInEndSection': 1512,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12473512',\n",
       "     'text': 'apeutic agents for the first-line and second-line treatment of metastatic breast cancer, and their clinical use is widespread. However, for women whos',\n",
       "     'offsetInBeginSection': 112,\n",
       "     'offsetInEndSection': 262,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/10426454',\n",
       "     'text': 're among the most active cytotoxic agents for the treatment of metastatic breast cancer. Given their activity, relative non-cross-resistance, partiall',\n",
       "     'offsetInBeginSection': 106,\n",
       "     'offsetInEndSection': 256,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/11129728',\n",
       "     'text': 'litaxel and doxorubicin or epirubicin is highly active against metastatic breast cancer, yet may produce congestive heart failure. Liposome-encapsulat',\n",
       "     'offsetInBeginSection': 22,\n",
       "     'offsetInEndSection': 172,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/8629032',\n",
       "     'text': 'he combination paclitaxel/epirubicin is safe for patients with metastatic breast cancer and, at this early evaluation, shows promising antitumor activ',\n",
       "     'offsetInBeginSection': 1957,\n",
       "     'offsetInEndSection': 2107,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/11432615',\n",
       "     'text': 'BACKGROUND\\nTreatment of metastatic breast cancer (MBC) with paclitaxel (T) and doxorubicin has yielded high response rates but the regimen is associat',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/9516602',\n",
       "     'text': \"l) and epirubicin, the 4'-epimer of doxorubicin, in women with metastatic breast cancer. A total of 85 patients with histologically proven metastatic \",\n",
       "     'offsetInBeginSection': 86,\n",
       "     'offsetInEndSection': 236,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/11970750',\n",
       "     'text': 'to improve disease-free and overall survival in patients with node-positive breast cancer beyond that obtained with doxorubicin/cyclophosphamide combi',\n",
       "     'offsetInBeginSection': 89,\n",
       "     'offsetInEndSection': 239,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17028669',\n",
       "     'text': ' docetaxel, are among the most widely used chemotherapeutic agents in solid tumor oncology, with efficacy against tumors of the breast, lung, head and',\n",
       "     'offsetInBeginSection': 27,\n",
       "     'offsetInEndSection': 177,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/10511918',\n",
       "     'text': 'fers a new opportunity for devising effective therapy for patients with breast cancer. High response rates have been obtained by combining epirubicin ',\n",
       "     'offsetInBeginSection': 79,\n",
       "     'offsetInEndSection': 229,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/9463787',\n",
       "     'text': ' available for both analogues in the advanced, metastatic setting of breast cancer. Both also have been compared as single agents with doxorubicin wit',\n",
       "     'offsetInBeginSection': 846,\n",
       "     'offsetInEndSection': 996,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/14499011',\n",
       "     'text': 'he 1990s, the taxanes have emerged as the most powerful compounds in breast cancer. Paclitaxel and docetaxel have been evaluated in the metastatic set',\n",
       "     'offsetInBeginSection': 54,\n",
       "     'offsetInEndSection': 204,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27811367',\n",
       "     'text': 'rubicin + cyclophosphamide and paclitaxel in the treatment of metastatic/advanced breast cancer.\\n\\n\\nRESULTS\\nThis network meta-analysis included 8 rando',\n",
       "     'offsetInBeginSection': 286,\n",
       "     'offsetInEndSection': 436,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35976445',\n",
       "     'text': 'gstanding,\\xa0Food and Drug Administration (FDA)-approved therapies against TNBC. Additionally, the FDA approved\\xa0PARP inhibitors such as olaparib and ate',\n",
       "     'offsetInBeginSection': 696,\n",
       "     'offsetInEndSection': 846,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/14768404',\n",
       "     'text': 'In patients with advanced breast cancer, treatment with paclitaxel and doxorubicin has been shown to produce impressive overall response rates (up to ',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/11970739',\n",
       "     'text': 'The taxanes are emerging as the most powerful compounds in breast cancer. Both compounds, paclitaxel and docetaxel, have been evaluated in the metasta',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/9463787',\n",
       "     'text': 'een evaluated in randomised trials as first-line treatment of non-small-cell lung cancer (NSCLC). The results of these trials taken together suggest t',\n",
       "     'offsetInBeginSection': 1811,\n",
       "     'offsetInEndSection': 1961,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12435293',\n",
       "     'text': 'ention. Both of these agents are highly active in patients with advanced breast cancer. In addition, they can be utilized in combination with anthracy',\n",
       "     'offsetInBeginSection': 232,\n",
       "     'offsetInEndSection': 382,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/9463787',\n",
       "     'text': 'are not equitoxic. Either agent by itself, in the treatment of metastatic breast cancer, remains appropriate; however, lack of cumulative toxicity may',\n",
       "     'offsetInBeginSection': 1335,\n",
       "     'offsetInEndSection': 1485,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/11396360',\n",
       "     'text': 'Doxorubicin/paclitaxel (Taxol) combinations are very active in advanced breast cancer, with objective response rates up to 90%, but have shown a high ',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32365878',\n",
       "     'text': 'BACKGROUND\\nBreast cancer (BC) is a heterogeneous disease for which the commonly used chemotherapeutic agents primarily include the anthracyclines (dox',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/9865686',\n",
       "     'text': 'rance) are the most active cytotoxic agents in the treatment of advanced breast cancer. In the pre-taxane era, randomized trials demonstrated that dox',\n",
       "     'offsetInBeginSection': 67,\n",
       "     'offsetInEndSection': 217,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/8604450',\n",
       "     'text': 'axel appear to be valuable agents for use in anthracycline-resistant breast cancer patients, and may find a place in anthracycline-containing combinat',\n",
       "     'offsetInBeginSection': 1228,\n",
       "     'offsetInEndSection': 1378,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/11346678',\n",
       "     'text': 'he most powerful compounds in breast cancer. Both compounds, paclitaxel and docetaxel, have been evaluated in metastatic settings before adjuvant tria',\n",
       "     'offsetInBeginSection': 93,\n",
       "     'offsetInEndSection': 243,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16210917',\n",
       "     'text': 'ombination protocols with gemcitabine and supports the use of gemcitabine/paclitaxel combination in the clinical management of advanced breast cancer.',\n",
       "     'offsetInBeginSection': 1300,\n",
       "     'offsetInEndSection': 1450,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32365878',\n",
       "     'text': 'NA library screen identified relevant gene products that could be targeted alongside current chemotherapeutic agents for the treatment of invasive BC.',\n",
       "     'offsetInBeginSection': 1898,\n",
       "     'offsetInEndSection': 2048,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16210917',\n",
       "     'text': 'd to provide a rationale for clinical investigations. To this end, CG5 breast cancer cells were treated in vitro with gemcitabine followed by epirubic',\n",
       "     'offsetInBeginSection': 211,\n",
       "     'offsetInEndSection': 361,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/26918039',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/9516602',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/9865686',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/11970750',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/11970739',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/8629032',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/11432615',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32365878',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/10511918',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/11346678',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/16210917',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/11396360',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/11129728',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/9463787',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/10426454',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/14768404',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/17028669',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/8604450',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/12473512',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/9865708',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/12435293',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/27811367',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/14499011',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/11552225',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35976445']},\n",
       "  {'id': '63eeec79f36125a426000006',\n",
       "   'type': 'factoid',\n",
       "   'body': 'Talquetamab was developed for treatment of which disease?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/11449698',\n",
       "     'text': 'cepted as a standard chemotherapy (SC) for initial treatment of pulmonary tuberculosis in Japan. We studied the frequency of the treatment completion,',\n",
       "     'offsetInBeginSection': 81,\n",
       "     'offsetInEndSection': 231,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/8100702',\n",
       "     'text': 'its of commonly used disease modifying drugs in the treatment of rheumatoid arthritis (RA) and (b) the influence of age, gender, and disease duration ',\n",
       "     'offsetInBeginSection': 64,\n",
       "     'offsetInEndSection': 214,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33890981',\n",
       "     'text': 'cell redirecting bispecific antibody talquetamab is a promising novel antimyeloma agent. These results provide the preclinical rationale for ongoing s',\n",
       "     'offsetInBeginSection': 1620,\n",
       "     'offsetInEndSection': 1770,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36464766',\n",
       "     'text': 'recting bispecific antibody therapy with talquetamab for relapsed/refractory multiple myeloma (RRMM) and developed CRS with concurrent ICANS after rec',\n",
       "     'offsetInBeginSection': 529,\n",
       "     'offsetInEndSection': 679,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36464766',\n",
       "     'text': 'specific antibody therapy with talquetamab for relapsed/refractory multiple myeloma (RRMM) and developed CRS with concurrent ICANS after receiving a s',\n",
       "     'offsetInBeginSection': 539,\n",
       "     'offsetInEndSection': 689,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25949982',\n",
       "     'text': \"ocrinology unit with excessive sweating. We started methimazole for Graves' disease. Without any additional immunosuppressive treatment, at week 12 of\",\n",
       "     'offsetInBeginSection': 95,\n",
       "     'offsetInEndSection': 245,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12772593',\n",
       "     'text': 'ing imbalance of the sympathetic and vagus nervous system. In this case report, it is suggested that tofisopam is effective for the treatment of PSVT.',\n",
       "     'offsetInBeginSection': 861,\n",
       "     'offsetInEndSection': 1011,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26193648',\n",
       "     'text': 'um was an anticoagulant unlikely to cause adverse effects such as hemorrhage and might be an effective drug for treatment of portal venous thrombosis.',\n",
       "     'offsetInBeginSection': 924,\n",
       "     'offsetInEndSection': 1074,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33890981',\n",
       "     'text': ' an orphan G protein-coupled receptor, are significantly higher on multiple myeloma (MM) cells, compared with normal plasma cells or other immune cell',\n",
       "     'offsetInBeginSection': 41,\n",
       "     'offsetInEndSection': 191,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36006441',\n",
       "     'text': 'as a surface protein on plasma cells and is a validated target for multiple myeloma (MM). A soluble form of BCMA (sBCMA) is elevated in the sera of pa',\n",
       "     'offsetInBeginSection': 58,\n",
       "     'offsetInEndSection': 208,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12772593',\n",
       "     'text': 'quency of PSVT was significantly decreased and subjective symptoms of arrhythmia were eliminated after the administration of tofisopam. R-R interval v',\n",
       "     'offsetInBeginSection': 488,\n",
       "     'offsetInEndSection': 638,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36462062',\n",
       "     'text': 'm a historic lens, treatment for patients with relapsed/refractory multiple myeloma (R/R MM) has advanced significantly since the advent of immunomodu',\n",
       "     'offsetInBeginSection': 3,\n",
       "     'offsetInEndSection': 153,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26179525',\n",
       "     'text': \" developed aortitis during treatment with adalimumab (ADA) for ileocolic Crohn's disease (CD). The patient complained of a high fever, abdominal pain,\",\n",
       "     'offsetInBeginSection': 19,\n",
       "     'offsetInEndSection': 169,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36462062',\n",
       "     'text': 'uss the novel Food & Drug Administration (FDA)-approved medications for R/R MM, including the recently approved first-in-class BCMA-directed bispecifi',\n",
       "     'offsetInBeginSection': 564,\n",
       "     'offsetInEndSection': 714,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18673132',\n",
       "     'text': 'Subjects with nonalcoholic fatty liver disease are at risk of progressive liver failure. Lifestyle changes including weight-loss strategies and increa',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15866475',\n",
       "     'text': 'ere have been many encouraging studies on medical treatment of pulmonary hydatid disease due to Echinococcus granulosus infection. Our aims were to de',\n",
       "     'offsetInBeginSection': 2,\n",
       "     'offsetInEndSection': 152,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26193648',\n",
       "     'text': ', and with anticoagulation therapy using danaparoid sodium for portal venous thrombosis. The portal venous thrombosis disappeared 4\\xa0weeks after the tr',\n",
       "     'offsetInBeginSection': 538,\n",
       "     'offsetInEndSection': 688,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/36462062',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/18673132',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/15866475',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/26179525',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/26193648',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33890981',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/11449698',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/12772593',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36464766',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/8100702',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36006441',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/25949982']},\n",
       "  {'id': '642321a5690f196b51000047',\n",
       "   'type': 'summary',\n",
       "   'body': 'Please summarize Feline Spongiform Encephalopathy(FSE',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/11206004',\n",
       "     'text': 'BSE) in cattle. Feline Spongiform Encephalopathy (FSE) is a related disorder in domestic cats. Because of the link between BSE and FSE, cats are put o',\n",
       "     'offsetInBeginSection': 183,\n",
       "     'offsetInEndSection': 333,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12783238',\n",
       "     'text': 'rm encephalopathy. Here we report an immunohistological analysis of the first FSE-affected cheetah born in France. The duration of clinical signs, of ',\n",
       "     'offsetInBeginSection': 149,\n",
       "     'offsetInEndSection': 299,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/10349202',\n",
       "     'text': 'This review summarizes current knowledge of prion diseases and investigates connections between the bovine spongiform encephalopathy epidemic, observe',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19335885',\n",
       "     'text': 'd-limb ataxia and increased aggressiveness were necropsied and a post mortem diagnosis of Feline Spongiform Encephalopathy (FSE) was made. A wide spec',\n",
       "     'offsetInBeginSection': 70,\n",
       "     'offsetInEndSection': 220,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/12442705',\n",
       "     'text': 'spongiform encephalopathy was confirmed by histological brain examination and positive immunohistochemistry for PrPSc. This is the first time that a c',\n",
       "     'offsetInBeginSection': 521,\n",
       "     'offsetInEndSection': 671,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/1279883',\n",
       "     'text': 's for scrapie-like diseases. Thirteen cats were referred with clinical neurological signs potentially indicative of feline spongiform encephalopathy (',\n",
       "     'offsetInBeginSection': 132,\n",
       "     'offsetInEndSection': 282,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/12783238',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/11206004',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/1279883',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/12442705',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/19335885',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/10349202']},\n",
       "  {'id': '6428d7da690f196b51000050',\n",
       "   'type': 'yesno',\n",
       "   'body': 'Can untranslated regions (UTRs) regulate gene expression?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21093468',\n",
       "     'text': \" (mRNA) 3' untranslated regions (UTRs) where they prevent translation or cause degradation of the message. Steroid hormone receptors (SHRs) are ligand\",\n",
       "     'offsetInBeginSection': 196,\n",
       "     'offsetInEndSection': 346,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18615019',\n",
       "     'text': 'Structured RNAs embedded in the untranslated regions (UTRs) of messenger RNAs can regulate gene expression. In bacteria, control of a metabolite gene ',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20563548',\n",
       "     'text': 'slated regions (UTRs) are important sequence elements that modulate the expression of genes. Using the β-glucuronidase (GUS) reporter gene driven by t',\n",
       "     'offsetInBeginSection': 9,\n",
       "     'offsetInEndSection': 159,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21912852',\n",
       "     'text': \"slated regions (UTRs) are important sequence elements that modulate the expression of genes. We evaluated the potential of the 3'-UTRs of 9 seed stora\",\n",
       "     'offsetInBeginSection': 9,\n",
       "     'offsetInEndSection': 159,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32995550',\n",
       "     'text': 'n of gene expression; however, the exact sequence features contributing to gene regulation are not yet fully understood. In this study, we report the ',\n",
       "     'offsetInBeginSection': 78,\n",
       "     'offsetInEndSection': 228,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/8813126',\n",
       "     'text': \" The 3' untranslated regions (3' UTRs) of R1 and R2 messages contain sequences that are important in regulating gene expression through changes in message stability\",\n",
       "     'offsetInBeginSection': 182,\n",
       "     'offsetInEndSection': 346,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31234415',\n",
       "     'text': \"isms located in 5' untranslated regions (5'UTRs) can regulate gene expression and have clinical impact. Recognition of functionally significant sequen\",\n",
       "     'offsetInBeginSection': 27,\n",
       "     'offsetInEndSection': 177,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16430990',\n",
       "     'text': 'gene expression can be regulated by the differential use of alternative untranslated regions. Tissue-specific expression of transcripts that have different untranslated regions (UTRs) can control protein expression',\n",
       "     'offsetInBeginSection': 149,\n",
       "     'offsetInEndSection': 363,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29165424',\n",
       "     'text': 'These structures may regulate cap-dependent translation initiation through helicase-mediated remodelling of RNA structures and higher-order RNA interactions',\n",
       "     'offsetInBeginSection': 329,\n",
       "     'offsetInEndSection': 485,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28985357',\n",
       "     'text': \"have demonstrated that 3' untranslated regions (3'-UTRs) regulate gene expression by controlling mRNA stability and translation. Due to intrinsic limi\",\n",
       "     'offsetInBeginSection': 35,\n",
       "     'offsetInEndSection': 185,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22110399',\n",
       "     'text': \"tes on miRNAs, little is known about the influence of the rest of 3' untranslated regions (3'UTRs) of target genes on microRNA function. We conducted \",\n",
       "     'offsetInBeginSection': 149,\n",
       "     'offsetInEndSection': 299,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20015997',\n",
       "     'text': 'To gain insight into the role of untranslated regions (UTRs) in regulation of foreign gene expression, replication, and pathogenicity of Newcastle dis',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28740488',\n",
       "     'text': 'ortant features that are relevant to the post-transcriptional and translational regulation of gene expression. Most studies of bacterial UTRs have foc',\n",
       "     'offsetInBeginSection': 51,\n",
       "     'offsetInEndSection': 201,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24067953',\n",
       "     'text': \"ions (UTRs) are known to play an important role in posttranscriptional regulation of gene expression. Here we map the 3' UTRs of Kaposi's sarcoma-asso\",\n",
       "     'offsetInBeginSection': 19,\n",
       "     'offsetInEndSection': 169,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20720301',\n",
       "     'text': 'post-transcriptional regulation of gene expression via the modulation of nucleocytoplasmic mRNA transport, translation efficiency, subcellular localization, and message stability',\n",
       "     'offsetInBeginSection': 70,\n",
       "     'offsetInEndSection': 248,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33821006',\n",
       "     'text': \"of extremely conserved 5' untranslated regions (UTRs) in noncanonical translational regulation that is linked to the emergence of essential developmen\",\n",
       "     'offsetInBeginSection': 173,\n",
       "     'offsetInEndSection': 323,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/7662369',\n",
       "     'text': \"The 3' untranslated region (3' UTR) can control gene expression by affecting the localization, stability and translation of mRNAs. The recent finding \",\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20563548',\n",
       "     'text': ' transient expression protoplasts. Therefore, the enhancements were independent of the promoter sequence. Real-time quantitative RT-PCR analysis showe',\n",
       "     'offsetInBeginSection': 759,\n",
       "     'offsetInEndSection': 909,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28129533',\n",
       "     'text': \"in most eukaryotic mRNAs. These 3' untranslated regions (3' UTRs) hold the key for many aspects of regulated gene expression, influencing mRNA stabili\",\n",
       "     'offsetInBeginSection': 52,\n",
       "     'offsetInEndSection': 202,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25577389',\n",
       "     'text': \"lar, RNA elements lying in untranslated regions (5' and 3'UTRs) are poorly studied because of their peculiar features (i.e., a combination of primary \",\n",
       "     'offsetInBeginSection': 93,\n",
       "     'offsetInEndSection': 243,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/18615019',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/8813126',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33821006',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/21093468',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/25577389',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/22110399',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/29165424',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/28985357',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/28129533',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32995550',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/31234415',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/16430990',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/28740488',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/24067953',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/20015997',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/21912852',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/7662369',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/20720301',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/20563548']},\n",
       "  {'id': '63f9cbb433942b094c00000c',\n",
       "   'type': 'yesno',\n",
       "   'body': 'Is alternative splicing associated with heart disease?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30468920',\n",
       "     'text': 'assembly of the contractile apparatus. Recently, FHOD3 mutations have been found associated with heart diseases. We identified novel FHOD3 splicing va',\n",
       "     'offsetInBeginSection': 753,\n",
       "     'offsetInEndSection': 903,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34273561',\n",
       "     'text': ' humans, cardiac mRNA splicing is involved in the pathophysiology of heart failure. Mutations in the splicing factor RNA binding motif protein 20 (RBM',\n",
       "     'offsetInBeginSection': 96,\n",
       "     'offsetInEndSection': 246,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32276354',\n",
       "     'text': 'in the heart development and function; RBM20 mutations associated with idiopathic dilated cardiovascular disease (DCM); and the consequences of RBM20-',\n",
       "     'offsetInBeginSection': 1072,\n",
       "     'offsetInEndSection': 1222,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30051286',\n",
       "     'text': 'eart, with a particular focus on the factors controlling cardiac alternative splicing and their role in cardiomyopathies and subsequent heart failure.',\n",
       "     'offsetInBeginSection': 827,\n",
       "     'offsetInEndSection': 977,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22561820',\n",
       "     'text': ' from individual genes; however, aberrant mRNA splicing is associated with various conditions, including heart disease. A recent study provides new me',\n",
       "     'offsetInBeginSection': 76,\n",
       "     'offsetInEndSection': 226,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35938400',\n",
       "     'text': 'e been reported in human heart defects. Defects in alternative splicing are associated with many heart diseases, yet relatively little is known about ',\n",
       "     'offsetInBeginSection': 213,\n",
       "     'offsetInEndSection': 363,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35938400',\n",
       "     'text': 'GATA4 have functional consequences and many are associated with dilated cardiomyopathy, suggesting a novel role for GATA4 in achieving the necessary c',\n",
       "     'offsetInBeginSection': 2108,\n",
       "     'offsetInEndSection': 2258,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34573439',\n",
       "     'text': 'f the available findings on the role of alternative splicing in cardiovascular disease, with a focus on atherosclerosis, myocardial infarction, heart ',\n",
       "     'offsetInBeginSection': 1130,\n",
       "     'offsetInEndSection': 1280,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35862102',\n",
       "     'text': 'ients with heart failure. However, mechanisms that maintain triadin isoform composition in the heart remain elusive.\\n\\n\\nMETHODS\\nWe analyzed triadin exp',\n",
       "     'offsetInBeginSection': 562,\n",
       "     'offsetInEndSection': 712,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29186814',\n",
       "     'text': ' smooth and cardiac muscles. Alteration of Cav1.2 channel function has been implicated in multiple cardiovascular diseases, such as hypertension and c',\n",
       "     'offsetInBeginSection': 99,\n",
       "     'offsetInEndSection': 249,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20124440',\n",
       "     'text': 'e with >98% accuracy.\\n\\n\\nCONCLUSIONS\\nOur data indicate that mRNA splicing is broadly altered in human heart disease and that patterns of aberrant RNA s',\n",
       "     'offsetInBeginSection': 1585,\n",
       "     'offsetInEndSection': 1735,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26846640',\n",
       "     'text': 'cus on the major and minor spliceosome, the factors controlling RNA splicing, and the role of alternative splicing in cardiac development and disease.',\n",
       "     'offsetInBeginSection': 1151,\n",
       "     'offsetInEndSection': 1301,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29304022',\n",
       "     'text': 'ecular mechanism of how this splicing factor is associated with dilated cardiomyopathy. Here, we review our current knowledge of muscle-specific splic',\n",
       "     'offsetInBeginSection': 444,\n",
       "     'offsetInEndSection': 594,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20124440',\n",
       "     'text': 'several types of cancer, and a small number of disease-associated changes in splicing have been reported in heart disease. However, genome-wide approa',\n",
       "     'offsetInBeginSection': 147,\n",
       "     'offsetInEndSection': 297,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21859973',\n",
       "     'text': ' A number of human diseases are associated with alternative mRNA splicing, which has received comparatively little attention in the study of cardiac disease',\n",
       "     'offsetInBeginSection': 278,\n",
       "     'offsetInEndSection': 434,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27825848',\n",
       "     'text': 'man, mis-regulation of alternative splicing has been associated with heart failure. In this short review, we focus on alternative splicing of sarcomer',\n",
       "     'offsetInBeginSection': 385,\n",
       "     'offsetInEndSection': 535,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35938400',\n",
       "     'text': 'olved in cytoskeleton organization and calcium ion import, with functional consequences associated with the protein isoforms.\\n\\n\\nCONCLUSIONS\\nThis study',\n",
       "     'offsetInBeginSection': 1685,\n",
       "     'offsetInEndSection': 1835,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26846640',\n",
       "     'text': 'd disease. In the heart, alternative splicing is increasingly being recognized as an important layer of post-transcriptional gene regulation. Moreover',\n",
       "     'offsetInBeginSection': 618,\n",
       "     'offsetInEndSection': 768,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/29304022',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/21859973',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/22561820',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/26846640',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34573439',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/27825848',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/29186814',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35862102',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34273561',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/30051286',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35938400',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32276354',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/20124440',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/30468920']},\n",
       "  {'id': '61fa941ec9dfcb9c09000005',\n",
       "   'type': 'yesno',\n",
       "   'body': \"Should Intepirdine be used for Alzheimer's disease?\",\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29848076',\n",
       "     'text': 'cognition for both idalopirdine and intepirdine, as adjunct to cholinesterase inhibitors. Paradoxically, 5-HT6 receptor agonists have also been shown ',\n",
       "     'offsetInBeginSection': 1014,\n",
       "     'offsetInEndSection': 1164,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/9179132',\n",
       "     'text': \"rement after instillation of tropicamide cannot be used as a reliable diagnostic test for Alzheimer's disease. Moreover, test-retest reliability with \",\n",
       "     'offsetInBeginSection': 1482,\n",
       "     'offsetInEndSection': 1632,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29212555',\n",
       "     'text': \"BACKGROUND\\nIn an effort to intervene earlier in Alzheimer's disease (AD), clinical trials are testing promising candidate therapies in preclinical dis\",\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/29848076',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/9179132',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/29212555']},\n",
       "  {'id': '6422e2f1690f196b51000043',\n",
       "   'type': 'factoid',\n",
       "   'body': 'What human cells are usually targeted with a Gal-Nac conjugated siRNA or ASO',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28158620',\n",
       "     'text': 'Targeted delivery of antisense oligonucleotides (ASO) to hepatocytes via the asialoglycoprotein receptor (ASGR) has improved the potency of ASO drugs ',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31303442',\n",
       "     'text': ' to selected tissues. One example is the targeted delivery of ASOs to hepatocytes, achieved with N-acetylgalactosamine (GalNAc) conjugation to ASO, wh',\n",
       "     'offsetInBeginSection': 237,\n",
       "     'offsetInEndSection': 387,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31099004',\n",
       "     'text': 'rein we describe a targeted carrier system that can deliver siRNA to cancer cells overexpressing the human epidermal growth factor 2 (HER2) receptor. ',\n",
       "     'offsetInBeginSection': 191,\n",
       "     'offsetInEndSection': 341,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26546271',\n",
       "     'text': 'Fn-GAL4:ASO transfection of non- or terminally-differentiated THP-1 cells and Vero cells resulted in 35.2 ± 19.1%, 36.4 ± 1.8% and 22.9 ± 6.9% (respec',\n",
       "     'offsetInBeginSection': 2007,\n",
       "     'offsetInEndSection': 2157,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29808997',\n",
       "     'text': 'eptor (ASGPR) can serve as potent targeting moieties for hepatocellular carcinoma (HCC) cells. However, efficient targeting to HCC via galactose moiet',\n",
       "     'offsetInBeginSection': 209,\n",
       "     'offsetInEndSection': 359,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24992960',\n",
       "     'text': 'uration of the effect of two ASOs targeting human apolipoprotein C-III and human transthyretin (TTR) in transgenic mice. The unconjugated ASOs are cur',\n",
       "     'offsetInBeginSection': 986,\n",
       "     'offsetInEndSection': 1136,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34797690',\n",
       "     'text': 'ependent localization of ASOs delivered by a modified treatment of suspension cells. Our results show that in macrophages, the uptake rate of PS-ASOs ',\n",
       "     'offsetInBeginSection': 1157,\n",
       "     'offsetInEndSection': 1307,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20964335',\n",
       "     'text': 'se siRNA conjugates have the potential for targeted delivery of siRNAs to hepatocytes and hepatic stellate cells for efficient gene silencing in vivo.',\n",
       "     'offsetInBeginSection': 1291,\n",
       "     'offsetInEndSection': 1441,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20964335',\n",
       "     'text': 'ne glycol) (M6P-PEG) for targeted delivery of siRNAs to hepatocytes and hepatic stellate cells (HSCs), respectively. These siRNA conjugates were purif',\n",
       "     'offsetInBeginSection': 295,\n",
       "     'offsetInEndSection': 445,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26546271',\n",
       "     'text': ' was achieved via the in-frame fusion of either Saccharomyces cerevisiae GAL4 or Homo sapien sapien PKR (respectively) to a truncation of Atx lethal f',\n",
       "     'offsetInBeginSection': 515,\n",
       "     'offsetInEndSection': 665,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22970170',\n",
       "     'text': '6% siRNA and exhibited a higher stability than naked siRNA in plasma. Hepatocyte-specific targeting was confirmed by in vivo delivery experiment, in w',\n",
       "     'offsetInBeginSection': 1124,\n",
       "     'offsetInEndSection': 1274,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22443209',\n",
       "     'text': 'njugates were taken up by cancer cells but not normal mammary epithelial cells or human blood monocytes. By 120 min of incubation, most of the cells h',\n",
       "     'offsetInBeginSection': 511,\n",
       "     'offsetInEndSection': 661,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19245252',\n",
       "     'text': 'conjugated to siRNA targeted against EGFP expressed in human cervical cancer (HeLa) cells and shown to efficiently silence protein expression over 72 ',\n",
       "     'offsetInBeginSection': 48,\n",
       "     'offsetInEndSection': 198,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31303442',\n",
       "     'text': 'del. Finally, GalNAc conjugation enhanced ASO activity in human circulating tumor cells from HCC patients, demonstrating the potential of this approac',\n",
       "     'offsetInBeginSection': 1112,\n",
       "     'offsetInEndSection': 1262,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22970170',\n",
       "     'text': 'ere studied in vivo in a concanavalin A (ConA)-induced hepatitis model. C57BL/6 mice were treated with Gal-LipoNP Fas siRNA by i.v. injection 72 h bef',\n",
       "     'offsetInBeginSection': 711,\n",
       "     'offsetInEndSection': 861,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24992960',\n",
       "     'text': 'mouse ASGPR, which results in enhanced ASO delivery to hepatocytes versus non-parenchymal cells. After internalization into cells, the GN3: -ASO conju',\n",
       "     'offsetInBeginSection': 523,\n",
       "     'offsetInEndSection': 673,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34797690',\n",
       "     'text': ')-labeled PS-ASOs and GalNAc-PS-ASOs in J774A.1 mouse macrophages and primary mouse or rat hepatocytes using simultaneous coherent anti-Stokes Raman s',\n",
       "     'offsetInBeginSection': 792,\n",
       "     'offsetInEndSection': 942,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28335269',\n",
       "     'text': '. These results suggest that Gal-DOX-siRNA-L could effectively target tumor cells, enhance transfection efficacy and subsequently achieve the co-deliv',\n",
       "     'offsetInBeginSection': 1363,\n",
       "     'offsetInEndSection': 1513,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15767784',\n",
       "     'text': 'ting xenoreactivity and the complement activation with human serum in PIEC cells. We also demonstrated the concordant inhibitory effect of siRNA and h',\n",
       "     'offsetInBeginSection': 606,\n",
       "     'offsetInEndSection': 756,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/28335269',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/19245252',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/15767784',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/26546271',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/31303442',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/24992960',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/29808997',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34797690',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/22970170',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/22443209',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/20964335',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/28158620',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/31099004']},\n",
       "  {'id': '64299fa957b1c7a315000002',\n",
       "   'type': 'summary',\n",
       "   'body': 'What is rebound COVID-19?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35734093',\n",
       "     'text': 'Clinical rebound of COVID-19 after nirmatrelvir/ritonavir treatment has been reported. We performed clinical, virologic, and immune measurements in se',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36181334',\n",
       "     'text': ' infection is rebound COVID-19, which occurs between five and eight days following the cessation of antiviral treatment. Most case reports of rebound ',\n",
       "     'offsetInBeginSection': 72,\n",
       "     'offsetInEndSection': 222,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33132535',\n",
       "     'text': 'o its end, will COVID-19 return again in what is known as a second rebound of the pandemic? In this work, we developed a predictive model that can est',\n",
       "     'offsetInBeginSection': 444,\n",
       "     'offsetInEndSection': 594,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35794889',\n",
       "     'text': 'nts who were treated with Paxlovid experienced rebound COVID-19 infections and symptoms 2 to 8 days after completing a 5-day course of Paxlovid. The C',\n",
       "     'offsetInBeginSection': 55,\n",
       "     'offsetInEndSection': 205,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32388934',\n",
       "     'text': 'till under global pandemic. China is facing the risks of importation and local rebound of COVID-19. Under the circumstances, preparations for medical ',\n",
       "     'offsetInBeginSection': 33,\n",
       "     'offsetInEndSection': 183,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35345769',\n",
       "     'text': '00 daily cases, from May 6 to August 14, 2020) and a rebound phase (>100 daily cases, from August 15 to December 31, 2020).\\n\\n\\nResults\\nArea-level socio',\n",
       "     'offsetInBeginSection': 842,\n",
       "     'offsetInEndSection': 992,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35794889',\n",
       "     'text': 'hree types of COVID-19 rebound outcomes (COVID-19 infections, COVID-19 related symptoms, and hospitalizations) were examined. Hazard ratios and 95% co',\n",
       "     'offsetInBeginSection': 1222,\n",
       "     'offsetInEndSection': 1372,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35982673',\n",
       "     'text': '.1 was the predominant subvariant. The risks of both COVID-19 rebound infections and symptoms 2-8 days after Paxlovid treatment were higher in the BA.',\n",
       "     'offsetInBeginSection': 959,\n",
       "     'offsetInEndSection': 1109,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36472873',\n",
       "     'text': 'ith nirmatrelvir-ritonavir have experienced rebound of COVID-19 infections and symptoms; however, data are scarce on whether viral rebound also occurs',\n",
       "     'offsetInBeginSection': 34,\n",
       "     'offsetInEndSection': 184,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35192224',\n",
       "     'text': 'the spread of COVID-19, and the framework proposed in this study will facilitate the targeted prevention and control of the ongoing COVID-19 pandemic.',\n",
       "     'offsetInBeginSection': 1959,\n",
       "     'offsetInEndSection': 2109,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35794889',\n",
       "     'text': 'ay COVID-19 rebound rates after Paxlovid treatment were 3.53% and 5.40% for COVID-19 infection, 2.31% and 5.87% for COVID-19 symptoms, and 0.44% and 0',\n",
       "     'offsetInBeginSection': 1607,\n",
       "     'offsetInEndSection': 1757,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35898366',\n",
       "     'text': 'ires no additional antiviral treatment. We present the cases of COVID-19 relapse (COVID-19 rebound) in two patients following treatment with Paxlovid.',\n",
       "     'offsetInBeginSection': 543,\n",
       "     'offsetInEndSection': 693,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35309520',\n",
       "     'text': '9 mitigation strategies are still in place. An effective COVID-19 mitigation protocol may facilitate a more successful rebound since consumers may per',\n",
       "     'offsetInBeginSection': 54,\n",
       "     'offsetInEndSection': 204,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/35345769',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35982673',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35192224',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35794889',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35309520',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35734093',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32388934',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35898366',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33132535',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36472873',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36181334']},\n",
       "  {'id': '6432fb1957b1c7a31500001e',\n",
       "   'type': 'list',\n",
       "   'body': 'What clinical applications is Zanubrutinib approved for in the United States?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35950210',\n",
       "     'text': 'ond-generation inhibitor, was recently approved in treatment-naive and refractory/relapsed patients. Here, we review the use of BTK inhibitors in WM i',\n",
       "     'offsetInBeginSection': 363,\n",
       "     'offsetInEndSection': 513,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35770040',\n",
       "     'text': 'ial, the Food and Drug Administration (FDA) approved zanubrutinib for treating WM. This trial directly compared zanubrutinib to ibrutinib in patients ',\n",
       "     'offsetInBeginSection': 1223,\n",
       "     'offsetInEndSection': 1373,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33306268',\n",
       "     'text': 'ed accelerated approval in the United States for treatment of relapsed/refractory mantle cell lymphoma. The objective of this analysis was to develop ',\n",
       "     'offsetInBeginSection': 172,\n",
       "     'offsetInEndSection': 322,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31875923',\n",
       "     'text': \"n's tyrosine kinase inhibitor with promising clinical activity in B-cell malignancies. Zanubrutinib was shown to be mainly metabolized through cytochr\",\n",
       "     'offsetInBeginSection': 49,\n",
       "     'offsetInEndSection': 199,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35306909',\n",
       "     'text': \"BTK) approved for the treatment of Waldenström's macroglobulinemia, mantle cell lymphoma, and marginal zone lymphoma. As a class, BTKs have been linke\",\n",
       "     'offsetInBeginSection': 112,\n",
       "     'offsetInEndSection': 262,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33025948',\n",
       "     'text': 'pproved by the U.S. Food and Drug Administration (FDA) in late 2019 for r/r MCL on the basis of combined overall response rate of 84% in a total of 11',\n",
       "     'offsetInBeginSection': 317,\n",
       "     'offsetInEndSection': 467,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35651781',\n",
       "     'text': ' treating adults with mantle cell lymphoma who have received at least one prior therapy, for adults with Waldenström macroglobulinemia, and for adults with relapsed or refractory marginal zone lymphoma who have received at least one anti-CD20-based therapy',\n",
       "     'offsetInBeginSection': 633,\n",
       "     'offsetInEndSection': 889,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35770040',\n",
       "     'text': 'ast BTK inhibitor to currently penetrate the market for B-cell lymphoproliferative malignancies, we highlight the emergence of zanubrutinib as a key p',\n",
       "     'offsetInBeginSection': 1882,\n",
       "     'offsetInEndSection': 2032,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35651781',\n",
       "     'text': ' treatment of adult patients with MCL who have received at least one prior therapy, for adults with WM, and for adults with MZL who have received at least one anti-CD20-based therapy',\n",
       "     'offsetInBeginSection': 3256,\n",
       "     'offsetInEndSection': 3438,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35651781',\n",
       "     'text': 'ies on zanubrutinib treatment appear promising in patients with several types of B-cell malignancies, including mantle cell lymphoma (MCL), Waldenströ',\n",
       "     'offsetInBeginSection': 2614,\n",
       "     'offsetInEndSection': 2764,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32753893',\n",
       "     'text': ' FDA recently approved zanubrutinib for the treatment of patients with relapsed/refractory MCL based on the results of two Phase 2 clinical trials sho',\n",
       "     'offsetInBeginSection': 461,\n",
       "     'offsetInEndSection': 611,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32869675',\n",
       "     'text': 'nt. Zanubrutinib is currently approved for the treatment of patients with relapsed mantle cell lymphoma and has demonstrated an impressive safety and ',\n",
       "     'offsetInBeginSection': 697,\n",
       "     'offsetInEndSection': 847,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35306909',\n",
       "     'text': \"nated cryptococcosis in the setting of zanubrutinib use for Waldenström's macroglobulinemia. At the time of diagnosis, his Waldenström's macroglobulin\",\n",
       "     'offsetInBeginSection': 1137,\n",
       "     'offsetInEndSection': 1287,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34051727',\n",
       "     'text': 'recently licensed in refractory mantle cell lymphoma and under assessment in phase 3 clinical trials for other B cell malignancies. To date, there are',\n",
       "     'offsetInBeginSection': 78,\n",
       "     'offsetInEndSection': 228,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35680835',\n",
       "     'text': 'foundation for precision therapy. In this review the clinical application and new progress for zanubrutinib in B-cell lymphoma was summarized briefly.',\n",
       "     'offsetInBeginSection': 510,\n",
       "     'offsetInEndSection': 660,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36252483',\n",
       "     'text': 'oved for the treatment of mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). While its role in pulmon',\n",
       "     'offsetInBeginSection': 611,\n",
       "     'offsetInEndSection': 761,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33777941',\n",
       "     'text': 'pan. In most cases, these compounds have been used for the treatment of B-lymphocyte tumors. However, an increasing number of trials instead addresses',\n",
       "     'offsetInBeginSection': 689,\n",
       "     'offsetInEndSection': 839,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34558376',\n",
       "     'text': '6, zanubrutinib, BGB-3111, and Waldenström macroglobulinemia. Prospective clinical trials evaluating the efficacy and safety of ibrutinib, acalabrutin',\n",
       "     'offsetInBeginSection': 308,\n",
       "     'offsetInEndSection': 458,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36252483',\n",
       "     'text': 's approved for the treatment of mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). While its role in ',\n",
       "     'offsetInBeginSection': 605,\n",
       "     'offsetInEndSection': 755,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32861286',\n",
       "     'text': 'utinib, are all approved in the United States for the treatment of relapsed mantle cell lymphoma (MCL). BTKi as a class have become the preferred ther',\n",
       "     'offsetInBeginSection': 82,\n",
       "     'offsetInEndSection': 232,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32869675',\n",
       "     'text': 'nubrutinib is currently approved for the treatment of patients with relapsed mantle cell lymphoma and has demonstrated an impressive safety and effica',\n",
       "     'offsetInBeginSection': 703,\n",
       "     'offsetInEndSection': 853,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34664792',\n",
       "     'text': 'bolism and transport of zanubrutinib, and its potential for clinical drug-drug interactions (DDIs). Phenotyping studies indicated cytochrome P450 (CYP',\n",
       "     'offsetInBeginSection': 176,\n",
       "     'offsetInEndSection': 326,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34558376',\n",
       "     'text': 'anubrutinib, have been evaluated in prospective clinical trials for the treatment of Waldenström macroglobulinemia. All three agents have demonstrated',\n",
       "     'offsetInBeginSection': 1159,\n",
       "     'offsetInEndSection': 1309,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34558376',\n",
       "     'text': 'been evaluated in prospective clinical trials for the treatment of Waldenström macroglobulinemia. All three agents have demonstrated high overall resp',\n",
       "     'offsetInBeginSection': 1177,\n",
       "     'offsetInEndSection': 1327,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31933167',\n",
       "     'text': 'al in the USA on 14 November 2019 for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy, ba',\n",
       "     'offsetInBeginSection': 201,\n",
       "     'offsetInEndSection': 351,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33025948',\n",
       "     'text': 'd other B-cell malignancies. These current results and areas of further interest indicate an exciting future for zanubrutinib in the treatment of MCL.',\n",
       "     'offsetInBeginSection': 1151,\n",
       "     'offsetInEndSection': 1301,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/34558376',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33025948',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32861286',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34051727',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34664792',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/31933167',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35950210',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35680835',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36252483',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35651781',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/31875923',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35770040',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33777941',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35306909',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32753893',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32869675',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33306268']},\n",
       "  {'id': '61f7cb37882a024a10000029',\n",
       "   'type': 'yesno',\n",
       "   'body': 'Is rilonacept effective for pericarditis?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36250662',\n",
       "     'text': 'ditis: a pivotal symptomatology and outcomes study) evaluated the efficacy and safety of rilonacept (IL-1α and -β cytokine trap) in recurrent pericard',\n",
       "     'offsetInBeginSection': 228,\n",
       "     'offsetInEndSection': 378,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33200890',\n",
       "     'text': '-1 has been implicated as a mediator of recurrent pericarditis. The efficacy and safety of rilonacept, an interleukin-1α and interleukin-1β cytokine t',\n",
       "     'offsetInBeginSection': 22,\n",
       "     'offsetInEndSection': 172,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36398320',\n",
       "     'text': 'both IL-1α and IL-1β, thereby inhibiting the IL-1 pathway. It is safe and efficacious in the treatment of recurrent pericarditis in the RHAPSODY II an',\n",
       "     'offsetInBeginSection': 721,\n",
       "     'offsetInEndSection': 871,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23754188',\n",
       "     'text': '>50% of rilonacept-treated patients over 2 years. Treatment with rilonacept had a substantial steroid-sparing effect and was generally well-tolerated.',\n",
       "     'offsetInBeginSection': 2012,\n",
       "     'offsetInEndSection': 2162,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36316102',\n",
       "     'text': 'rapies while transitioning to rilonacept monotherapy was feasible without triggering pericarditis recurrence.\\n\\n\\nTRIAL REGISTRATION NUMBER\\nNCT03737110.',\n",
       "     'offsetInBeginSection': 1909,\n",
       "     'offsetInEndSection': 2059,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33882846',\n",
       "     'text': ' and as an exploratory endpoint in a Phase 2 trial evaluating the efficacy and safety of rilonacept (IL-1α/IL-1β cytokine trap) to treat RP.\\n\\n\\nMETHODS',\n",
       "     'offsetInBeginSection': 151,\n",
       "     'offsetInEndSection': 301,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35350578',\n",
       "     'text': 'IL-1 agents such as anakinra and rilonacept have been demonstrated highly effective in patients with recurrent pericarditis associated with an inflamm',\n",
       "     'offsetInBeginSection': 2187,\n",
       "     'offsetInEndSection': 2337,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34459270',\n",
       "     'text': 'nce, more persistent clinical response, and higher amount of days with no or minimal pericarditis symptoms, compared with placebo. The median time to ',\n",
       "     'offsetInBeginSection': 667,\n",
       "     'offsetInEndSection': 817,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19649332',\n",
       "     'text': 'or CNICA/NOMID. It is yet to be determined whether rilonacept would be an effective treatment for other chronic inflammatory conditions such as gout, ',\n",
       "     'offsetInBeginSection': 1977,\n",
       "     'offsetInEndSection': 2127,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35639340',\n",
       "     'text': ' include canakinumab, anakinra, and rilonacept. Both anakinra and rilonacept have demonstrated efficacy in randomized trials of patients with recurren',\n",
       "     'offsetInBeginSection': 615,\n",
       "     'offsetInEndSection': 765,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34008144',\n",
       "     'text': 'th additional morbidity from long-term steroid use. Recent randomized trials indicate the efficacy of the interleukin-1 inhibitors anakinra and rilona',\n",
       "     'offsetInBeginSection': 225,\n",
       "     'offsetInEndSection': 375,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33229362',\n",
       "     'text': 'play a major role in RP. This phase II study evaluated rilonacept efficacy and safety in RP.\\n\\n\\nMETHODS\\nThis multicentre, open-label study enrolled adu',\n",
       "     'offsetInBeginSection': 163,\n",
       "     'offsetInEndSection': 313,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33737453',\n",
       "     'text': 'CLUSIONS\\nIn patients with RP, anti-IL-1 agents (anakinra and rilonacept) are efficacious for prevention of recurrences, without severe adverse events.',\n",
       "     'offsetInBeginSection': 1552,\n",
       "     'offsetInEndSection': 1702,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33737453',\n",
       "     'text': 'hs (IQR,12-39), patients receiving anti-IL-1 agents (anakinra or rilonacept) had a significantly reduction in pericarditis recurrences (incidence rate',\n",
       "     'offsetInBeginSection': 907,\n",
       "     'offsetInEndSection': 1057,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34319478',\n",
       "     'text': 'nt pericarditis, has recently reached phase 3 with promising results in terms of efficacy and safety. Alterations in the function of the inflammasome ',\n",
       "     'offsetInBeginSection': 476,\n",
       "     'offsetInEndSection': 626,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34459270',\n",
       "     'text': 'OBJECTIVE\\nTo review the pharmacology, efficacy, and safety of rilonacept for the prevention and treatment of recurrent pericarditis (RP).\\n\\n\\nDATA SOURC',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34156376',\n",
       "     'text': 'Rilonacept (Araclyst) has been approved to treat recurrent pericarditis and to reduce the risk of recurrence in adults and children 12 years of age an',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34569270',\n",
       "     'text': 'and rilonacept, have demonstrated beneficial impact in clinical outcomes with a reasonable safety profile in randomized clinical trials. There is stil',\n",
       "     'offsetInBeginSection': 830,\n",
       "     'offsetInEndSection': 980,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34160952',\n",
       "     'text': 'ness of anakinra with a good safety profile. Other IL-1 receptor antagonists have shown promising results (canakinumab, rilonacept). Further evaluatio',\n",
       "     'offsetInBeginSection': 1070,\n",
       "     'offsetInEndSection': 1220,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34334059',\n",
       "     'text': '\\n\\nAREAS COVERED\\nThe review is aimed at providing an update on the efficacy and safety of current medical therapies for recurrent pericarditis includin',\n",
       "     'offsetInBeginSection': 558,\n",
       "     'offsetInEndSection': 708,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36316102',\n",
       "     'text': 'ith rilonacept, which was hypothesised to allow accelerated withdrawal of common multidrug pericarditis regimens.\\n\\n\\nMETHODS\\nRHAPSODY was a multicentre',\n",
       "     'offsetInBeginSection': 462,\n",
       "     'offsetInEndSection': 612,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32866928',\n",
       "     'text': 'ndent on corticosteroids. Rilonacept (KPL-914), an interleukin-1α and β inhibitor, is in development for the treatment of RP. RHAPSODY, a double-blind',\n",
       "     'offsetInBeginSection': 216,\n",
       "     'offsetInEndSection': 366,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34599390',\n",
       "     'text': ' IL-1-targeted therapies, such as anakinra and rilonacept, were found to effectively blunt the acute inflammation and reduce the risk for recurrences.',\n",
       "     'offsetInBeginSection': 1109,\n",
       "     'offsetInEndSection': 1259,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23754188',\n",
       "     'text': 'OBJECTIVE\\nTo determine the long-term safety and efficacy of rilonacept, an anti-interleukin-1 fusion protein, in patients with active systemic juvenil',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36316102',\n",
       "     'text': 'rilonacept at the labelled dose level and discontinued oral pericarditis therapies during the 12-week run-in; randomised patients received study drug ',\n",
       "     'offsetInBeginSection': 767,\n",
       "     'offsetInEndSection': 917,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34650361',\n",
       "     'text': 'kin 1 blockers anakinra and rilonacept, particularly indicated in refractory forms dependent on corticosteroids. Other medically relevant therapeutic ',\n",
       "     'offsetInBeginSection': 624,\n",
       "     'offsetInEndSection': 774,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34459270',\n",
       "     'text': ' administered IL-1 \"trap,\" indicated for the treatment of RP, and reduction in risk of recurrent pericarditis in adults and children ≥12 years of age.',\n",
       "     'offsetInBeginSection': 1622,\n",
       "     'offsetInEndSection': 1772,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/33229362',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34459270',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/23754188',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34160952',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34599390',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33200890',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/19649332',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35350578',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36250662',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34156376',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34008144',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36398320',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35639340',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33737453',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33882846',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34319478',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36316102',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34650361',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34569270',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32866928',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34334059']},\n",
       "  {'id': '6413712a201352f04a00003e',\n",
       "   'type': 'list',\n",
       "   'body': 'The 1p19q co-deletion is associated with what types of tumors?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34125374',\n",
       "     'text': 'INTRODUCTION\\nAnaplastic oligodendrogliomas are high-grade gliomas defined molecularly by 1p19q co-deletion. There is no curative therapy, and standard',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33361717',\n",
       "     'text': 'deletion of 1p19q (1p19q codel) is a prerequisite for diagnosis of oligodendroglioma, making it imperative that histopathology laboratories introduce ',\n",
       "     'offsetInBeginSection': 58,\n",
       "     'offsetInEndSection': 208,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25971646',\n",
       "     'text': \"ty and review the process of 1p19q co-deletion assessment using FISH in gliomas from a clinician's perspective. We also consider common alternative me\",\n",
       "     'offsetInBeginSection': 956,\n",
       "     'offsetInEndSection': 1106,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24197863',\n",
       "     'text': ' expression was strongly associated with the 1p/19q co-deletion in oligodendroglial tumors, indicating a potential surrogate marker of the 1p/19q stat',\n",
       "     'offsetInBeginSection': 958,\n",
       "     'offsetInEndSection': 1108,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28340142',\n",
       "     'text': 'creased in high-risk IDH-mutant with 1p/19q co-deletion gliomas and IDH-wild-type glioblastomas but not in IDH-wild-type lower grade or IDH-mutant, no',\n",
       "     'offsetInBeginSection': 1387,\n",
       "     'offsetInEndSection': 1537,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25971646',\n",
       "     'text': '1p19q co-deletion is a chromosomal alteration associated with primary brain tumours of oligodendroglial histology. It is an established predictive and',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23344797',\n",
       "     'text': 'neurocognitive toxicity of radiotherapy should be the initial therapy for AO tumors with codeleted 1p19q, or whether temozolomide, an oral agent with ',\n",
       "     'offsetInBeginSection': 1439,\n",
       "     'offsetInEndSection': 1589,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26257825',\n",
       "     'text': 'H results for 1p19q co-deletions (n\\u2009=\\u20099) or EGFR amplification (n\\u2009=\\u20098). Gliomas positive for 1p19q co-deletions did not have other frequently recurren',\n",
       "     'offsetInBeginSection': 547,\n",
       "     'offsetInEndSection': 697,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18565359',\n",
       "     'text': 'uation. Data concerning low-grade gliomas were more controversial. Oligodendroglial tumors with 1p deletion or 1p19q codeletion seemed to have a bette',\n",
       "     'offsetInBeginSection': 1462,\n",
       "     'offsetInEndSection': 1612,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29704080',\n",
       "     'text': 'o map spatial metabolite differences across three molecular subgroups of glial tumors, defined by the IDH1/2 mutation and 1p19q-co-deletion, using mag',\n",
       "     'offsetInBeginSection': 41,\n",
       "     'offsetInEndSection': 191,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25537428',\n",
       "     'text': ', IDH mutation and 1p19q co-deletion were significantly associated with AO/AOA (p\\xa0<\\xa00.0001). No tumors with IDH mutation and 1p19q co-deletion infiltr',\n",
       "     'offsetInBeginSection': 630,\n",
       "     'offsetInEndSection': 780,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30656222',\n",
       "     'text': 'ate the differences in pattern of care and outcome by comparing grade II and grade III molecularly defined 1p19q co-deleted gliomas. We evaluated 1618',\n",
       "     'offsetInBeginSection': 151,\n",
       "     'offsetInEndSection': 301,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/18710393',\n",
       "     'text': 'Co-deletion of chromosome arms 1p and 19q, characteristic of oligodendroglial tumors, was recently found to be mediated by t(1;19)(q10;p10). To evalua',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21653654',\n",
       "     'text': ' in 10q24.33. A strong INA protein expression has been reported in oligodendroglial tumours and was associated with 1p19q deletion. To assess the rele',\n",
       "     'offsetInBeginSection': 109,\n",
       "     'offsetInEndSection': 259,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24197863',\n",
       "     'text': ' The positive expression of INA was observed in 10 cases (52\\xa0%) of oligodendroglial tumors with the 1p/19q co-deletion, and in only 3 cases of oligode',\n",
       "     'offsetInBeginSection': 443,\n",
       "     'offsetInEndSection': 593,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32005184',\n",
       "     'text': 'BACKGROUND\\nGliomas consist of a heterogeneous group of tumors. This study aimed to report the incidences of O6-methylguanine-DNA-methyltransferase (MG',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26257825',\n",
       "     'text': 'a broader picture of the genomic alterations occurring in glioma cases. Gliomas with 1p19q co-deletion had a relatively quiet genome, apart from the s',\n",
       "     'offsetInBeginSection': 1193,\n",
       "     'offsetInEndSection': 1343,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20035368',\n",
       "     'text': 'tions. Seven of the eight tumors with co-deletion of 1p/19q were WHO grade II gliomas. There were no statistical differences between tumors with 1p/19',\n",
       "     'offsetInBeginSection': 775,\n",
       "     'offsetInEndSection': 925,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24197863',\n",
       "     'text': 'α-Internexin (INA) has been proposed as a biomarker of oligodendroglial tumors with the 1p/19q co-deletion. On the other hand, sequence studies have r',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34729052',\n",
       "     'text': 'on loss, p53 overexpression, and 1p/19q co-deletion detection in adult diffuse gliomas (Grade II, III, and IV) and to correlate them with clinicopatho',\n",
       "     'offsetInBeginSection': 586,\n",
       "     'offsetInEndSection': 736,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20081802',\n",
       "     'text': 'In glial tumors, the loss of heterozygosity of the 1p and 19q chromosomal arms is thought to be a marker of good prognosis in oligodendroglial tumors.',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26257825',\n",
       "     'text': 'ng copy number changes and loss of heterozygosity were identified in 17 glioma samples with positive FISH results for 1p19q co-deletions (n\\u2009=\\u20099) or EG',\n",
       "     'offsetInBeginSection': 443,\n",
       "     'offsetInEndSection': 593,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28340142',\n",
       "     'text': 'Background\\nCo-deletion of 1p and 19q marks a diffuse glioma subtype associated with relatively favorable overall survival; however, heterogeneous clin',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34729052',\n",
       "     'text': 'IDH1/2, ATRX, and p53 is useful for the molecular classification of diffuse gliomas, which could be useful for the evaluation of prognosis, especially',\n",
       "     'offsetInBeginSection': 1511,\n",
       "     'offsetInEndSection': 1661,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24608451',\n",
       "     'text': 'p and/or 19q with or without deletions were seen in 76.9% of mixed oligoastrocytic tumors, 7.7% of pure OD tumors and one glioblastoma.\\n\\n\\nCONCLUSIONS\\n',\n",
       "     'offsetInBeginSection': 1207,\n",
       "     'offsetInEndSection': 1357,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20587495',\n",
       "     'text': 'sociated with the 1p19q codeletion were predominantly located in the frontal lobe (p=0.044). The magnetic resonance image characteristics of indistinc',\n",
       "     'offsetInBeginSection': 589,\n",
       "     'offsetInEndSection': 739,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34729052',\n",
       "     'text': 'ate dehydrogenase (IDH) mutations and 1p/19q co-deletion with histopathological features into an \"integrated diagnosis\" in the revised classification ',\n",
       "     'offsetInBeginSection': 166,\n",
       "     'offsetInEndSection': 316,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20446099',\n",
       "     'text': 'seminated tumor with mixed immunohistochemical features of oligodendroglioma and neurocytoma was encountered and treated. Stereotactic right frontal c',\n",
       "     'offsetInBeginSection': 219,\n",
       "     'offsetInEndSection': 369,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20035368',\n",
       "     'text': 'tion to previous reports, loss of 1p/19q occurs commonly in insular oligodendroglial tumors. With respect to 1p/19q, insular gliomas do not appear to ',\n",
       "     'offsetInBeginSection': 1300,\n",
       "     'offsetInEndSection': 1450,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/24608451',\n",
       "     'text': 'had an OD component. 1p and 19q codeletions were seen in 72.7% of oligodendrogliomas (World Health Organization [WHO] Grade II), 90.9% of anaplastic o',\n",
       "     'offsetInBeginSection': 454,\n",
       "     'offsetInEndSection': 604,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/32005184',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33361717',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/25971646',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34125374',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/29704080',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/20446099',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34729052',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/25537428',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/20035368',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/21653654',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/18565359',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/28340142',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/18710393',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/26257825',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/24197863',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/20587495',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/24608451',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/23344797',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/20081802',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/30656222']},\n",
       "  {'id': '6429ad3857b1c7a315000003',\n",
       "   'type': 'factoid',\n",
       "   'body': 'The X-inactive specific transcript (Xist) gene is responsible for mediating the X-chromosome inactivation in females, where one X-chromosome is silenced and transcriptionally inactivated. What does Xist encode?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/23166390',\n",
       "     'text': 'e master regulator of X-inactivation. The Xist gene produces a non-coding RNA that functions as the primary switch for X-inactivation, coating the X c',\n",
       "     'offsetInBeginSection': 432,\n",
       "     'offsetInEndSection': 582,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/14973270',\n",
       "     'text': 'cific transcript) plays a crucial role in X-inactivation. This non-coding RNA becomes upregulated on the X chromosome that is to be inactivated upon d',\n",
       "     'offsetInBeginSection': 20,\n",
       "     'offsetInEndSection': 170,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/21471966',\n",
       "     'text': ' X-linked gene products between the sexes. The developmental regulation of this process has been extensively investigated in mice, where the X chromosome of paternal origin (Xp) is silenced during early embryogenesis owing to imprinted expression of the regulatory RNA',\n",
       "     'offsetInBeginSection': 80,\n",
       "     'offsetInEndSection': 348,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25000994',\n",
       "     'text': 'evelopment and is initiated by a unique locus, which produces a long noncoding RNA, Xist. The Xist transcript triggers gene silencing in cis by coatin',\n",
       "     'offsetInBeginSection': 241,\n",
       "     'offsetInEndSection': 391,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/9722171',\n",
       "     'text': 'rom the allele on the inactive X. The Xist transcript does not encode a protein but remains sequestered within the nucleus and co-localises with the i',\n",
       "     'offsetInBeginSection': 333,\n",
       "     'offsetInEndSection': 483,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/9069284',\n",
       "     'text': 's unusual in that it appears not to code for a protein but produces a nuclear RNA which colocalizes with the inactive X chromosome. The creation of a ',\n",
       "     'offsetInBeginSection': 660,\n",
       "     'offsetInEndSection': 810,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32482714',\n",
       "     'text': 'gulator of X chromosome inactivation in mammals. Xist produces a long noncoding (lnc)RNA that accumulates over the entire length of the chromosome fro',\n",
       "     'offsetInBeginSection': 63,\n",
       "     'offsetInEndSection': 213,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/9722171',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/25000994',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/23166390',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32482714',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/9069284',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/21471966',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/14973270']},\n",
       "  {'id': '63f92fd033942b094c00000b',\n",
       "   'type': 'summary',\n",
       "   'body': 'What are microexons?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34346508',\n",
       "     'text': 'The splicing of microexons (very small exons) is frequently dysregulated in the brain of individuals with autism spectrum disorder. However, little is',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34155820',\n",
       "     'text': 'Microexons are small sized (≤51\\u2009bp) exons which undergo extensive alternative splicing in neurons, microglia, embryonic stem cells, and cancer cells, ',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35895262',\n",
       "     'text': ' data for detection and quantification of microexons, extremely short exons of length up to 30\\xa0nt, require specialized computational workflows. Here, ',\n",
       "     'offsetInBeginSection': 229,\n",
       "     'offsetInEndSection': 379,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/10805741',\n",
       "     'text': 'ns six copies of the simple sequence GGGGCUG. The enhancer activates heterologous microexons and will work when located either upstream or downstream ',\n",
       "     'offsetInBeginSection': 716,\n",
       "     'offsetInEndSection': 866,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31559909',\n",
       "     'text': 'Neuronal microexons represent the most highly conserved class of alternative splicing events and their timed expression shapes neuronal biology, inclu',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34836511',\n",
       "     'text': 'BACKGROUND\\nMicroexons are a particular kind of exon of less than 30 nucleotides in length. More than 60% of annotated human microexons were found to h',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33859668',\n",
       "     'text': ' regulation of gene expression. Exons with a length ≤ 30 nt are defined as microexons that are unique in identification. However, microexons, especial',\n",
       "     'offsetInBeginSection': 123,\n",
       "     'offsetInEndSection': 273,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30526869',\n",
       "     'text': '2018), and Gonatopoulos-Pournatzis et\\xa0al. (2018) uncover novel mechanisms by which the cell regulates splicing of cryptic splice sites and microexons.',\n",
       "     'offsetInBeginSection': 75,\n",
       "     'offsetInEndSection': 225,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33621242',\n",
       "     'text': 'expression or activity of splicing factors (SFs). Microexons are extremely small exons (3-27 nucleotides long) that are highly evolutionarily conserve',\n",
       "     'offsetInBeginSection': 73,\n",
       "     'offsetInEndSection': 223,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34348142',\n",
       "     'text': 'Microexons (≤27 nt) play critical roles in nervous system development and function but create unique challenges for the splicing machinery. The mechan',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/27502555',\n",
       "     'text': 'ved AS program comprising hundreds of alternative exons, microexons and introns that is differentially regulated in planarian stem cells, and comprehe',\n",
       "     'offsetInBeginSection': 416,\n",
       "     'offsetInEndSection': 566,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25525873',\n",
       "     'text': '-like regulation. These microexons modulate the function of interaction domains of proteins involved in neurogenesis. Most neural microexons are regul',\n",
       "     'offsetInBeginSection': 457,\n",
       "     'offsetInEndSection': 607,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33482885',\n",
       "     'text': 'BACKGROUND\\nMicroexons, exons that are ≤\\u200930 nucleotides, are a highly conserved and dynamically regulated set of cassette exons. They have key roles in',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30388412',\n",
       "     'text': 't control splicing and apply it to microexons with important functions in nervous system development and that are commonly misregulated in autism. App',\n",
       "     'offsetInBeginSection': 279,\n",
       "     'offsetInEndSection': 429,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31999954',\n",
       "     'text': 'Microexons represent the most highly conserved class of alternative splicing, yet their functions are poorly understood. Here, we focus on closely rel',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30833759',\n",
       "     'text': 'ution are poorly understood. Neuronal microexons represent the most conserved class of alternative splicing in vertebrates, and are critical for prope',\n",
       "     'offsetInBeginSection': 80,\n",
       "     'offsetInEndSection': 230,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35145097',\n",
       "     'text': 'It is challenging to identify the smallest microexons (≤15-nt) due to their small size. Consequently, these microexons are often misannotated or misse',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35858306',\n",
       "     'text': 'evealing that the vertebrate retina expresses the largest number of tissue-enriched microexons of all tissue types. A subset of these microexons is in',\n",
       "     'offsetInBeginSection': 293,\n",
       "     'offsetInEndSection': 443,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28188674',\n",
       "     'text': ' ability of the spliceosome to recognize a set of very small (3-30 nucleotide, 1-10 amino acid) exons named microexons. Despite their small size, micr',\n",
       "     'offsetInBeginSection': 125,\n",
       "     'offsetInEndSection': 275,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32535349',\n",
       "     'text': 'The discovery and characterization of a network of highly conserved neuronal microexons has provided fundamental new insight into mechanisms underlyin',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20659428',\n",
       "     'text': 'f the domain with dynamin 1. Thus microexons provide a mechanism for the control of tissue-specific interactions of ITSN1 and Src with their partners.',\n",
       "     'offsetInBeginSection': 1225,\n",
       "     'offsetInEndSection': 1375,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35089784',\n",
       "     'text': 'tricted to neurons by the posttranscriptional processing of the enhancer of microexons (eMIC) domain in Srrm234. In Drosophila, this processing is dep',\n",
       "     'offsetInBeginSection': 347,\n",
       "     'offsetInEndSection': 497,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30404949',\n",
       "     'text': 'skipping of microexons is an increasingly recognized class of alternative splicing events. However, the functional significance of microexons and thei',\n",
       "     'offsetInBeginSection': 26,\n",
       "     'offsetInEndSection': 176,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25838543',\n",
       "     'text': ' an emerging class of highly conserved AS events associated with the regulation of protein interaction networks in developing neurons and neurological disorders',\n",
       "     'offsetInBeginSection': 880,\n",
       "     'offsetInEndSection': 1040,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20659428',\n",
       "     'text': 'nce analysis of ITSN1 and Src genes revealed the conservation of alternatively spliced microexons affecting the structure of the SH3 domains in verteb',\n",
       "     'offsetInBeginSection': 305,\n",
       "     'offsetInEndSection': 455,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/35895262',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/20659428',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35858306',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35089784',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/31559909',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34346508',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/31999954',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35145097',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33859668',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/25525873',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33621242',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/30388412',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34348142',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33482885',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/10805741',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/30526869',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32535349',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34836511',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/28188674',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/25838543',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34155820',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/27502555',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/30404949',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/30833759']},\n",
       "  {'id': '64041f38201352f04a00001f',\n",
       "   'type': 'yesno',\n",
       "   'body': 'Is tebentafusp effective for uveal melanoma?',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19032679',\n",
       "     'text': 'therapeutic option today against metastatic uveal melanoma, has not proved to be effective. Therefore, new molecular targets important for malignant p',\n",
       "     'offsetInBeginSection': 182,\n",
       "     'offsetInEndSection': 332,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16489097',\n",
       "     'text': 'therapeutic option today against metastatic uveal melanoma, has not proved to be effective. Therefore, new molecular targets important for malignant p',\n",
       "     'offsetInBeginSection': 184,\n",
       "     'offsetInEndSection': 334,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35716258',\n",
       "     'text': 'PURPOSE\\nAnti-angiogenesis drug therapy is ineffective in treating uveal melanoma since it only targets angiogenesis leaving vasculogenic mimicry aside',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35115315',\n",
       "     'text': 'Tebentafusp, the first drug shown to extend overall survival in people with uveal melanoma, was greenlighted by the FDA in late January to treat patie',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35804863',\n",
       "     'text': 'cell receptor against the cancer molecule tebentafusp showed impressive antitumor effects. Meanwhile, oncolytic viruses and small molecule inhibitors ',\n",
       "     'offsetInBeginSection': 1143,\n",
       "     'offsetInEndSection': 1293,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34551229',\n",
       "     'text': ' with metastatic uveal melanoma. Data showing a proven overall survival benefit with a systemic treatment are lacking. Tebentafusp is a bispecific pro',\n",
       "     'offsetInBeginSection': 178,\n",
       "     'offsetInEndSection': 328,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/20375921',\n",
       "     'text': 'n the remaining case. Uveal melanoma, like cutaneous melanoma, commonly expresses GPNMB. Ongoing clinical trials of CDX-011 should be extended to pati',\n",
       "     'offsetInBeginSection': 1488,\n",
       "     'offsetInEndSection': 1638,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36442912',\n",
       "     'text': ' people of Asian or Pacific Island ancestry. While uveal melanoma is most common in Caucasian populations, other HLA-restricted cancer therapeutics ar',\n",
       "     'offsetInBeginSection': 703,\n",
       "     'offsetInEndSection': 853,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32816891',\n",
       "     'text': 'd at baseline and on-treatment.\\n\\n\\nRESULTS\\nTebentafusp was generally well-tolerated and active in both patients with metastatic uveal melanoma and pati',\n",
       "     'offsetInBeginSection': 671,\n",
       "     'offsetInEndSection': 821,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34551229',\n",
       "     'text': ' reported.\\n\\n\\nCONCLUSIONS\\nTreatment with tebentafusp resulted in longer overall survival than the control therapy among previously untreated patients w',\n",
       "     'offsetInBeginSection': 1932,\n",
       "     'offsetInEndSection': 2082,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36102132',\n",
       "     'text': 'ith investigator choice therapy.\\n\\n\\nEXPERT OPINION\\nTebentafusp has transformed the treatment paradigm for metastatic uveal melanoma and should be the p',\n",
       "     'offsetInBeginSection': 759,\n",
       "     'offsetInEndSection': 909,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29692251',\n",
       "     'text': ' malignancy in adults. So far, there have been no effective targeted therapeutic agents in patients with uveal melanoma. Artesunate is a semi-syntheti',\n",
       "     'offsetInBeginSection': 64,\n",
       "     'offsetInEndSection': 214,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/1589858',\n",
       "     'text': 'no effective treatment currently exists for metastatic uveal melanoma. However, several new approaches involving interferons and interleukin and combination chemotherapy have shown some activity against metastatic cutaneous melanoma. The effectiveness against metastatic uveal melanomas has not been determined',\n",
       "     'offsetInBeginSection': 235,\n",
       "     'offsetInEndSection': 545,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35236927',\n",
       "     'text': \"AC (Immune-mobilizing monoclonal TCRs against cancer), has now shown an overall survival benefit when compared to investigator's choice. This review a\",\n",
       "     'offsetInBeginSection': 603,\n",
       "     'offsetInEndSection': 753,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31344957',\n",
       "     'text': 'rials have been conducted for metastasized uveal melanoma, no definitive treatment strategy exists for this rare disease. The outcomes of most immunot',\n",
       "     'offsetInBeginSection': 872,\n",
       "     'offsetInEndSection': 1022,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36229663',\n",
       "     'text': 'iographic progression. Our findings indicate that tebentafusp has promising clinical activity with an acceptable safety profile in patients with previ',\n",
       "     'offsetInBeginSection': 1301,\n",
       "     'offsetInEndSection': 1451,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31336704',\n",
       "     'text': 'anoma, kinase inhibitors and immune checkpoint inhibitors are usually ineffective in patients with metastatic uveal melanoma. Tebentafusp is a novel f',\n",
       "     'offsetInBeginSection': 206,\n",
       "     'offsetInEndSection': 356,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/33839690',\n",
       "     'text': 'rolong survival among patients with an aggressive form of eye cancer. If approved, tebentafusp could become the standard of care for metastatic uveal ',\n",
       "     'offsetInBeginSection': 102,\n",
       "     'offsetInEndSection': 252,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35254876',\n",
       "     'text': 'o assess its safety, pharmacokinetics, pharmacodynamics, and preliminary clinical activity in patients with metastatic uveal melanoma (mUM).\\n\\n\\nMETHODS',\n",
       "     'offsetInBeginSection': 206,\n",
       "     'offsetInEndSection': 356,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29692251',\n",
       "     'text': 'e on uveal melanoma remains unknown.\\n\\n\\nOBJECTIVE\\nWe evaluated the anti-tumor effects of artesunate on uveal melanoma cells, and analyzed in terms of W',\n",
       "     'offsetInBeginSection': 553,\n",
       "     'offsetInEndSection': 703,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35468881',\n",
       "     'text': 'Chemotherapy resistance poses an obstacle for effective treatment of uveal melanoma. In this study, we aim to investigate the effects of jumonji domai',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36094043',\n",
       "     'text': 'year. This medication, tebentafusp, is likely to improve life expectancy for all patients with metastatic melanoma assuming they have appropriate huma',\n",
       "     'offsetInBeginSection': 906,\n",
       "     'offsetInEndSection': 1056,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36442912',\n",
       "     'text': 'al generated significant excitement, given the relative paucity of effective systemic therapies for advanced uveal melanoma. More broadly, tebentafusp',\n",
       "     'offsetInBeginSection': 248,\n",
       "     'offsetInEndSection': 398,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35060440',\n",
       "     'text': ' action, degree of efficacy and safety profile, tebentafusp is expected to change the standard of care for treating metastatic and, potentially locali',\n",
       "     'offsetInBeginSection': 1191,\n",
       "     'offsetInEndSection': 1341,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36065296',\n",
       "     'text': \"ntly validated by the FDA's approval of tebentafusp for treatment of metastatic uveal melanoma. ImmTAV® are an application of this technology undergoi\",\n",
       "     'offsetInBeginSection': 550,\n",
       "     'offsetInEndSection': 700,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/29692251',\n",
       "     'text': ' of uveal melanoma cells, impaired the traits of CSCs in vitro.\\n\\n\\nCONCLUSION\\nArtesunate may be a potential interest for the therapy of uveal melanoma.',\n",
       "     'offsetInBeginSection': 1594,\n",
       "     'offsetInEndSection': 1744,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31344957',\n",
       "     'text': ' which a remarkably increased one-year overall survival rate, and similarly increased disease control rate, were observed in early phase studies.\\n\\n\\nCO',\n",
       "     'offsetInBeginSection': 1213,\n",
       "     'offsetInEndSection': 1363,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/19032679',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36442912',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34551229',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35716258',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36102132',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/29692251',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/20375921',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35060440',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35804863',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35254876',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36229663',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36065296',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35468881',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32816891',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35236927',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/16489097',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/33839690',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/31344957',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/1589858',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36094043',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35115315',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/31336704']},\n",
       "  {'id': '6426bb49690f196b5100004d',\n",
       "   'type': 'summary',\n",
       "   'body': 'What is the Fenton reaction',\n",
       "   'snippets': [{'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26948406',\n",
       "     'text': 'm 5.0 nM to 1.0 μM with a detection limit of 2.4 nM. Because of the rapid kinetics of Fenton reaction and high specificity for H2O2, the proposed meth',\n",
       "     'offsetInBeginSection': 1128,\n",
       "     'offsetInEndSection': 1278,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/25496478',\n",
       "     'text': 'INTRODUCTION\\nFenton reaction is the main source of free radicals in biological systems. The reactivity of this reaction can be modified by several fac',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/19806722',\n",
       "     'text': 'The photo-Fenton reaction, oxidation of photoproduced ferrous iron by hydrogen peroxide, produces reactive oxidants that may be important to degradati',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/17166556',\n",
       "     'text': 'rogen peroxide. Fenton reaction is a powerful oxidation technology used for the oxidation of groundwater pollutants. For the application of Fenton rea',\n",
       "     'offsetInBeginSection': 118,\n",
       "     'offsetInEndSection': 268,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31476718',\n",
       "     'text': 'Fenton reaction is widely used for hazardous pollutant degradation. Reducing agents (RAs) have been proven to be efficient in promoting the generation',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34190261',\n",
       "     'text': 's that FeII-counteranion complexes are the real catalyst for fast aqueous Fenton reactions. In addition, we found that the Fenton oxidation mediated b',\n",
       "     'offsetInBeginSection': 708,\n",
       "     'offsetInEndSection': 858,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35780882',\n",
       "     'text': 'It has been well recognized that the Fenton reaction requires a rigorous pH control and suffers from the fast self-degradation of H2O2. In an effort t',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35395600',\n",
       "     'text': ' in aqueous environments. The Fenton reaction, as an effective organic pollution treatment technology, is particularly suitable for the treatment of a',\n",
       "     'offsetInBeginSection': 292,\n",
       "     'offsetInEndSection': 442,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/30991337',\n",
       "     'text': 'xidative process. Bimetallic Fe/Al system for the Fenton reaction in water involves both surface-mediated and aqueous-phase reactions. A pilot scale t',\n",
       "     'offsetInBeginSection': 1203,\n",
       "     'offsetInEndSection': 1353,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/36080218',\n",
       "     'text': 'f oxygen to systemic organs. The Fenton reaction is the reaction between iron and hydrogen peroxide, generating hydroxyl radical, which is highly reac',\n",
       "     'offsetInBeginSection': 121,\n",
       "     'offsetInEndSection': 271,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/26948406',\n",
       "     'text': 'on, which cleaves FDNA to detach ROX from PTAD, thus in turn, lights the ROX fluorescence. Under physiological condition, H2O2 can be determined from ',\n",
       "     'offsetInBeginSection': 980,\n",
       "     'offsetInEndSection': 1130,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32369069',\n",
       "     'text': 'e Fenton reaction is regarded as an advanced oxidation process that can efficiently remediate environmental pollutants. However, the one-time irrevers',\n",
       "     'offsetInBeginSection': 2,\n",
       "     'offsetInEndSection': 152,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35098712',\n",
       "     'text': 'Fenton reaction has important implications in biology- and environment-related remediation. Hydroxyl radicals (•OH) and hydroxide (OH-) were formed by',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22105135',\n",
       "     'text': 'TIRON) was studied by cyclic voltammetry to better understand the enhanced reactivity of the DHB driven Fenton reaction. It was determined that the am',\n",
       "     'offsetInBeginSection': 641,\n",
       "     'offsetInEndSection': 791,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34130454',\n",
       "     'text': 's considered to be of great significance in the initial attack of lignocellulose in wood-decaying fungi. Quinone redox cycling is the main way to indu',\n",
       "     'offsetInBeginSection': 21,\n",
       "     'offsetInEndSection': 171,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/11695453',\n",
       "     'text': 'Abstract Fenton reaction has been often used to treat industrial wastewater or landfill leachate. However, most mechanistic research into the Fenton r',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/34190261',\n",
       "     'text': 'take place in the human body and have been demonstrated to cause oxidative DNA damage. However, the molecular-level understanding of DNA damage mediat',\n",
       "     'offsetInBeginSection': 29,\n",
       "     'offsetInEndSection': 179,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31259456',\n",
       "     'text': 'In this review, the power of a classical chemical reaction, the Fenton reaction for initiating radical polymerizations, is demonstrated. The reaction ',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32596808',\n",
       "     'text': 'Fenton reaction-mediated oncotherapy is an emerging strategy which uses iron ions to catalytically convert endogenous hydrogen peroxide into hydroxyl ',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15963810',\n",
       "     'text': 'ntative of continental conditions. This study highlights that the iron redox cycling is driven by Fenton reaction whatever Fenton mechanism is conside',\n",
       "     'offsetInBeginSection': 721,\n",
       "     'offsetInEndSection': 871,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31476718',\n",
       "     'text': 'gated. Results show the catalytic performance of RAs in BA degradation by Fenton reaction followed an order of NH2OH > AA > Cys. Compared with the con',\n",
       "     'offsetInBeginSection': 528,\n",
       "     'offsetInEndSection': 678,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35098712',\n",
       "     'text': 'ds to a 33-fold higher H2O2 utilization efficiency in comparison with Fe(II)/H2O2 Fenton reaction, and the pseudo-first-order reaction rate constant (',\n",
       "     'offsetInBeginSection': 613,\n",
       "     'offsetInEndSection': 763,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/28531840',\n",
       "     'text': 'The Fenton process, one of several advanced oxidation processes, describes the reaction of Fe(II) with hydrogen peroxide. Fe(II) is oxidized to Fe(III',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/22105135',\n",
       "     'text': 'e dihydroxybenzene (DHB) driven Fenton reaction is more efficient to degrade recalcitrant substrates than the simple Fenton reaction. The enhanced rea',\n",
       "     'offsetInBeginSection': 28,\n",
       "     'offsetInEndSection': 178,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/35780882',\n",
       "     'text': 'iron anode oxidation). Eighty percent of 1,2-DCA were degraded by the CaO2-based Fenton reaction. The final pH was neutral, inferring that the reactio',\n",
       "     'offsetInBeginSection': 765,\n",
       "     'offsetInEndSection': 915,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32668496',\n",
       "     'text': 'on reaction was used to improve the adsorption ability of chitosan. The formed Fe3+ in Fenton reaction was utilized. HO· broke the hydrogen bonds and ',\n",
       "     'offsetInBeginSection': 1393,\n",
       "     'offsetInEndSection': 1543,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/16504301',\n",
       "     'text': 'The Fenton or Fenton-type reaction between aqueous ferrous ion and hydrogen peroxide generates a highly oxidizing species, most often formulated as hy',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/32668496',\n",
       "     'text': 'straightforward application and control. The Fenton reaction generates highly reactive HO•, which has been applied effectively. However, the effect of',\n",
       "     'offsetInBeginSection': 90,\n",
       "     'offsetInEndSection': 240,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/15963810',\n",
       "     'text': ' the Fenton reaction of iron(II) with H2O2 can contribute, in a significant amount, to OH radicals production in cloud droplets. However, the destruct',\n",
       "     'offsetInBeginSection': 32,\n",
       "     'offsetInEndSection': 182,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'},\n",
       "    {'document': 'http://www.ncbi.nlm.nih.gov/pubmed/31343117',\n",
       "     'text': 'Here, the Fenton reaction is used to prepare silk hydrogels through oxidation of tyrosine residues in silk fibroin, leading to dityrosine crosslinking',\n",
       "     'offsetInBeginSection': 0,\n",
       "     'offsetInEndSection': 150,\n",
       "     'beginSection': ('abstract',),\n",
       "     'endSection': 'abstract'}],\n",
       "   'documents': ['http://www.ncbi.nlm.nih.gov/pubmed/26948406',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34190261',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/30991337',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/15963810',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/31343117',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35780882',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/25496478',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35098712',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/31476718',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32596808',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/31259456',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/16504301',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32668496',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/36080218',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/32369069',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/34130454',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/28531840',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/22105135',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/17166556',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/19806722',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/35395600',\n",
       "    'http://www.ncbi.nlm.nih.gov/pubmed/11695453']}]}"
      ]
     },
     "execution_count": 7,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "test_batch_json"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "e206a223",
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "haystack-py310",
   "language": "python",
   "name": "haystack-py310"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.10.10"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
